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microRNA:target interactions in tendinopathy 
David A Bardell 
Tendon disease is a significant cause of morbidity in both human and equine species, impacting on 
quality of life, general mobility, capacity to work and ability to participate in recreational sports. 
Clinically apparent tendinopathy is preceded by asymptomatic degenerative changes, but these are 
not well understood. Based on their longevity, use and the epidemiological similarities in naturally 
occurring disease in functionally analogous energy storing tendons, horses present an attractive and 
relevant model for investigating pathophysiological factors relevant to human tendon. 
Non-coding RNAs are important epigenetic modulators of gene expression and one subclass which 
has attracted significant attention is that of the microRNAs (miRNAs). These 21-25 nucleotide 
molecules are powerful post-transcriptional regulators of gene expression, typically by inhibiting 
translation of their mRNA targets into functional gene products. Altered expression of miRNAs, 
reported in a wide range of diseases, implicates them as important contributors to disease 
processes. 
Using an unbiased approach applied to human energy storing tendon harvested during surgical 
interventions, this is the first study to thoroughly interrogate changes in the small non-coding RNA 
(sncRNA) transcriptome occurring with clinical tendinopathy. This thesis presents evidence that the 
sncRNA transcriptome of tendinopathic tissue differs markedly to that of healthy tendon and may 
provide novel information on underlying pathogenic mechanism in tendon disease. Following 
validation of a selected panel of differentially expressed (DE) miRNAs from this data set, the 
expression of these miRNAs was then investigated in equine superficial digital flexor tendinopathy, 
identifying three miRNAs (miR-29a, miR-181 and miR-199a) showing similar changes in both species.   
Bioinformatics analysis highlighted the observed alteration in miRNA expression was consistent with 
enhanced cellular proliferation, inhibition of cellular degeneration, and regulation of MAPK and 
TGFβ signalling, inflammation, autophagy, mitochondrial homeostasis and oxidative stress response. 
Focussing on miR-181, gain and loss of function studies in monolayer cultures of primary equine and 
human tenocytes, and three-dimensional matrix-embedded equine tenocyte constructs, changes in 
distribution and expression of autophagy related proteins and mitochondrial dynamics were 
characterised.  
Data presented here thus identify that within a sncRNA transcriptome altered significantly in 
tendinopathy, dysregulation of miRNA expression is preserved/conserved to a degree between 
human and equine species. Additionally, results suggest miR-181 may have a role in tendinopathy by 
regulating autophagy and mitochondrial dynamics in equine and human tenocytes via LC3B activity, 
whilst changes in P62/SQSTM1, NRF2, BNIP3, COXIV and Parkin were observed in equine tenocytes 
in three-dimensional tissue-engineered constructs.   
This thesis supports the use of the horse as a model organism for investigating clinical tendon 
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Chapter 1 – Introduction 
 
1.1 Tendon structure and function  
The musculotendinous unit is an anatomical construct with the principle function of generating and 
transmitting force. This allows for locomotor and as well as postural and positional movements. 
Although functionally this operates as a continuous unit, the two main component tissues muscle 
and tendon are very different metabolically, structurally, and biochemically. Within each tissue type 
further subdivisions occur related to more specialised functional ability. Skeletal muscle is classified 
into three subtypes biochemically (Type I, Type IIA and Type IIB), with evidence of some ability of 
fibre types to interconvert (Essen et al 1975). Tendons are designed principally for effective 
transmission and absorption of uniaxial tensile forces, are poorly vascularised and relatively sparsely 
populated with cells. However, tendon is a complex tissue. Composition varies not only with 
development, ageing and functional requirements, but also in response to altered mechanical 
stimuli.  Tendons are broadly classified into those with a principally positional function and those 
which store and return energy during locomotion. Tendinopathies constitute a common morbidity in 
both human and veterinary medicine, with over 30 million human tendon-related procedures 
estimated to take place annually worldwide (Loiacono et al 2019). Despite being a digitigrade 
quadruped, the horse is frequently cited as a relevant model for investigating mechanical, 
biochemical and pathophysiological aspects relevant to human tendon (Innes and Clegg 2010, Lui et 
al 2011, Patterson-Kane and Rich 2014, Thorpe et al 2016a). This is based on equine longevity, use 
and epidemiological similarities in injury to functionally analogous tendons, with energy storing 
tendons being overrepresented in both species. Examples of tendons commonly associated with 











Table 1.1 Energy storing and positional tendons commonly reported in association with injury, 
and/or functional studies in both human and equine species.  
                  Equine                                                                                                                   Human 
Energy storing tendons 
Superficial digital flexor tendon                                                                                   Achilles tendon 
Deep digital flexor tendon                                                                                            Posterior tibial tendon 
Suspensory ligament                                                                                                     Patellar tendon 
                                                                                                                                          Supraspinatus tendon  
Positional tendons 




Historically, the collagenous matrix has been extensively studied in order to understand the 
mechanical properties of tendon and gain insight into tendon deterioration. In recent years 
however, it has become apparent that differences in mechanical properties between tendon types 
are determined largely by the composition of the non-collagenous matrix. The hierarchical structure 
of tendon has been well described (Kastelic et al 1978) and a schematic representation of this is 




















Figure 1.1 Schematic representation of tendon structure. Tropocollagen molecules comprising 
heterotrimeric left handed helical arrangement of collagen molecules aggregate into roughly 
cylindrical microfibrils. Microfibrils coalesce to form fibrils, and subsequently fibres, of varying 
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1.1.1 Extracellular matrix composition 
In terms of structure, tendon can be described as a viscoelastic fibre-reinforced composite material. 
Consisting of 55-70% water, the most abundant protein is collagen (60-85% of dry weight), 60-90% 
of which is type I (Kjær 2004), with types III, V, XI, XII and XIV present in lesser amounts (Screen et al 
2015). The basic type I collagen molecule is a left handed triple helix consisting of two α1 and one α2 
chains secreted by the fibroblast into the extracellular space, where N- and C- terminal propeptides 
are cleaved, to produce a mature tropocollagen molecule approximately 280 nm long (Cheng and 
Screen 2007, Mouw et al 2014). Tropocollagen molecules associate axially and longitudinally, in a 
quarter-staggered arrangement, stabilised by intra- and inter-molecular covalent crosslinks, to form 
functionally continuous higher order structures. A variable number of hierarchical levels have been 
described, but typically consist of microfibrils, fibrils and fascicles (Kastelic et al 1978, Sharma and 
Maffulli 2005, Cheng and Screen 2007). Collagen fibrils exhibit a crimp waveform which is 
propagated through the higher level structures due to adjacent fibrils aligning in register (Patterson-
Kane and Rich 2014). Fascicles are arranged with varying degrees of helical pitch (Kalson et al 2012, 
Thorpe et al 2013a). Despite changes in tendon cross sectional area, collagen content as a 
percentage of dry weight does not alter along the length of SDFT, and total collagen only increases 
significantly in the region approaching the metacarpophalangeal joint (Birch et al 2002). 
A bimodal distribution of collagen fibril diameter develops in the equine superficial digital flexor 
tendon (SDFT) over the period from neonate to skeletal maturity. This also occurs in the suspensory 
ligament (SL) and human Achilles tendon, but not common digital extensor tendon (CDET) or deep 
digital flexor tendon (DDFT), where fibre diameter distribution remains unimodal and significantly 
larger (Parry et al 1978a, Parry et al 1978b, Birch et al 1999, Magnusson et al 2002). Median fibril 
diameter is significantly smaller in SDFT (47.8 nm) than DDFT (122.8 nm), with 90% of SDFT and 55% 
of DDFT fibres less than 150 nm (Birch et al 1999). Mass average SDFT and SL fibril diameter (169±19 
nm and 122±14 nm respectively are significantly lower than that of the CDET (229±36 nm), 
suggesting larger fibril diameters are associated with conferring a stiffer matrix (Birch 2007). Profiles 
of enzymatically-derived collagen crosslinks also differ between tendon types. 
Hydroxylysylpyridinoline cross-links predominate in energy storing tendon (SDFT, DDFT and SL), 
whilst histidinohydroxymesodesmosine is the major type found in CDET. 
Histidinohydroxylysinonorleucine and dehydro-hydroxylysinonorleucine are also present in CDET, 
but largely absent from energy storing tendon types (Birch 2007, Birch et al 2008b). The 
consequence of these differences is not known, but increasing inter-molecular crosslinking alters the 
charge profile, affecting intra-fibre and cell-collagen interactions, which can produce major changes 
in physical properties and cell-matrix interactions (Avery and Bailey 2006).  
Fibrils and fascicles are embedded within a complex proteoglycan-rich matrix, which is continuous 
with the encompassing epitenon. Proteoglycans consist of a core protein covalently linked to 
glycosaminoglycans (GAGs) – long, linear, charged polysaccharides composed of disaccharide 
repeats. Differences in structure and steric arrangement of these GAG sidechains confer differing 
biochemical and hydrodynamic properties, thus contributing to developmental, organisational and 
mechanical characteristics of tendon infrastructure (Mouw et al 2014). Principal proteoglycans 
include the small leucine rich proteoglycans (SLRPs) decorin, biglycan, fibromodulin and lumican, 
tenomodulin and larger proteoglycans aggrecan, versican, cartilage oligomeric matrix protein 
(COMP), lubricin and tenascin-c.  Variably, COMP (Smith et al 1997, Thorpe et al 2013b) and decorin 
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(Corps et al 2006) are described as the most abundant tendon proteoglycans. COMP is expressed 
exclusively in load-resisting soft tissues (tendon, ligament, cartilage, meniscus and intervertebral 
disc) although expression levels vary within and between individual tissues (Smith et al 2002a). 
In SDFT, COMP levels show the greatest dynamic change with age and mechanical loading compared 
to other appendicular tendons and ligaments (Smith et al 1997). Synthesis is critically dependent on 
appropriate mechanical loading (Smith et al 1999), increasing during musculoskeletal maturation 
and peaking at approximately 2 years of age. Greatest expression occurs in the mid metacarpal 
region of SDFT, where tensional forces predominate. Thereafter levels decline exponentially in the 
metacarpal region of SDFT, whilst remaining constant in other SDFT regions and tendinous 
structures (Smith et al 1997). COMP is also present in the proliferative zone of articular cartilage, but 
absent in resting and hypertrophic zones, suggesting a role in cellular proliferation (Smith et al 
1997).   
Interfascicular boundaries are wider and more clearly delineated in SDFT compared with CDET (Ali et 
al 2018, Thorpe et al 2012) with more distinct and abundant interfascicular matrix (IFM) which stains 
more intensely for proteoglycan and glycoprotein (Thorpe et al 2016b). Sulphated GAG composition 
varies, being significantly lower in CDET (2.5 µg mg-1 dry weight) than either SDFT (9.1 µg mg-1), DDFT 
(10.6 µg mg-1) or SL (13.2 µg mg-1) (Birch 2007). GAG content is significantly lower in the mid 
metacarpal region of SDFT relative to the other regions (Birch et al 2002).  
 
Decorin appears to be ubiquitously expressed both between tendon types and matrix sub-
compartments, consistent with its importance in collagen fibrillogenesis (Thorpe et al 2016b). 
However, Thorpe and co-workers (2016c) describe greater expression in SDFT fascicular matrix (FM) 
than IFM in older horses. Biglycan, which competes for the same collagen binding sites, is suggested 
to show greater abundance in SDFT IFM than FM (Thorpe et al 2016b). 
Lumican and fibromodulin, which share binding sites on collagen type I and modulate collagen fibril 
organisation, circumferential growth and cross-linking, appear to be preferentially located in CDET, 
with lumican more abundant in IFM and fibromodulin predominating in FM (Thorpe et al 2016b). 
However, Thorpe and colleagues (2016c) describe greater fibromodulin expression in SDFT FM than 
IFM, expression of which decreases with age. 
Lubricin (also known as proteoglycan 4 or superficial zone proteoglycan) is localised to IFM of both 
SDFT and CDET, with elastin significantly located in SDFT IFM and largely absent in CDET (Thorpe et 
al 2016b).  
Further quantitative and qualitative differences in protein expression between SDFT IFM and FM 
have also been reported (Thorpe et al 2016c). Of the ten types of collagen identified in IFM and FM 
COL17A1 and COL18A1 were only present in FM, whilst COL7A1 and COL22A1 only in IFM.  Proteins 
expressed in greater abundance in FM were mainly extracellular matrix (ECM) proteins including 
COL1A1, COL1A2, COL12A1, thrombospondins 1 and 4, fibromodulin, COMP and decorin. In old 
horses, no difference in COMP between FM and IFM has also been reported (Thorpe et al 2016c). 
Glycoproteins were more abundant in IFM, with heparin sulphate exclusively identified in IFM, not in 
FM (Thorpe et al 2016b). Of proteins common to both IFM and FM approximately 80% were more 
highly expressed in IFM, the majority of which were cellular proteins. 
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Matrix composition varies not only between positional and energy storing tendons, and fascicular 
and intrafascicular compartments, but also in response to discrete regional mechanical 
requirements. The insertion of tendon onto bone is a highly specialised area, with four distinct zones 
described in this transitional region; tendon proper, fibrocartilage, mineralised fibrocartilage and 
bone (Thomopoulos et al 2003). Tendons are principally designed to withstand tensile forces, but 
where they change direction around articulations or bony prominences, tendon may take on a more 
fibrocartilaginous appearance similar to that seen at the insertion region (Corps et al 2006). Human 
supraspinatus (SSP) tendon demonstrates this force-dependent regional variation in matrix proteins. 
Decorin is present throughout the tendon, whilst aggrecan and biglycan expression is highest near 
the insertion site where compression and shear forces are more likely, and where clinical injury 
often initiates (Matuszewski et al 2012).  Thomopoulos and co-workers (2003) reported similar 
changes in rat SSP tendon, with increased expression of collagen types II, IX and X and aggrecan at 
the insertion site, and decorin and biglycan more highly expressed in tensile regions (Thomopoulos 
et al 2003). These authors also reported a change in tenocyte shape from spindle shaped to 
rounded, a finding also reported in regions of equine SDFT subjected to compressive forces and 
demonstrating a more fibrocartilaginous appearance (Webbon 1978).   
 
1.1.2 Cellular content of tendons 
Tenocytes are specialised fibroblasts, account for 95% of the cellular content of tendon and secrete 
both collagenous and non-collagenous matrix proteins. A specialised population of tendon 
stem/progenitor cells (TSPC) has been identified (Bi et al 2007), which reside in ECM rich niches and 
express tendon-related factors such as scleraxis (SCX), tenomodulin (TNMD), COMP and tenascin-c 
(TNC). They are closely related to, but distinct from, bone marrow stem cells (BMSC), possessing 
fibroblast marker CD90.2, but not BMSC marker CD18 (Bi et al 2007). Proliferation and 
differentiation of TSPCs into functionally competent tenocytes appears to be linked to biglycan and 
fibromodulin expression (Bi et al 2007). Single cell gene expression analysis has identified three 
distinct subpopulations, clusters I and II with high expression levels of nestin, which show 
particularly strong tenogenic and regenerative capacity, with cluster I additionally showing elevated 
levels of CD31 and CD34 expression, and a nestin negative population with elevated expression of 
SCX, COL1, TNC, thrombospondin 4, Mohawk (MKX) and COMP (Yin et al 2016).  
Embryologically, development of limb tendons occurs progressively in a proximal to distal direction, 
with loose aggregations of tendon progenitors aligning between differentiating cartilage and muscle 
tissue prior to condensing to form tendon structures (Huang 2017). Expressed in the early stages of 
embryological limb development, TGFβ is a potent and critical inducer of SCX expression in early 
tendon development (Gaut and Duprez 2016). Scleraxis is a transcriptional activator, important in 
driving commitment and maintenance of progenitor cells to tenogenic differentiation (Pryce et al 
2009, Tan et al 2020). In conjunction with MKX, SCX positively regulates COL1A1 transcription, 
additionally activating expression of TNMD, another critical regulator of tenocyte differentiation and 
maturation (Shukunami et al 2018).  
Mature tenocytes typically have elongated nuclei and long cytoplasmic extensions. Complex three-
dimensional inter-communicating networks of nanotubules up to several hundred micrometers long 
permit communication between adjacent cells via gap junctions (Egerbacher et al 2020). In regions 
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where tendons are exposed to compressive forces, and towards the osteo-tendinous junction, they 
assume a more rounded, chondrocyte-like appearance. Tenocytes are distributed heterogeneously, in 
linear arrays, throughout tendon substance, cellularity being significantly greater in the IFM than the 
FM (Thorpe et al 2016b). The IFM cell population is also morphologically distinct, cells being typically 
rounder in shape with a more stem cell-like appearance than tenocytes resident in the FM, with a 
shorter population doubling time and tendency to form colonies in culture (Zhang et al 2021). 
Additionally, cells isolated from IFM of porcine Achilles tendon displayed specific, discriminatory 
markers differentiating them from tenocytes isolated from FM (Zhang et al 2021). These authors 
demonstrated CD105, CD31, CD73, CD146, α-smooth muscle actin, elastin, osteocalcin, tubulin 
polymerisation promoting protein, substance-P and collagen IV were all highly expressed by IFM 
tenocytes, but absent, or only weakly expressed by FM tenocytes (Zhang et al 2021). Endothelial cells, 
neurones and chondrocytes are also present in small amounts.  
Histologically, foetal SDFT is indistinguishable from the adjacent energy storing DDFT (Webbon 1978) 
however, DDFT cellularity decreases with age, unlike in SDFT, where cellularity is maintained (Birch 
et al 1999, Birch et al 2008a, Birch et al 2008b). Batson and co-workers (2003) also report CDET 
cellularity is preserved with ageing, although is much lower than that of SDFT. Interestingly, these 
authors did find a significant reduction in SDFT cellularity with age, although it remained consistently 
higher than that in age-matched CDET. Frequent regions of acellularity are also reported in core mid-
metacarpal SDFT regions compared to peripheral zones (Webbon 1978). These differences in 
cellularity suggest contrasting metabolic activity in mature tendon both between tendon types and 
region of matrix and may represent a possible mechanism for repair of accumulated damage (Birch 
et al 1999, Birch 2007, Thorpe et al 2016c).  
 
 
1.1.3 Matrix metabolism 
Despite differences in cellularity, levels of mRNA for collagens I and III, fibromodulin and lubricin 
were significantly lower in SDFT than corresponding CDET, whilst COMP and decorin levels were not 
different between tendon types (Birch et al 2008a).   
In a heterogenous equine population, Ribitsch and colleagues (2019) detected COMP, versican and 
decorin expression in SDFT across the age range examined (1 day to 23 years). However, these 
authors report expression of collagens I, III and V almost exclusively restricted to individuals less 
than 4 years of age, with tenascin-c, tenomodulin and scleraxis showing similar expression profiles, 
suggesting limited turnover of these molecules once skeletal maturity has been reached. Evidence 
from environmental 14C levels in human Achilles tendon indicates tendon collagenous matrix 
deposition occurs during the first 17 years of life, roughly equivalent in terms of musculoskeletal 
maturation, with little turnover subsequently (Heinemeier et al 2013).   
Matrix metabolism can be assessed by markers of synthesis including mRNA expression, and (for 
type I collagen) levels of carboxyl- and amino-terminal propeptides (PICP and PINP) cleaved during 
the production of tropocollagen. Degradation markers include the carboxyl-terminal telopeptide of 
type I collagen (ICTP) and matrix metalloprotease (MMP) expression. MMP1, MMP8 and MMP13 
mediate the initial stages of collagen degradation, whilst MMP2 and MMP9 (gelatinases) target 
denatured collagen. MMP3 (stromelysin) degrades matrix glycoproteins and activates MMP1 and 
MMP9. Expression of MMP2 and MMP9 (both pro- and active forms) have been shown to be similar 
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in SDFT and CDET. Significantly higher levels of pro-MMP3 have been detected in CDET, but without 
mRNA evidence of increased transcription, suggesting CDET is ‘constitutively primed’ for greater 
degradative activity (Birch et al 2008a). Significantly higher levels of MMP-generated collagen type I 
degradation fragments ICTP are detectable in CDET than SDFT (Thorpe et al 2010), consistent with 
higher MMP1 and MMP13, and lower TIMP3 activity reported by Birch and co-workers (2008a). 
There is, additionally evidence of disproportionate accumulation of degradation products in SDFT 
(Thorpe et al 2010).  
Collagen cross-linking produced by non-enzymatic glycosylation increases progressively with ageing. 
These crosslinks exhibit natural fluorescence and tissue fluorescence has been used as an indicator 
of collagen residence time. Tissue fluorescence significantly increases with age in both SDFT and 
CDET, Batson and co-workers (2003) describing a good correlation with age of horse, but is 
consistently and significantly lower in CDET than SDFT (Birch 2007, Thorpe et al 2010). Corroborating 
this, measurement of spontaneous L-to-D racemic conversion of aspartate (a natural ageing-related 
phenomenon) shows a linear increase in D:L ratio with age in both tendons, with far greater D-
aspartate accumulation in SDFT (Thorpe et al 2010). These authors calculated collagen half-life to be 
approximately 198 years for SDFT compared with 34 years for CDET. Non-collagenous matrix, by 
comparison is more labile and, conversely turned over more rapidly in SDFT than CDET, half-lives 
being calculated as 2.2 years and 3.5 years respectively (Thorpe et al 2010).  
Taken together, these data support the theory of more active matrix degradation in CDET than SDFT. 
 
1.1.4 Mechanical properties of tendon 
Mechanical behaviour of tendon is described in terms of stress, strain, stiffness, hysteresis and 
elastic modulus (Heinemeier and Kjær 2011). These qualities are defined in Table 1.2.  
Deformation of tendon under load occurs at many different levels within the structure; straightening 
of the crimp pattern, elongation of the triple helical tropocollagen molecules, sliding between 
adjacent tropocollagen molecules, fibrils, and fascicles, and straightening of the fascicular helix 
(Sharma and Maffulli 2005, Thorpe et al 2013a). Positional tendons are required to be relatively 
inextensible under physiological loads whilst energy-storing tendons need to be able to stretch and 
recoil to increase efficiency of locomotion. The helical arrangement of fascicles reported in both 
human and equine flexor tendons (Kalson et al 2012, Thorpe et al 2013a) is not evident, or greatly 
reduced, in positional tendons (Thorpe et al 2013a, Thorpe et al 2015a). In response to applied 
strain, fibre sliding occurs in CDET to a significantly greater extent than in SDFT and at normal 
physiological loading may be the major mechanism responsible for extension, with little or no 
fascicle sliding required (Thorpe et al 2013a). In contrast, fascicle sliding may be the major 
mechanism with SDFT, in conjunction with helical ‘unwinding’, contributing to greater extension and 
better recoil characteristics. Fascicle rotation was significantly greater in SDFT than CDET (Thorpe et 
al 2013a). SDFT fascicles show less hysteresis than CDET, with better recovery characteristics 
following applied strain.  
Strain in energy storing tendons has been measured at approximately 10% and 16% in human 
Achilles and equine SDFT respectively during intense exercise (Lichtwark and Wilson 2005, Stephens 
et al 1989). This contrasts with approximately 3% for the positional human anterior tibialis 
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(Maganaris and Paul 2000) and 2.5% for CDET estimated by Birch and co-workers (2008a). In vitro 
failure strains of 9.9% for Achilles tendon (Wren et al 2001), 12.5-17.3% for SDFT (Dowling and Dart 
2005) and 9.7% for CDET (Batson et al 2003), indicate that energy storing tendons operate with little 
or no safety margin. These data suggest propensity for damage, and importance of matrix 
homeostasis is therefore greater in elastic tendons, conflicting with the observed indices of 
metabolic activity described above.  
Use of explants for investigating material properties of tendon has produced much useful and 
detailed data. These methods, however, possess inherent limitations, and material properties of 
tendon components may not truly reflect in vivo behaviour of tendon as a biological entity. 
Application of load results in stress relaxation, or ‘conditioning’, a process resulting in a 40-60% 
reduction in applied stress due to linear stretch (Dudhia et al 2007). Stress relaxation of the IFM 
occurs to a significantly greater degree in CDET than SDFT. Moreover, this is an age-dependent 
phenomenon, occurring typically within the first few hours in aged equine explants, but up to 12 
hours in tissue derived from younger animals (Dudhia et al 2007). Isolation of fascicles allows 
independent interrogation of fascicular and interfascicular matrix mechanical properties, but at the 
expense of incurring artefactual changes. Fascicle isolation results in swelling and non-uniform 
elongation, producing significantly lower elastic modulus than whole tendon, whilst failing at lower 
stress and strain (Thorpe et al 2012).   
 
Sample handling protocols also impact on tissue mechanical properties. Dudhia and co-workers 
(2007) found application of cyclical strain induced a significant age-related reduction in ultimate 
tensile stress of fresh SDFT explants, which did not occur in explants  rendered (and confirmed) non-
viable by one 2 hour freeze-thaw cycle to -20oC. Conversely, Huang and colleages (2011) reported no 
statistically significant alterations in mechanical properties of human digital flexor tendons subjected 




































Table 1.2 Material qualities used to define tendon mechanical properties. 
Viscoelastic: possessing both viscous and elastic properties in response to an applied force. Viscosity 
describes resistance of a fluid to flow; elasticity describes the ability of a solid to retain its original form 
under the influence of an applied force.  
Stress: force relative to cross sectional area = Force (F)  
                                                                                   Area (A)     
Strain: extension under load as a percent of resting length = Change in length (ΔL) 
                                                                                                              Original length (L0)  
             
Ultimate tensile stress: applied tensile force at which a tendon will fracture. 
Failure strain: the degree of extension at which a tendon will fail. 
Stress relaxation: time dependent reduction in stress when a constant strain is applied. 
Creep: time dependent increase in strain when a constant stress is applied. 
Stiffness: change in tendon length in relation to the applied force – proportional to cross sectional 
area. 
Fatigue loading: repetitive loading/unloading cycles continued to the point at which structural damage 
occurs.  
Hysteresis: energy dissipated (as heat) due to material viscosity. Defined on a stress/strain graph by 
the area (AH) between the curves generated during one loading/unloading cycle. 
 
Elastic modulus: describes the relationship of strain to applied uniaxial stress. Represented by the 












1.1.5 Mechanical properties differ between positional and energy storing tendons 
In whole tendon, elastic modulus and ultimate tensile stress are significantly lower in SDFT than 
CDET. Isolated fascicles demonstrate no difference in these properties between tendon types, but 
surprisingly, fascicle failure strain was significantly higher in CDET than SDFT (Thorpe et al 2015c). 
The difference in failure strain between isolated fascicles and parent tendon was 4 times higher in 
SDFT than in CDET, indicating the importance of the IFM in contributing to tendon mechanical 
properties (Thorpe et al 2012).  
CDET fascicles and IFM demonstrate greater hysteresis than SDFT (Thorpe et al 2012, Thorpe et al 
2015c, Thorpe et al 2017). A significant positive correlation between COMP levels and ultimate 
tensile stress, elastic modulus and stiffness was found in 2 year old horses (Smith et al 2002a). This 
correlation was absent in older animals, suggesting high levels are important during development 
(Smith et al 2002b). Water content shows a significant negative correlation with elastic modulus, and 
is lower in CDET than SDFT, DDFT and SL (Birch 2007). SDFT water content also reduces significantly 
from the mid metacarpal level distally (Birch et al 2002), indicating regional heterogeneity in elastic 
modulus.   
Both fascicles and IFM of SDFT demonstrate greater fatigue resistance than CDET. Fascicles resist 
approximately 20 times more cycles before failure, with significantly less hysteresis, and greater 
resistance to developing creep, indicating greater elasticity of SDFT (Thorpe et al 2016a, Thorpe et al 
2017). IFM exhibits similar, but less pronounced differences between tendon types (Thorpe et al 
2016a).  
 
1.1.6 Tendon response to exercise 
Tendon has the capacity to adapt acutely and chronically to increases in mechanical loading. As little 
as 30 minutes exercise resulted in significant upregulation of COL1A1, scleraxis and tenomodulin in 
rat Achilles tendon (Mendias et al 2012). In vitro evidence suggests TGFβ1 is an important mediator 
of mechanically induced collagen synthesis in fibroblasts (Heinemeier et al 2007). Electrical 
stimulation of the sciatic nerve in rats over 4 days resulted in significant upregulation of TGFβ1, 
COL1A1, COL3A1, MMP2, TIMP1, TIMP2 and lysyl oxidase (Heinemeier et al 2007). COL1A1 
expression appears to be associated with acute exercise, rather than chronic. Response to 
mechanical loading in vivo is mediated by induction of growth factors TGFβ1 and IGF1. In a rat 
exercise model, both degree and distribution of IGF1 expression in Achilles tendon fibroblasts has 
been shown to vary in a dynamic manner with changes in mechanical loading of the tendon 
(Hansson et al 1988). 
Increased collagen synthesis in response to acute exercise has been demonstrated in human patellar 
tendon using 13C labelled amino acids (Miller et al 2005) and Achilles tendon, using peritendinous 
microdialysis to measure precursor peptides and degradation products (Langberg et al 1999). 
Chronic exercise results in approximately 30% increased cross sectional area (CSA) of human Achilles 
tendon, a change that may also be evident unilaterally in long term physical activity which favours 
one limb. Short term exercise may result in small, regional changes in CSA (Heinemeier and Kjær 
2011). Tendon hypertrophy in response to exercise has not been found consistently in female 
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athletes (Heinemeier and Kjær 2011). The difference in patellar tendon CSA between trained and 
untrained men was not detectable in women (Magnusson et al (2007).  
Rooney and co-workers (2017) showed distinctly different temporal responses in rat supraspinatus 
tendon over an eight week exercise period. An initial increase in tendon CSA 24 hrs after onset of 
exercise was accompanied by reduction in elastic modulus, maximum stress and load. After two 
weeks, CSA had returned to control values, but tendon stiffness, modulus, maximum load and 
maximum stress had increased, whilst hysteresis reduced. These changes were maintained until 
study termination at 8 weeks (Rooney et al 2017). These authors also describe a reduction in MMP 
activity both in the acute and chronic stages, favouring a more anabolic environment, although MMP 
identities and degree of reduction are not given. Tenocyte morphology changed within 48 hrs of 
initiation of exercise, with cells becoming rounder for up to two weeks, returning to normal at eight 
weeks. Cell density and collagen organisation remained unchanged (Rooney et al 2017). Although 
critical comparisons are often lacking, these authors indicate that there is a beneficial temporal 
progression of adaptive changes to non-injurious levels of exercise. 
In horses, however, ultimate force, ultimate stress, stiffness index and elastic modulus of SDFT did 
not differ following an 18 month athletic training regime between exercise and control groups (Birch 
et al 2008b). Although GAG content decreased in SDFT, DDFT, SL and CDET in response to exercise, 
gross and histological appearance, cellularity, CSA, collagen content, type, and degree of crosslinking 
were unchanged (Birch et al 2007, Birch et al 2008b). Following a similar regime, Smith and co-
workers (1999) demonstrated lower COMP levels in SDFT than in unexercised controls, whilst 
Patterson-Kane and colleagues (1997a) identified an alteration in distribution of collagen fibril 
diameters. A decrease in mean average fibril diameter (from 132 nm to 105 nm) in core SDFT 
regions, changing fibre diameter distribution from that reported during normal ageing, where no 
regional variation exists (Birch et al 1999). Greater tensile strength is attributed to large diameter 
fibrils due to the potential for a higher density of intrafibrillar covalent cross-linking between 
collagen molecules. Small diameter fibrils are assumed to be more important in terms of promoting 
elasticity due to increased fibril-ground substance interaction by virtue of their greater surface area 
(Patterson-Kane et al 1997a). 
 
1.1.7 Age-related changes 
In human patellar tendon, no significant differences in mechanical properties or dimensions 
between old and young men are described. A significant reduction in collagen concentration is 
reported in old men compared to young, but enzymatic (pyridinoline) and particularly non-
enzymatic (pentosidine) crosslinking significantly increases (Couppé et al 2009). The authors 
postulate this is a mechanism to maintain mechanical properties of ageing tendon in the face of 
collagen loss. Expression of decorin, aggrecan, biglycan and versican are shown to decrease with age 
in Achilles tendon (Corps et al 2006). Transcriptomic analysis of Achilles tendon identified over 300 
genes differentially expressed between old and young donors (Peffers et al 2015). Both protein 
coding and non-coding transcripts were represented, but changes in ECM-related genes were not 
significant. Interestingly, differences in splice variants of ECM relevant proteins COL1A1, COL3A1 and 
disintegrin and metalloproteinase domain-containing protein 12 (ADAM12) were recognised 
43 
 
between old and young groups. Network analysis of differentially expressed genes implicated cell 
function, growth and proliferation as most affected, suggesting ageing may impact on tenocyte 
ability to sense and respond appropriately to environmental stimuli (Peffers et al 2015). Supporting 
this, an increase in tenocyte senescent phenotype is reported in rat Achilles tendon with ageing, 
with reduced tenocyte proliferative capacity, and a concurrent increase in expression of MMP2 and 
MMP9 and down regulation of TIMP1 and TIMP2 (Tsai et al 2011, Yu et al 2013). Additionally, Kohler 
and co-workers (2013) describe reduced TSPC number and capacity for self-renewal and 
differentiation in ageing human Achilles tendon (Kohler et al 2013).  
Proteomic analysis also identified age related changes in cell phenotype in equine SDFT.  A 
significant reduction in the anti-apoptotic and anti-inflammatory heat shock protein 27 is reported, 
coupled with increased cytoskeletal and gap junction proteins. No changes in the major structural 
ECM proteins were evident, with only reductions in SLRPs fibromodulin, mimecan and asporin being 
identified (Peffers et al 2014). Recently, intrafascicular chondroid-like bodies (ICBs) have been 
described in SDFT samples from aged horses (Ali et al 2021). These ICBs are discrete spherical to 
ovoid accumulations of cartilaginous ECM dispersed between tendon fascicles, containing abnormal 
tenocytes with rounded, rather than fusiform nuclei. Additionally, calcium deposits were present 
within some. Although the significance of these was unclear, the authors suggested they may 
represent a response to microtrauma and could potentially impact on the viscoelastic properties of 
the tendon (Ali et al 2021). 
Tenocytes are believed to undergo principally oxidative metabolism (Birch et al 1997), but as the 
tendon matures, there is a shift towards anaerobic glycolysis, compatible with the reported age-
related reduction in blood flow (Astrom 2000, Sharma and Maffulli 2005).   
In SDFT, ageing is associated with significant reductions in both number of load cycles to failure and 
ultimate tensile strength, with increased failure strain (Dudhia et al 2007). Ageing does not affect 
fascicle or IFM hysteresis, but isolated fascicles and IFM demonstrate an approximately 66-77% 
decrease in number of cycles to failure in old compared to young horses (Thorpe et al 2017). This is 
associated with more severe fibre kinking, discontinuity and widening of inter-fibre spaces in older 
fascicles (Thorpe et al 2014). Collagen fibril crimp angle and length undergo a non-uniform reduction 
with age in equine SDFT. The greatest change occurs in core relative to peripheral regions, where 
values decline to 65-75% of those in young animals (Wilmink et al 1992, Patterson-Kane et al 1997b). 
Crimp straightening then occurs at lower strains in central fibres, leading to non-uniform distribution 
of force within the tendon. Cross-linking from collagen glycosylation increases with ageing in both 
CDET and SDFT, but at a greater rate in SDFT.  
Thorpe and colleagues (2016c) report little effect of ageing on IFM or FM protein composition of 
SDFT. Fibromodulin decreases with age in both FM and IFM, with COL6A3 and the SLRP mimecan 
also decreasing in FM. Percentage of CSA occupied by IFM significantly reduces with age in SDFT, 
from approximately 15% to 9%, a change not seen in CDET (Thorpe et al 2013b) and reported  to be 
more pronounced in the distal SDFT (Ali et al 2018).  
Concurrently, although IFM failure strain does not change (Thorpe et al 2015c), IFM stiffness 
increases, decreasing capacity for fascicle sliding and rotation, mechanisms of far greater importance 
to SDFT function than CDET (Thorpe et al 2013b, Thorpe et al 2017). Consequently, a compensatory 
increase in fibre sliding in response to load occurs, which, coupled with an age related increase in 
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IFM stress relaxation, reduces recoil and increases hysteresis (Thorpe et al 2013a, Thorpe et al 2014, 
Thorpe et al 2015a). Fascicle stress relaxation does not increase with age in SDFT, but elastic 
modulus and failure stress do (Thorpe et al 2015c).  
Elastic modulus decreases with age in CDET (Thorpe et al 2015c). No age-related alteration in fibre or 
fascicle response to applied strain, recovery or hysteresis is reported, although fascicle and IFM 
stress relaxation increases with age, producing a significant increase in failure extension (Thorpe et 
al 2015c). Ageing does not affect fascicle or IFM hysteresis or fatigue resistance in CDET (Thorpe et al 
2013a, Thorpe et al 2014, Thorpe et al 2017). Figure 1.2 illustrates IFM force-extension curves for 
SDFT and CDET, demonstrating the far more profound effect of ageing on the former. 
 
 
Figure 1.2 Age-related changes in force-extension curves for equine superficial digital flexor (SDFT) 
and common digital extensor (CDET) tendon interfascicular matrix. Significantly greater extension 
occurs at lower forces in young SDFT than old, demonstrating increased interfascicular matrix 
stiffening with age. Changes in CDET tend to be opposite, but are minor in comparison and not 
statistically significant. (Redrawn from Thorpe et al 2013b). 
 
1.2 Pathophysiology of tendinopathies  
Musculoskeletal injuries account for 11-24% of all presentations to primary care facilities in the UK 
(Clarke-Cornwell et al 2006, Jordan et al 2007). Incidence of tendinopathies varies between 0.3-5.5% 
(Littlewood et al 2013, Albers et al 2014)  in the general population, up to 11% for athletic 
individuals, with a prevalence in some disciplines of 18.5 – 44.6% (Lian et al 2005, Lopes et al 2012). 
Tendinopathies thus have a major impact both in terms of quality of life and financial consequences 
from loss of productivity and earnings, compensation and treatment costs (Hopkins et al 2016).  
Tendinopathies are also a cause of significant morbidity and wastage in the equine population (Lam 
et al 2007). Most research into incidence and aetiology has focussed on the Thoroughbred due to 
the financial importance of the racing industry, although a high incidence of ligament and tendon 
injuries has also been reported in eventing (Singer et al 2008), show-jumping and dressage 
disciplines (Murray et al 2006). Musculoskeletal injuries account for up to 82% of all injuries 
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sustained during flat and National Hunt racing in the UK. Of these 46% involve ligaments or tendons 
(Williams et al 2001), with the superficial digital tendon (SDFT) of the forelimb particularly 
susceptible to injury.  
The parallels between human and equine tendinopathy are interesting. In both species there is a 
high prevalence in predominantly energy storing tendons, that is positively associated with ageing 
and occupational/exercise status and a tendency for recurrent injury (Paavola et al 2002, Ely et al 
2009, Thorpe et al 2010, Gajhede-Knudsen et al 2013, Reardon et al 2013). This suggests 
deterioration in the ability to maintain matrix composition, or maladaption to mechanical loading 
during ageing.  
 
1.2.1 Matrix changes associated with tendinopathies 
Typically diseased tendon shows gross discolouration, increased cellularity, greater GAG content, 
greater water content, neovascularisation and greater proportion and altered distribution of type III 
collagen (Birch et al 1998, Birch et al 2002, Jelinsky et al 2011).  
Chondroid metaplasia is a frequent finding in mid metacarpal SDFT of mature horses (Webbon 
1978), and conversion to a more fibrocartilagenous phenotype has been identified in rat 
supraspinatus tendon as a result of overuse, increasing expression of COL2A1, aggrecan and SOX9 
(Archambault et al 2007). 
In chronic tendinopathies, up-regulation of collagens I and III and down regulation of MMP3 are 
relatively consistent findings (Ireland et al 2001, Jones et al 2006, Jelinsky et al 2011). Various studies 
have also reported upregulation of MMP11, ADAM12 (Jones et al 2006), MMP2 (Alfredson et al 
2003), MMP9, MMP13, MMP14, MMP19 and TIMP1 (Jelinsky et al 2011) in chronic Achilles 
tendinopathy.  
Proteoglycan expression is also inconsistent. Jelinsky and co-workers (2011) report no change in 
aggrecan, versican, decorin, biglycan, fibromodulin, or lumican with Achilles tendinopathy. Ireland 
and colleagues (2001) report increases in tenascin-C, osteonectin, heparin sulphate proteoglycan 
and biglycan, with reduced aggrecan.  Corps and co-workers (2006) showed upregulation of 
aggrecan and biglycan in painful, intact tendon, but within 48 hours of tendon rupture, report 
reduction in decorin, with aggrecan, biglycan and versican expression to levels equivalent to control 
tissue. Chronically painful and ruptured Achilles also express distinctly different metalloproteinase 
and TIMP profiles, indicating unique proteolytic environments between the two disease states 
(Jones et al 2006). 
In addition to variations due to differences in chronicity and severity of disease, inconsistencies may 
be due to differences in analysis techniques, specific tendon studied, age and gender of patient. 
Control tissue may be taken from an unaffected region of the same tendon, one closely anatomically 
located, or a distant and functionally unrelated one. Robust peripheral clock properties are exhibited 
by both positional and elastic tendon in vivo and primary tenocytes in vitro (Yeung et al 2014), 




1.2.2 Mechanical influences on tendinopathies 
In the horse, weight distribution is unequal between thoracic and pelvic limbs with approximately 
60% of body weight borne by the forelimbs at rest. During locomotion, the SDFT is loaded early in 
the stance phase, undergoing significant extension and recoil during the stride cycle. The adjacent 
DDFT is loaded later in the stance phase of locomotion and subjected to lower peak forces (Platt et 
al 1994). During galloping or jumping effort, the forces that these tendons are subjected to are 
amplified significantly. Muscles of both tendons are similar in architecture, being multipennate with 
short fibre lengths but muscle fibre types differ. Both muscles are classified as digital flexors but due 
to fibre length and orientation show limited capacity to shorten, their functionality being more 
attuned to maximising the efficiency of energy return from passive loading of the musculotendinous 
unit and damping high frequency vibrations associated with locomotion (Wilson et al 2001). The 
tendinous component promotes postural stability and potential energy absorption during 
locomotion (Zarucco et al 2004). The DDF consists of a greater proportion of fast MHC-2A and MHC-
2X fibres MHC isoforms, with slow MHC1 oxidative types predominating in the SDF (Butcher et al 
2007). This has been one reason proposed as contributing to the predisposition of SDFT lesions, in 
that the faster DDF fibres fatigue more easily, placing greater reliance for metacarpo-phalangeal 
joint support on the SDFT which ordinarily operates close to its failure limit  during exercise (Butcher 
et al 2007). The Achilles tendon performs an analogous function in man. It is the largest and 
strongest tendon in the human body and a compound tendon of the gastrocnemius and soleus 
muscles, each contributing approximately equally (Cummins et al 1946). Additionally, forces are not 
distributed uniformly over the cross-sectional area, due to different contributions from the 
gastrocnemius and soleus muscles, generating significant shear forces within the tendon (Arndt et al 
1998). Slow oxidative (Type I) muscle fibres predominate in soleus (80-90%), whilst gastrocnemius 
has a more even split between Type I and II fibres (Johnson et al 1973), producing differences in 
fatigue resistance and force generating capacities in the muscular components of the unit. In 
addition, anatomical malalignment (typically hyperpronation of the foot) is stated as contributing to 
60% of disorders due to oblique loading.   
Of the four musculotendinous units comprising the rotator cuff complex of the shoulder, the SSP is 
the most commonly injured component (Matuszewski et al 2012). Due to its anatomical location, it 
is subject to compression, shear and torsion in addition to tensile loading. Whilst tensional forces are 
largely resisted by the fibrillar collagens, the non-collagenous matrix is principally responsible for 
modulating shearing and compressive forces (Screen et al 2015). 
Strains of 16.6% have been recorded in vivo in SDFT in galloping horses (Stephens et al 1989) and 
8.3% in human Achilles tendon (Lichtwark and Wilson 2005). These are similar to the in vitro failure 
strains of 12.5-17.3% reported for SDFT (Dowling and Dart 2005) and 9.9% for Achilles tendon (Wren 
et al 2001), indicating that these tendons operate with little or no safety margin. 
Whilst an acute traumatic event may account for a proportion of tendon injuries, the majority of 
clinical tendinopathy is understood to be the culmination of preceding, asymptomatic matrix 
degeneration. Several mechanisms have been proposed as contributors to tendon disease, with 
histological changes having been classified as hypoxic degeneration, hyaline degeneration, lipoid 
degeneration, mucoid degeneration, fibrinoid degeneration, calcification and fibrocartilaginous or 
osseous metaplasia (Paavola et al 2002). These can occur independently or concurrently, often with 
evidence of neovascularisation, but can also be found in up to 30% of Achilles tendons from a 
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healthy asymptomatic population (Paavola et al 2002). Overuse activity has been implicated in a 
number of tendinopathies, typically from monotonous, asymmetric and excessive duration and 
intensity of exercise (Paavola et al 2002). Although the mechanism is not clear it is likely as a result 
of microtrauma to the matrix. Animal models of repetitive exercise have supported this, with 
increased tendon vascularity, cellularity and disruption of collagen fibre integrity described 
(Backman et al 1990, Barbe et al 2003, Soslowsky et al 2000). Exercise per se does not negatively 
influence tendon integrity and has been shown to result in no (Huang et al 2004, Birch et al 2008b), 
or beneficial (Heinemeier et al 2012) effect on tendon properties.  
A 24 hour period of physiologically relevant cyclical loading (5% strain at 1 Hz) reduced ultimate 
tensile strength of fresh equine SDFT explants by approximately 40% compared to unloaded controls 
(Dudhia et al 2007). These changes were attributed to concurrent upregulation of MMP2 and  
MMP9, although increase in expression was not shown to be different between age groups (Dudhia 
et al 2007). The regional transition to a greater proportion of smaller diameter fibrils seen with 
mechanical loading in equine SDFT is consistent with reducing tensile strength, thus lowering failure 
strain (Patterson-Kane et al 1997a). This is supported by data comparing fibril size between ruptured 
Achilles tendons and age and sex matched controls, where site-specific loss of larger diameter fibrils 
at the rupture site was identified (Magnusson et al 2002). Interestingly, these patients reported 
rupture was not associated with excessive force generation and absence of pre-existing symptoms.  
This suggests significant structural changes can occur without clinical symptoms of tendinopathy 
(Magnusson et al 2002). 
 
1.2.3 Inflammation in tendinopathy 
There is ongoing debate and conflicting evidence about the role of inflammation in tendinopathies 
(Riley 2008, Millar et al 2010, Chisari et al 2019).  In a heterogenous population in terms of age, sex, 
affected tendon and duration of disease, Jelinsky and co-workers (2011) detected statistically 
significant upregulation of several cytokines and cytokine-related molecules. However, magnitude of 
change rarely exceeded the 1.5 fold change predetermined by the authors as necessary to be 
considered differentially expressed, concluding no evidence for direct regulation of pro-
inflammatory cytokines. Inflammatory cytokines are frequently not detected in chronic Achilles 
disease (Alfredson et al 2003).  
Millar and colleagues (2009) identified significant upregulation of 14 inflammation associated genes 
in a rat model of overuse supraspinatus tendinopathy. Five of these up regulated genes (IL18, IL15, 
IL6, MIF and TNFα) were also found to be overexpressed in torn human supraspinatus tendon (Millar 
et al 2009). In grossly normal subscapularis tendon with histological evidence of moderate to 
advanced tendinopathy, macrophage, mast cell and T-cell infiltration was significantly higher than in 
torn supraspinatus tendon harvested from the same joint (Millar et al 2010).  
Cyclic loading of fresh SDFT fascicles, designed to initiate overuse damage, increased COX2, MMP13 
and IL6 expression, demonstrating an immediate inflammatory response (Thorpe et al 2015b). Cell 
morphology also altered significantly in loaded samples, with cells becoming rounder, particularly in 
areas where fibre damage was evident. Similar results are reported in bovine DDFT (Spiesz et al 
2015). In naturally occurring equine SDFT tendinopathy, Dakin and co-workers (2012) identified a 
significant increase in macrophages in the sub-acute phase of injury (3-6 weeks post-injury), with 
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pro-inflammatory macrophage populations predominating. This changed to predominantly anti-
inflammatory phenotype in chronic disease (>3 month post-injury) (Dakin et al 2012). 
These data support a role for inflammation in early tendinopathy, which resolves as disease 
progresses. 
 
1.2.4 Neural influences in tendinopathy 
Tendon is sparsely innervated, but sensory, nociceptive and autonomic nerve fibres have been 
identified, often in association with blood vessels. Acetylcholine, alpha-adrenergic and muscarinic 
receptors are also present in tendon-associated vasculature (Scott and Bahr 2009). Sparse sensory 
innervation may explain why tendinopathic changes identified ultrasonographically or with MRI are 
clinically asymptomatic. Microvasculature proliferation and sprouting of free nerve endings have 
been reported in tendinopathy, often in close approximation. Neuroma formation has been reported 
in both patellar and Achilles tendinopathy. In-growing nerve endings principally express CGRP and 
substance P, both of which are potent vasodilators, mediate nociceptive signalling (Scott and Bahr 
2009) and stimulate production of pro-inflammatory cytokines IL1β, IL6 and TNFα (Hernanz et al 
2003). Substance P also stimulates cell growth, proliferation and angiogenesis. This cascade of 
events is termed ‘neurogenic inflammation’. Upregulation of glutamate signalling also occurs in 
degenerate rat supraspinatus tendon. Glutamate is a potent nociceptive neurotransmitter and 
vasodilator and can initiate apoptosis (Molloy et al 2006). Neuropeptides may therefore modulate 
important aspects of tendinopathy including pain, vascular hypertrophy and tissue remodelling 
(Scott and Bahr 2009). 
 
1.2.5 Vascular influences on tendinopathy 
Tendon is a relatively poorly vascularised tissue and oxygen uptake by human Achilles tendon is 
approximately one sixth that of the gastrocnemius muscle at rest (Kubo et al 2008). There are three 
routes of vascularisation, the myotendinous and osteotendinous junctions and through paratenon or 
synovial structures, the importance of each system varying between tendons. During exercise, both 
tendon oxygen consumption and blood flow increase significantly, maintaining tissue oxygen 
saturation (Kubo et al 2008). On cessation of exercise, oxygen uptake returns rapidly resting values 
whilst blood flow remains higher for longer, generating a relative hyperaemia and producing higher 
saturation values in recovery. However, blood flow decreases with age and, focally, under 
mechanical loading. This is particularly compromised at sites of torsion, friction and compression 
(Sharma and Maffulli 2005). Eighty percent of Achilles ruptures occur in the region 3-6 cm proximal 
to the calcaneal insertion, the point at which the gastrocnemius and soleus tendons have merged, 
the tendon is narrowest, and is least vascular (Hess 2010). Correspondingly, the most frequently 
injured mid metacarpal region of the SDFT is also the least vascular region (Kraus-Hansen et al 1992) 
with the smallest CSA (Smith et al 1994). The region of the posterior tibial tendon (PTT) most 
affected by degenerate changes and rupture coincides with a zone of hypovascularity just distal to 
the medial malleolus (Frey et al 1990). These similarities between regional hypovascularity and 
common injury sites suggest hypoxia may contribute to tendon degeneration. Apoptosis increases in 
primary human tenocytes exposed to a hypoxic environment, with significantly increased expression 
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of BCL1, HIF1α, clusterin, caspases 3 and 7 and HSP70. Hypoxic culture also elevated IL6 and IL8 
levels, indicating the potential for initiating leucocyte recruitment, and dysregulated collagen 
production, upregulating collagen IIIA and reducing collagen IA (Millar et al 2012). The capacity for 
hypoxia to initiate and regulate tendinopathy by influencing inflammation, apoptosis and collagen 
synthesis is supported by clinical evidence. In early stage subscapularis tendinopathy, upregulation 
of HIF1α, BCL2 and clusterin is accompanied by elevated inflammatory cell infiltration, with 
increased collagen III expression in torn supraspinatus tendon in the same joints (Millar et al 2012). 
Progressive increases in HIF1α expression are shown to correlate with extent of apoptosis and 
severity of rotator cuff injury (Benson et al 2010). 
Relative paucity of blood flow also reduces efficiency of heat dissipation. A mean core SDFT 
temperature of 43.3oC was recorded during 5 minutes of galloping exercise, the highest registered 
temperature being 45.4oC (Wilson and Goodship 1994). These authors suggest this is unlikely to be 
sufficient to damage the ECM, but exceeds the threshold of 42.5oC for fibroblast viability. 
Mathematical modelling suggests similar core temperatures are possible in Achilles tendon during 
running (Wilson and Goodship 1994). Upregulation of heat shock proteins (HSP27 and HSP70) are 
reported by Millar and co-workers (2009) in a rat model of supraspinatus overuse.   
 
1.2.6 Endocrine influences on tendinopathy 
Tendinopathies are known to occur more frequently in diabetic patients (Oliva et al 2016). Blood 
glucose is normally tightly regulated between 4-7 mM, but in diabetics can rise much higher. The 
ability of primary human tenocytes to withstand conditions of oxidative stress in vitro is significantly 
compromised under conditions mimicking hyperglycaemia (Poulsen et al 2014). These authors also 
show that oxidative stress under normoglycaemic conditions results in significant upregulation of 
COL1A1 and COL1A2 mRNA. This suggests that oxidative stress, lethal to cells exposed to elevated 
glucose concentrations, is anabolic under conditions mimicking normoglycaemia. Expression of 
HIF1α is significantly reduced at glucose concentrations above 6 mM, whilst expression of FOXO1 
dramatically increases at higher glucose concentrations. The switch from HIF1α dominance 
(prodifferentiation via upregulation of SOX9 and scleraxis) to FOXO1 dominance (proapoptosis) 
corresponds to the upper level of normoglycaemia (Poulsen et al 2014). Chronically high glucose also 
increases expression of MMP9 and MMP13 and impairs angiogenesis (Oliva et al 2016).  
There is some evidence of a sex predisposition with certain tendinopathies. Posterior tibial tendon 
dysfunction is three times more common in women than men. Average age at presentation is 
approximately 40 years and incidence increases with age. Other risk factors, however, include 
obesity, hypertension, treatment with corticosteroids (either local injection or oral intake) and 
diabetes mellitus (Holmes and Mann 1992). Tendon collagen synthesis in women varies with 
menstrual cycle, is affected by oral contraceptives, and increases in post-menopausal women 
(Magnusson et al 2007). Incidence of Achilles tendon injury is up to 12 times higher in men than 
women, commonly affecting men in the fourth to fifth decade of life (Hess 2010). This however has 
been linked to participation in recreational and competitive sport, rather than directly with male 
gender.  
Triiodothyronine and thyroxine are known to affect collagen synthesis and crosslinking (Oliva et al 
2016). Clinically, hypothyroidism is associated with tendon calcification, the mechanism postulated 
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to be increased hypoxaemia-induced apoptosis secondary to perturbed vascularisation (Oliva et al 
2016). 
 
1.2.7 Other factors implicated in tendinopathies 
A genetic predisposition for developing rotator cuff tears (Harvie et al 2004), Achilles tendinopathy 
(Abrahams et al 2013) and SDFT injury (Tully et al 2014) has been proposed. The latter two 
conditions have been associated with sequence variants in both the  3’UTR of the COL5A1 gene and 
polymorphisms in the tenascin C gene (Mokone et al 2005, Tully et al 2014). Although type V 
collagen is a minor component of tendon, it interacts with types I and III and plays an important role 
in fibril assembly and lateral growth (Birk 2001). The 3’UTR of COL5A1 contains binding sites for miR-
608 and a polymorphic form of this miRNA is also reported, which may also impact on collagen 
expression (Abrahams et al 2013).  
Fluoroquinolone antimicrobials have also been implicated in architectural modification of tendon, by 
decreasing transcription of decorin, weakening the biomechanical properties (Bernard-Beaubois et 
al 1998). 
Corticosteroid administration is a recognised, although controversial, therapeutic option in 
tendinopathy. Whilst beneficial in the short term, intermediate to long term outcomes show a 
reduction in mechanical properties and predisposition to re-injury, with atrophy of Achilles and 
patellar tendons reported (Hart 2011). Systemic corticosteroid administration, or treatment of 
adjacent synovial structures, has also been implicated as a risk factor in developing tendinopathies 
(Pomeroy et al 1999). 
 
1.2.8 Mechanisms of tendon repair 
Tenocytes are capable of maintaining and orchestrating beneficial adaptive changes to tendon 
matrix, despite the apparently lower metabolic activity in those tendons more at risk of injury. 
However, following matrix damage, reparative mechanisms are inadequate, with increased 
proteolytic activity, altered tenocyte differentiation pattern to a more fibrochondrogenic phenotype, 
with altered collagen type deposition. Consequently, there is a high risk of re-injury following an 
episode of tendinopathy. Approximately 43% re-injury rate is reported for SDFT tendinopathy (Dyson 
2004, Reardon et al 2012, Reardon et al 2013) and up to 30% for Achilles tendon (Gajhede-Knudsen 
et al 2013).  
Tendon healing has been classified as occurring in three overlapping phases (Sharma and Maffulli 
2005). 
 Inflammatory phase – inflammatory cell infiltration occurs with phagocytosis of necrotic 
material.  Angiogenesis is triggered, and epitenon and endotenon tenocyte proliferation is 
stimulated. Tenocytes migrate to area of tissue damage and type III collagen synthesis 
begins.  
 Proliferative phase – synthesis of type III collagen and glycosaminoglycans peaks, increasing 
water content of damaged tissue. Neural ingrowth occurs. 
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 Remodelling phase –  
o 6-10 weeks post injury, tenocyte metabolism remains high but cellularity starts to 
decrease.  Type I collagen synthesis increases, glycosaminoglycan synthesis 
decreases. Tenocytes and collagen fibres become aligned in direction of stress.  
o 10 weeks to 1 year, maturation of fibrous tissue occurs. Tenocyte metabolism and 
vascularity decline.  
Healing due to intrinsic tenocytes produces improved biomechanics and more collagen and 
glycosaminoglycans than fibroblasts migrating in from external tissue, resulting in a better quality 
repair (Sharma and Maffulli 2005). A greater understanding of tenocyte behaviour in response to 
mechanical and chemical environmental stimuli, and an ability to manipulate this to produce a more 
effective reparative response is key to developing effective treatment strategies.  
 
 
1.3 microRNAs and tendinopathy 
The term 'epigenetics', first introduced by Waddington (1968) is defined as the 'interactions 
between genes and their products which bring phenotype into being'. This term, therefore, refers to 
alterations in gene expression by mechanisms separate to, and independent of, changes in the 
underlying DNA sequence. Epigenetics was originally considered to encompass two main 
mechanisms; methylation of cytosine bases within DNA, the pattern and extent of which can 
enhance or inhibit transcription factor binding, and modification of the histone packing proteins by 
methylation, acetylation and phosphorylation (Riasat et al 2020). However, this field has now 
expanded to encompass another system of regulation, since the discovery of microRNAs in the late 
1990s and subsequent elucidation of RNA interference mechanisms. Furthermore, it is becoming 
increasingly recognised that the non-protein coding fraction of the genome has a critical function in 
normal physiological development and function, as well as the course of many disease processes 
(Esteller 2011).  
The non-coding RNA (ncRNA) family is diverse and subdivided into long (>200 nucleotides) and short 
(<200 nucleotides) non-coding subgroups (Figure 1.3). microRNAs (miRNAs), a subclass of the small 
non-coding RNA (sncRNA) group are the most extensively studied.  As key players in the RNA 
interference (RNAi) pathway, miRNAs act as regulators of gene expression, many being highly 
conserved across species, indicating involvement in critical cellular processes (Bartel 2018). 
Widespread alterations in miRNA expression have been identified in many different human 
disorders, generating interest in harnessing them as therapeutic or disease modifying agents 






Figure 1.3 RNA classification dendrogram illustrating the relationship of non-coding RNAs with 
other RNA classes and the position of microRNAs within the non-coding subgroup. mRNA = 
messenger RNA, ncRNA = non-coding RNA, tRNA = transfer RNA, rRNA = ribosomal RNA, tDR = tRNA-
derived RNA, tiRNA = 5’-tRNA stress-induced fragments, miRNA = microRNA, siRNA = small 
interfering RNA, piRNA = PIWI-interacting RNA, snRNA = small nuclear RNA, snoRNA = small 
nucleolar RNA, sdRNA = snoRNA-derived miRNA, scaRNA = small Cajal body-specific RNA, vtRNA = 
vault RNA, nt = nucleotide.  
 
1.3.1 microRNA synthesis and function 
Originally identified in 1993 in C. elegans where lin-4 and let-7 RNAs were identified as essential for 
correct temporal development through four different larval stages. miRNAs are characterised by 
their size (21-25 nucleotides) and derivation from hairpin precursors.  
There are several pathways by which mature miRNAs can be generated (Figure 1.4), but most of the 
more highly conserved and abundantly expressed are believed to derive from dedicated miRNA gene 
loci, with expression under direct RNA Polymerase II (POL II) transcriptional control. Approximately 
25-30% are processed from introns of protein coding genes, with expression therefore under the 
same regulatory control as the co-expressed gene (Chiang et al 2010, Bartel 2018). Both dedicated 
non-coding transcripts and introns of protein coding ones may contain single or multiple primary 
miRNA (pri-miRNA) sequences. The pri-miRNA, transcribed by POL II is processed in the nucleus by 
the trimeric microprocessor complex containing the RNase III enzyme Drosha in combination with 
two molecules of the RNA binding protein DGCR8. This produces a stem-loop structured precursor 
(pre-miRNA) of approximately 70 nucleotides (35 base pairs), with a two base pair offset, which is 
exported to the cytoplasm by Exportin-5/RAN-GTP (Bartel 2018). Here a second RNase III enzyme, 
Dicer I, in combination with binding protein TRBP cleaves the hairpin loop to produce the double 
stranded miRNA:miRNA* duplex.  
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The miRNA:miRNA* duplex then combines with an Argonaute (AGO) protein (in mammals typically 
either AGO-1, -3, or -4), facilitated by chaperone proteins HSC70/HSP90. Once combined with AGO, 
unwinding of the duplex occurs and either the miRNA or miRNA* strand is selected for retention into 
the functional multi-protein RNA-induced silencing complex (RISC). The alternate strand is expelled 
and subsequently degraded. Strand retention is dictated by the configuration of the 5’ (5p) terminus 
of each strand. The Argonaute binding pocket shows preferential affinity for a terminal uracil or 
adenosine and least stable 5’ terminal pairing (Bartel 2018). 
The biosynthesis of miRNAs is now known to be far more complex than the canonical pathway 
originally described, with both Drosha and Dicer independent pathways identified. Some intronic 
sequences, when processed by the spliceosome, resemble pre-miRNAs, with no, or very short, 5’ or 
3’ flanking sequences which can be removed by alternative nucleases. These structures, called 
‘mirtrons’ then enter the conventional processing pathway downstream of Drosha/DGCR8 having 
bypassed the need for this step. Additionally, some snoRNA and tRNA transcripts can contain hairpin 
structures which are processed to yield pre-miRNA substrates for Dicer activity (Stavast and Erkeland 
2019). This process is now known to be widespread and conserved (Scott and Ono 2011).  
There is also a Dicer/TRBP independent pathway, which so far has only been identified as 
responsible for production of one annotated miRNA (miR-451) (Cheloufi et al 2010). This requires 
Drosha/DGCR8 processing of the pri-miR-451 transcript, with final maturation of the pre-miR-451 
occurring in combination with Argonaute-2 (which has intrinsic endonuclease activity) and the 
exoribonuclease PARN (Krol et al 2010). 
miRNAs mediate their effects through binding principally to sites within the 3’untranslated region 
(3’UTR) of their target, with variable, but imperfect complementarity (Filipowicz et al 2008). Target 
sites are also recognised within coding regions and the 5’UTR of mRNAs, although reportedly of 
minor importance in both frequency and response effect (Bartel 2009, Filipowicz et al 2008). The 
result is either repression of mRNA transcription or translation, or enhanced enzymatic mRNA 
degradation (Selbach et al 2008, Bartel 2009). The latter mechanism is of major importance in plant 
miRNAs, where miRNA-target binding shows a far higher degree of complementarity. However, in 
mammals, only 20 gene transcripts susceptible to this mechanism have been identified to date 
(Bartel 2018). The major method in mammals is translational repression, mediated by two main 
routes, the relative importance of each being determined by the developmental stage of the 
organism (Bartel 2018). Recruitment of the adapter protein TNRC6 by Argonaute promotes 
interaction with the mRNA poly(A) tail and its associated poly(A)-binding protein, additionally 
recruiting the deadenylase complexes PAN2-PAN3 and CCR4-NOT. The subsequent shortening of the 
poly(A) tail, destabilising the mRNA. The CCR4-NOT complex additionally recruits DDX6 and 4E-T, 
which inhibit initiation of translation. This second mechanism occurs rapidly and predominates 
during embryological development, but is of minor importance in post-embryonic regulation (Bartel 
2018).   
Binding specificity and activity are both dictated by the sequence at the 5’ terminus of the miRNA, 
centred on nucleotides 2-7. This ‘seed’ sequence forms Watson-Crick pairing with the target site 
(typically) within the mRNA 3’UTR. Additional pairing between miRNA nucleotides 1 and 8 are also 
described, with 7 or 8 base pair matching necessary for effective canonical function. Activity with 
only six base pair matching frequently results in weak or undetectable efficacy (Bartel 2018). 
Additional base pairing may occur further downstream from the seed sequence. These are termed 
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supplementary sites if seed pairing is 7-8 base pairs, or compensatory if seed pairing is imperfect 
with only six matches (Bartel 2018). A single miRNA may have several binding sites within the 3’UTR 
of each mRNA (seven have been identified for lin-4 within the 3’UTR of the lin-14 gene (Wjghtman et 
al 1993)). The degree of repression is influenced by the number and proximity of seed sequences. A 
linear correlation is described between number of seed sequences and log2 fold change of down 
regulated genes, with a synergistic effect apparent if seed sequences are less than 40 nucleotides 
apart (Selbach et al 2008). Each miRNA may target multiple mRNAs, with an average target number 
of 400 proposed (Bartel 2009). A single mRNA may be influenced by multiple miRNAs, with 
expression of over 60% of human genes predicted to be regulated by miRNAs (Noren Hooten et al 
2013).  
Once incorporated into the RISC complex, miRNA half-life may extend to several days, and stability is 
often further enhanced if the RISC is associated with its target mRNA, indicating stability is target-
dependent (Krol et al 2010). 
Relatively non-specific control of miRNA production is exerted through controlling expression and 
activity of the microprocessor and Dicer/TRBP complexes. Positive feedback loops have been 
identified for let-7 miRNAs, with the mature miRNA targetting the pri-miRNA, to enhance 
processing. Let-7 also targets Dicer mRNA, triggering a more general negative feedback loop (Krol et 
al 2010). Long non-coding RNA transcripts have been identified which act as miRNA ‘sponges’, 
combining with high affinity, preventing their inhibitory effect, such as the interaction described by 
Lu and co-workers (2017) between lncH19 and miR-29b-3p. A 5’ to 3’ exonuclease XRN-2 has been 
identified which catalyses degradation of mature miRNAs, but requires the miRNA to dissociate from 






Figure 1.4 Major miRNA biosynthetic pathways.  
A-C. Canonical pathway. Single (A), or clustered (B) primary microRNAs (pri-miRNA) transcribed from 
dedicated gene loci. Pri-miRNAs co-transcribed in introns of protein coding genes (C) under control 
of the same promotor as the encoded gene, and spiced out of the encoded gene during production 
of mature mRNA. The stem of the pri-miRNA hairpin is then further processed by the 
endoribonuclease Drosha combined with the double-stranded RNA binding protein DGCR8 
(DiGeorge Syndrome Critical Region 8). The product, a shorter (~70 base pair) hairpin precursor 
miRNA (pre-miRNA) is exported to the cytoplasm by the RAN-GTP-Exportin-5 complex. A second 
endoribonuclease (Dicer) – binding protein (TRBP -transactivation response element RNA-binding 
protein) complex cuts the loop of the hairpin, producing the miRNA duplex. This is loaded into the 
Argonaute protein where strand selection occurs. The guide strand (red) is expelled, the active 
strand (blue) is retained, forming the RNA induced silencing complex (RISC). 
D. Short intergenic sequences may encode the pre-miRNA with little or no additional bases. 
Spliceosome processing generates the pre-miRNA, bypassing the requirement for Drosha/DGCR8 
activity. Downstream processing then follow the pathway outlined above. 
E. miR-451 follows a Dicer-independent pathway. Transcribed from a dedicated gene locus, pri-
miRNA-451undergoes Drosha/DGCR8 trimming, but following export to the cytoplasm, pre-miRNA-
451 combines directly with Argonaut-2, which itself performs partial cleavage. The functional RISC is 
completed by the action of RNA exonuclease poly(A)-specific ribonuclease (PARN).                      
(legend continues overleaf) 
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F. snoRNAs and tRNAs can contain integral pre-miRNA sequences which are liberated during 
processing, bypassing the requirement for Drosha/DGCR8 activity. 
 
Other regulatory mechanisms include adenosine-to-inosine editing of pri-mRNAs preventing further 
processing and polyuridylation of 3’ end of pre-miRNAs, blocking Dicer interaction and inducing 
degradation (Bartel 2018). There is evidence that mature miRNAs are generally more stable than 
mRNA transcripts, this stability being enhanced by 3’ adenylation or methylation indicating sequence 
configuration at the 3’ end is important in degradation of miRNAs (Krol et al 2010). This is supported 
by the phenomenon of target-RNA-directed miRNA degradation (TDMD), where highly 
complementary miRNA-target binding induces miRNA degradation initiated from the 3’ end. This 
appears to be of particular importance for rapid decay of neuronal miRNAs (de la Mata et al 2015). 
As well as acting in an intracrine fashion, miRNAs can exert a more widespread effect, being secreted 
into the circulation as part of a miRNA binding protein or high-density lipoprotein complex, or as 
part of the microvesicle/exosome cargo (Jung and Suh 2014). 
  
1.3.2 Role of microRNAs in tendinopathies/musculoskeletal disease 
The recognition of the widespread influence of miRNAs in physiological and pathological processes 
has resulted in an extensive body of research in this area, despite their relatively recent discovery. 
Tendinopathies are relatively under researched compared to arthroses and myopathies, and their 
pathogenesis is incompletely understood. Many of the factors believed to be implicated in tendon 
pathology have been shown to be influenced by miRNAs, but there are limited studies specifically 
investigating their role. Table 1.3 lists those studies identified which specifically link miRNA 
expression to tendon.  
Multiple metabolic alterations occur during the normal physiological ageing process, including stem 
cell exhaustion, cellular senescence, mitochondrial dysfunction, deregulated nutrient sensing, pro-
inflammatory state and loss of proteostasis (López-Otín et al 2013). miRNAs have been implicated in 
regulation of all these via their reported interactions with insulin signalling, AMPK/Sirtuin pathway, 
mTOR signalling, TLR-NFκB-MAPK pathway and HIF1α signalling (Victoria et al 2017). A subset of 
miRNAs (miR-1/206 and miR-133 families) have been shown to be critical in myoblast proliferation 
and myocyte differentiation (Goljanek-Whysall et al 2012) and differential expression of miRNAs has 
been identified in muscle ageing (Soriano-Arroquia et al 2016), sarcopaenia (Brown and Goljanek-
Whysall 2015) and disease (Goljanek-Whysall et al 2012). Embryonic development of functional 
myotendinous junction is known to be dependent on a critical dystroglycan expression gradient 
controlled my miR-9a in Drosophila (Yatsenko et al 2014). 
Tendon stem/progenitor cell (TSPC) senescence has been reported to be associated with miR-140-5p 
upregulation inhibiting Pin1 (Chen et al 2015a). Down regulation of miR-135a with ageing promotes 
senescence in TSPCs by derepressing ROCK1 expression (Chen et al 2015b). The capacity of TSPCs to 
differentiate into functional tenocytes decreases with age due to upregulation of miR-217 inhibiting 
EGR1 expression (Han et al 2017). A similar inhibitory effect on TDSCs via EGR1 has also been 
identified for miR-124-3p with a subsequent suppression of collagen type 1, fibromodulin and 
tenascin C expression (Wang et al 2016). 
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In human Achilles tendon, downregulation of miR-1245a (a driver of cellular proliferation) with age is 
reported by Peffers and co-workers (2015), whilst Pease and colleagues (2017) identified differential 
expression of an additional 26 microRNAs with ageing, although direction of change was not stated. 
Four of these (miR-1287, miR-1304, miR-1909, miR-3614) were common to both male and female-
derived tissue and are linked with cellular proliferation. 
Noren Hooten and co-workers (2013) identified significant reduction in miR-151a-3p, miR-181a-5p 
and miR-1248 in the serum of older people. These microRNAs have been shown to target pro-
inflammatory cytokines IL6, IL8 (miR-1248, miR-181a-5p), IL1α, IL1β, TNFα and FGF2 (miR-181a-5p) 
and anti-inflammatory IL10 and TGFβ (miR-181a-5p). Olivieri and colleagues (2012) identified 
overexpression of miR-21 in an aged population. This microRNA targets TGFβR1 and TGFβR2 
subunits, downregulating this anti-inflammatory signalling pathway. Direct secretion of IL6 and TNFα 
via the NFκB pathway can also be triggered by miR-21 acting as a ligand at TLRs (Fabbri 2012). 
Downregulation of IRAK expression has also been reported, exerting an anti-inflammatory action 
(Olivieri et al 2013). The recognition of miR-155, miR-21 and miR-146 as critical regulators of 
inflammation has led to them being termed ‘inflamma-miRs’.The consequence is that ageing 
predisposes to a more inflammatory phenotype. This may suggest that age-related changes in 
tendon may be an integral part of body-wide ageing processes (Xu and Tahara 2013).  
Although computational analysis has identified miRNA target sites in some cytokines (IL1α, IL6, IL10, 
IL11, IL12B, IL13, IL16, IL23, IL25), an additional, indirect regulatory mechanism has been proposed 
(Asirvatham et al 2009). AU-rich elements within the 3’UTR of cytokine transcripts regulate 
transcript stability by association with AU-rich element binding proteins (ARE-BP) which either 
promote or retard transcript stability. ARE-BPs involved in the decay pathway are a richer source of 
predicted miRNA targets, although few have been functionally confirmed (Asirvatham et al 2009). 
Chronic inflammation can lead to fibrosis, and both pro- (miR-21, miR-199a-5p, miR-199b) and anti- 
(miR-29a, b, c) fibrotic miRNAs have been identified, affecting multiple tissue types (O’Reilly 2016). 
miR-29 has been described as a master regulator of fibrosis, with decreased expression associated 
with fibrosis in multiple organs (O’Reilly 2016). miR-29a has been shown to regulate collagen 
expression both directly (Millar et al 2015, Lu et al 2017, Watts et al 2017) and indirectly by 
influencing the TGFβ signalling pathway (Chen et al 2014, Ciechomska et al 2014, Lu et al 2017), 
increasing MMP1 activity  by inhibiting TIMP1.  
Using microarray analysis, extensive changes in microRNA expression patterns associated with 
Collagens type I and III, MMP9, MMP2, JAK2/STAT3 signalling pathway, inflammation and energy 
homeostasis have been identified in both intact and torn tendon in the inflammatory environment 
of an arthritic joint (Thankam et al 2016, 2018, 2019). Type V collagen is a minor component of 
tendon, but an important stabiliser of fibril structure. miR-608 targets COL5A1 and a SNP at 
rs4919510 within the MIR608 gene is significantly associated with Achilles tendinopathy (Abrahams 
et al 2013).  
Acute exercise alters miRNA expression in rat Achilles tendon (Mendias et al 2012). A single 30 
minute exercise session resulted in upregulation of six (miR-378, miR-1, miR-133a, miR-133a*, miR-
133b, miR-206) and down regulation of seven (miR-100, miR-140, miR-let-7a, miR-let-7e, miR-338, 
miR-381, miR-743a) miRNAs. These miRNAs are associated with cell proliferation and ECM synthesis 
(miR-378 miR-100), skeletal muscle adaptation (miR-1, miR-133a, miR-133a*, miR-133b, miR-206), 
chondrogenesis and neovascularisation (miR-140). miR-338 and  miR-381 were predicted to target 
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scleraxis, and decreased expression of these corresponded with increased scleraxis expression 
(Mendias et al 2012).  
Inhibition of miR-100 and increased miR-378 are associated with increased cell proliferation and 
angiogenesis. Decreases in miR-let-7a and 7e are consistent with previous reports of an inverse 
relationship between let-7 expression and cell proliferation. Up regulation of miR-1, miR-133a, (miR-
133a*), miR-133b and miR-206 is consistent with expression profiles seen in striated muscle in 
response to mechanical loading and ischaemia (Mendias et al 2012). 
Hypoxic insult has been implicated in the pathogenesis of tendinopathies (Benson et al 2010, Millar 
et al 2012) and upregulation of multiple miRNAs following exposure to a hypoxic culture 
environment has been demonstrated in a variety of cell types (Kulshreshtha et al 2007). Rapid 
reduction in miR-199a levels, in response to hypoxia derepresses its direct target HIF1α.  A major 
regulator of altered gene expression in hypoxia, HIF1α directly upregulates miR-181 and miR-210 
expression and promotes p53-mediated cell cycle arrest or apoptosis (Kulshreshtha et al 2007, Rane 
et al 2009). Downregulation of anti-fibrotic miR-29b has also been reported under hypoxia (Ivan et al 
2008).  
Hypoxia, mechanical loading, inflammation, and genetic predisposition can all potentially enhance 
apoptotic tenocyte death (Scott et al 2005, Nell et al 2012, Millar et al 2009, Benson et al 2010). 
Apoptosis has been identified as important both as a cause (Yuan et al 2002) of tendinopathy and as 
part of the tissue repair process (Lui et al 2007) and is closely linked with the autophagy and necrosis 
pathways (Xu et al 2012).  
Both intrinsic and extrinsic apoptotic pathways have been shown to be regulated by microRNAs, and 
apoptotic and autophagic pathways are influenced by common miRNAs. Increased apoptotic activity 
in tendinopathy may therefore impact on autophagic and necroptosis pathways. Autophagy is a 
highly conserved eukaryotic cellular recycling process critical to cell survival and maintenance. Three 
types of autophagy are described in mammalian cells, macro-, micro- and chaperone-mediated 
autophagy. Chaperone-mediated autophagy is highly specific, restricted to proteins containing a 
particular pentapeptide motif, common to approximately 30% of cytosolic proteins (Parzych and 
Klionsky 2014).  This motif is recognised by several chaperone proteins which unfold the targeted 
protein and translocate it directly across the lysosomal membrane for degradation. In contrast, 
micro- and macroautophagy can be either selective or non-selective.  Microautophagy involves 
direct uptake of cytoplasmic contents into the lysosome by invaginations of the lysosomal 
membrane, whilst macroautophagy involves de novo formation of a double-membrane phagophore 
which progressively engulfs the cargo to form an autophagosome, which subsequently fuses with a 
lysosome, forming an autolysosome, leading to degradation of the sequestered cargo by acidic 
hydrolases. Macroautophagy occurs constitutively at low levels, but is up regulated under conditions 
of cellular stress (Parzych and Klionsky 2014). Bulk (non-selective) autophagy is used for bulk 
turnover of cytoplasm under conditions starvation, whilst selective autophagy specifically targets 
damaged or superfluous organelles and invasive microbes. Reactive oxygen species (ROS) produced 
as by-product of oxidative phosphorylation induce oxidative damage to mitochondria resulting in 
increased ROS production and ultimately release of cytochrome c and cellular injury (Song et al 
2018). Mitochondrial quality is controlled by several mechanisms, proteolytic degradation of 
damaged proteins, cycles of mitochondrial fission and fusion and elimination of dysfunctional 
mitochondria by a selective form of macro-autophagy termed mitophagy (Narendra et al 2010). 
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Mitophagy can occur through several mechanisms; Type 1, 2 and 3 are described (Lemasters 2014), 
and pathways are classified as ubiquitin-dependent or -independent (Palikaras et al 2018). Several 
miRNAs (miR-155, miR-101, miR-204 and miR-224) are known to regulate autophagy (Szekerczés et 
al 2020), and down regulation of miR-181a with ageing in skeletal muscle disrupts mitophagy, 
resulting in accumulation of autophagy-related proteins and abnormal mitochondria (Goljanek-





Author Gene identity Organism Tendon type Age-related findings 
Peffers et al 
2015 
miR-1245a Human Achilles 
tendon 
Reduced expression with ageing. 
Peffers et al 
2016 
miR-500a-5p, miR-
548j-5p, miR-618,  
miR-10 




miR-500, miR-548 and miR-618 showed 
increased expression with ageing. 
miR-10 methylation significantly increased 
with ageing. 
Pease et al 
2017 
26 miRs  Human Achilles 
tendon 
26 DE miRs identified in old v young female-
derived tissue, 4 of which (miR-1287, miR-
1304, miR-1909, miR-3614) also DE in old 
versus young male-derived tissue. Direction 
of change not stated. 
Han et al 
2017 
miR-217 Human Achilles 
tendon 
Tenogenic differentiation capacity of TSPCs 
decreases with age due to p16 induced 
upregulation of miR-217 resulting in reduced 
EGR1 expression. 
Chen et al 
2015a 
miR-140-5p Human Achilles 
tendon 
miR-140-5p associated with TSPC senescence 
via direct inhibition of Pin1 expression. 
Chen et al 
2015b 
miR-135a Rat Achilles 
tendon 
Down regulation of miR-135a with ageing 
promotes senescence in TSPCs via interaction 
with ROCK1. 






Equine SDFT miR-34b miR-181b up regulated with age  
miR-29a, miR-34a, miR-199a, miR-199b down 
regulated with age. 
Author Gene identity Organism Tendon type Mechanical loading related findings 











the let-7 cluster 
and microRNAs 
predicted to bind 












miR-378, miR-1, miR-133a, miR-133a*, miR-
133b, miR-206 up regulated in response to 
30 minutes exercise.  
 
miR-100, miR-140, miR-let-7a, miR-let-7e, 
miR-338, miR-381, miR-743a down regulated 
with exercise. 
 
miR-21, miR-221, miR-222, miR-1, miR-133a, 
miR-133a*, miR-133b, miR-29a, miR-29b, 
miR-29c, miR-140 up regulated after TGFβ 
challenge. 
 
miR-205, miR-338, miR-381,  miR-let-7a, miR-
let-7b, miR-let-7e down regulated after TGFβ 
challenge. 
Table 1.3 continues overleaf 
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Author Gene identity Organism Tendon type Pathology related findings 
Yatsenko  
et al 2014 
miR-9a Drosophila Myotendinous 
junction 
miR-9a controls dystroglycan expression to 
establish critical gradient required to 
establish functional myotendinous junction. 
Millar et al 
2015 












IL-33 upregulation in early tendinopathy 
suppresses miR-29a, promoting COL3A1 
expression. Application of exogenous miR-
29a directly targets and inhibits COL3A1, but 
not type I collagens due to alternative 
polyadenylation sites in type I transcripts. 
 
Watts et al 
2017 
miR-29a Equine SDFT Application of exogenous miR-29a to 
collagenase-induced SDFT lesions 
significantly reduced COL3A1 expression 2 
weeks post-treatment, without affecting that 
of COL1A1, reduced lesion size at 6, 12 and 
16 weeks post-injury and improved 
histological score at 2 and 16 weeks. 
Chen et al 
2014 
miR-29b Rat  Digital flexor 
tendon 
Chitosan promotes miR-29b and P21 
expression and inhibits fibroblast growth, 
TGFβ-1 and Smad3.     
Lu et al 2017 miR-29b-3p Human 
 
Mouse 






miR-29b-3p directly targets lncRNA H19, 
TGFβ-1 and COL1A1, suppressing tenogenic 
differentiation and tendon repair. 
Usman et al 
2015 
miR-210 Rat Achilles 
tendon 
Application of exogenous miR-210 following 
surgical transection accelerated 
improvements in ultimate tensile strength 
and capillary density. Increased expression of 
Col1a1 with larger fibre diameter and 
improved histological appearance of repair.  
Wang et al 
2016 
miR-124-3p Human Hamstring 
tendon 
miR-124-3p directly targets EGR1 reducing 
tenogenic differentiation of TDSCs and 
suppressing collagen 1, fibromodulin and 
tenascin C expression.  
Laguette  
et al 2011 
miR-608 Human  DNA derived 
from blood 
samples 
Functional binding site for miR-608 identified 
in 3’-UTR of COL5A1 gene. 
 
Abrahams  
et al 2013 
miR-608 Human  DNA derived 
from blood 
samples 
SNP in miR-608 associated with development 
of chronic Achilles tendinopathy. 
Table 1.3 continues overleaf 
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Author Gene identity Organism Tendon type Pathology related findings (cont.) 






Equine  SDFT miR-29a, miR-181b, miR-199a, miR-199b  
down regulated with disease. 
 
mir-34a, miR-34b up regulated with disease. 
Thankam  






Human  Biceps tendon miRs associated with COL1A2, COL3A1, 
MMP9, MMP2 highly significantly altered in 
intact tendon in an inflammatory 
environment (glenohumeral arthritis).  
 
miR-498 up regulated, all others down 
regulated. 
Thankam  




Human Rotator cuff 196 miRs down regulated  (≥ -3FC) 
34 miRs up regulated (≥ +2FC) in RCTI, with 
extensive associations with JAK2/STAT3 
pathway and inflammation. 
Thankam  
et al 2019 
13 miRNAs 




AMPK  and TREM-
1 pathways 
Human Rotator cuff miR-145-5p, miR-991-5p, miR-100-5p, miR-
150-5p, miR-193b-3p, miR-103a-3p, miR-31-
5p, miR-195-5p, miR-497-5p, miR-15a-5p, 
miR-16-5p, miR-let-7b-5p down regulated in 
RCTI. 
 




Table 1.3 (includes preceding two pages) microRNAs identified as significant in tendon ageing and 
disease. MSC = mesenchymal stem cells; TSPC = tendon stem progenitor cells; DE = differentially 
expressed; EGR1 = early growth response 1; PIN1 = Peptidyl-prolyl cis-trans isomerase NIMA-
interacting 1; ROCK1 = rho associated coiled-coil containing protein kinase 1; ECM = extracellular 
matrix; SDFT= superficial digital flexor tendon; UTR = untranslated region; lncRNA = long non-coding 
RNA; TDSC = tendon derived stem cells; SNP = single nucleotide polymorphism; AMPK = AMP-
activated protein kinase; TREM-1 = triggering receptors expressed on myeloid cells-1; RCTI = rotator 










1.3.3 Diagnostic, prognostic and therapeutic potential of microRNAs  
The recognition of microRNAs as key regulators of gene expression, their involvement in critical 
cellular process and identification of detectable changes with a range of disease processes renders 
them potentially useful for diagnostic, prognostic and therapeutic purposes.  
The clinical trials.gov database lists 398 clinical studies (searched 28/03/2020), including phase 4 
trials, investigating microRNAs as biomarkers for the diagnosis and prognosis of multiple diseases 
and monitoring response to treatment. Currently only phase 1 and 2 clinical trials investigating 
therapeutic potential are registered. These are exploring miR-16 and miR-29 mimics and miR-21, 
miR-92, miR-122 and miR-155 antagomiRs as treatments for a variety of indications including 
hepatitis c virus, wound healing, T-cell lymphoma and mesothelioma (Hanna et al 2019). Given the 
pleiotropic capability of microRNAs, significant potential for off-target effects may limit their 
potential as therapeutic agents. Indeed, phase 1 and phase 2 trials of miR-34 mimic for treatment of 
solid tumours were terminated due to severe adverse immune responses (Rupaimoole and Slack 
2017). RNA therapeutics have however reached the stage of clinical approval. Patisiran (Onpattro®) 
is a small-interfering RNA targeting transthyretin production by the liver. This received FDA approval 
in 2018 and has a marketing authorisation in the UK for treating hereditary transthyretin 
amyloidosis. Nusinersen (Spinraza®) was approved by the European Medicines Agency in May 2017 
for treatment of the genetic disease spinal muscular atrophy. This synthetic antisense 
oligonucleotide compensates for the loss of function mutation in the survival motor neuron (SMN) 1 
gene by modulating alternative splicing of the SMN 2 gene product, producing a transcript identical 
to that of a functional SMN1 gene. 
RNA-based therapies have been explored to a small degree in tendon healing. Synthetic 
oligonucleotides targeting the TGFβ1 gene reduced adhesion formation after digital flexor tenotomy 
in chickens, but also reduced ultimate tensile strength (Wu et al 2016). Following surgical 
transection of Achilles tendon in rats, exogenous miR-210 accelerated neovascularisation and 
improved tensile strength during early healing. Although these differences were only detectable two 
weeks post-injury, improved histological appearance and increased collagen fibre diameter were 
evident at 6 weeks (Usman et al 2015).  Intra-articular injection of miR-210 also improved meniscal 
healing in rats following surgically induced injury (Kawanishi et al 2014). Intralesional injection of 
miR-29a one week after collagenase induced SDF tendinopathy in horses resulted in significant 
reduction in COL3A1 two weeks post-treatment without affecting type 1 collagen, reduced lesion 
size and improved histological scores (Watts et al 2017). Although these results should be 
interpreted with caution as the models do not mimic naturally occurring tendinopathy in their 
pathogenesis, they demonstrate the potential for this technology to have a positive impact on a 





1.4 Aims and objectives of project 
The aims of this project were: 
1) To characterise expression profiles of sncRNAs in human elastic energy storing tendon, using 
an unbiased technique (RNA-sequencing) in samples obtained from patients with naturally 
occurring tendinopathy and healthy control tendon, with the objective of identifying how, 
and to what extent, sncRNAs are differentially expressed between healthy and diseased 
states (Chapter 3). 
 
2) To perform a targeted validation of RNA-seq results using RT-qPCR, focussing on a selected 
panel of 11 miRNAs known, or predicted, to be implicated in processes pertinent to 
tendinopathy (fibrosis, matrix degradation, inflammation, oxidative stress, cellular 
differentiation and apoptosis; Chapter 3). 
 
3) To investigate concordance of RT-qPCR results obtained in human tissue with changes in 
expression of the same miRNAs in healthy and diseased equine SDFT tissue, with the 
objective of determining if similar dysregulation occurs between species, and identify 
candidate miRNAs for further investigation of biological networks and cellular pathways 
common to both species (Chapters 3 and 4).    
 
4) To select the most promising candidate miRNA for further investigation of its role in equine 
tenocyte function using gain- and loss-of-function studies in both monolayer culture and 
three-dimensional tissue-engineered constructs, and an induced autophagy/mitophagy 
model in monolayer culture. Analysis of candidate miRNA-target interactions at biochemical, 
ultrastructural and histological levels informed the objective of establishing whether 
manipulation of expression of this miRNA alters tenocyte and/or extracellular matrix 
interaction and function in a way that may yield potential therapeutic benefit (Chapters 5 
and 6).   
 
5) To identify if human tenocytes demonstrate analogous changes to those seen in equine 
tenocytes when subjected to the same experimental methodologies in monolayer culture, 
with the objective of determining if equine tenocytes are a valid experimental model for 




Chapter 2 - Materials and methods 
 
A full list of reagents, consumables and equipment used is given in Appendix 1. 
 
2.1 Tissue sample acquisition 
 
2.1.1 Human tissue 
Supraspinatus tendon (SSP) was harvested from patients with clinically diagnosed rotator cuff 
disease, undergoing surgical repair procedures. Collection was performed under Health Research 
Authority (HRA) ethical approval (16/WS/0207), and with informed patient consent. Sample handling 
and RNA extraction were performed at University of Glasgow’s Institute of Infection, Immunity and 
Inflammation, courtesy of Dr Neal Millar, Academic Consultant Orthopaedic Surgeon at the 
University of Glasgow, Scotland. Details of the six samples provided are given in Table 2.1. 
 
Sample number Sample name Organism Sex Age Status Source 
SSP1 18139-7 / 0946/18 SSP Human F 39 Diseased SSP Glasgow 
SSP2 18139-8 / 0947/18 SSP Human F 39 Diseased SSP Glasgow 
SSP3 18139-9 / 0866/18 SSP Human M 51 Diseased SSP Glasgow 
SSP4 18139-10 / 0944/18 SSP Human M 50 Diseased SSP Glasgow 
SSP5 18139-11 / 0864/18 SSP Human M 59 Diseased SSP Glasgow 
SSP6 18139-12 / 0887/18 SSP Human F 45 Diseased SSP Glasgow 
 
Table 2.1 Details of six human supraspinatus tendon samples harvested from patients with 
clinically diagnosed rotator cuff disease. M = male; F = female; Age given in years; SSP = 
supraspinatus tendon. 
 
Following informed patient consent under HRA ethical approval (17/WM/0099), posterior tibial 
tendon was harvested from patients with clinically diagnosed acquired flat foot deformity 
undergoing surgical reconstruction procedures at Aintree University Hospital, Liverpool. Tissue was 
collected by Andrew Molloy or Professor Lyndon Mason, both Consultant Trauma and Orthopaedic 
Surgeons at Aintree University Hospital, into RNAlater® stabilisation solution (Invitrogen) and stored 
at 4oC until collected by the author. Following equilibration in RNAlater® stabilisation solution 
(Invitrogen), at 4oC overnight, samples were removed, blotted dry, weighed and placed in 1.5 mL 
reaction tubes for storage at -80oC. 








Table 2.2 Details of three human posterior tibial tendon samples harvested from patients with 
clinically diagnosed flat foot deformity. M = male; Age given in years; PTT = posterior tibial tendon. 
 
Hamstring tendon (mixed gracilis and semitendinosus) was obtained from patients undergoing 
reconstructive surgery following anterior cruciate ligament rupture. Tissue was collected at 
Broadgreen Hospital, Liverpool, UK under Liverpool Musculoskeletal Biobank HRA ethical approval 
(15/NW/0661) and following informed patient consent. Samples were collected into RNAlater® or 
tenocyte culture media without foetal calf serum (TCM-NOFBS – see section 2.2). Sample 
information is given in Table 2.3.  
 
Sample number Sample name Organism Ethnicity Sex Age Status Source 
C1 LMB-KM-249 Human White British M 31 Healthy ST/GR Liverpool 
C2 LMB-MBL-252 Human Malaysian M 35 Healthy ST/GR Liverpool 
C3 LMB-GA-253 Human White British F 17 Healthy ST/GR Liverpool 
C4 LMB-HB-254 Human Indian F 23 Healthy ST/GR Liverpool 
C5 LMB-AS-255 Human White British F 23 Healthy ST/GR Liverpool 
C6 LMB-MK-257 Human White British F 29 Healthy ST/GR Liverpool 
C7 LMB-MH-258 Human White British M 24 Healthy ST/GR Liverpool 
C8 LMB-MW-260 Human White British M 23 Healthy ST/GR Liverpool 
C9 LMB-RM-261 Human White British M 26 Healthy ST/GR Liverpool 
C10 LMB-MM-265 Human White British M 48 Healthy ST/GR Liverpool 
C11 LMB-SM-270 Human White British M 30 Healthy ST/GR Liverpool 
C12 LMB-AP-278 Human White British M 41 Healthy ST/GR Liverpool 
C13 LMB-JL-280 Human Chinese M 18 Healthy ST/GR Liverpool 
C14 LMB-SF-282 Human White British F 26 Healthy ST/GR Liverpool 
C15 LMB-RL-286 Human White British M 24 Healthy ST/GR Liverpool 
C16 LMB-SG-289 Human White British M 32 Healthy ST/GR Liverpool 
C17 LMB-MT-291 Human White British M 25 Healthy ST/GR Liverpool 
 
Table 2.3 Details of 17 human hamstring tendon samples harvested from patients undergoing 
surgical repair of anterior cruciate rupture. M = male; F = female; Age given in years; ST = 
semitendinosus tendon; GR = gracilis tendon. 
 
  
Sample number Sample name Organism Sex Age Status Source 
P1 P1M60081217 Human M 60 Diseased PTT Liverpool 
P2 P2M71191217 Human M 71 Diseased PTT Liverpool 
P3 P3M65130318 Human M 65 Diseased PTT Liverpool 
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2.1.2 Equine tissue 
Superficial digital flexor tendon (SDFT) was acquired fresh from horses consigned for slaughter to F. 
Drury & Sons Ltd, The Abattoir, Tockenham, Wiltshire, UK. Samples were collected as a by-product of 
the agricultural industry. Specifically, the Animal (Scientific Procedures) Act 1986, Schedule 2, does 
not define collection from these sources as scientific procedures. Collection of this material 
therefore did not require ethical approval. Slaughtering was achieved using a firearm to effect 
brainstem destruction from a free bullet. Once death was confirmed, the distal forelimbs were 
recovered by disarticulation at the radio-carpal joint.   
To determine optimal handling for subsequent RNA extraction, one distal forelimb was left intact, 
whilst the skin and superficial fascial layers of tissue were removed from the contralateral limb to 
expose the SDFT. Transverse sections approximately 0.5 cm thick were harvested from the mid-
metacarpal region and placed in either RNAlater® stabilisation solution, ice cold Dulbecco’s 
phosphate buffered saline (DPBS; Sigma-Aldrich) or frozen in dry ice for transport. Following 
transport to the lab, mid-metacarpal sections of SDFT were dissected from the intact limb and 
placed in RNAlater® for RNA extraction, or tenocyte culture media without foetal bovine serum (FBS, 
TCM-NOFBS – see section 2.2) for tenocyte isolation. Details of equine tendon samples utilised in 
this study are given in Table 2.4. 
 
Use Sample name Organism Sex Age  Status Source 
RNA H1 Equine NR 3 Normal SDFT Peffers/Wardle 
RNA H2 Equine NR 25 Normal SDFT Peffers/Wardle 
RNA H3 Equine NR 4 Normal SDFT Peffers/Wardle 
RNA H16 Equine NR 3 Normal SDFT Peffers/Wardle 
RNA H18 Equine NR 19 Normal SDFT Peffers/Wardle 
RNA H23N Equine NR 6 Normal SDFT Peffers/Wardle 
RNA H23D Equine NR 6 Diseased SDFT Peffers/Wardle 
RNA H24N Equine NR 9 Normal SDFT Peffers/Wardle 
RNA H24D Equine NR 9 Diseased SDFT Peffers/Wardle 
RNA H27 Equine NR 18 Normal SDFT Peffers/Wardle 
RNA H47 Equine NR 7 Diseased SDFT Peffers/Wardle 
RNA H52 Equine NR 6 Diseased SDFT Peffers/Wardle 
RNA H62 Equine NR 7 Diseased SDFT Peffers/Wardle 
3D EqDB1 Equine F 9 Normal SDFT Drury & Sons Ltd 
3D EqDB3 Equine MN 9 Normal SDFT Drury & Sons Ltd 
RNA EqDB5 Equine MN 5 Normal SDFT Drury & Sons Ltd 
RNA EqDB6 Equine F 11 Normal SDFT Drury & Sons Ltd 
2D, 3D, ICC, RNA EqDB7 Equine MN 5 Normal SDFT Drury & Sons Ltd 
RNA EqDB8 Equine MN 4 Normal SDFT Drury & Sons Ltd 
2D, 3D, RNA EqDB9 Equine F 12 Normal SDFT Drury & Sons Ltd 
2D, 3D, RNA EqDB10 Equine F 18 Normal SDFT Drury & Sons Ltd 
2D, RNA EqDB11 Equine F 3 Normal SDFT Drury & Sons Ltd 




Table 2.4 (includes preceding page) Details of 53 equine superficial digital flexor tendon (SDFT) 
samples utilised in various aspects of this study. All horses were euthanised for reasons unrelated 
to this study and tissue acquired from fresh abattoir material. SDFT = superficial digital flexor 
tendon; NR = not recorded; ME = male entire; MN = male neutered; F = female; Age given in years; 
RNA = RNA extraction; ICC = immunocytochemistry; 2D = monolayer cell culture; 3D = tissue-
engineered tendon construct. 
 
Samples EqDB1 - EqDB40 (listed in Table 2.4) were collected and processed by the author. Samples 
H1, H2, H3, H16, H18, H23, H24, H27, H47, H52 and H62 (listed in Table 2.4) were provided by 
Professor Mandy Peffers, from the University of Liverpool Veterinary School Musculoskeletal 
Use Sample name Organism Sex Age  Status Source 
2D, 3D, RNA EqDB12 Equine F 8 Normal SDFT Drury & Sons Ltd 
RNA EqDB13N Equine MN Aged Normal SDFT Drury & Sons Ltd 
RNA EqDB13D Equine MN Aged Diseased SDFT Drury & Sons Ltd 
RNA EqDB14 Equine MN 4 Normal SDFT Drury & Sons Ltd 
RNA EqDB15 Equine F 6 Normal SDFT Drury & Sons Ltd 
RNA EqDB16 Equine F 16 Normal SDFT Drury & Sons Ltd 
RNA EqDB17 Equine MN 17 Normal SDFT Drury & Sons Ltd 
2D, RNA EqDB18 Equine MN 9 Normal SDFT Drury & Sons Ltd 
RNA EqDB19 Equine MN 15 Normal SDFT Drury & Sons Ltd 
RNA EqDB20 Equine F 20 Normal SDFT Drury & Sons Ltd 
RNA EqDB21 Equine MN 9 Normal SDFT Drury & Sons Ltd 
RNA EqDB22 Equine MN 9 Normal SDFT Drury & Sons Ltd 
RNA EqDB23 Equine MN 5 Normal SDFT Drury & Sons Ltd 
3D, RNA EqDB24 Equine F 9 Normal SDFT Drury & Sons Ltd 
RNA EqDB25 Equine MN 4 Normal SDFT Drury & Sons Ltd 
RNA EqDB26 Equine MN 16 Normal SDFT Drury & Sons Ltd 
RNA EqDB27 Equine F 15 Normal SDFT Drury & Sons Ltd 
RNA EqDB28 Equine MN 13 Normal SDFT Drury & Sons Ltd 
RNA EqDB29 Equine F 14 Normal SDFT Drury & Sons Ltd 
RNA EqDB30 Equine MN 3 Normal SDFT Drury & Sons Ltd 
RNA EqDB31 Equine F 5 Normal SDFT Drury & Sons Ltd 
RNA EqDB32 Equine MN 25 Normal SDFT Drury & Sons Ltd 
RNA EgDB33 Equine ME 5 Normal SDFT Drury & Sons Ltd 
RNA EqDB34 Equine F 9 Normal SDFT Drury & Sons Ltd 
RNA EqDB35 Equine MN 19 Normal SDFT Drury & Sons Ltd 
RNA EqDB36 Equine F 22 Normal SDFT Drury & Sons Ltd 
RNA EqDB37 Equine MN 21 Normal SDFT Drury & Sons Ltd 
RNA EqDB37 Equine MN 21 Diseased SDFT Drury & Sons Ltd 
RNA EqDB38 Equine F 15 Normal SDFT Drury & Sons Ltd 
RNA EqDB39 Equine F 5 Normal SDFT Drury & Sons Ltd 
RNA EqDB40 Equine MN 9 Normal SDFT Drury & Sons Ltd 
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Biobank. RNA extraction was performed by Miss Roisin Wardle and RNA made available for use in 
this study.  
 
2.2 Primary tenocyte isolation 
 
2.2.1 Cell culture media 
Tenocyte culture medium (TCM; TCM-NOFBS without foetal bovine serum) 
To 500 mL DMEM low glucose (1 g L-1) phenol red free media (Life Technologies 11880-036), was 
added: 
 1 mL Amphotericin B 250 µg mL-1 (ThermoFisher 15290026) 
 5 mL Penicillin-Streptomycin  (contains 10,000 U penicillin + 10 mg streptomycin mL-1; Sigma 
P4333-20ML) 
 5 mL L-glutamine solution 200 mM (Sigma G7513-20ML) 
 50 mL Foetal Bovine Serum (Life Technologies 10270106) 
Final medium composition: 100 U mL-1 penicillin, 0.1 mg mL-1 streptomycin, 0.5µg mL-1 amphotericin 
B and 2 mM L-glutamine +/- 10% Foetal Bovine Serum. 
NOTE – using phenol red free media will permit fluorescence microscopy.  
Freezing medium (FM) 
Foetal bovine serum to which was added 10% by volume DMSO (Sigma-Aldrich D8418) 
 
2.2.2 Equine primary tenocyte isolation protocol  
Materials required: 
 Sterile 60 mm Petri dishes  
 Scalpel blades 
 Rat tooth forceps 
 Collagenase type II (ThermoFisher 17101015) 
 Powdered trypsin (Sigma T4799-5G – lyophilised trypsin from porcine pancreas) 
 TCM 
 TCM-NOFBS  
 DPBS (Sigma-Aldrich D8537) 
 50 mL Falcon centrifuge tubes 
 70 µm cell strainers 
 Rotating/shaker incubator set at 37oC 
 Haemocytometer 
 Trypan Blue solution 0.4% (Sigma-Aldrich T8154) 
 FM and cryogenic vials or culture flasks/plates 
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Work in Class II biological safety cabinet. 
Cut up tendon tissue as finely as possible (approximately 2 mm x 2 mm x 2mm cubes) using a scalpel 
blade. 
Place in 50 mL Falcon tube. 
Incubate with 20-30 mL TCM-NOFBS containing 0.1% (1 mg mL-1) collagenase type II in rotating 
incubator at 37oC for 20-24 hours. 
Centrifuge (260 g for 15 minutes) and remove supernatant. 
Re-suspend in 20-30 mL TCM-NOFBS containing 0.4% (4 mg mL-1) collagenase type II. 
Incubate at 37oC for 4 hrs (rotating incubator). 
Centrifuge (260 g for 15 minutes) and remove supernatant. 
Re-suspend in 20-30 mL DPBS to wash. 
Centrifuge (260 g for 15 minutes) and remove supernatant. 
Re-suspend in 20-30 mL TCM-NOFBS containing 0.25% (2.5 mg mL-1) trypsin.  
Place in rotating incubator at 37oC for 1 hour. 
Centrifuge (260 g for15 minutes) and remove supernatant. 
Re-suspend in 20-30 mL DPBS to wash. 
Centrifuge (260 g for 15 minutes) and remove supernatant. 
Re-suspend in 5-10 mL TCM. 
Pass through 70 µm cell strainer to remove undigested tissue debris and produce single cell 
suspension – may need to flush through strainer with extra TCM. 
Count cells and assess viability (Trypan Blue exclusion), freeze, or seed onto T75 or T175 uncoated 





2.2.3. Human primary tenocyte isolation protocol 
Attempts at tenocyte isolation by digestion (as employed with equine tenocytes) failed to yield any 
viable cells. Tenocyte isolation was performed using an explant method. 
Materials required: 
 Sterile 60 mm Petri dishes for cutting samples in 
 Sterile culture flasks or 6 well plates 
 Scalpel blades 
 Rat tooth forceps 
 DPBS (Sigma-Aldrich D8537) 
 TCM 
 Serological pipettes and filling gun 
 TrypLE Select Enzyme (1x) (Life Technologies 12563029) 
 Haemocytometer 
 Trypan Blue solution 0.4% (Sigma-Aldrich T8154) 
 FM and cryogenic vials or culture flasks/plates 
 
Remove adherent muscle and peritendinous tissue from sample.  
Wash in DPBS and weigh sample.  
Cut up tendon tissue as finely as possible (approximately 2 mm x 2 mm x 2 mm cubes) and seed into 
culture flask or 6 well plate containing TCM.  
Change media every 2-3 days.  
Once tenocytes are visible adjacent to tissue pieces and adherent to vessel surface, remove tissue 
from culture vessel (aspirate with media using serological pipette).  
Continue media changes every 2-3 days until cells reach 75-80% confluence.  
Dissociate cells, count and assess viability (Trypan Blue exclusion test) prior to re-seeding or freezing 





2.3 Monolayer cell culture techniques 
 
2.3.1 Monolayer culture 
For cell amplification purposes, tenocytes were seeded at approximately 4000 cells cm-2 into T75 or 
T175 culture flasks. For all experimental monolayer culture work, tenocyte seeding density was 
approximately 10,000 cm-2 in 6 well plates (100,000 cells  well-1) and 8,500 cm-2 in 12 well plates 
(30,000 cells well-1).   
Culture surface areas: 
 6 well plate = 9.6 cm2  well-1 
 12 well plate = 3.5 cm2 well-1 
Cells cultured for immunocytology were seeded into 6 or 12 well plates containing laminin coated 
cover slips (see 2.3.2).  
Equine and human tenocytes were cultured in phenol red free TCM in a 5% O2, 5% CO2 atmosphere 
at 37oC. Medium was changed every 2-3 days, with dissociation of cells for re-seeding or freezing 
performed when cell growth had resulted in approximately 80% confluence. Dissociation was 
achieved using TrypLE Select (Life Technologies), a recombinant microbial produced trypsin 
replacement enzyme, according to the following protocol. 
Remove media from culture vessel. 
Add warmed DPBS (12 mL for T75, 25 mL for T175, 2 mL well-1 for 6 well plate), swirl and remove. 
Add second aliquot DPBS, swirl and remove. 
Add TrypLE Select solution: 
 5 mL T75 flask 
 8  mL T175 flask 
 1 mL well-1 6 well plate 
Incubate at 37oC for 5-7 minutes. 
Tap culture vessel sharply several times and view under microscope to confirm cell dissociation. 
Add TCM to culture vessel to inactivate enzyme: 
 10 mL T75 flask 
 12 mL T175 flask 
 1 mL well-1 6 well plate 
Aspirate vessel contents and transfer to 15 mL or 50 mL centrifuge tube (combine cell suspensions 
where appropriate).  
Centrifuge at 180 g for 5 minutes.  
Discard supernatant and resuspend cell pellet in known volume of TCM (typically 5-10 mL). 
Take 10 µL of cell suspension and mix with 10 µL Trypan Blue in 1.5 mL reaction tube. 
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Pipette 10 µL of mix under cover slip of haemocytometer. 
Count cells and determine percentage viability. 
Then: 
 Seed cells into new culture vessel for amplification or experiment  
 Freeze  
o Re-centrifuge (180 g for 5 minutes) 
o Remove supernatant 
o Resuspend cells in appropriate volume of FM and aliquot into 1.8 mL cryogenic vials 
(typically as aliquots of 500,000 or 1 million cells) 
 
2.3.2 Laminin coating cover slips 
Materials required: 
 Laminin (Invitrogen 23017-015 natural mouse laminin 1.10 mg mL-1 – stored at -80oC – 
defrost laminin stock in fridge to prevent solidifying) - working solution 10 µg mL-1 in DPBS 
(keep in fridge) 
 Fine point forceps 
 DPBS (Sigma-Aldrich D8537) 
 (Sterile) 10 mm diameter cover slips (VWR 631-1576 microscope cover glasses) 
 6 or 12 well plates 
 1000 µL and 100 µL pipettes and tips 
 
Work in Class II biological safety cabinet 
Transfer coverslips into plate wells (ideally coverslips sterile, but incubate under UV in culture hood 
for 30 minutes per side otherwise). 
Pipette laminin onto cover slip. 
 100 µL well-1 for 12 well plate – place first drop onto coverslip and use this to drag coverslip 
to centre of well, then add remaining volume. Laminin bleb should form a convex meniscus 
on top of cover slip. If too great a volume used or meniscus breaks, coverslip will float on top 
of laminin. 
 500 – 1000 µL well-1 for 6 well plate if using larger diameter coverslips or 2-3 x 10 mm cover 
slips well-1. 
 
Incubate at 37oC for minimum 30 – 60 minutes. 
If coverslip floating, turn over. 




2.4 Three-dimensional equine tendon construct techniques  
 
2.4.1 Culture media and reagent preparation 
Tenogenic culture medium (TGM; TGM-C once TGFβ3 has been added) 
To 500 mL tenocyte culture media (TCM – see 2.2.1) was added: 
 10 mg Aprotinin (Sigma A1153-10MG – from bovine lung) – add to 5 mL media then sterile 
(0.2 µm) filter before adding to rest of media. 
 29 mg Ascorbate-2-phosphate (Sigma A4544-25G – L-ascorbic acid) – add to 5 mL media 
then sterile (0.2 µm) filter before adding to rest of media. 
 5 mL Non-essential amino acids (100x) (Sigma M7145-100ML). 
 1 µL mL-1 of 1 ng µL-1 working solution TGFβ3 (R&D Systems 243-B3-002) - DO NOT ADD YET. 
Calculate volume of medium required for batch of constructs being created and aliquot this volume 
to separate tube. To this add 1 µL mL-1 of 1 ng µL-1 working solution TGFβ3 (see below) just before 
use to achieve final concentration of 1ng mL-1 TGFβ3. This forms Tenogenic Complete Medium 
(TGM-C). 
TGFβ3 (R&D Systems 243-B3-002) reconstitution 
To a vial containing 2 µg TGFβ3 powder, add 100 µL 4 mM HCl containing 1 mg mL-1 bovine serum 
albumin (BSA) to give stock solution* of 20 µg mL-1. 
Take 5 µL of 20 µg mL-1 stock solution and add to 95 µL 4 mM HCl with 1 mg mL-1 BSA to give a 1 ng 
µL-1 working solution. 
Aliquot in 1.5 mL reaction tubes and freeze at -20oC. 
Add to TGM at 1 µL mL-1 media to give 1 ng mL-1 Tenogenic Complete Medium (TGM-C). 
*product supplied as lyophilised powder as CF (carrier free) or in combination with BSA as a 
stabiliser. Only need to add BSA if reconstituting CF formulation. 
Fibrinogen stock solution (20 mg mL-1) preparation protocol 
Materials required: 
 DMEM low glucose (1 g L-1) medium (Life Technologies 11880-036) with no other additives. 
NOTE – using TGM may result in solution clotting during freeze/thaw cycle and failure to 
form adequate clot with construct. Can use DPBS (Sigma-Aldrich D8537), which will result in 
slightly less thrombin requirements (approx. 10 µL well-1, when optimising fibrinogen: 
thrombin ratios for constructs). 
 500 mg Fibrinogen (Sigma F8630-1G – from bovine plasma) 
 2 x 50 mL sterile Falcon tubes 
 0.2 µm Sartorius Minisart filters (Appleton Woods FC121 – cellulose acetate membrane). Do 
not use filters with PTFE membrane eg. VWR International – fibrinogen will clog membrane. 
 1.5 mL reaction tubes 
 Needles and syringes 
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 Balance  
 Cell culture hood 
 Rotating plate (end-over-end) incubator or rotating plate in warm room. 
 
Switch on rotating plate incubator and set temperature to 37oC. 
 
Check balance is level and adjust if necessary. Press CAL, wait for balance to calibrate. Add empty 
50mL falcon tube and tare. 
 
Weigh out amount of fibrinogen required to make a 20 mg mL-1 stock (e.g. 500 mg for 25 mL final 
volume) carefully into empty sterile 50 mL falcon tube – powder will stick to everything. 
 
Record weight of fibrinogen.  
 
In sterile cell culture hood transfer the volume of medium required to 50 mL Falcon tube containing 
the fibrinogen. The fibrinogen will clump and sit on top of the medium and stick to the sides of the 
tube. 
 
Swirl gently (most of the fibrinogen will stay on top of the medium) and incubate at 37oC. Do not 
vortex the solution at any stage. 
 
Place Falcon tube in rotating (end over end) incubator at 37oC (or use rotating plate in warm room). 
Check every 30 minutes until the fibrinogen is dissolved – may need to tap tube occasionally. After 4 
hours the fibrinogen should be dissolved. 
 
In the cell culture hood, sterile filter the fibrinogen stock solution using a syringe and 0.2 µm sterile 
disposable ‘button’ filter. Aliquot filtrate into 1.5 mL reaction tubes and store at -20oC. 
 
Each batch should be tested for the optimal amount of thrombin required when making constructs. 
(Similarly each batch of thrombin requires testing separately (see ‘optimising fibrinogen/thrombin 
ratios for tendon constructs’ below). 
 
Thrombin stock solution (200 U mL-1) preparation protocol 
Materials required: 
 Thrombin (Sigma T4648-1KU – from bovine plasma) 
 DMEM low glucose (1 g L-1) media (Life Technologies 11880-036) – with no other additives  
 0.2 µm Sartorius Minisart filters (Appleton Woods FC121) (or Sigma 16534K Minisart filters) 
 5 mL syringe and needle 
 1.5 mL reaction tubes and rack 
 




Sterilise by passing through 0.2 µm filter and aliquot into 1.5 mL sterile reaction tubes and freeze at -
20oC. 
 
Optimising fibrinogen/thrombin ratios for tendon constructs 
Materials required: 
 Cell culture hood 
 200 µL and 1000 µL pipettes and tips 
 6 well plate  
 7 mL Bijou tubes 
 Fibrinogen 20 mg mL-1 stock solution 
 Thrombin 200 U mL-1 stock solution  
 TGM-C (see 2.4.1) 
 Ice tray 
 
Work in Class II biological safety cabinet and keep tubes of stock solutions on ice.  
 
In Bijou tube mix 400 µL TGM-C with 100 µL Fibrinogen 20 mg mL-1 stock solution for each well (2400 
µL media : 600 µL Fibrinogen solution for 6 well plate).  
 
Pipette 500 µL of this mix into each well.  
 
Working one well at a time, optimal thrombin dose is established as follows: 
 Mix 20 µL* Thrombin stock solution with 500 µL TGM-C in a clean Bijou and pipette entire 
volume into first well, ensuring thorough mixing by pipetting with Fibrinogen/TGM-C 
solution already there.  
 Rock plate backwards and forwards gently to ensure even covering of well floor and watch 
for setting. Needs to set fairly quickly but giving enough time to ensure even distribution 
within well. Looking for even, firm clot with no watery component and adherent to 
circumference without contracting.  
 Repeat steps above, using increasing (or decreasing) volumes of Thrombin stock solution 





2.4.2 Preparation of  SylgardTM 184 silicone elastomer plates 
Materials required: 
 SylgardTM 184 silicone elastomer base (World Precision Instruments SYLG184) 
 5 mL serological pipettes and filling gun 
 50 mL Falcon tube  
 6 x 6 well plates 
 Minutien insect pins (Fine Science Tools 26002-20) 
 Size 0 (3.5 Metric) braided silk suture (Ethicon Mersilk) 
 Forceps  
 Ruler  
 Permanent marker 
 Rotor mixer  
 Incubator (set to 60oC) 
 Cell culture hood 
 
Set incubator to 60oC. 
Transfer 45 mL SylgardTM base (highly viscous, easier to pour than pipette) to a 50 mL Falcon tube. 
Add 5 mL of curing reagent and invert on a rotor mixer at room temperature for 10 minutes to 
ensure complete mixing. 
Distribute SylgardTM between six plates by pouring - equivalent to a depth of approximately 2 mm 
and a volume of 1.5 mL in each of 36 wells. 
Replace lids on plates and cure at 55-60oC overnight. 
Pinning construct anchors into SylgardTM plates: 
On the underside of the plate mark two dots 1.25 cm apart in the middle of each well using a ruler 
and permanent marker pen. 
Cut 0.8 cm pieces of suture (two for each well). 
Place minutien insect pin through one end of the suture (braided suture easily unravels) and pin into 
the SylgardTM over one of the dots. 
Place a second pin through the other end of the suture in line with the dots but pointing towards the 
outside edge of the well. 
Repeat for the other dot to produce two diametrically pinned lengths of suture material with a 1.2 cm 










Figure 2.1 Final appearance of six well plate with polymerised SylgardTM 184 silicone elastomer 
coated base and pinned suture construct anchors in place. 
 
Store pinned plates at room temperature. 
To sterilise plates, soak in 100% ethanol for 0.5-1.5 hours under UV light in cell culture hood. 
Drain off excess ethanol in the hood. 
Before use, rinse plates once in 5 mL DPBS for 5 minutes. 
 
2.4.3 Tendon construct methodology 
Materials required: 
 TGM (3.5 mL construct-1) 
 DPBS (Sigma-Aldrich D8537) 
 TrypLE Solution 
 Thrombin (200 U mL-1 stock solution) – 35 µL construct-1 * 
 Fibrinogen (20 mg mL-1 stock solution) – 100 µL construct-1 
 TGFβ3 (1 ng µL-1 stock solution) – 3 .5 µL construct-1 
 Tenocyte suspension (600,000 cells construct-1, suspended in TCM) 
 10 µL, 100 µL and 1000 µL pipettes and tips 
 7 mL Bijou tubes (1 per construct) 
 15 mL centrifuge tubes 
 50 mL Falcon tubes 
 Haemocytometer 
 1.5 mL reaction tubes and rack  
 Trypan Blue solution 0.4% 
 Cell culture hood 
 SylgardTM  6 well plates (pre-prepared - see 2.4.2)  
 5 mL and 10 mL serological pipettes and filling gun 
*  volume of thrombin will vary depending on previous optimisation of thrombin:fibrinogen ratio 
(see 2.4.1).  
Stock solutions (stored at -20oC) 
and defrosted on ice for use 
Warmed to 37oC 
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Rinse SylgardTM plates before use – 5 mL DPBS per well for 5 minutes. 
To TGM, add 1 µL mL-1 TGFβ3 stock solution to make Tenogenic Complete Medium (TGM-C). 
Aliquot a volume of TGM-C equivalent to 500 µL construct-1 to a separate tube and add a volume of 
Thrombin stock solution equivalent to 35 µL* construct-1. 
*  volume of thrombin will vary depending on previous optimisation of thrombin:fibrinogen ratio 
(see 2.4.1). 
Drain DPBS from plate wells. 
Add 535µL TGM-C/Thrombin mix to each well (volume will vary depending on volume of thrombin 
added after optimisation). 
Spin down cells (180 g for 5 minutes) and resuspend in a volume of TGM-C equivalent to 400 µL 
construct-1, to make a suspension of 1.5 x 106 cells mL-1. 
Make fibrinogen/cell suspension mix – do this individually for each construct as gel sets very quickly: 
 Aliquot 400 µL of cell suspension (equivalent to 600,000 cells) to clean Bijou tube 
 Reset pipette to 500 µL. 
 Add 100 µL Fibrinogen stock solution to cell suspension. 
 Mix well and immediately pipette entire volume into well containing TGM-C/Thrombin 
solution. 
 Mix well by pipetting up and down 2-3 times (Total volume = ~1 mL fibrin gel/cell suspension 
per well). 
 Move plate backwards and forwards rapidly to ensure mixture forms a flat layer covering the 
entire well floor and is in contact with the pins before the fibrin gel forms. 
Incubate at 37°C for 5 minutes to set. 
 
Repeat for each well required. 
 
Add 2.5 mL TGM-C to each well. 
 
Place in 37oC incubator (5% CO2, 5% O2). 
 
Change media the following day and score carefully around the edge of each well with pipette tip to 
breakdown adhesions. 
 
Change media every 2-3 days, scoring with pipette tip towards the middle of the well at every media 






Harvest constructs at 28 days and process as follows: 
 Histology – make two cuts in the SylgardTM base of each well parallel to the pinned construct 
using a scalpel blade. Remove constructs, still pinned to a strip of SylgardTM, from well, rinse 
briefly in DPBS and place in 7 mL Bijou tubes containing fixative: 
o 4% paraformaldehyde (Sigma 441244-1KG) for routine histology. 
o 2.5% glutaraldehyde (Taab Laboratories Equipment G002) in 0.1 M sodium 
cacodylate (Taab Laboratories Equipment S011) buffer for electron microscopy.  
  
 RNA extraction – make two cuts in the SylgardTM base of each well parallel to the pinned 
construct using a scalpel blade. Remove constructs, still pinned to a strip of SylgardTM, from 
well, rinse briefly in DPBS and place in 7 mL Bijou tubes containing RNAlater® (Life 
Technologies AM7021). Following equilibration at 4oC overnight, remove anchor pins and 
suture material, blot constructs dry, weigh and place in 1.5 mL reaction tubes for storage at -
80oC. 
 
 Protein extraction – remove anchor pins, rinse constructs in DPBS, place in 1.5 mL reaction 





2.5 Cholesterol conjugated microRNA/oligonucleotide transfection 
 
DharmaconTM cholesterol conjugated oligonucleotides were obtained from GE Healthcare Ltd, Little 
Chalfont UK. Sequence details and modifications are given in Table 2.5. 
 
Product Description  Modifications  Sequence 
miR-181 Mimic 
Modified catalogue product C-




miRIDIAN mimic  
5’Cholesterol on 
passenger strand;   
3’Cy5 on guide strand 
 5’- AACAUUCAACGCUGUCGGUGAGU -3’ 
miR-181 antagomiR  
ssRNA-23 mer  
5’ Fluorescein  
23 x Methoxys  
6 x Phosphorothioates  






Scrambled control sequence  
ssRNA-21 mer  
21 x Methoxys  
6 x Phosphorothioates  






Table 2.5 Sequences and modifications of DharmaconTM cholesterol conjugated oligonucleotides 
utilised in this study. * = phosphorothionate modified nucleotide; m = 2’-O-methylation modified 
nucleotide 
Manufacturer supplied, concentrated oligonucleotides were diluted with RNase free water according 
to manufacturer’s siRNA resuspension protocol to produce a stock solution of 100 µM. Final 
concentration was verified spectrophotometrically by measuring absorbance at 260 nm (A260) 
(Nanodrop 2000; ThermoScientific), then calculating concentration using Beer’s Law, according to: 
A260 = εCL    where ε is the extinction coefficient (from the Product Transfer Form), C is the siRNA 
concentration, and L is the path length.  
Therefore C = A260/εL  
Stock solutions were stored in aliquots in 0.2 mL PCR tubes at -20oC and defrosted on ice 
immediately prior to use. Working solutions were produced by further dilution in either TCM 
(monolayer cultures) or TGM-C (3D constructs) according to: 
 Mimic and scrambled control - 100 nM - equivalent to 1 µL stock solution mL-1 medium 




2.5.1 Treatment protocol for monolayer cultures  
Each treatment was duplicated for each biological replicate.  
Materials required: 
 Dissociated tenocytes suspended in TCM at known concentration 
 TCM 
 6 or 12 well cell culture plates 
 10µL, 200 µL and 1000 µL pipettes and tips 
 100 µM stock solutions of mmu-miR-181a-5p mimic, antagomiR and scrambled control 
oligonucleotides defrosted on ice 
 Cell culture hood 
 30 mL or 60 mL tubes 
Day 1 
Seed cells into plate wells: 
 6 well plate - 100,000 cells per well  
 12 well plate – 30,000 cells per well 
 
Add additional TCM if needed. 
Incubate plates overnight at 37oC in a 5% O2, 5% CO2 atmosphere. 
Day 2  
Prepare 3 aliquots of TCM of appropriate volume for transfection (6 well plate = 2 mL well-1; 12 well 
plate = 1 mL well-1). 
To one aliquot add 1 µL mL-1 100 µM mimic stock solution = 100 nM. 
To one aliquot add 2 µL mL-1 100 µM antagomiR stock solution = 200 nM. 
To one aliquot add 1 µL mL-1 100 µM scrambled control stock solution = 100 nM. 
Aspirate TCM from wells and replace with appropriate treated TCM. 
Return plates to incubator. 
Day 3 
Can check uptake of mimic and antagomiR treatments under fluorescence microscope (uptake in 
50% of cells is good enough). 
Day 4 






2.5.2 Treatment protocol for three-dimensional tendon constructs 
Tenocytes were seeded into a fibrin gel matrix (see 2.4.3). Twenty four hours after seeding, at the 
first media change, TGM-C was replaced with TGM-C spiked with either mmu-miR-181a-5p mimic, 
antagomiR or scrambled control oligonucleotide at the concentrations specified above. Treatment 
was repeated at every subsequent media change until constructs were harvested at 28 days.  
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2.6 CCCP assay for induced autophagy/mitophagy 
 
Carbonyl cyanide m-chlorophenylhydrazone (CCCP) is a protonophore (H+ ionophore), causing 
uncoupling of the proton gradient that is established during the normal activity of electron carriers 
in the mitochondrial electron transport chain, reducing the ability of ATP synthase to function 
optimally. It also has a number of effects on cellular calcium. 
Materials required: 
 Cell cultures (12 well plates) 
 CCCP 20 mM stock solution thawed on ice (C2759 Sigma-Aldrich; Molecular weight 204.62, 
powder for reconstitution in DMSO) 
 TCM 
 DMSO (D8418 Sigma-Aldrich Dimethyl sulfoxide for molecular biology) 
 10 µL, 200 µL and 1000 µL pipettes and tips 
 7 mL Bijou tubes 
 
Optimising time and concentration variables for tenocyte exposure to CCCP 
Three experiments were run to optimise CCCP concentration and time of exposure consistent with 
highest concentration compatible with cell survival and assessed by immunocytochemistry against 
two target proteins TOMM20 and P62/SQSM1: 
1) 10 or 20 µM CCCP solution for 4 or 6 hours 
2) 20 µM CCCP solution for 8 hours 
3) 20 µM CCCP solution for 1, 2, 3, 4, 5 and 6 hours 
Calculate volumes of CCCP/DMSO dilutions needed (1 mL well-1 for 12 well plate). 
Make up required CCCP dilutions and DMSO equivalents in Bijous: 
 For 10 µM CCCP solution, add 0.5 µL 20 mM stock mL-1 media. 
 For 20 µM CCCP solution, add 1 µL 20 mM stock mL-1 media.  
 For DMSO controls, add equivalent volume DMSO mL-1 media. 
Aspirate media from wells and add 1 mL appropriate CCCP dilutions to each designated well. 
Three sets of control wells were prepared: 
 Equivalent DMSO concentration for subsequent incubation with primary antibody. 
 DMSO control wells of equivalent concentration for subsequent incubation without primary 
antibody. 
 Untreated controls (TCM only). 





2.6.1 CCCP treatment protocol for miR-181-treated tenocytes 
Day 1 
Seed cells into plate wells: 
 Protein extraction 
o 6 well plate – 100,000 cells per well = 1.2 million cells per donor (2 plates per donor). 
o Add 2 mL culture media. 
 RNA extraction or immunocytochemistry 
o 12 well plate – 30,000 cells per well = 360,000 cells per donor (1 plate per donor). 
o Add 1.5 mL culture media. 
Day 2 
Change media – replace with mmu-miR-181a-5p mimic, antagomiR and scrambled control 
oligonucleotide treated TCM (see 2.5.1): 
 6 well plate - 2 mL well-1  
 12 well plate - 1 mL well-1 
 
Day 3 (24hrs after transfection) 
Treat with CCCP to achieve 20 µM concentration: 
 6 well plate - add 2 µL 20mM CCCP stock solution or DMSO. 
 12 well plate – add 1 µL 20mM CCCP stock solution or DMSO. 
 
NOTE: Add CCCP/DMSO stock solutions directly to mmu-miR-181a-5p mimic, antagomiR and 
scrambled control oligonucleotide treated TCM already in wells. 
Return plates to incubator for 6 hours. 









 Cell cultures 
 Methanol -pre-chilled in -40oC freezer (Fisher Scientific M/4000/15) 
 Relevant primary antibodies (defrosted on ice) 
 Relevant secondary antibodies (in fridge at 4oC) 
 DAPI diluted in DPBS 1:10,000 (Sigma-Aldrich D9542-1MG; DAPI powder, reconstituted in 
DPBS (Sigma-Aldrich D8537) to 1 mg mL-1 stock solution. Add 1 µL to 10 mL DPBS to achieve 
working solution. 
 Hydromount® (National Diagnostics HS-106) 
 10 µL, 200 µL, and 1000 µL pipettes and tips 
 Serological pipettes and filling gun  
 Glass microscope slides 
 DPBS (Sigma-Aldrich D8537)   
 Bovine Serum Albumin (Sigma-Aldrich A2153; lyophilised powder ≥96% (agarose gel 
electrophoresis). 
 Horse serum (ThermoFisher Scientific (GibcoTM) 16050122; horse serum New Zealand origin) 
 Glycine (Sigma-Aldrich G8898; glycine powder for electrophoresis ≥99%). 
 Tween® 20 (Sigma-Aldrich P1379; non-ionic detergent). 
 
Make up blocking solution: 
1% (10 mg mL-1) BSA  
10% horse serum 
0.3 M glycine (75.07g mol-1 ≡ 22.52mg mL-1) 
0.1% DPBS-Tween  
DPBS 
 
Remove media from wells. 
Wash with DPBS and remove. 
Fix in ice cold methanol for 5 minutes – put on rocker at room temperature. 
Remove methanol and wash with DPBS. 
Remove DPBS and add 500 µL blocking solution per well (12 well plate). 
Incubate in blocking solution for 1 hour on rocker at room temperature. 
To 100 mL DPBS add:  
1 g BSA  
10 mL horse serum 
2.2521 g glycine 




Dilute primary antibodies in blocking solution: 
 anti-TOMM20 (ab186734 rabbit) use at 1:75 dilution 
 anti-TOMM20 (ab56783 mouse) use at 1:75 dilution 
 anti-LC3B (ab192890 rabbit) use at 1:100 dilution 
 anti-p62/SQSTM1 (ab109012 rabbit) use at 1:100 dilution  
 anti-Parkin 1:100 (ab15954 rabbit) – discontinued 
 anti-Parkin (ab77924 mouse) use at 1:100 dilution 
 anti-Peroxiredoxin 6 (ab133348 rabbit) use at 1:00 dilution 
 
Remove blocking solution from wells. 
Add primary antibody diluted in blocking solution (100 µL well-1 for 12 well plate). 
Incubate overnight on rocker in cold room (4oC). 
Remove primary antibody (can be reused up to 5 times). 
Perform 3 x 5 minute DPBS washes. 
Dilute secondary antibody in blocking solution –150 µL per well for 12 well plate - keep protected 
from light: 
 Red (532) Goat anti-mouse IgG (Invitrogen A11002) use at 1:1000 dilution. 
 Red (532) Goat anti-rabbit IgG (Invitrogen A11009) use at 1:1000 dilution. 
 Green (488) Goat anti-rabbit IgG (Invitrogen A11008) use at 1:1000 dilution. 
 
Incubate at room temperature for 1 hour - keep protected from light. 
Remove secondary antibody – discard. 
Perform 3 x 5 minute DPBS washes - keep protected from light. 
Add 300 µL DAPI: 1:10000 in DPBS, incubate for 10 minutes at room temperature - keep protected 
from light. 
Remove DAPI – discard. 
Wash in DPBS for 10 minutes at room temperature - keep protected from light. 
Mount in Hydromount: 
 Spot Hydromount onto glass slide. 
 Take cover slip out of well, turn over and mount face down on glass slide. 
Cure overnight at room temperature - keep protected from light. 
Store at 4oC - keep protected from light. 
(Dilutions: 1:100 = 10 µL mL-1; 1:1000 = 1 µL mL-1; 1:10000 = 1 µL 10mL-1) 
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For antibodies to be used on samples of unproven reactivity, check antigenic conservation with 
species of interest. Specific antibody data sheet should give amino acid sequence of the antigen 
(immunogen) which the antibody was raised against (may be a short sequence, or whole peptide as 
antigen used to raise antibody).  
Data sheet may have a direct link to NCBI BLAST for relevant sequence – if so click on this. Page 
listing ‘Sequences producing significant alignments’ will open. Scroll down to find species of interest 
and click on it to access sequence comparison and identity. 
If the UniProt protein identifier is given, click on this to open Uniprot page and scroll down to find 
‘Sequence’ section. This will give the amino acid sequence of the protein. To the left of the sequence 
box is a link to BLAST; click on GO button. Alignments with various species will come up; scroll down 
to find species of interest and click on ‘View alignment’ link. Detailed report of sequence and identity 
will open. 
 
2.8 RNA extraction 
 
2.8.1 RNA extraction protocol for equine and human tendons 
Materials required: 
 Tendon samples in liquid nitrogen or on dry ice 
 BBraun MIKRO-DISMEMBRATOR U 
 Sample capsules and ball bearings for above 
 Clean Dewar of liquid nitrogen  
 Long handled haemostats with locking ratchet for liquid nitrogen immersion 
 60 mm diameter Petri dishes 
 Scalpel blades  
 Fine point forceps 
 1000 µL pipette and tips 
 1.5 mL reaction tubes and rack 
 7 mL Bijou tubes 
 70% ethanol and 1% Distel to clean surfaces and instruments  
 Tissue lysis buffer (from MirVanaTM kit) 
 
Ensure appropriate PPE available for liquid nitrogen work. 
Switch on dismembranator and set to 2000 rpm and 1 minute 30 seconds. 
Weigh sample – aim for approximately 100 mg tissue. 
Place in Petri dish and chop finely (approximately 2 mm x 2 mm x 2 mm cubes). 
Transfer to dry 7 mL Bijou tube and drop into liquid nitrogen. 
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Grasp dismembranator capsule body and lid with long handled haemostats (ensure ball bearing is in 
body of capsule) and lower into liquid nitrogen. 
When boiling stops, remove capsule and drain excess liquid nitrogen, taking care ball bearing does 
not get lost. 
Place on work surface – work quickly during this stage to minimise warming of capsule and sample. 
Remove Bijou containing sample from liquid nitrogen and tap sharply on work surface 3-4 times to 
loosen sample. Transfer sample to body of dismembranator capsule. 
Push lid firmly on to capsule body and place in dismembranator clamp. 
Switch on dismembranator – hold machine whilst running to reduce noise and vibration. 
Remove capsule from dismembranator and tap sharply on work surface 3-4 times to move sample to 
base of capsule. 
Open capsule and add lysis buffer: 
 Equine – 1500 µL for 100 mg tendon tissue results in fairly good solution, will fit easily into 
capsule and resulting solution will just fit into a 1.5 mL reaction tube. 
 Human – 1 mL lysis buffer per 100 mg powdered tissue. 
Lysis buffer will freeze. Replace lid on capsule and leave to thaw. 
Process next sample/s. 
When all samples have been processed to the stage they are in lysis buffer, pipette solutions 
vigorously to ensure completely solubilised and transfer to 1.5 mL reaction tubes.  
Store at -80oC or proceed to next stage of extraction (see 2.8.4 MirVanaTM RNA extraction protocol). 
 
2.8.2 RNA extraction protocol for equine tenocyte constructs 
Materials required: 
 Construct samples (previously weighed) 
 Mortar and pestle 
 2 clean Dewar flasks of liquid nitrogen  
 Long handled haemostats with locking ratchet for liquid nitrogen immersion 
 Dipping beaker for liquid nitrogen 
 Narrow blade spatula 
 Fine point forceps 
 60 mm diameter Petri dish to use as sterile instrument tray 
 1000 µL pipette and tips 
 1.5 mL reaction tubes and rack 
 70% ethanol and 1% Distel to clean surfaces and instruments 




Ensure appropriate PPE available for liquid nitrogen work. 
Transfer samples to dry reaction tube and drop into liquid nitrogen in one Dewar. 
Using long handled haemostats and dipping beaker, pour liquid nitrogen from second Dewar into 
mortar to cool mortar and pestle – the colder these are, the easier processing will be; work quickly 
during this stage to minimise warming of mortar, pestle and sample. 
Remove reaction tube containing sample from liquid nitrogen, pinch hinge between thumb and 
forefinger for a few seconds to prevent hinge snapping when tube opened and tap sharply on work 
surface to loosen sample. 
Transfer sample to mortar whilst still some liquid nitrogen left. 
Grind sample using pestle – may add more liquid nitrogen to mortar to keep cold. 
CARE – sample is very brittle and can easily be lost from mortar unless broken up gently.   
Add 500 µL lysis buffer (kit instructions recommend 10x volumes of lysis buffer per tissue mass). 
Lysis buffer will freeze – continue to grind to reduce to powder. 
Immerse one end of spatula in liquid nitrogen. When boiling stops, remove spatula and use to scrape 
frozen powder from mortar and pestle and transfer into 1.5 mL reaction tube. 
As mortar warms, powder will turn to sludge, then liquid. Use pipette to suck up residual sample and 
pipette vigorously to mix thoroughly in reaction tube. 
Clean mortar and pestle and any instruments used with 1% Distel then 70% ethanol prior to 
processing next sample. 
Transfer reaction tube to liquid nitrogen / -80oC freezer or proceed to next stage of extraction (see 
2.8.4 MirVanaTM RNA extraction protocol). 
 
2.8.3 RNA extraction protocol for monolayer cell cultures 
Materials required: 
 Cell cultures (6 or 12 well plates) 
 1000 µL pipettes and tips 
 DPBS - cold from fridge (Sigma-Aldrich D8537) 
 Lysis buffer (from MirVanaTM kit) 
 Cell scrapers (Sarstedt 83.1830) 
 Ice tray 
 1.5 mL reaction tubes and rack 
Aspirate and discard culture medium. 
Wash with DPBS and place culture plate on ice. 
Remove DPBS and add 600µL lysis buffer (from MirVanaTM kit) per well (12 well plate). 
Collect lysate with cell scraper and transfer to labelled 1.5 mL reaction tube. 
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Pipette vigorously to ensure complete lysis. 
Transfer reaction tube to liquid nitrogen / -80oC freezer or proceed to next stage of extraction (see 
2.8.4 MirVanaTM RNA extraction protocol). 
 
2.8.4 MirVanaTM RNA extraction protocol 
The MirVanaTM RNA extraction kit is designed to prevent loss of small RNAs during processing. The 
protocol for total RNA retrieval without small RNA enrichment was followed. 
Materials required: 
 MirVanaTM miRNA Isolation Kit (Invitrogen AM1560) contains: 
o Sample tubes and filters at room temperature 
o Acid-Phenol:Chloroform at 4oC 
o Homogenate Additive at 4oC 
o Wash Solution 1 and 2/3 at room temperature 
o Elution Solution (or use RNAse free water) at 95oC 
 Heating block set to 95oC 
 Molecular grade ethanol (100%) at room temperature (Sigma-Aldrich 51976-500ML-F) 
 100 µL pipette and tips 
 1000 µL pipette and tips 
 1.5 mL reaction tubes and rack 
 
Transfer sample/lysis buffer solution to clean 1.5 mL reaction tube: 
 600 µL for tendon tissue - aliquot any surplus solution into separate reaction tubes and 
freeze at -80oC. 
 500 µL for tendon constructs – entire volume.  
 600 µL Cell culture (12 well plate) 
Add Homogenate Additive: 
 60 µL per sample (tendon tissue)  
 50 µL per sample (tendon construct) (10% of sample volume) 
 60 µL Cell culture (from 12 well plate) 
Vortex briefly to mix. 




In fume hood add Acid-Phenol:Chloroform: 
 600 µL (tendon tissue) = same volume as original sample. 
 500 µL (tendon construct) = same volume as original sample. 
 600 µL cCell monolayer culture (12 well plate). 
Vortex tubes for 60 seconds. 
Centrifuge at room temperature at 10,000 g for 10 minutes to separate phases. 
Transfer top aqueous phase to clean 1.5 mL reaction tube and note volume removed (approximately 
350 – 400 µL yield from 500 µL original sample volume). 
Add 1.25 x harvested volume of 100% ethanol at room temperature (438 µL ethanol for 350 µL 
sample volume; 500 µL ethanol for 400 µL sample volume). 
Place filter cartridge into new sample tube (from kit) for each sample.  
Pipette sample/ethanol mix into filter cartridge, this can hold maximum 700 µL at a time (from 400 
µL sample + 1.25 x µL ethanol = ~900 µL – will need to add in 2 stages). 
Centrifuge tubes at room temperature at 10,000 g for 30 seconds. 
Discard flow through, repeat with any residual sample volume and discard second flow through. 
Using the same collection tube, replace filter cartridge and add 700 µL Wash Solution 1 into filter 
cartridge. 
Centrifuge at room temperature at 10,000 g for 30 seconds. 
Discard flow through, replace filter cartridge in same tube and add 500 µL Wash Solution 2/3. 
Centrifuge at room temperature at 10,000 g for 30 seconds. 
Discard flow through, replace filter cartridge and add second 500 µL volume of Wash Solution 2/3 
Centrifuge at room temperature at 10,000 g for 30 seconds. 
Discard flow through, replace filter cartridge and re-centrifuge for 1 minute at room temperature at 
10,000 g to remove all residual fluid from cartridge. 
Transfer filter cartridge to clean sample tube (from kit). 
Add 100 µL RNAse free water (or use Elution Solution provided in kit) at 95oC. 
Centrifuge at room temperature at 10,000 g for 30 seconds. 
Remove filter cartridge and dispose. 





2.9 RNA quantification and quality assessment 
 
2.9.1 Agarose gel electrophoresis 
Materials required: 
 RNA samples defrosted on ice (can also use PCR products to check primer integrity). 
 Agarose powder (Sigma-Aldrich A9639-100G) 
 Midori green DNA stain (Geneflow S6-0016) 
 6x Blue loading dye 
 1L 1x TAE (Tris/Acetic acid/EDTA) buffer - autoclaved to ensure RNase free (diluted from 50x 
TAE Buffer, Bio-Rad 1610743) 
 250 mL conical flask 
 1 L beaker 
 0.2 mL PCR tubes 
 10 µL pipette and tips 
 Microwave oven 
 Gel unit (horizontal) (Geneflow G9-0036) 
 
Place autoclave tape across 2 sides of tank tray to contain gel. 
Weigh out 1.0 g agarose powder (to make 100 mL 1% w/v gel). 
Mix agarose with 100 mL TAE buffer in conical flask. 
Microwave to dissolve agarose – swirl flask regularly to ensure mixing (solution may well boil). 
Allow to cool slightly, add 10 µL Midori green DNA stain and mix well. 
Pour into gel tray and place comb to create wells. 






Mix same volumes and ratios of ladder:dye as sample:dye. 
Mix well. 
Centrifuge to collect all liquid in bottom of tubes. 
Remove autoclave tape from gel tray once gel set. 
5 µL PCR products 
1 µL loading dye 
1 µL RNA sample 
1 µL loading dye 
4 µL RNAse free water 




Place gel tray in tank and pour over the rest of the TAE buffer to cover the gel (will take all the 
remaining buffer). 
Remove comb from gel. 
Load sample/dye mix into wells in gel – do this gently to avoid damaging wells and ensure mix stays 
within the well.  
Put lid on tank. 
Attach leads (red-red; black-black). 
Switch on power supply. 
Ensure set to Volts not mA. 
Set voltage using up/down arrows (70 – 90V). 
Press run. 
 
2.9.2 Nanodrop 2000 spectrophotometry 
Materials required: 
 RNA samples defrosted on ice 
 RNase free water (and buffer used to elute RNA into, if different) 
 10 µL pipette and tips 
 Lint-free tissue 
 NanoDrop 2000 spectrophotometer (ThermoFisher Scientific) 
Open Nanodrop software. 
Click on ‘Nucleic Acid’ application (top left of options). 
(Automatic dialogue box may open requesting wave length verification – if so ensure sample 
pedestal and sampling arm contact are clean, close arm and click ‘OK’). 
Open drop down menu in ‘Type’ box (top right of screen) and select ‘RNA’ (the number 40 should 
appear in the box immediately to the right). 
Ensure that ‘Add to report’ box is ticked (top of right hand panel, under ‘Measure’ icon). 
Clean NanoDrop pedestal and sampling arm contact with RNase free water and lint-free tissue. 
Pipette 1 µL RNase free water (or elution buffer) onto pedestal and close arm. 
Click on ‘Blank’ (top left of screen) – Blank must be measured before sample. 
Wipe pedestal/sampling arm contact clean. 
Pipette 1 µL sample onto pedestal and close arm. 
Type sample ID into ‘Sample ID’ box top right of screen. 
Click on ‘Measure’ (top left of screen). 
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When measurement completed, graph displays absorbance spectrum between 220 and 350 nm. 
RNA concentration (ng µL-1), absorbance at 260 nm (A260), 280 nm (A280), ratio of absorbance at 
260 and 280 nm (260/280) and 260 and 230 nm (260/230) are reported.  
Absorbance (A) is calculated as A = -log (Intensitysample / Intensityblank). 
Note: device measures absorbance using a 1 mm path length, but reports absorbance characteristics 
normalised to a 10 mm path length. 
Concentration is calculated using a modification of the Beer-Lambert equation c = Aɛ/L, where c = 
concentration, A = absorbance, ɛ = extinction coefficient (taken as 40 ng-cm µL-1), L = path length (in 
cm). RNA extinction coefficient automatically selected when inputting sample type before starting 
analyses. 
Record results. 
Wipe pedestal/sampling arm contact clean. 
Repeat for each sample. 
If measuring a lot of samples it is worth repeating the blank (manufacturer recommends doing this 
after 30 minutes) – can also measure blanking solution as a sample to check; reported absorbance 
characteristics should not vary by more than 0.04 A from original spectra. Also performing 
consecutive measurements on same sample periodically will check operational integrity (sample 





2.9.3 TapeStation electrophoresis  
Materials required: 
 RNA samples – thawed on ice 
 RNA Screen Tapes and reagents, either: 
o RNA Screen Tape (Agilent Technologies 5067-5576) -  
o RNA Screen Tape Sample Buffer (Agilent Technologies 5067-5577) 
o RNA Screen Tape Ladder (Agilent Technologies 5067-5578) 
or:  
o High Sensitivity RNA Screen Tape  
(Agilent Technologies 5067-5579)  
o High Sensitivity RNA Screen Tape Sample Buffer  
(Agilent Technologies 5067-5580) 
o High Sensitivity RNA Screen Tape Ladder ‡ 
(Agilent Technologies 5067-5581)  
 
‡ requires dilution; add 10 µL RNase free water to vial and vortex to mix 
 
 Loading tips (Agilent Technologies 5067-5153) 
 Optical tube strips (8x Strip) (Agilent Technologies 401428) 
 Optical tube strip caps (8x Strip) (Agilent Technologies 401425) 
 Vortex mixer with adapter for holding tubes (IKA Laboratory Equipment MS3 5067-
5700/4674100) 
 Heating block set to 72oC (Grant Instruments  BTA) 
 10 µL pipette and tips 
 Ice tray 
 Agilent 2200 Tape Station Instrument (Agilent Technologies) 
* RIN – RNA Integrity Number – an automatically calculated value to describe RNA integrity. Utilises  
an algorithm which incorporates the ratio of the areas under the 18S and 28S rRNA peaks on an 
electrophoretogram to the total area under the graph, the height of the 28S peak and the fast area 
(region between the 18S and 5S peaks) ratio (Schroeder et al 2006). RINe – RNA Integrity Number 
equivalent; value derived using the relative ratio of the fast zone signal to the 18S peak signal 
(Agilent Technologies). 
Equilibrate all reagents to room temperature and set heating block to 72oC. 
Briefly vortex and centrifuge buffer and ladder tubes prior to use. 
Add 5 µL Sample Buffer (1 µL if using High Sensitivity Buffer) to required number of tubes (no. of 
samples + 1). 
Add 1 µL RNA Ladder (2 µL if using diluted High Sensitivity Ladder) to one tube. 
Add 1 µL RNA sample (2 µL sample if using High Sensitivity reagents) to the remainder of tubes and 
cap tubes. 
Quantitative and 
RINe * functional 
range 25-500 ng µL-1 
Quantitative range 500-
10,000 pg µL-1, RINe * 
functional range 1000-
25,000 pg µL-1 
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Briefly centrifuge tubes to collect contents at bottom. 
Vortex tubes for 1 minute at 2000 rpm. 
Briefly re-centrifuge samples. 
Heat ladder and samples at 72oC for 3 minutes. 
Place on ice for 2 minutes. 
Re-centrifuge to ensure all sample at base of tubes. 
Load samples, Screen Tape and loading tips into Tape Station 2200 instrument for analysis (can take 




RNA was extracted from human tendon tissue derived from six patients with rotator cuff 
(supraspinatus tendon) tendinopathy and six patients undergoing anterior cruciate ligament 
reconstruction surgery (mixed semitendinosis and gracilis tendon). Details of these samples are 
given in Table 2.6. 
 
Sample number Sample name Organism Sex Age Status Source 
18139_7 0946/18 SSP Human F 39 Diseased Glasgow 
18139_8 0947/18 SSP Human F 39 Diseased Glasgow 
18139_9 0866/18 SSP Human M 51 Diseased Glasgow 
18139_10 0944/18 SSP Human M 50 Diseased Glasgow 
18139_11 0864/18 SSP Human M 59 Diseased Glasgow 
18139_12 0887/18 SSP Human F 45 Diseased Glasgow 
18139_13 LMB-KM-249 Human M 31 Healthy Liverpool 
18139_14 LMB-GA-253 Human F 17 Healthy Liverpool 
18139_15 LMB-HB-254 Human F 23 Healthy Liverpool 
18139_16 LMB-AS-255 Human F 23 Healthy Liverpool 
18139_17 LMB-MW-260 Human M 23 Healthy Liverpool 
18139_18 LMB-RM-261 Human M 26 Healthy Liverpool 
 
Table 2.6 Details of 12 human tendon samples (six tendinopathic supraspinatus and six healthy 
control mixed semitendinosis and gracilis tendons) submitted for small RNA-sequencing. M = male; 




Following elution into RNase free water and quantification (Nanodrop), samples were submitted to 
the Centre for Genomic Research, University of Liverpool, for library preparation and small RNA-
sequencing. Total RNA concentration and integrity was confirmed using Qubit (Thermofisher), but 
for 3 samples, concentration was too low and a Bioanalyser (Agilent) was used.  
 
Fifty five nanograms of total RNA per sample were used to prepare twelve libraries using a 
commercially available small RNA library preparation kit (NEBNext small RNA library prep kit) which 
retains strand selective information. This kit is developed to capture any small RNAs possessing a 5’ 
monophosphorylated and a 3’ hydroxylated end.  No specific ribosomal RNA depletion step was 
included, therefore library preparation used total RNA. PCR amplification used 15 cycles.   
 
Library for sequencing was size selected at 120-300 base pairs (bp) (library preparation adds 
approximately 126 bp to length of original sequences as adapter/primers).  
  
Paired-end, 150 bp sequencing was performed in a single lane on an Ilumina HiSeq 4000 machine, 
generating data from >280 M clusters (sequencing depth was approximately 23 M reads per 
sample).   
 
Data were processed using CASAVA (version 1.8.2) to generate output in FASTQ format.  
Raw FASTQ files were trimmed for the presence of adapter sequences using Cutadapt (version 1.2.1) 
with the option –O3, ensuring any reads which matched the adapter sequence for three bp or more 
were removed. Reads were further trimmed for quality using Sickle (version 1.200) using a minimum 
Phred (Q) score of 20. Reads shorter than 12 bp after trimming were discarded. If only one read of a 
pair passed this process, it was included in the R0 file.  
 
Trimmed R1-R2 read pairs were aligned using a Gencode fasta (.fa) file to reference genome 
(Gencode GRCh38.p12) using Bowtie2 (version 2.3.5). Reads from aligned BAM files were 
subsequently counted using featureCounts (version 1.6.4) against the Gencode reference annotation 
file (Gencode (GRCh38.p12) gft file) for non-miRNAs, and miRBase (hsa.gff3 file, release 22.1) for 
miRNAs, using Bowtie2 (version 2.3.5). Any counts to miRNAs from the Gencode file were removed 
to avoid duplication in downstream analysis.  
 
BAM files of small RNAs were counted separately against respective annotation files.  Information on 
3p/5p identity of miRNAs is included in miRBase, but absent in the Gencode annotation file. The 
Gencode annotation file was used to maximise identification and quantification of other (non-
miRNA) small RNA families as this information is unavailable in miRBase.  
 
Raw read counts (as .csv files) were then imported into the Bioconductor package DESeq2 (version 
1.22.2) for differential gene expression analysis. This pipeline normalises raw data based on the 
assumption that most genes are not differentially expressed (DE), using the median of read 
count/mean read count ratio for each gene to generate a scaling factor.  DESeq2 models data as a 
negative binomial distribution to account for biological and technical variation using local regression 
to estimate the relationship between mean and variance of each gene (Dillies et al 2012). 
Normalised counts are log2 transformed prior to application of a modified Fisher exact test to return 
exact P-values.  The Benjamini-Hochberg procedure for multiple hypothesis correction is then 
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applied. Results are reported as log2 fold change of normalised data and genes considered DE if log2 
fold change ≥1.5 with a Benjamini-Hochberg adjusted P-value <0.05. 
 
Principal component analysis (PCA) was used to visualise sources of variance in the data. All PCA 
calculations were performed in R (version 4.0.1, R Core Team (2020)), using the prcomp function 
within the package on regularised log transcript abundances, to extract principal components. Once 
extracted, principal components one and two were plotted using the ggplot2 plotting package, and 
samples were coloured according to the disease state of the tissue (red = diseased, blue = healthy). 
The variance each principal component explained was calculated manually as the square of the 
standard deviation. 
 
PCR validation  
RNA-Seq library preparation consumed all available RNA from four of the six SSP tendinopathy 
samples. Only two samples from the original cohort, both from 39 year old female patients, were 
therefore available for PCR validation purposes (Table 2.7). 
 
Sample number Sample name Organism Sex Age Status Source 
18139_7 0946/18 SSP Human F 39 Diseased SSP Glasgow 
18139_8 0947/18 SSP Human F 39 Diseased SSP Glasgow 
 
Table 2.7   Details of two human supraspinatus tendon samples harvested from patients with 
clinically diagnosed rotator cuff disease and used in RT-qPCR validation of RNA-seq data.  F = 
female; SSP = supraspinatus tendon; Age is given in years. 
 
RNA was available from all six original control samples (Table 2.8).  
 
Sample number Sample name Organism Sex Age Status Source 
18139_13 LMB-KM-249 Human M 31 Healthy ST/GR Liverpool 
18139_14 LMB-GA-253 Human F 17 Healthy ST/GR Liverpool 
18139_15 LMB-HB-254 Human F 23 Healthy ST/GR Liverpool 
18139_16 LMB-AS-255 Human F 23 Healthy ST/GR Liverpool 
18139_17 LMB-MW-260 Human M 23 Healthy ST/GR Liverpool 
18139_18 LMB-RM-261 Human M 26 Healthy ST/GR Liverpool 
 
Table 2.8 Details of six human hamstring tendon samples harvested from patients undergoing 
surgical repair of anterior cruciate rupture and used in RT-qPCR validation of RNA-seq data. M = 





RNA was extracted from three independent samples of diseased posterior tibial tendon to increase 
sample number available for RT-qPCR validation (Table 2.9). 
 
Sample number Sample name Organism Sex Age Status Source 
P1 P1M60081217 Human M 60 Diseased PTT Liverpool 
P2 P2M71191217 Human M 71 Diseased PTT Liverpool 
P3 P3M65130318 Human M 65 Diseased PTT Liverpool 
 
Table 2.9 Details of three human posterior tibial tendon (PTT) samples, harvested from patients 
with clinically diagnosed flat foot deformity, utilised as an independent cohort for RT-qPCR 
validation of RNA-seq data. M = male; Age is given in years. 
 
30 ng total RNA was reverse transcribed into cDNA for RT-qPCR. 
 
2.11 cDNA synthesis 
 
2.11.1 Reverse transcription protocol for miRNAs 
Selective conversion of mature miRNAs in the RNA template was performed by polyadenylation of 
mature miRNAs using poly(A) polymerase prior to conversion into cDNA by reverse transcriptase, 
using oligo-dT priming.  
Materials required: 
 RNA samples defrosted on ice 
 RNase free water (Sigma 3098) 
 miScript II RT Kit (Qiagen 218161) defrosted on ice – contains: 
o miScript HiSpec Buffer (5x) 
o miScript Nucleics Mix (10x) 
o miScript Reverse Transcriptase mix (Qiagen) 
 1.5 mL reaction tubes and rack  
 10 µL, 200 µL and 1000 µL pipettes and tips 
 0.2 mL PCR tubes 
 96 well freezer block 
 Ice tray 
 Thermal cycler (T100 BioRad)  
Keep reagents in ice and PCR tubes in freezer block. 
Calculate volume of each RNA sample required to provide 30 ng, 50 ng or 100 ng of template, using 
RNA concentration obtained from spectrophotometric analysis (NanoDrop 2000). 
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Calculate volume of RNase free water required to add to RNA template to make volume up to 12 µL. 
Prepare reaction mix as follows: 
 5 µL miScript HiSpec Buffer (5x) 
 2 µL miScript Nucleics Mix (10x) 
 1 µL miScript Reverse Transcriptase mix 
Pipette 8 µL of reaction mix into each PCR tube required. 
Add calculated volumes of RNase free water and RNA template to bring total volume per tube to 20 
µL. 
Briefly centrifuge PCR tubes to collect contents at base and transfer to thermal cycler. 
Perform a single step reaction: 
 Incubate at 37oC for 60 minutes 
 Reaction inactivation at 95oC for 5 minutes 
 Cool to 4oC 
Dilute samples with 180 µL RNase free water prior to storing at -20oC. 
 
2.11.2 Reverse transcription protocol for mRNAs 
Materials required: 
 RNA samples defrosted on ice 
 RNase free water (Sigma 3098) 
 Random hexamers (50 µM) (Invitrogen N8080127) 
 First Strand Buffer (5x) (Invitrogen Y02321) 
 DTT (0.1 M) (Invitrogen Y00147) 
 dNTPs (from 10 mM stock) (Sigma D4788-1MMO, T9656-1MMO,  D5038-1MMO, D4913-
1MMO) 
 Superscript II Reverse Transcriptase (Invitrogen 18064014) 
 Ribolock (40 U mL-1) (ThermoFisher EO0381) 
 1.5 mL reaction tubes and rack  
 10 µL, 200 µL and 1000 µL pipettes and tips 
 0.2 mL PCR tubes 
 96 well freezer block 
 Thermal cycler (T100 BioRad)  
Keep reagents in ice and PCR tubes in freezer block. 
Calculate volume of each RNA sample required to provide 500 ng, 200 ng, 100 ng or 50 ng of 
template (depending on application), using RNA concentration obtained from spectrophotometric 
analysis (NanoDrop 2000). 
Calculated volume of RNase free water required to add to RNA template to bring total volume per 




Prepare reaction mix as follows: 
 4 µL First Strand Buffer (5x) 
 2 µL DTT (0.1 M) 
 1 µL dNTP (from 10 mM stock) 
 Superscript II RT 
o 1 µL for 500 ng template 
o 0.5 µL for ≤200 ng template 
 1 µL Ribolock (40 U µL-1) 
 
Perform a two step reaction: 
Prepare reaction tubes by mixing RNase free water, template and random hexamers as follows: 
 X µL RNA template 
 Y µL RNase free water 
 1 µL Random hexamers (50 µM) 
 
 Run at 65oC for 10 minutes to denature and prime template. 
Place on ice immediately after to avoid RNA renaturing. 
Add 8.5 µL reaction mix per tube (9 µL if using 500 ng template) 
 Run at 42oC for 60 minutes 
 Cool to 4oC 




where X + Y = 10.5 µL  
(X + Y = 11 µL if using 500 ng template) 
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2.12 Quantitative real time PCR (RT-qPCR) 
 
2.12.1 Primer design and optimisation 
microRNAs 
miRNA-specific forward primers were purchased from Qiagen miScript Primer Assay range (Table 
2.10) as lyophilised powder and reconstituted with 550 µL RNase free water according to 
manufacturer’s instructions. 
 
Primer Identity Catalogue Number Mature miRNA Sequence 
Hs_SNORD61_11  218300/MS00033705 N/A 
Hs_RNU6-2_11  18300/MS00033740 N/A 
Hs_let-7f_1                 MIMAT0000067 218300/MS00006489 5'UGAGGUAGUAGAUUGUAUAGUU 
Hs_miR-29a_1            MIMAT0000086 218300/MS00003262  5'UAGCACCAUCUGAAAUCGGUUA 
Hs_miR-34a_1            MIMAT0000255 218300/MS00003318 5'UGGCAGUGUCUUAGCUGGUUGU 
Mm_miR-34b-5p_1   MIMAT0000382 218300/MS00007910 5'AGGCAGUGUAAUUAGCUGAUUGU 
Hs_miR-34b*_2          MIMAT0000685 218300/ MS00031780 5'UAGGCAGUGUCAUUAGCUGAUUG 
Hs_miR-34c_1            MIMAT0000686 218300/MS00003332  5'AGGCAGUGUAGUUAGCUGAUUGC 
Hs_miR-181a*_1        MIMAT0000270 218300/MS00006692 5'ACCAUCGACCGUUGAUUGUACC 
Hs_miR-181a_2          MIMAT0000256 218300/MS00008827 5'AACAUUCAACGCUGUCGGUGAGU 
Hs_miR-181b_1         MIMAT0000257 218300/MS00006699  5'AACAUUCAUUGCUGUCGGUGGGU 
Hs_miR-181c_2          MIMAT0000258 218300/MS00008841   5'AACAUUCAACCUGUCGGUGAGU 
Hs_miR-181d_2         MIMAT0002821 218300/MS00031500 5'AACAUUCAUUGUUGUCGGUGGGU 
Hs_miR-199a_1          MIMAT0000231 218300/MS00006741  5'CCCAGUGUUCAGACUACCUGUUC 
Hs_miR-199b_1         MIMAT0000263 218300/MS00003731 5'CCCAGUGUUUAGACUAUCUGUUC 
 
Table 2.10 Details of Qiagen miScript primers utilised in this study. Hs = Homo sapiens; Mm = Mus 
musculus. 
 
Reverse priming was achieved using Universal Primer Assay (Qiagen). 
 
Messenger RNAs 
Gene specific primers for were purchased from Primerdesign Ltd, Chandlers Ford, UK (Table 2.11 ), 
Eurogentec, Camberley, UK (Table 2.12), or Sigma, Welwyn Garden City, UK (Tables 2.13. and 2.14).  
Primers supplied by Primerdesign (Table 2.11) utilised the design and optimisation service offered by 
the company and were provided as a lyophilised powder of pre-mixed forward and reverse primers 
and were resuspended in 660 µL RNase-free water, to produce a 6 µM stock solution. 
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Target Species Primer sequence 
IL-1RAP F Equine ATGAGATTTGGTGGACCATTGATG 
IL-1RAP R Equine CTCCATTCATCTTCTGTTAGAGTCTG 
IL-7 F Equine GACCAGGGTCCTGGGAGT 
IL-7R Equine GGGGAGGAATTCCAAAGATATACC 
Insulin-like Growth Factor 1 F Equine TCAGTTCGTGTGTGGAGACAG 
Insulin-like Growth Factor 1 R Equine TCCAGCCTCCTCAGATCACAG 
ILGF1 receptor F Equine GGGAATGGAGTGCTGTATGCA 
ILGF1 receptor R Equine GCTCTCGGCTCATGGTGATC 
Insulin receptor F Equine CTGGATCAACCCGACAATTGTC 
Insulin receptor R Equine TCGACAATCTCCAGGAAGGTC 
NFκB2 F Equine GTGATCGTCGAACAGCCTAAG 
NFκB2 R Equine GAGGCACCTGGCAGTCC 
p38-MAPK (MAPK14) F Equine TGAATGAAGACTGCGAGCTGA 
p38-MAPK (MAPK14) R Equine CTGGTTGTAATGCATCCAGTTCA 
P62 (SQSTM1) F Equine TGTGAATTTCCTCAAGAACGTAGG 
P62 (SQSTM1) R Equine CCTGGAGAGACGGAGGTCA 
PARK7 F Equine GAAGGAACAAGAAAAGAGGAAAGGC 
PARK7 R Equine TAGCCTGTGGGTGTGTTGTAAC 
PRDX3 F Equine TGCTTGACAAATGTATTGTGGTC 
PRDX3 R Equine GTGCTGGGTGACGGCAG 
PRDX6 F Equine GCTCTCTCAATAGACAGTGTTGAAG 
PRDX6 R Equine AGGTCTCGATTCTTATCATCAATGATG 
SIRT1 F Equine TGCTGAAGCAGTAAGAAAGTGC 
SIRT1 R Equine CATGGAAAATGTAACGATTTGGTGG 
SMAD7 F Equine TCCAGATGCTGTGCCTTCC 
SMAD7 R Equine TCTCCTCCCAGTATGCCACC 
TGFβ-R1 F Equine GTGCCGACATCTATGCAATGG 
TGFβ-R1 R Equine TCATAATAAGGCAGCTGGTAATCTTC 
TGFβ-R2 F Equine CCTGTGTCGAAAGCATGAAGG 
TGFβ-R2 R Equine GGTCAGAGTCTCACACACCATC 
TNF F  Equine TACCGAATGCCTTCCAGTCAATC 
TNF R Equine GGGTTTGCTACAACATGGGCTA 
 
Table 2.11 Targets and sequences of equine primers supplied by Primerdesign Ltd (Chandlers Ford, 






Primers supplied by Eurogentec (Table 2.12) were previously designed by Dr Simon Tew and made 
available for use in this project. Eurogentec primers were reconstituted in RNase-free water 
according to the manufacturers’ Technical Data Sheet to produce 100 µM stock solutions. These 
were further diluted with RNase-free water to 20 µM for use. 
  
Target Species Primer sequence 
TNF F  Equine CCTTCCAGTCAATCAACCCTCT 
TNF R Equine CACGCCCACTCAGCCACT 
IL1 F Equine GCCTAAGAATACTACATCCAGAGA 
IL1 R Equine GGCATTGATTAGACAACAGTGAA 
GAPDH F Equine GCATCGTGGAGGGACTCA 
GAPDH R Equine GCCACATCTTCCCAGAGG 
 
Table 2.12 Targets and sequences of equine primers supplied by Eurogentec (Camberley, UK) 
utilised in this study. F = forward; R= reverse. 
 
Primers supplied by Sigma (Tables 2.13 and 2.14) were designed by the author (with the exception of 
the mouse TOMM20-directed primer), according to the protocol given below, and ordered as the 
following formulation: 
 Synthesis scale – 0.025 µmole 
 Purification – Desalt 
 Format – Dry 
Sigma primers were reconstituted in RNase-free water according to the manufacturers’ Technical 
Data Sheet to produce 100 µM stock solutions. These were further diluted with RNase-free water to 
20 µM for use.  
 





Target Species Primer sequence 
IL1a F Equine GGCAAAGAAATCAAGATGGCGA 
IL1a R Equine TTCAGAGTCTTCCCGTTGGC 
PARK2 F Equine AGTGAGCATGATCGTGTTTGT 
PARK2 R Equine TTAGCAACCGCCTCCTTGAG 
TGFβ1 F Equine CAGCATGTGGAGCTGTACCA 
TGFβ1 R Equine GGAACTGAACCCGTTGATGC 
TGFβ2 F Equine GAAGCAAGATTCGCAGACTTGA 
TGFβ2 R  Equine TCGATCTTGGGTGTTTTGCC 
TGFβ3 F Equine ACCAATTACTGCTTCCGCAAC 
TGFβ3 R Equine GTCAATGTAGAGAGGGCGCA 
 
Table 2.13 Targets and sequences of equine primers supplied by Sigma (Welwyn Garden City, UK) 
utilised in this study. F = forward; R = reverse. 
 
 
Target Species Primer sequence 
GAPDH F  Human CAAGGTCATCCATGACAACTTTG 
GAPDH R  Human GGCCATCCACAGTCTTCTGG 
COX IV F  Human TGGGAGTGTTGTGAAGAGTGA 
COX IV R  Human GCAGTGAAGCCGATGAAGAAC 
TOMM20 F  Mouse AGTCGAGCGAAGATGGTGG 
TOMM20 R  Mouse GCCTTTTGCGGTCGAAGTAG 
PARK2 F  Human CCCAGTGACCATGATAGTGTTTG 
PARK2 R  Human TGCTGGTGTCAGAATCGACC 
P62/SQSTM1 F Human CCGTGAAGGCCTACCTTCTG 
P62/SQSTM1 R  Human CGTCCTCATCGCGGTAGTG 
P62/SQSTM1 F  Human GTGAAGGCCTACCTTCTGGG 
P62/SQSTM1 R  Human GTCCTCATCGCGGTAGTGC 
MAP1LC3B F  Human CCGCACCTTCGAACAAAGAG 
MAP1LC3B R  Human AGATTGGTGTGGAGACGCTG 
COXI F  Human CTGCTATAGTGGAGGCCGGA 
COXI R  Human GGGTGGGAGTAGTTCCCTGC 
INSR F  Human GCCCTGTGACGCATGAAATC 
INSR R  Human GGACGTCTAAATAGTCTGTCACGTA 
 
Table 2.14 Targets and sequences of human primers supplied by Sigma (Welwyn Garden City, UK) 





Protocol for primer design 
Open the following applications: 
 NCBI Primer-BLAST https://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
 NCBI Gene https://www.ncbi.nlm.nih.gov/gene 
 
In NCBI Gene, type the name of the gene of interest in the search box. 
Click on the result relevant to the species of interest eg TOMM20 Homo sapiens: 
 
 






Scroll down to ‘mRNA and Protein(s)’ under the heading ‘NCBI Reference Sequences (RefSeq)’: 
 
  
Click on the hyperlinked code of the transcript of interest. There may be multiple transcript options 








The following screen will open: 
  
 
Copy the ‘ACCESSION’ number ... 
 
 





1) PCR product size – Min 50, Max 400 bp. 
2) Exon junction span - select ‘Primer must span an exon-exon junction’ from drop down 
list. 
3) Organism – enter species of interest (default is Homo sapiens). 
Note: Can change the ‘Primer melting temperatures (Tm)’ or the ‘#of primers to return’ if required. 
 
Click on ‘Get Primers’. 







Once primers have been designed, the following screen will open listing (usually) 10 primer pairs and 
their characteristics including length, Tm, self-complementarity etc.  
 
 
Aim for primer pairs with: 
 No additional products  
 GC content ~50% (40-55% OK) 
 1-2oC difference max for Tm 
 Lowest complementarity 
 Short (100-200bp) products (not >500bp)  







2.12.2 RT-qPCR protocol for miRNAs  
Fluorescence based RT-qPCR reaction mix was prepared as follows: 
Per reaction: 
 5 µL SYBR Green Supermix (PrecisionPLUS, Primerdesign) 
 0.7 µL miR-specific forward primer (miScript 10x Primer Assay, Qiagen) 
 0.7 µL reverse primer (miScript 10x Universal Primer Assay, Qiagen) 
 0.6 µL RNAse free water (Sigma) 
To this was added: 
 5 µL pre-diluted cDNA sample 
To give a total reaction volume of 12 µL. 
RT-qPCR run cycle (Bio-Rad CFX) 
A two stage amplification cycle protocol was employed. The initial denaturation step (95oC) being 
followed by a combined annealing and extension phase. Forty amplification cycles were run, 
followed by melt curve generation (55-95oC in 0.5oC increments) Annealing temperature was set to 
58oC for miR-181 primers, 55oC for all other miR-specific primers (Figure 2.2). 
 
 
Figure 2.2 RT-q PCR run cycle protocol for miRNA quantification. 
Technical replicates were run in triplicate. Expression relative to SNORD61 was calculated using the 
delta Ct method. Calculation of P-values was by either Kruskal Wallis, Mann Whitney U, or Student’s 
t-test with significance defined as P<0.05 (GraphPad Prism version 5.01 for Windows, GraphPad 
Software, San Diego California USA, www.graphpad.com).  
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2.12.3 RT-qPCR protocol for mRNAs  
Fluorescence based RT-qqPCR reaction mix was prepared as follows (volumes are per reaction): 
Primerdesign primers: 
 5 µL  SYBR Green Mastermix (PrecisionPLUS, Primerdesign)    
 0.6 µL  Forward/Reverse primer mix   
 1.4 µL RNAse free water   
Eurogentec or Sigma primers: 
 5 µL  SYBR Green Mastermix (PrecisionPLUS, Primerdesign)   
 0.18 µL 20 µM Forward primer solution    
 0.18 µL 20 µM R primer solution   
 1.64 µL RNAse free water (Sigma)   
To this was added:   
 5 µL pre-diluted cDNA sample   
To give a total reaction volume of 12 µL.  
RT-qPCR run cycle (Bio-Rad CFX) 
A two stage amplification cycle protocol was employed. The initial denaturation step (95oC) being 
followed by a combined annealing and extension phase, run at a default temperature of 60oC. Forty 
amplification cycles were run, followed by melt curve generation (65-95oC in 0.5oC increments) 
(Figure 2.3).  If aberrant melt curves were generated, a temperature gradient plate was run (Figure 
2.4) to optimise the annealing temperature and samples re-run.  
 
 




Figure 2.4 Temperature gradient RT-qPCR cycle run protocol for melt curve optimisation. 
 
Technical replicates were run in triplicate.  Expression relative to GAPDH was calculated using the 
delta Ct method. Kruskal Wallis test with Dunn’s test for pairwise comparisons was used to calculate 
P-values with significance defined as P<0.05 (GraphPad Prism version 5.01 for Windows, GraphPad 





2.13 Protein extraction 
  
2.13.1 Protein extraction protocol for cell monolayer culture (6 well plates) 
Materials required: 
 Cell cultures 
 1000 µL pipette and tips 
 DPBS - cold from fridge (Sigma-Aldrich D8537) 
 RIPA buffer (Sigma R0278-50ML) 
 Protease inhibitor (Roche cOmplete ULTRA Tablets, Mini, EDTA-free protease inhibitor 
cocktail, Sigma 05892791001) 
 Ice tray 
 Cell scrapers 
 1.5 mL reaction tubes and rack 
 Centrifuge 
 Shaker incubator at 4oC 
 
Dissolve 1 protease inhibitor tablet in 10 mL RIPA buffer - 150 µL needed per construct. 
Aspirate and discard TCM/treated TCM from wells. 
Wash with DPBS x 2 and place culture plate on ice. 
Remove DPBS and add 1 mL RIPA buffer with added protease inhibitor per well (6 well plates). 
Incubate for 5 minutes on ice. 
Collect lysate with cell scraper and transfer to labelled 1.5 mL reaction tube in ice. 
Pipette vigorously to ensure complete lysis and place on shaker incubator in cold room (4oC) for 30 
minutes. 
Centrifuge tubes at 14,000 g for 10 minutes at 4oC. 
Collect and measure supernatant into clean reaction tube and discard pellet. 





2.13.2 Protein extraction protocol for equine tenocyte constructs 
Materials required: 
 Samples - on dry ice or in liquid nitrogen 
 Metal dismembranator capsules (from BBraun MIKRO-DISMEMBRATOR U) 
 Pestle (narrow plastic ended pestle from Sartorius Potter S motorised pestle) 
 2 clean Dewars of liquid nitrogen  
 Long handled haemostats with locking ratchet for liquid nitrogen immersion 
 Dipping beaker and haemostats for liquid nitrogen 
 Fine point forceps 
 60 mm diameter Petri dish to use as sterile instrument tray 
 100 µL pipette and tips 
 1.5 mL reaction tubes and rack in ice 
 70% ethanol and 1% Distel to clean surfaces and instruments 
 RIPA buffer (Sigma R0278-50ML) 
 Protease inhibitor (Roche cOmplete ULTRA Tablets, Mini, EDTA-free protease inhibitor 
cocktail, Sigma 05892791001) 
 
Dissolve 1 protease inhibitor tablet in 10 mL RIPA buffer - 150 µL needed per construct. 
Ensure appropriate PPE available for liquid nitrogen work. 
Remove any residual suture material from constructs and weigh samples. 
Using long handled haemostats immerse one half of a dismembranator capsule and pestle into liquid 
nitrogen – this will act as the mortar when grinding sample. 
When boiling stops, remove capsule and pestle. Place pestle on sterile Petri dish, drain liquid N2 
from capsule and place on work surface.  
Remove reaction tube containing sample from liquid nitrogen/dry ice, pinch hinge between thumb 
and forefinger for a few seconds to prevent hinge snapping when tube opened and tap sharply on 
work surface to loosen sample. 
Transfer sample to mortar and add liquid N2 from second Dewar. 
Work quickly during this stage to minimise warming of capsule and sample. Wrap mortar in thick 
band of paper towel to hold. 
Grind sample using pestle (add more liquid nitrogen to mortar if boils dry before powder formed).  
CARE – sample is very brittle and can easily be lost from mortar unless broken up gently. Grinding 
the sample with liquid N2 in the mortar reduces the risk of sample being lost from the mortar when it 
fragments.   
Add 100 µL RIPA buffer/protease inhibitor mix once sample reduced to powder. DO NOT add buffer 
until sample is powdered, as buffer will freeze and sample will not grind properly. 
Place to one side and start processing next sample. 
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As mortar warms, buffer will melt and dissolve powdered sample. When liquid, use pipette to suck 
up buffer/sample solution to mix and transfer to 1.5 mL reaction tube. 
Rinse mortar with 50 µL RIPA buffer/protease mix and add this to reaction tube with sample. 
Place reaction tube on ice whilst processing remaining samples.  
Clean pestle (and mortar if need to reuse it) and any instruments used with 1% Distel then 70% 
ethanol prior to processing next sample. 
Transfer all reaction tubes in a rack onto the orbital shaker in the cold room (4oC) and run shaker at 
200 rpm overnight. 
Centrifuge at 14000 g for 10 minutes at 4oC. 
Collect (and measure) supernatant (discrete coherent pellet will form so easy to pipette off liquid). 
Freeze at -80oC or perform Pierce Assay for protein concentration determination (see 2.13.3). 
 
2.13.3 Protein concentration assay (Pierce assay)  
Materials required: 
 Samples of protein extracts thawed on ice 
 Bovine serum albumin standards (ThermoFisher 23208 - Pre-diluted Protein Assay 
Standards. Bovine Serum Albumin (BSA) set: 2000, 1500, 1000, 750, 500, 250 and 125 µg 
mL-1) (or make your own). 
 96 well cell culture plate 
 Pierce Assay Reagent  (ThermoFisher 226600 – Pierce 660 nm Protein Assay Reagent.  
 10 µL, 100 µL and 1000 µL pipettes and tips  
 SPECTROstar Nano spectrometer-based absorbance microplate reader (BMG Labtech). 
In 96 well plate add 10 µL of standards/sample in duplicates or triplicates + 150 µL Pierce Assay 
Reagent.   
Put on plate shaker for 1 minute or just tap gently to mix – CARE solution does not splash onto plate 
lid and ensure all bubbles are removed (use 1000 µL pipette to gently ‘blow’ on wells to remove 
bubbles). 
Incubate at room temperature for 5 minutes. 
Read absorbance at 660 nm wavelength on microplate reader. 
Calculate standard curve and sample protein concentrations using Excel spreadsheet (anchor line of 








 ProtoGel 30% w/v Acrylamide (National Diagnostics EC-890). 
 ProtoGel Resolving Buffer (4x) (National Diagnostics EC-892). 
 ProtoGel Stacking Buffer (National Diagnostics EC-893). 
 10% Ammonium persulfate (APS) stock solution (pre-prepared from ammonium persulfate; 
Sigma-Aldrich A3678). 
 N,N,N′,N′-Tetramethylethylenediamine (TEMED) (Sigma T9281-100ML). 
 Tris-Glycine-SDS PAGE Buffer (10x) (National Diagnostics EC-870) or: 
o Tris base (Trizma® base – Sigma T6066-1KG) 
o Glycine powder for electrophoresis (Sigma-Aldrich G8898) 
o Sodium dodecyl sulfate (SDS) (Sigma L3771-100G) 
 
 Protein Loading Buffer (x5) (National Diagnostics EC-887). 
 Isopropanol (Sigma-Aldrich I9516-500ML). 
 Distilled water 
 Water - Molecular Biology Reagent (Sigma W4502-1L) – for protein dilution. 
 Chameleon Duo Pre-stained Protein Ladder (LI-COR 928-60000). 
 5 mL and 10 mL serological pipettes and gun. 
 10 and 200 µL pipettes and tips. 
 Pasteur pipettes. 
 30 mL Universals or 15 mL Falcon tubes. 
 Heating block set to 95oC. 
 PowerPac Basic Power Supply (Bio-Rad 1645050). 
 Electrophoresis tank (Bio-Rad Mini-PROTEAN Tetra System 165-8006) – includes 1.5 mm gel 
casting glasses and apparatus. 
 
2.14.1 Solutions and reagents for SDS-PAGE 
1x Running Buffer – need 1 L.  
Dilute 10x Tris-Glycine-SDS PAGE buffer in distilled water, or make up: 
 3.03 g Tris base (0.025 M) 
 14.4 g Glycine (0.192 M) 
 1 g SDS (0.1%)  
 1000 mL distilled water 
 
pH 8.5 (do not adjust pH).  






10% ammonium persulfate (APS) stock solution  
Dissolve 500 mg ammonium persulfate powder (Sigma-Aldrich A3678) in 5 mL of distilled water. 
Freeze at -20°C in 250 µL aliquots (enough to make 2 x gels). 
 
2.14.2 Protocol for casting gels 
 
Set up gel casting stand. Make sure base of casting glasses are level and held tightly together to 
prevent leaking (use plates for 1.5 mm gel). 
 
Prepare two tubes for the resolving and stacking gel solutions as indicated in Table 2.15  (do not add 
APS or TEMED yet, as the solution will polymerise – add these just before pouring the solution into 
the casting glasses). 
 
Reagent Resolving gel (12%) Stacking gel (4%) 
1 gel 2 gels 2 gels 
ProtoGel 30% Acrylamide 4 mL 8 mL 1.3 mL 
ProtoGel Resolving Buffer (4x) 2.5 mL 5 mL N/A 
ProtoGel Stacking Buffer N/A N/A 2.5 mL 
Distilled water 3.3 mL 6.6 mL 6.1 mL 
APS (10% stock solution) 100 µL 200 µL 50 µL 
TEMED 20 µL 40 µL 25 µL 
 
Table 2.15 Relative quantities of reagents for casting gels used for Western blotting. 
 
 
Add APS and TEMED to the resolving gel solution, mix by inverting. Using 10 mL serological pipette, 
add ~8 mL of the resolving gel solution into the gap between the two glasses, leaving 2 cm below the 
bottom of the comb level – avoid creating bubbles. 
 
Quickly add a ~1 mL of isopropanol on top of the resolving gel to obtain a flat interface and remove 
surface bubbles. Leave to polymerise for 30 minutes at room temperature. 
 
Once polymerised, pour off isopropanol and carefully rinse with distilled water several times. Remove 
any excess of liquid with a filter paper – do not touch gel. 
 
Add APS and TEMED to the stacking gel solution, mix by inverting and pour onto top of resolving gel 
(~3 mL per gel to form positive meniscus at top of short plate). Carefully place the appropriate comb 




Once polymerised, gently remove comb for use, or store with comb in place, wrapped in tissue paper 
soaked with distilled water and sealed in a plastic bag (up to 2 days at 4oC). 
 
 
2.14.3 Protocol for loading and running gels 
 
Calculate the volume of protein sample needed to obtain required mass of protein for all samples and 
volumes of molecular grade water and 5x loading buffer needed to make up required total loading 
volume. Use 5-30 µg protein. 
 
Mix samples and water first, then add 1:5 (loading buffer:undiluted sample) of 5x protein loading 
buffer – do this in fume hood. Protein with loading buffer can be prepared in advance and stored at   
-20°C until use.  
 
Maximum loading volumes (Sample + buffer + water) for 1.5 mm thick gels: 
 
 30 µL if using 15 well comb 
 
 60 µL if using 10 well comb  
 
Heat the samples at 95°C for 5 minutes in heating block. Briefly centrifuge to collect sample at base of 
tube (this must be done just before loading the samples). 
 
Place the gel in the electrophoresis tank, with the wells facing the interior of the tank. If running only 
one gel, place a plastic buffer dam on the opposite side of the gel box.  
 
Pour cold running buffer into the electrophoresis tank between the gels, making sure that the 
reservoir between the gels is completely filled and that the buffer level comes to the mark on the side 
of the tank. Note: running buffer must be cold - put the electrophoresis tank over ice box. 
 
Load molecular marker (Chameleon Duo, LI-COR) in the first well; 5 µL for 10 well gel; 3 µL for 15 well 
gel. Then load samples in their respective wells. Do this in fume hood. Tilting gel holder in tank makes 
it easier to see wells. 
 
Top up running buffer if necessary – CARE – use serological pipette to avoid disturbing samples. 
 
Close electrophoresis tank making sure that the red (positive) and black (negative) electrode wires are 
correctly connected to the power supply. 
 
Use constant voltage setting on power supply. Apply a voltage of 120 V for 11/2 hours. Check current 
is running by looking for bubbles forming on the electrodes.  Run until the loading buffer reaches the 





2.15 Western blotting 
 
Materials required: 
 Tris base (Trizma® base – Sigma T6066-1KG) 
 Methanol (Sigma-Aldrich 322415-1L) 
 6-amino-n-hexanoic acid (Sigma-Aldrich 07260-500G) 
 3MM Chr Chromatography Paper 10 cm x 100 m (GE Healthcare Whatman 3030-672) 
 Ponceau S Solution (Sigma-Aldrich P7170-1L) 
 TWEEN 20 (Sigma-Aldrich P1379-500ML) 
 Distilled water 
 Phosphate Buffered Saline Tablets (Sigma-Aldrich P4417-50TAB) 
 PVDF Western Blotting Membrane (Roche 03010040001) 
 Marvel Original Dried Skimmed Milk Powder (Premier Foods) 
 Odyssey Blocking Buffer (now discontinued) 
o TBS (LI-COR 927-50000) 
o PBS (LI-COR 927-40000) 
 Intercept Blocking Buffer 
o PBS (LI-COR 927-7000) 
 Primary antibodies: 
o Rb anti-LC3B (ab192890) - use at 1:1000 dilution  
o Ms anti-MFN1 (ab57602) - use at 1:1000 dilution  
o Ms anti-MFN2 (ab56889) - use at 1:1000 dilution  
o Rb anti-NRF2 C-20 (sc-722) - use at 1:400 dilution  
o Ms anti-P62 (ab56416) - use at 1:1000 dilution  
o Ms anti-PARKIN (ab77924) - use at 1:200 dilution  
o Rb anti-TOMM20 (ab186734) - use at 1:1000 dilution  
o Rb anti-BNIP3 (ab109362) - use at 1:1000 dilution  
o Rb anti-COXIV (ab16056) - use at 1:1000 dilution  
o Rb anti-LAMP1 (ab62562) - use at 1:500 dilution  
o Ms anti-Vinculin (ab130007) - use at 1:1000 dilution  
 
 Secondary antibodies: 
o IRDye 800CW Goat anti-Rabbit IgG (LI-COR 926-32211) – use at 1:10,000 dilution  
o IRDye 800CW Goat anti-Mouse IgG (LI-COR 925-32210) – use at 1:10,000 dilution  
o IRDye 680RD Goat anti-Mouse IgG (LI-COR 926-68070) – use at 1:10,000 dilution  
 
 Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad 170-3940) 
 Chemi Doc XRS+ Imaging System (Bio-Rad 1708265) 





2.15.1 Solutions required for Western blotting 
PBS-T: (0.05% Tween20® in PBS)  
 5 Phosphate buffered saline tablets (Sigma P4417-50TAB) 
 1000 mL distilled water 
 50 µL Tween20® (Sigma P7949-500ML) 
(Note: if looking at phosphorylated proteins use TBS-T – also need TBS blocking buffer). 
 
Anode I Buffer:  0.3 M Tris in 20% methanol solution, pH 10.4. 
 36.34 g Tris base 
 800 mL distilled water 
 200 mL methanol 
 
 
Anode II Buffer: 25 mM Tris in 20% methanol solution, pH 10.4. 
 3.02 g Tris base 
 800 mL distilled water  
 200 mL methanol 
 
 
Cathode Buffer: 40 mM 6-amino-n-hexanoic acid in 20% methanol solution, pH 7.6. 
 5.24 g 6-amino n hexanoic acid 
 800 mL distilled water 
 200 mL methanol 
 
 
2.15.2 Western blotting protocol 
 
Remove gel from glass plates. Trim wells from top of gel and place in Anode II buffer to equilibrate for 
≥10 minutes. 
 
Cut approximately 6 cm x 8.5cm square of PVDF membrane. Do not touch membrane - handle using 
tissue forceps. Activate membrane by incubating in methanol on rocker for ≥10 minutes and then 
rinse in Anode II solution.  
                                                                              
For each gel cut 18 pieces of chromatography paper slightly larger than gel (8 cm x 10 cm). Soak in 
transfer buffers as follows:  
 
 6 papers in Anode I buffer 
 3 papers in Anode II buffer 




Load the transfer cell in the following order: 
 
 Cathode (-) (top) 
 9 papers soaked in Cathode solution 
 Gel 
 Membrane 
 3 papers soaked in Anode II solution 
 6 papers soaked in Anode I solution 
 Anode (+) (bottom) 
 
Remove air bubbles by rolling. 
 
Soak up any excess transfer buffers next to the blot with paper towel and close cell. 
 
Run transfer unit at 200 mA for 1 hour (The transfer time may vary depending on the properties of 
the proteins, and should be determined empirically).  
 
Remove membrane carefully, rinse with distilled water and stain with Ponceau S. 
 
Return Ponceau S stain to bottle and wash membrane 3-4 times with distilled water until background 
staining removed and the bands are clearly visible. Do not wash with PBS-T before imaging or all bands 
will become weaker and image quality will be poor.  
 
Image Ponceau staining using BIO-RAD Chemi Doc. 
 
Wash the membrane 3 x 5 minutes with PBS-T until Ponceau staining completely removed. 
 
Block membrane with 10 mL 3% milk in PBS-T or LI-COR Odyssey or Intercept Blocking Buffer for 60 
minutes at room temperature on rocker (keep blocking solution to dilute secondary antibody in later). 
 
Incubate overnight at 4°C on rocker with primary antibody diluted in 3% milk/PBS-T or LI-COR Blocking 
Buffer. 
 
Wash 3 times for 5 minutes with PBS-T. 
 
Incubate for 1 hour at room temperature with secondary antibody diluted in 10 mL 3% milk/PBS-T or 
LI-COR Blocking Buffer.  
 
Wash 3 times for 5 minutes with PBS-T. 
 





2.16 Histological processing  
 
Tendon constructs for histological evaluation were submitted pinned to a backing of silicone 
elastomer (SylgardTM, Dow Corning Corporation) in appropriate fixative (see 2.4.3). All processing 
was performed by Miss Valerie Tilston of the University of Liverpool Veterinary Laboratory Services 
Group, Leahurst Campus.  
 
2.16.1 Routine histology 
Processing for light microscopy was performed by Mrs Valerie Tilston and consisted of paraffin 
embedding, sectioning, mounting and staining with haematoxylin and eosin, Masson’s trichrome 
and elastin von Gieson’s stains.  
Materials required: 
 Potassium permanganate (Sigma-Aldrich 223468-500G) 
 Oxalic acid 1% (TCS Biosciences HK015) 
 Ethanol (Sigma-Aldrich 51976-500ML-F) 
 Millers Stain (HD Supplies HS235-500) 
 Van Giesons Stain (TCS Biosciences HS780-500) 
 Xylene (Fisher Scientific X/0250/17) 
 Haematoxylin 95% monohydrate (Atom Scientific RRBD61-X or TCS Biosciences HD1475) 
 Sodium iodate (Acros Organics 201761000) 
 Aluminium Potassium Sulphate (Acros Organics 217485000,) 
 Glacial Acetic Acid (Fisher Scientific A/0360/PB17) 
 Eosin Y Stain (TCS Biosciences Ltd HS250-1L) 
 Celestine Blue (Sigma-Aldrich 206342) 
 Ferric Ammonium Sulphate (BDH Chemicals 271644) 
 Glycerol (VWR International 24388.295) 
 Ponceau de Xylidine (HD Supplies HD1800) 
 Acid Fuchsin (Biostain Ready Reagents RRBD93/X)  
 Phosphomolybidic acid (Acros Organics 206381000)  
 Light Green (HD Supplies HD1535)  
 DPX (Thermo Scientific LAMB/DPX) 
 Distilled water 
 Microscope slides (Solmedia MSS61012S, MSS4511YW) 
 Cover slips (FisherScientific FB58670) 
 Tissue processing/embedding cassettes (Fisher Scientific 10746851) 
 Tissue processor (Sakura Fintek Tissue-Tek Vacuum Infiltration Processor) 
 Paraffin wax (Solmedia Ultraplast premium embedding medium WAX060) 




Dehydration and infiltration of formalin fixed tissue was performed in a Tissue-Tek vacuum 
infiltration automatic tissue processor overnight, using the following protocol:  
 10% formalin for 1 hour 45 minutes 
 70% ethanol for 30 minutes 
 70% ethanol for30 minutes 
 86% ethanol for 30 minutes 
 96% ethanol for 1 hour 30 minutes 
 Absolute ethanol for 1 hour 30 minutes 
 Absolute ethanol for 1 hour 30 inutes 
 Xylene for 1 hour 
 Xylene for 2 hours 
 Wax 1 for 1 hour 
 Wax 2 for 1 hour 
 Wax 3 for 1 hour 
 Wax 4 for 1 hour 
 End  
 
Samples were embedded in paraffin, 4 µm paraffin sections cut on a Leica RM2125 RT microtome, 
floated on a waterbath and placed on slides. Dewaxing, rehydration, staining and dehydration of 
sections was performed as detailed below. Mounting was completed by application of DPX and 
cover slip. 
Millers Elastin Stain (EVG) staining method 
Dewax sections in xylene for 5 minutes. 
Transfer sections to fresh xylene and rehydrate by taking through descending concentrations of 
ethanol; 100%       96%       85%       70%       distilled water. 
Treat sections with 1% potassium permanganate for 5 minutes. 
Rinse in distilled water. 
Decolourise in 1% oxalic acid for 1 minute. 
Wash briefly in running water. 
Rinse in 95% ethanol. 
Stain in Millers stain (HD Supplies, HS235-500) for 3 hours. 
Rinse in 95% ethanol to remove excess stain. 
Wash in running water. 
Counterstain with Van Giesons stain (TCS Biosciences, HS780-500) for 4 minutes. 
Blot, air dry and dehydrate in absolute ethanol. 
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Clear in xylene and mount in DPX. 
Elastin tissue stains deep blue; collagen stains red; other tissues stain yellow. 
 
Mayers Haematoxylin formulation 
 1 g Haematoxylin 95% monohydrate (RRBD61-X, Atom Scientific, Manchester, UK or TCS 
Biosciences Ltd HD1475). 
 0.2 g Sodium iodate (Acros Organics 201761000). 
 50 g Aluminium Potassium Sulphate (Acros Organics 217485000). 
 1 L distilled water. 
 20 mL glacial acetic acid (Fisher Scientific A/0360/PB17). 
Dissolve haematoxylin in distilled water using gentle heat. 
Add aluminium potassium sulphate and dissolve using gentle heat. 
Cool, add sodium iodate and mix. 
Filter the solution and add 20 mL glacial acetic acid. 
 
Eosin stain formulation 
 50 mL 1% Eosin Y Stain (TCS Biosciences Ltd HS250-1L). 
 390 mL 95% ethanol. 
 2 mL glacial acetic acid (Fisher Scientific A/0360/PB17). 
 
Haematoxylin and eosin (H&E) staining method 
Dewax sections in xylene for 5 minutes. 
Transfer sections to fresh xylene and rehydrate by taking through descending concentrations of 
ethanol; 100%       96%       85%       70%       distilled water. 
Stain sections in Haematoxylin for 5 minutes. 
‘Blue’ sections under running tap water for 6 minutes. 
Stain sections in Eosin for 2 minutes. 
3 x 1 minute washes in 96% alcohol (dip sections up and down to remove excess Eosin). 
3 x washes in 100% alcohol. 






Mount sections in DPX and coverslip. 
Haematoxylin – basic dye staining basophilic structures (ribosomes, nucleus, RNA-rich regions) blue-
purple. 
Eosin – alcohol based acidic dye colours eosinophilic structures (protein rich) pink. 
Structures do not have to be acidic or basic, the terms basophilic and eosinophilic reflects the affinity 
to the dyes. 
 
Masson Trichrome stain formulation 
 Celestine Blue Solution  
o 2.5 g Celestine Blue (Sigma-Aldrich 206342). 
o 25 g Ferric Ammonium Sulphate (BDH Chemicals 271644). 
o 70 mL Glycerol (VWR International 24388.295). 
o 500 mL distilled water. 
 Cytoplasmic Stain   
o 2 parts 1% Ponceau de Xylidine (HD Supplies HD1800). 
o 1 part 1% Acid Fuchsin (Biostain Ready Reagents RRBD93/X) in 1% acetic acid. 
 1% Phosphomolybidic acid (Acros Organics 206381000). 
 2% Light Green (HD Supplies HD1535). 
 
Masson’s Trichrome staining method: 
Dewax sections in xylene for 5 minutes. 
Transfer sections to fresh xylene and rehydrate by taking through descending concentrations of 
ethanol; 100%       96%       85%       70%       distilled water. 
Stain in Celestine Blue for 5 minutes. 
Rinse with tap water and stain with Mayers Haematoxylin for 5 minutes. 
‘Blue’ in tap water for 6 minutes. 
Stain with Cytoplasmic Stain for 7 minutes. 
Rinse in tap water. 
Differentiate in 1% phosphomolybdic acid for 5 minutes. 
Rinse in tap water. 
Counterstain in 2% Light Green (dilute 1:10 in 1% acetic acid) for 5 minutes. 
Differentiate in 1% acetic acid for 1-2 minutes to remove excess green. 
Blot with fibre free blotting paper. 
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Dehydrate through increasing grades of alcohol (70%, 85%, 96%, 100%) clear in xylene and mount 
with DPX ((LAMB/DPX). 
Nuclei stain black; muscle, red blood cells, fibrin and cytoplasmic granules stain red; collagen, 
reticulin, amyloid and mucin stain green. 
 
Grading histological appearance of tendon constructs 





















Table 2.16 Grading scheme used to score tendon contruct histological appearance. The scheme is 
modified from elements contained in the Bonar (Cook et al 2004) and Movin (Movin et al 1997) 
scores for classification of the histopathological appearance of diseased tendon.    
Characteristic Score 
Extracellular Matrix organisation  
- Compact  
- In part compact, in part loose 






- Spindle-shaped (normal) 
- Mixture of spindle and round cells 






- Homogenous Distribution of cells 





- Uniaxial  





- Low Cellularity  
- Intermediate Cellularity  






- Parallel arrangement, tight cohesive bundles, 
homogenous polarisation pattern, normal 
crimping 
- Separation of individual fibre bundles, 
maintenance of overall bundle architecture     
- Bundle changes; loss of demarcation of bundles, 
loss of normal polarisation pattern 
- Marked separation of bundles, complete loss of 
architecture  











Histological scores were compared across treatment groups using the Kruskal Wallis test with Dunn’s 
multiple comparison test. Inter- and intra-rater reliability of scoring investigated using weighted 
Cohen’s kappa coefficient (GraphPad Prism version 5.01 for Windows, GraphPad Software, San 
Diego California USA, www.graphpad.com). 
 
2.16.2 Electron microscopy 
Processing for transmission electron microscopy (TEM) was performed by Mrs Marion Pope and 
consisted of resin embedding, sectioning, mounting and staining with Toluidine blue (for light 
microscopy evaluation) and uranyl acetate and lead citrate staining (TEM evaluation). 
Materials required: 
 Glutaraldehyde 25% E.M. Grade (Taab Laboratories Equipment G002). 
 Sodium cacodylate (Taab Laboratories Equipment S011). 
 Osmium tetroxide (Taab Laboratories Equipment O001). 
 Uranyl acetate (Taab Laboratories Equipment U007). 
 Maleic acid (Taab Laboratories Equipment M003). 
 Ethanol, absolute (Taab Laboratories Equipment E047). 
 Acetone E.M. grade (Taab Laboratories Equipment A018). 
 Taab epoxy resin components (Taab Laboratories Equipment T001, D025, M011, 
D032). 
 Embedding moulds (Taab Laboratories Equipment E095). 
 Toluidine blue (Taab Laboratories Equipment SD211). 
 Borax (Taab Laboratories Equipment B021). 
 Methanol (Taab Laboratories Equipment M023). 
 Reynold’s lead citrate stain 3% (Taab Laboratories Equipment L037). 
 Curing oven at 60oC (Genlab Ltd MINO/4/CLAD). 
 Richert-Jung Ultracut ultramicrotome (Leica Microsystems (UK) Ltd). 
 Diatome ultra diamond knife (Agar Scientific AGG3397). 
 200 mesh TEM thin bar copper grids (Agar Scientific AGG2700C). 
 Phillips EM208S Transmission Electron Microscope (Thermo Fisher Scientific). 
 
Fixation:  
Primary: 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4 for 4 hours. 
 
Wash 0.1 M sodium cacodylate buffer pH 7.4 for 30 minutes. 
 
Secondary fixation and contrast stain:  osmium tetroxide 1% aqueous for 1 hour. 
 
Wash 0.1 M sodium cacodylate buffer pH 7.4 for 30 minutes. 
 
‘en bloc’ staining  2% uranyl acetate in 0.69% maleic acid pH 4.5 for 1 hour. 
 
Dehydrate in ascending concentrations of ethanol 50%      70%      90% for 2 x 5 minutes each. 
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100% ethanol 3 x 10 minutes each. 
 
100% acetone 3 x 5 minutes each. 
  
Infiltrate with epoxy resin in ascending resin: acetone mixes: 
 resin 1 : 3 acetone for 1 hour. 
 resin 2 :  2 acetone for 1 hour. 
 resin 3 : 1 acetone for 1 hour. 
 100% resin 2 x 1 hour. 
 
Embed in 100% epoxy resin in flat embedding mould. 
 
Polymerise at 60oC overnight. 
 
Sectioning : 
For light microscopy evaluation:  
 Semi-thin sections (0.5 µm) cut on Reichert-Jung Ultracut ultramicrotome. 
 Stained with 1% Toluidine blue in 1 % borax.  
 
For TEM: 
 Ultrathin Sections (60-90 nm) cut with Diatome diamond knife on Reichert-Jung Ultracut 
ultramicrotome.  
 Mount on 200 mesh copper grids. 
 Contrast stain with saturated solution of uranyl acetate in 50% methanol for 5 minutes. 
 Incubate with Reynold’s Lead citrate stain for 5 minutes. 
 
Viewed and imaged in Phillips EM208S Transmission Electron Microscope at 80 kV. 
 
 
2.17 Statistical analysis  
 
Small RNA-sequencing data were analysed for differential gene expression using the Bioconductor 
package DESeq2 (version 1.22.2). Genes were considered DE if log2 fold change ≥1.5 with a 
Benjamini-Hochberg adjusted P-value <0.05. All principal component analysis calculations were 
performed in R (version 4.0.1, R Core Team (2020)), using the prcomp function, with principal 
components one and two plotted using the ggplot2 plotting package. See Chapter 3 for further 
details.  
  
miRNA:target interactions, associated network and pathway analysis was performed using QIAGEN 
Ingenuity Pathway Analysis (QIAGEN Inc., Redwood City, CA, USA, 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis, Krämer et al 2014). 
See Chapter 4 for further details.  
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Analysis of inter- and intra-rater repeatability of the modified grading system applied to tissue-
engineered three-dimensional equine tendon constructs (Chapter 6) was investigated using Cohen’s 
kappa coefficient (κ), calculated in Excel (Microsoft Corporation, 2018. Microsoft Excel, available at: 
https://office.microsoft.com/excel). Tables were constructed for total score and each component of 
the grading scheme for both repeated, blinded grading by the same operator and blinded grading by 
two independent operators. Agreement due to chance was calculated and subtracted from both the 
sum of number of agreements and total number of comparisons possible, with the ratio of the 
residuals defining Cohen’s kappa for each component, which varied between 0 (agreement 
equivalent to chance alone) and 1 (perfect agreement). 
All other statistical analyses were performed using GraphPad Prism version 5.01 for Windows 
(GraphPad Software, San Diego California USA, www.graphpad.com).   
RT-qPCR data were analysed non-parametrically.  In Chapter 3, comparison of relative miRNA 
expression between tendinopathic tissue and controls for both human and equine data, human 
tendinopathy validation work and comparisons between control and posterior tibial tendon (PTT) 
tissue utilised the Mann-Whitney test as conditions for its application were satisfied.  Comparisons 
between control and supraspinatus (SSP) tissue, and between SSP and PTT samples (Chapter 3), 
utilised the Student t test, as less than three data points were present in the SSP comparator group, 
which precluded the use of non-parametric analysis. These results are presented in Appendix 2, 
Figure A2.2. Comparison of ages between donors of tendinopathic and control tissue utilised the 
Student t-test.  
Analysis of gene expression (Chapters 5, 6 and 7) and tissue-engineered three-dimensional tendon 
construct grading data (Chapter 6), between miR-181a mimic, antagomiR and scrambled control 
sequence treated groups were analysed using the Kruskal Wallis test with Dunn’s test for pairwise 
comparisons. Comparison of target gene expression (Chapter 5, 6 and 7) and histological grading 
scores (Chapter 6) between scrambled control sequence treated and untreated groups, where 
performed, utilised the Mann-Whitney test when conditions for its application were satisfied. 
Results are presented in Appendix 5, Figure A5.1, Appendix 6, Figures A6.1 and A6.3, and Appendix 
7, Figure A7.1 respectively. Where less than three data points were present in one comparator 
group, the Student t test was used. Histological scoring between scrambled control and untreated 
constructs contained some categories where all data points in the untreated group had the same 
numerical value, it was therefore not possible to generate P-values for these categories. 
Protein levels between miR-181a mimic, antagomiR and scrambled control sequence treated groups 
derived from Western blot images (Chapters 6 and 7) were analysed using one way ANOVA with 
Tukey’s multiple comparison test for pair-wise comparisons. Comparisons between scrambled 
control sequence treated and untreated groups (Chapter7) utilised the Student-t test and are 
presented in Appendix 7, Figure A7.3.  








Non-coding RNAs (ncRNA) are broadly classified into long (>200 nucleotides) and short (<200 
nucleotides) subgroups (see Chapter 1, Figure 1.3). Within the short non-coding RNA (sncRNA) 
subgroup, several distinct families are recognised, including ones derived from fragmentation of 
transfer RNA (tRNA) which possess a regulatory function (tRNA-derived RNA (tDR) and 5’-tRNA 
stress-induced fragments (tiRNA)), microRNAs (miRNA), small interfering RNAs (siRNA), PIWI-
interacting RNAs (piRNA), small nuclear RNAs (snRNA), small nucleolar RNAs (snoRNA; within which, 
small Cajal body-specific RNA (scaRNA) and sno-derived RNA (sdRNA) are distinctly identifiable 
components), Y-RNAs, and vault RNAs (vtRNA).  
Highly abundant in the nucleus, snRNAs are important in intron splicing, stabilisation and maturation 
of mRNA. Regulation of histone gene transcription, and translational repression of several mRNAs by 
binding to their 3’UTR, thereby preventing polyadenylation and facilitating degradation, is also 
reported (Valadkhan and Gunawardane 2013). 
There are two major classes of snoRNAs; box C/D and box H/ACA snoRNAs, which guide 2’-O-ribose-
methylation, and pseudouridylation of target mRNAs respectively. Within the H/ACA class, location 
of a specific subset is restricted to within Cajal bodies (a nuclear organelle), with these subsequently 
referred to as scaRNA. snoRNAs act to modify ribosomal RNA during ribosomal biogenesis, but also 
target snRNAs and mRNAs (Mattick and Makunin 2006). 
miRNAs and siRNAs are both approximately 20-25 nucleotides in length and function in a similar 
manner, directing mRNA cleavage or translational repression. Distinguished by differences in their 
biogenesis, miRNAs are processed from transcripts which form hairpin structures, with each hairpin 
precursor yielding a single miRNA:miRNA* duplex. Conversely, siRNAs are derived from linear double 
stranded RNA duplexes each of which can generate multiple siRNA duplexes. Target specificity also 
differs, with miRNAs able to repress translation of genes from multiple different loci, whereas 
siRNAs tend to act on genes from adjacent genomic locations (Bartel 2004). Other RNA species 
possessing hairpin elements, such as tRNA and snoRNA can, additionally, be processed into miRNAs 
(see Chapter 1, Figures 1.3 and 1.4).  
PIWI-interacting RNAs are 21-35 nucleotide RNAs processed from long, single stranded precursor 
transcripts derived principally, but not exclusively, from transposable element (TE) sequences and 
show great diversity between species. Mature piRNAs bind to a specific clade of Argonaute proteins 
and exert their effect in a similar manner to miRNA and siRNAs, interacting with target mRNAs 
through base pairing, which are then cleaved by the endonuclease activity of the Argonaute protein 
(Rojas-Ríos and Simonelig 2018). Due to their derivation from, and targeting of, TE mRNA, they 
provide a flexible mechanism for gene silencing, as they are not constrained by the conserved nature 
of miRNAs and siRNAs (Ozata et al 2018). 
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Y-RNAs are essential for initiation of chromosomal DNA replication and, in association with the Ro60 
protein are associated with RNA stability and cellular stress responses (Kowalski and Krude 2015).  
In humans, four vtRNA paralogues have been identified, vtRNA1-1, vtRNA1-2, vtRNA1-3 and vtRNA2-
1. These are integral components of the vault complex which is involved in nucleo-cytoplasmic 
transport, intracellular detoxification processes, signalling, resistance to apoptosis and nuclear pore 
complex formation (Amort et al 2015).  
Although the function of many of these sncRNA species is not fully understood, their importance as 
epigenetic modifiers of phenotype is being increasingly recognised. Of the sncRNAs, miRNAs have 
been the most extensively studied, and were the family which we were principally interested to 
explore in relation to tendon disease. 
The number of identified microRNAs (miRNAs) recorded in publically available data bases, such as 
miRMaster (Fehlmann et al 2017), miRCarta (Backes et al 2018), miRGeneDB (Fromm et al 2020) and 
miRBase (Kozomara et al 2019) has increased dramatically in recent years, with 2,656 mature human 
miRNAs listed in the most recent release (v22) of miRBase (Kozomara et al 2019, Alles et al 2019). 
The number of miRNAs listed, however, differs between databases, which vary in their remit and 
stringency of inclusion criteria. The total number of true miRNAs is unknown, as not only are there 
potentially as yet undiscovered miRNAs, but only 26% of human miRNAs listed in miRBase release 22 
are annotated with a high level of confidence, the majority lacking robust experimental validation 
(Alles et al 2019; Friedländer et al 2008). Traditional experimental approaches to identification of 
miRNAs including cloning and Sanger sequencing have been complemented more recently by 
computational predictions analysing genomic DNA for sequences resembling known miRNA 
precursors, adjacent to known miRNA genes, or conserved sequences lying outwith known protein 
coding regions, which have the potential to form stem-loop structures (Bartel 2004, Friedländer et al 
2008). It is therefore possible that databases contain a high number of false-positives from 
computational predictions. Against this background, the increasing interest in the role of miRNA 
dysregulation in several disease states, has stimulated research into determining differential 
expression (DE) profiles of these regulatory RNAs using a number of technologies. Of these, reverse 
transcription quantitative PCR (RT-qPCR) offers the narrowest approach, relying on a priori selection 
of a small number of miRNAs identified from computational prediction, or previous research, as 
relevant to the disease process of interest. Microarrays are a dye-based detection system utilising 
sequence specific probe hybridisation and offer a relatively cost effective technology for 
dramatically increasing the number of targets investigated in transcriptome analysis. However, their 
use requires that arrays are available for the species and targets of interest. Hybridisation artefacts 
can, however, produce a non-uniform effect on expression measurement, result in loss of sensitivity 
in differentiating targets with high sequence similarity, and sequence content may influence 
detected probe intensities (Oshlack et al 2010). Background signal and cross-hybridisation also 
confound identification of low abundance transcripts and small changes in transcript expression, 
both of which may carry biological significance (‘t Hoen et al 2008). The development of high-
throughput sequencing technologies and their application to measuring RNA expression levels (RNA-
seq) offers a powerful tool to gain an insight into profiling gene expression levels without any prior 
knowledge of the organism or disease process being investigated (Rapaport et al 2013).  Expression 
of each transcript is measured by the number of ‘reads’ which map to the same sequence code, 
which in turn is determined by the sequencing depth – the total number of reads obtained from 
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each sample during a sequencing run.  Whilst offering a far wider dynamic range, lower technical 
variability and higher sensitivity than RT-qPCR or microarray techniques, RNA-seq is expensive and 
generates large, complex datasets requiring a sophisticated analytical pipeline (Oshlack et al 2010). 
High throughput sequencing has also been shown to be biased towards certain small RNAs (those 
with high CG content), independent of sequencing platform, but strongly linked to the method of 
library preparation (Linsen et al 2009). Indeed, using an equimolar mixture of 473 synthetic human 
miRNAs, Linsen and co-workers (2009) reported profiling results indicating up to four orders of 
magnitude difference between least and most frequently detected miRNAs.  However, whilst this 
precludes determination of absolute transcript abundance, these biases are systematic, reproducible 
and affect miRNAs over the entire read frequency distribution, allowing determination of differences 
in relative expression between samples (Linsen et al 2009). Differential expression profiling 
determined using RNA-seq has also been shown to positively correlate to qPCR results, as this latter 
technique also demonstrates similar quantification biases (Linsen et al 2009, Pradervand et al 2010). 
Despite the limitations stated above, small RNA profiling by RNA-seq is considered the method of 
choice for studying small RNA expression (Linsen et al 2009), as it is not susceptible to hybridisation 
artefacts inherent in using microarrays, can accurately discriminate miRNA family members differing 
by only a single nucleotide, can detect 5’ and 3’ variants, and requires no pre-existing knowledge or 
assumptions of which miRNAs are relevant to the studied condition (Linsen et al 2009). Additionally, 
this technology is applicable to all species, including those for which limited genomic data is 
available (Rapaport et al 2013). Although we were principally interested in how miRNA expression 
changed with disease in tendinopathy, we broadened our RNA-seq analysis to capture other 
sncRNAs by expanding our library size selection to include sequences of 120 to 300 base pairs. 
Although this would give us a greater breadth of coverage within our samples, this does come at the 
potential cost of reducing sequencing depth for the miRNA component. 
Our aim was to establish sncRNA profiles for both healthy and diseased human elastic energy storing 
tendon using RNA-seq and ascertain which sncRNAs showed significant DE between cohorts. Having 
demonstrated sncRNA transcriptomes differ significantly  between healthy and diseased tissue, we 
then undertook to validate a selection of miRNAs (miRs -let-7f, -29a, -34a, -34b, -34c, -181a, -181b, -
181c, -181d, -199a and -199b) using RT-qPCR. These miRNAs were chosen based on their predicted 
or validated targeting of pathological processes believed to be important in tendinopathy (fibrosis, 
matrix degradation, inflammation, oxidative stress, cellular differentiation and apoptosis). 
 
Further, as equine tendon has frequently been proposed as a model for investigation of human 
tendon biomechanics and disease (Dudhia et al 2007, Innes and Clegg 2010, Lui et al 2011, Thorpe et 
al 2014), we were interested if analogous miRNA expression changes occurred in equine as in human 
tendinopathy. To this end, using RT-qPCR, we investigated expression of these same miRNAs in 
equine superficial digital flexor tendon (SDFT), comparing clinically normal and diseased tissue.  
 
RT-qPCR validation of RNA-seq data was achieved for nine of the 11 miRNAs investigated, with four 
of these miRNAs also showing some level of agreement in equine SDFT, suggesting similarity in 








3.2.1 Small RNA-sequencing  
RNA was extracted from human supraspinatus (SSP) tendon tissue collected from six patients with 
rotator cuff tendinopathy undergoing surgical repair, and from mixed semitendinosis and gracilis 
(hamstring) tendon from six patients undergoing anterior cruciate ligament reconstruction surgery 




Table 3.1 Donor and tissue details for six diseased and six healthy control human tendon samples 
processed for RNA extraction for small RNA sequencing. F = female, M = male, SSP = supraspinatus 
tendon, HST = hamstring (mixed semitendinosis and gracilis) tendon. 
 
Following elution into RNase free water, RNA concentration and quality were assessed, and samples 
submitted to the Centre for Genomic Research, University of Liverpool, for library preparation and 
small RNA-sequencing. Fifty five nanograms of total RNA per sample were used for library 
preparation using a commercially available small RNA library preparation kit (NEBNext small RNA 
library prep kit). Library preparation adds approximately 126 bp to the original sequence length, and 
library for sequencing was size selected at 120-300 base pairs (bp). Paired-end, 150 bp sequencing 
was performed in a single lane on an Ilumina HiSeq 4000 machine, generating data from >280 M 
clusters (sequencing depth approximately 23 M reads per sample).   
 
Data were processed using CASAVA (version 1.8.2) to generate output in FASTQ format.  
Raw FASTQ files were trimmed for the presence of adapter sequences using Cutadapt (version 1.2.1) 
with the option –O3, ensuring any reads which matched the adapter sequence for three bp or more 
Sample number Sample name Organism Sex Age (years) Tissue Source 
18139_7 0946/18 SSP Human F 39 Diseased SSP Glasgow 
18139_8 0947/18 SSP Human F 39 Diseased SSP Glasgow 
18139_9 0866/18 SSP Human M 51 Diseased SSP Glasgow 
18139_10 0944/18 SSP Human M 50 Diseased SSP Glasgow 
18139_11 0864/18 SSP Human M 59 Diseased SSP Glasgow 
18139_12 0887/18 SSP Human F 45 Diseased SSP Glasgow 
18139_13 LMB-KM-249 Human M 31 Healthy HST Liverpool 
18139_14 LMB-GA-253 Human F 17 Healthy HST Liverpool 
18139_15 LMB-HB-254 Human F 23 Healthy HST Liverpool 
18139_16 LMB-AS-255 Human F 23 Healthy HST Liverpool 
18139_17 LMB-MW-260 Human M 23 Healthy HST Liverpool 
18139_18 LMB-RM-261 Human M 26 Healthy HST Liverpool 
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were removed. Reads were further trimmed for quality using Sickle (version 1.200) using a minimum 
Phred (Q) score of 20. Reads shorter than 12 bp after trimming were discarded.  
Trimmed read pairs were aligned to reference genome (Gencode GRCh38.p12) using Bowtie2 
(version 2.3.5) and subsequently counted using featureCounts (version 1.6.4) against the Gencode 
reference annotation file (Gencode (GRCh38.p12) gft file) for non-miRNAs, and miRBase (hsa.gff3 
file, release 22.1) for miRNAs, using Bowtie2 (version 2.3.5). Any counts to miRNAs from the 
Gencode file were removed to avoid duplication in downstream analysis.  
 
Principal component analysis (PCA) was used to visualise sources of variance in the data. All PCA 
calculations were performed in R (version 4.0.1, R Core Team (2020), using the prcomp function 
within the package on regularised log transcript abundances, to extract principal components. Once 
extracted, principal components one and two were plotted using the ggplot2 plotting package, and 
samples were coloured according to the disease state of the tissue (red = diseased, blue = healthy). 
The variance each principal component explained was calculated manually as the square of the 
standard deviation. 
 
3.2.2 Reverse transcription quantitative real-time polymerase chain reaction validation of 
small RNA-sequencing data 
Library preparation for RNA-sequencing consumed all available RNA from four of the six SSP 
tendinopathy samples, only two samples, both from 39 year old female patients were therefore 
available for RT-qPCR validation purposes. Total RNA was extracted from three independent samples 
of diseased posterior tibial tendon (PTT), according to the protocol detailed in Chapter 2, sections 
2.8.1 and 2.8.4. RNA was available from all six original control samples. RT-qPCR validation of RNA-
seq results was, therefore, performed on both dependent (six healthy control and two tendinopathic 
SSP samples) and independent (three tendinopathic PTT samples) cohorts. 




Sample number Sample name Organism Sex Age (years) Tissue Source 
18139_7 0946/18 SSP Human F 39 Diseased SSP Glasgow 
18139_8 0947/18 SSP Human F 39 Diseased SSP Glasgow 
P1 P1M60081217 Human M 60 Diseased PTT Liverpool 
P2 P2M71191217 Human M 71 Diseased PTT Liverpool 
P3 P3M65130318 Human M 65 Diseased PTT Liverpool 
18139_13 LMB-KM-249 Human M 31 Healthy Liverpool 
18139_14 LMB-GA-253 Human F 17 Healthy Liverpool 
18139_15 LMB-HB-254 Human F 23 Healthy Liverpool 
18139_16 LMB-AS-255 Human F 23 Healthy Liverpool 
18139_17 LMB-MW-260 Human M 23 Healthy Liverpool 
18139_18 LMB-RM-261 Human M 26 Healthy Liverpool 
 
Table 3.2 Donor and tissue details for five diseased and six healthy control human tendon samples 
used for RT-qPCR validation of small RNA-sequencing data. F = female, M = male, SSP = 
supraspinatus tendon, PTT = posterior tibial tendon. 
 
Reverse transcription to cDNA used 30 ng total RNA template for miRNA expression analysis. 
Protocol details are given in Chapter 2, section 2.11.1. Levels of miRNAs -29a-3p, -34a-5p, -34b-5p, -
34c-5p, -181a-3p, -181b-5p, -181c-5p, -181d-5p, -199a-5p, -199b-5p and -let-7f-5p were determined 
using commercially available primers (Qiagen, Manchester, UK) and normalised to SNORD61 as 
internal control (validated for this purpose as a stable small non-coding RNA in human tenocytes 
(Appendix 7, Table A7.1)). Primer sequences and RT-qPCR details are listed in Chapter 2, sections 
2.12.1 (Table 2.10) and 2.12.2 (Figure 2.2) respectively. For all RT-qPCR data, technical replicates 
were run in triplicate and expression relative to SNORD61 calculated using the delta Ct method 
(Livak and Schmittgen 2001).  
 
3.2.3 Reverse transcription quantitative real-time polymerase chain reaction validation of 
equine tendinopathy as a model for miRNA dysregulation in human tendon disease 
Total RNA extracted from equine superficial digital flexor tendons (SDFT) for use in a separate study 
was made available for validation purposes (courtesy of Professor Mandy Peffers and Miss Roisin 
Wardle). This cohort consisted of six horses with normal SDFT, three horses with diseased SDFT and 















Table 3.3 Donor and tissue details for 11 horses used for RT-qPCR validation of equine superficial 
digital flexor tendon (SDFT) disease as a model of human tendinopathy. NB. Information on sex of 
animals was not available. 
 
Reverse transcription to cDNA used 100 ng RNA template for miRNA expression analysis. Protocol 
details are given in Chapter 2, section 2.11.1. 
Three candidate small non-coding RNA reference genes were investigated for use as internal 
controls. Based on previous reports (Sperveslage et al 2014, Bignotti et al 2016), expression of small 
nuclear RNA-U6, small nucleolar RNA-61 (SNORD61), and small nucleolar RNA-68 was assessed. Of 
these, SNORD61 demonstrated least variation in expression. Across all biological replicates, and 
between those with normal or diseased SDFT, SNORD61 threshold cycle (Ct) values varied by less 
than, or equal to, three cycles. Where normal and diseased tissue from the same individuals was 
available, SNORD61 Ct values varied by ≤0.75 cycles (Appendix 2, Table A2.1). Levels of miRNAs   -
29a, -34a, -34b, -34c, -181a, -181b, -181c, -181d, -199a, -199b and -let-7f were determined using 
commercially available primers (Qiagen, Manchester, UK) and normalised to SNORD61 as internal 
control. Mature sequences of equine (eca) miRNAs -let-7f, -29a, -34a, -34c, -181a, -181b, -199a and -
199b are identical to those reported for Homo sapiens (hsa), justifying our use of the same primers. 
Sequences for eca-miR-181c and eca-miR-181d are not reported, but we were interested to 
determine if expression of these miRNAs could be detected in equine tissue. The sequence for eca-
miR-34b differs substantially from that of hsa-miR-34b, therefore we utilised a primer designed to 
target the murine orthologue of this miRNA, as this has an identical sequence to the equine version. 
Primer sequences and RT-qPCR details are listed in Chapter 2, sections 2.12.1 (Table 2.10) and 2.12.2 
(Figure 2.2) respectively. For all RT-qPCR data, technical replicates were run in triplicate and 
expression relative to SNORD61 calculated using the delta Ct method (Livak and Schmittgen 2001). 
 
Sample name Organism Age (years) Tissue 
H1 Equine 3 Normal SDFT 
H2 Equine 25 Normal SDFT 
H3 Equine 4 Normal SDFT 
H16 Equine 3 Normal SDFT 
H18 Equine 19 Normal SDFT 
H23N Equine 6 Normal SDFT 
H23D Equine 6 Diseased SDFT 
H24N Equine 9 Normal SDFT 
H24D Equine 9 Diseased SDFT 
H27 Equine 18 Normal SDFT 
H47 Equine 7 Diseased SDFT 
H52 Equine 6 Diseased SDFT 
H62 Equine 7 Diseased SDFT 
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3.2.4 Statistical analysis 
For small RNA-sequencing data, raw read counts (as .csv files) were imported into the Bioconductor 
package DESeq2 (version 1.22.2) for differential gene expression analysis. Normalised counts were 
log2 transformed prior to application of a modified Fisher exact test to return exact P-values.  The 
Benjamini-Hochberg procedure for multiple hypothesis correction was then applied. Results are 
reported as log2 fold change of normalised data and genes considered differentially expressed if 
log2 fold change ≥1.5 with a Benjamini-Hochberg adjusted P-value <0.05. 
 
Statistical analysis of RT-qPCR data was performed using GraphPad Prism version 5.01 for Windows 
(GraphPad Software, San Diego California USA, www.graphpad.com). Comparison of relative 
microRNA expression between tendinopathic tissue and controls for both human and equine data 
were analysed non-parametrically using the Mann Whitney test. For human tendinopathy validation 
work, comparisons between control and PTT tissue utilised the Mann-Whitney test as conditions for 
its application were satisfied. Comparisons between control and SSP tissue, and between SSP and 
PTT samples, utilised the Student t test, where less than three data points were present in the SSP 
comparator group, which precluded the use of non-parametric analysis. These results are presented 
in Appendix 2, Figure A2.2. Comparison of ages between donors of tendinopathic and control tissue 





3.3.1 RNA-seq profiling of small non-coding RNA in human tendon 
 
Donors of tendinopathic SSP tissue were significantly older than donors of healthy control tissue 
(47.2±7.8 yrs and 23.8±4.6 yrs respectively; P<0.0001).  
 
Concentrations of RNA submitted for sequencing varied between 4.8 and 51.2 ng μL-1. Quality, as 
indicated by RNA integrity number was moderate, varying between 3.4 and 6.9, but was not 
different between groups (P=0.98). 
 
We identified a total of 1311 small RNA transcripts using small RNA-seq. Read mapping to the 
Gencode GRCh38.p12 GTF file gave 98.4% alignment. Identification of transcripts mapped to miRNAs 
was performed separately using miRBase hsa.gff3 file (release 22.1) to identify 3p and 5p variants. 
716 transcripts were from non-miRNA RNA (three protein coding, four vault RNA, nine small Cajal 
body-specific RNA, 39 small nuclear RNA, 244 small nucleolar RNAs (80 H/ACA, 64 C/D box), 208 Y-
RNAs and 209 pseudogenes (see Appendix 3, Table A3.1 for full list of transcript identities, 
expression changes and P-values).  There were 565 annotated miRNA transcripts identified, 
representing 347 miRNA families, with between one and 16 member miRNAs expressed per family. 
Additionally, two previously annotated miRNAs subsequently removed from the most recent update 
of the miRBase database (release 22), due to lack of experimental validation (miR-4461 and miR-
6723) and one novel predicted miRNA were identified. Of the annotated miRNAs, duplicate counts 
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were returned for 35, triplicate counts for three, quadruplicate for two and quintuplicate for one, 
representing transcripts for the same mature miRNA derived from different gene loci. Deduplication 
of miRNAs was performed prior to statistical analysis, giving 148 up regulated, 415 down regulated 
in diseased supraspinatus (SSP) tendon compared to control samples, and two which were 
unchanged (see Appendix 3, Table A3.2 for full list of annotated miRNAs, expression changes and P-
values). Magnitude and direction of fold change of all identified transcripts is illustrated in Figure 3.1 
(A). Principal component analysis (PCA) of datasets identified separation of diseased and healthy 
control samples, healthy controls clustering more tightly than diseased, with >80% of the variation 
between cohorts explained by the first two principal components (Figure 3.1 (B)).  
 
A total of 385 small RNAs were significantly DE (log2 fold change ≥1.5 with Bejaminin-Hochberg 
adjusted P-value <0.05) between tendinopathic samples and healthy controls (Figure 3.1 (C)). Of 
these, 162 were non-miRNA transcripts, identified as pseudogenes (n=31), Y-RNAs (n=46), C/D box 
class snoRNAs (n= 48, representing 20 specific SNORDs), H/ACA class snoRNAs (n=22, representing 
18 specific SNORAs), snRNAs (n=9, representing 6 snRNAs), scaRNAs (n=2), vault RNA (n=1) and 
protein coding RNAs (n=3) (Table 3.4). 
 
A total of 223 miRNAs were significantly DE (log2 fold change ≥1.5 with Bejaminin-Hochberg 
adjusted P-value <0.05) between tendinopathic samples and healthy controls. The majority were 
down regulated (n=207), with 16 up regulated (Table 3.4). All up regulated miRNAs and the top 20 












































Figure 3.1 RNA-seq identifies differential small RNA profiles between healthy and diseased human 
tendon tissue. A. Volcano plot illustrating direction, magnitude and significance of all annotated 
non-miRNA and miRNA transcripts.  B. Principal Component Analysis plot demonstrating separation 
and clustering of diseased and healthy cohorts. C. Heat map and consensus dendrogram of all 385 
significantly DE small non-coding RNAs. Samples were from healthy hamstring tendon (n=6) and 
tendinopathic supraspinatus tendon (n=6). Significance was defined as ≥1.5 log2 fold change with 




Table 3.4 Small non-coding RNAs differentially expressed between healthy and diseased tendon 
samples. Samples were from healthy hamstring tendon (n=6) and tendinopathic supraspinatus 
tendon (n=6). Significance was defined as ≥1.5 log2 fold change with adjusted P-value <0.05. 
 
Table 3.5 Up regulated and top 20 down regulated miRNAs, ranked by fold change (FC), identified 
by RNA-seq as significantly differentially expressed (≥1.5 FC; adjusted P-value <0.05) between 
healthy human hamstring tendon (n=6) and tendinopathic supraspinatus tendon (n=6). miRNAs in 
italics (ranked 117, 128, 141 and 185 by FC) are also shown, as down regulation of related miRNAs 
was subsequently observed in equine superficial digital flexor tendinopathy. hsa = Homo sapiens. 
RNA Species Number 
 Differentially Expressed Up regulated Down regulated 
Vault RNA 1 1 0 
Small Cajal body-specific RNA 2 2 0 
Small nuclear RNA 6 2 4 
Pseudogenes 31 14 17 
Small nucleolar RNA 38 34 4 
Y-RNA 46 46 0 
microRNA 223 16 207 
Up regulated miRNAs Down regulated miRNAs 
Identity Log2 FC Adjusted P-value Identity Log2 FC Adjusted P-value 
hsa-miR-6724-5p 4.00 1.16E-06 hsa-miR-451a -7.15 1.63E-14 
hsa-miR-4667-3p 3.90 0.019236 hsa-miR-374a-3p -6.76 2.92E-17 
hsa-miR-4485-3p 3.73 0.005572 hsa-miR-19b-3p -6.57 7.27E-08 
hsa-miR-3652 2.93 0.003391 hsa-miR-101-3p -6.35 3.38E-29 
hsa-miR-612 2.86 0.028223 hsa-miR-144-5p -6.32 3.82E-08 
hsa-miR-3917 2.64 0.000822 hsa-miR-32-5p -5.97 2.50E-12 
hsa-miR-632 2.50 6.48E-07 hsa-miR-3613-5p -5.92 7.49E-19 
hsa-miR-3654 2.38 0.020232 hsa-miR-335-5p -5.88 3.17E-16 
hsa-miR-193b-5p 2.18 0.007485 hsa-miR-660-5p -5.85 1.04E-21 
hsa-miR-12136 2.14 0.018255 hsa-miR-130a-3p -5.79 8.79E-09 
hsa-miR-10392-5p 2.12 0.000215 hsa-miR-340-5p -5.66 3.21E-28 
hsa-miR-2110 2.05 2.59E-05 hsa-miR-383-5p -5.65 3.81E-05 
hsa-miR-1291 1.90 4.08E-07 hsa-miR-598-3p -5.53 1.74E-06 
hsa-miR-3655 1.78 0.007444 hsa-miR-142-3p -5.42 5.47E-11 
hsa-miR-10394-3p 1.77 0.044227 hsa-miR-140-5p -5.37 1.10E-30 
hsa-miR-6125 1.67 0.008724 hsa-miR-374a-5p -5.34 1.09E-20 
   hsa-miR-30d-3p -5.27 4.42E-07 
   hsa-miR-653-5p -5.22 3.62E-07 
   hsa-miR-374b-3p -5.20 5.04E-07 
   hsa-miR-382-3p -5.13 5.39E-09 
   hsa-miR-199a-5p -2.98 1.68E-11 
   hsa-miR-181d-5p -2.82 6.14E-11 
   hsa-miR-181c-5p -2.59 0.000197 
   hsa-miR-29a-3p -1.91 7.22E-05 
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3.3.2. RT-qPCR validation of microRNAs differentially expressed in human tendon disease 
 
Next, using RT-qPCR, we undertook to validate a selected panel of miRNAs identified by RNA-seq. 
Library preparation for RNA-seq had depleted all available RNA from four of the six SSP 
tendinopathic samples, therefore three additional tendon samples were utilised for validation. These 
consisted  of tendinopathic posterior tibial tendon (PTT). Although from different anatomical 
locations, both SSP and PTT are classified as elastic, energy storing tendons. RT-qPCR validation of 
RNA-seq results in the tendinopathic cohort therefore consisted of two SSP samples for which RNA-
seq data was available (dependent validation) and three PTT samples (independent validation). 
Samples from the control cohort had all previously been submitted for RNA-seq analysis. 
Donors of tendinopathic (SSP and PTT) tissue were significantly older than donors of healthy control 
tissue (54.8±14.9 yrs and 23.8±4.6 yrs respectively; P<0.0009).  
For RT-qPCR validation, 30 ng total RNA was reverse transcribed into cDNA and RT-qPCR performed 
for miRNAs -29a-3p, -34a-5p, -34b-5p, -34c-5p, -181a-3p, -181b-5p, -181c-5p, -181d-5p, -199a-5p, -
199b-5p and -let-7f-5p.These miRNAs were chosen based on their (or their family’s) involvement in 
the following processes relevant to tendon homeostasis and disease. Known to directly target 
COL1A1 and COL3A1 (Maurer et al 2010) and MMP2 (Jones et al 2011), mir-29a expression is 
reduced in tendinopathy (Millar et al 2015). This impacts on the transition from type I to type III 
collagen deposition in early stage disease and facilitate matrix degradation. miR-34 is an important 
regulator of cell proliferation, differentiation and apoptosis, inducing cellular senescence and 
apoptosis in human and murine fibroblasts respectively (He et al  2007). miR-34a also regulates 
fibrosis in an age- and context-dependent manner (Cui et al 2017), whilst down regulation of miRs 
-34b and -34c caused accumulation of abnormal, dysfunctional mitochondria and impaired clearance 
from degenerate neuronal cells (Miñones-Moyano et al 2011). Processes regulated by the miR-181 
family pertinent to tendinopathy are inflammation (Xie et al 2013, Lu et al 2015), fibrosis (Chen et al 
2018), apoptosis and autophagy (Liu et al 2017, Pop-Bica et al 2018, Rezaei et al 2019). Upregulation 
of miR-181 is important in skeletal muscle differentiation and regeneration (Naguibneva et al 
2006), with reduced miR-181a expression implicated in age-related degenerative changes such as 
disrupted MAPK and TGFβ signalling and mitochondrial function (Soriano-Arroquia et al 2016, 
Goljanek-Whysall et al 2020). Expression of several miR-181 family members is also sensitive to 
hypoxia (Kulshreshtha et al 2007, Nallamshetty et al 2013), as is expression of miR-199a (Rane et al 
2009). Additionally, miRs -199a and -199b both regulate fibrosis, upregulation being associated 
with a number of fibrotic diseases (da Costa Martins et al 2010, Lino Cardenas et al 2013). The highly 
conserved let-7 family of miRNAs have important functions in developmental progression, one of 
which is cellular differentiation. We investigated expression of miR-let-7f as a potential marker of 
tendon stem/progenitor cell proliferation and differentiation capacity, as age-related reduction in 
expression is associated with reduced capacity for these processes in bone marrow derived 
mesenchymal stem cells (Yu et al 2011). 
 
Our chosen panel of miRNAs represent, in the majority, ones identified by RNA-seq as showing 
significantly reduced expression in our tendinopathic cohort. However, miR-34b-5p was not 
detected by RNA-seq and miR-181b-5p was detected, but not DE. We included these in our 
validation to confirm these negative findings. 
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Considering all tendinopathic samples as a single cohort, RT-qPCR validation of RNA-seq results was 
achieved for nine of the 11 chosen miRNAs, with only miR-29a and miR-let-7f failing. Graphical 
results are presented in Figure 3.2, with boxplots of regularised log counts obtained by RNA-seq for 
these miRNA families given in Appendix 2, Figure A2.1). Further evaluation of these results identified 
that for miR-29a, changes in expression differed with tendon type, expression increasing significantly 
relative to controls for SSP tendon, contradicting RNA-seq findings, whilst expression in PTT tendon 
significantly reduced, corroborating RNA-seq data (Appendix 2, Figure A2.2 (A)). Indeed, there did 
appear to be some effect of tendon type on expression change, with miRNAs -34b, -181a, -199a and 
-199b showing some difference, although the small numbers involved in this sub-analysis demand 
these results are interpreted with caution. No significant difference in miR-let-7f expression was 
found with any tendon grouping (see Appendix 2, Figure A2.2 for full details of miRNA expression 







































































































































P = 0.79 P = 0.009 
P = 0.18 P = 0.004 
P = 0.02 P = 0.46 
miR-29a-3p 
(Log2 fold change  -1.91) 
miR-34a-5p 
(Log2 fold change  -2.03) 
miR-34b-5p 
(Not detected by RNA-seq) 
miR-34c-5p 
(Log2 fold change  -1.66) 
miR-181a-3p 
(Log2 fold change  -4.28) 
miR-181b-5p 


















































































































P = 0.004 P = 0.004 
P = 0.018 P = 0.009 
P = 0.43 
miR-181c-5p 
(Log2 fold change  -2.59) 
miR-181d-5p 
(Log2 fold change  -2.82) 
miR-199a-5p 
(Log2 fold change  -2.98) 
miR-199b-5p 
(Log2 fold change  -4.86) 
miR-let-7f-5p 
(Log2 fold change  -2.11) 
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Figure 3.2 (preceding two pages) RT-qPCR validation of human tendon RNA-seq data. Relative 
expression of A. miR-29a-3p, B. miR-34a-5p, C. miR-34b-5p, D. miR-34c-5p, E. miR-181a-3p, F. miR-
181b-5p, G. miR-181c-5p, H. miR-181d-5p, I. miR-199a-5p, J. miR-199b-5p, K. miR-let-7f-5p between 
Control (healthy hamstring tendon) and Diseased (tendinopathic supraspinatus and posterior tibial  
tendon). Data were normalised to SNORD61 expression. Graphs show median and inter-quartile 
range. Mann Whitney U test; * = P <0.05; ** = P <0.01. Log2 fold change values for each miRNA, as 
determined by RNA-seq are given in parentheses with each graph for comparison.  
 
 
3.3.3 Validation of equine superficial digital flexor tendinopathy as a model to study 
miRNA dysregulation in human tendon disease  
 
Following successful validation of RNA-seq data from human tissue, we next employed RT-qPCR to 
determined expression of the same miRNAs in the energy storing equine SDFT, to explore any 
commonality between species. Three miRNAs, miR-29a, -181b and -199a showed significantly 
reduced expression in equine tendinopathic SDFT compared to healthy controls (Figure 3.3).  Two 
miRNAs showed complete agreement across RNA-seq and RT-qPCR results in both human and 
equine tissues, miR-34b, which showed no change in expression with disease, and miR-199a, which 
showed reduced expression in tendinopathic tissue in both species (Table 3.6). Interestingly, miRNAs 
-181a, -181c and 181d, all of which showed reduced expression with human tendinopathy (RNA-seq 
data being supported by RT-qPCR), showed no change in equine tissue with disease. However, 
miRNA 181-b, which was validated as unchanged in human disease, was significantly reduced in the 
equine samples (Figure 3.3 (F)). A summary comparison of results across human and equine tissue by 
both RNA-seq and RT-qPCR is presented in Table 3.6. Coincidentally, we have separately identified 
miR-181b to be significantly up regulated in equine SDFT with ageing (Figure 3.3 (L)). This suggests 
that miR-181b may be the dominant family member in this species, and, interestingly, that ageing 
and disease may promote different expression changes. Reduction in expression of miR-29a and 
miR-199a has previously been reported in association with tendon disease (Millar et al 2015, 





































































































































P = 0.045 P = 0.94 
P = 0.43 P = 0.13 










































































































P = 0.15 P = 0.03 
P = 0.66 


























Figure 3.3 miRNA dysregulation in equine superficial digital flexor tendinopathy demonstrates 
some similarities with that in human tendinopathy, as identified by RT-qPCR.  Relative expression 
of A. miR-29a, B. miR-34a, C. miR-34b, D. miR-34c, E. miR-181a, F. miR-181b, G. miR-181c, H. miR-
181d, I. miR-199a, J.miR-199b, K. miR-let-7f, between healthy (Control; n= 8) and Diseased (n = 5) 
equine SDFT. L. miR-181 expression in young (n =5) versus old (n = 3) clinically normal equine SDFT 
tissue for comparison. Data were normalised to SNORD61 expression. Graphs show median and 
inter-quartile range. * = P <0.05 (Mann Whitney U test). 
 
  









RNA-seq RT- qPCR RT-qPCR 
Detected Significant change   
miR-29a 3p,  ↓ (3p) − (3p) ↓ (3p) 
miR-34a 5p,  ↓ (5p) ↓ (5p) − (5p) 
miR-34b 3p − − (5p) − (5p) 
miR-34c 3p, 5p,  ↓ (5p) ↓(5p) − (5p) 
miR-181a 3p, 5p  ↓ (3p) ↓ (3p) − (3p + 5p) 
miR-181b 3p, 5p − − (5p) ↓ (5p) 
miR-181c 3p, 5p ↓(3p + 5p) ↓ (5p) − (5p) 
miR-181d 5p ↓ (5p) ↓ (5p) − (5p) 
miR-199a 3p, 5p ↓(3p + 5p) ↓ (5p) ↓ (5p) 
miR-199b 3p, 5p ↓(3p + 5p) ↓ (5p) − (5p) 
miR-let-7f 3p, 5p ↓ (5p) − (5p) − (5p) 
 
Table 3.6 Summary of RNA-seq validation by RT-qPCR in human tendinopathy and miRNA 
expression in equine tendinopathy. 3p, 5p = miRNA variants detected; (3p), (5p) in RT-qPCR 
columns indicates variant against which primer directed. ↓ = significant down regulation of 







In this chapter we established sncRNA expression profiles in human energy storing tendon and 
demonstrated that these transcriptomes differ substantially between healthy and diseased cohorts. 
Furthermore, we utilised RT-qPCR to validate these findings in a small number of miRNAs. 
Additionally, we have identified similar changes for some of these miRNAs occurring in tendinopathy 
of the equine energy storing superficial digital flexor tendon.  
 
RNA-seq has been described as the technology of choice to investigate small RNA expression 
patterns as it requires no pre-existing knowledge or assumptions about the samples, can 
discriminate between transcripts differing by only a single nucleotide and is subject to less technical 
variation and artefactual errors than alternative methods (Linsen et al 2009). Library preparation is 
reported to be the step in sample preparation that is most likely to result in bias, due to the 
requirement for reverse transcription to cDNA. During this step, any post-translational 
modifications, tendency to form secondary structures, variability in transcript lengths, CG content 
and specific enzymes used can all affect efficiency of reverse transcription and therefore the 
representation in the sequencing data (Gebetsberger et al 2015). These inherent quantification 
biases prevent accurate determination of absolute transcript numbers, but still permit analysis of 
differential expression between samples. Similar biases have been shown to occur with RT-qPCR 
quantification, with results showing good correlation between technologies, making RT-qPCR a valid 




With RNA-seq reads, we achieved very good alignment (98.4%) to the reference genome (Gencode 
GRCh38.p12). As miRNA expression was the primary focus of this study, transcripts identified as 
miRNAs were separately mapped using miRBase hsa.gff3 file (release 22.1), as this database contains 
more detailed miRNA-specific information (such as differentiating 3p and 5p variants). Identification 
of 41 miRNAs was replicated between two and five times, reflecting presence of immature 
transcripts derived from different gene loci. Where this occurred, read counts for each miRNA were 
combined prior to further analysis, as we were interested in DE of each miRNA, rather than from 
which locus each transcript was derived.   
 
The panel of miRNAs used for RT-qPCR validation (miRNAs -29a, -34a, -34b, -34c, -181a, -181b, -
181c, -181d, -199a, -199b and –let-7f) were chosen based on their predicted or validated targeting of 
pathological processes believed to be important in tendinopathy (as outlined in section 3.3.2). 
 
RNA-seq data identified eight let-7 miRNAs, with three members (let-7a, let-7c and let-7f) 
significantly down regulated with disease. The seminal let-7 family of miRNAs were originally 
identified due to their essential role in the transition of the larval L4 stage of Caenorhabditis elegans 
to the adult nematode. Let-7 family miRNAs are highly conserved across multiple animal species, 
both in terms of sequence, and the developmental stage at which they are expressed. There are ten 
mature human let-7 sequences, with let-7f formed from precursors from two distinct genomic 
locations (Roush and Slack 2008). Whilst a direct role for let-7 in vertebrate development has not 
been conclusively shown, one of the major functions attributed to this miRNA family is promotion of 
cellular differentiation (Roush and Slack 2008). Down regulation of miR-let-7f has been reported in 
bone marrow derived mesenchymal stem cells with ageing, concurrent with reduced potential for 
proliferation, differentiation and production of heat shock proteins by these cells (Yu et al 2011). We 
therefore chose to explore expression of this miRNA, as a potential marker of tendon 
stem/progenitor cell proliferative and differentiation capacity in tendinopathy, in our RT-qPCR 
validation panel. However, RNA-seq findings were not supported by RT-qPCR data in either human 
or equine tissue (Figure 3.2 (K), Figure 3.3 (K) and Table 3.6). Whilst this could represent a real 
finding, it may relate to the differences in analytical technique. RT-qPCR relies on stability of 
reference gene expression for normalisation of data, and primer specificity to the target of interest. 
Sequences of the 5p variants of all hsa-let-7 family members only differ from each other by one or 
two bases. High levels of sequence similarity may result in primer hybridisation artefacts and high 
levels of background signal, reducing sensitivity (Wang et al 2009, Oshlack et al 2010). Divested of 
these limitations, and by quantifying individual sequence reads against the reference genome, RNA-
seq offers greater sensitivity and accuracy than RT-qPCR, able to detect subtle changes in 
expression, down to 10%.  
 
Our findings with miR-29a were interesting. RNA-seq data demonstrated a significant reduction with 
disease in human SSP tendon (Appendix 3, Table A3.1), as did RT-qPCR data for equine SDFT (Figure 
3.3 (A)), supporting previous work (Millar et al 2015). However, RT-qPCR validation of RNA-seq was 
contradictory, indicating no significant change overall with disease (Figure 3.2 (A)). Examined in 
more detail, the expression of miR-29a varied with tendon type, being up regulated in diseased SSP,  
contradicting the findings of Millar and co-workers (2015), whilst down regulated in diseased PTT 
(Appendix 2, Figure A2.2 (A)). Both SSP and PTT are classified functionally as elastic energy storing 
tendons, although they do exhibit significant morphological differences, and our RT-qPCR results 
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suggest that miR-29a expression with disease may differ depending on specific tendon identity. Of 
all the miRNAs we investigated in our validation, miR-29a was unique in this respect; all others 
demonstrated much greater concordance in expression levels between SSP and PTT tendons 
(Appendix 2, Figure A2.2 (B-K)). This could reflect differences in the stage of disease at the time of 
tissue harvest, the fact that the two SSP samples were from female donors, whereas the PTT 
samples were from males, or that SSP donors were younger (39 years) than those from which PTT 
was obtained (60-71 years). The cohort of SSP tendinopathy patients reported by Miller and co-
workers (2015) was older (35-70 years) than ours and biased towards male patients, at a ratio of 2:1. 
The possibility of tendon-specific responses to disease is an intriguing one, but should be interpreted 
with caution due to the small numbers involved (n=2 for SSP; n=3 for PTT) and the other 
confounding factors outlined above.  
Probably the most extensively investigated miRNA in respect to tendon disease, miR-29a appears to 
regulate tendon mechanobiology in a number of ways. Using human clinical samples of SSP 
tendinopathy, a murine model of patellar tendinopathy, and in vitro gain- and loss- of function 
studies, Millar and co-workers (2015) demonstrated miR-29a to be significantly reduced with tendon 
disease, and play a critical role in the interaction between inflammatory cytokines and extracellular 
matrix changes. Known to directly target COL1A1 and COL3A1 transcripts (Maurer et al 2010), miR-
29a exerts a more profound inhibitory effect on COL3A1 mRNA than that presaging type I collagen. 
This is due to COL1A1 and COL1A2 transcripts possessing alternative polyadenylation signals, which 
reduce the length of their 3’UTRs, with subsequent loss of microRNA recognition elements, thus 
rendering them insensitive to translational repression. This does not appear to occur with COL3A1 
transcripts (Millar et al 2015). Millar and colleagues (2015) also demonstrated miR-29a to be key in 
the transition from type I to type III collagen deposition in early tendinopathy, by regulating IL33 
effect (Millar et al 2015). IL33 is up regulated in early tendinopathy and mediates the transition from 
collagen type 1 to type 3 synthesis. The cytosolic IL33 receptor is a direct miR-29a target, but IL33 
indirectly reduces miR-29a expression via phosphorylation of NFκB, thereby, in early tendinopathy, 
facilitating increased COL3A1 expression (Millar et al 2015).  
In addition to affecting synthetic function, miR-29a also plays a role in matrix degradation. Validated 
in vitro to target MMP2, reduced miR-29a levels are reported in aneurysmal, relative to normal 
thoracic aortic tissue (Jones et al 2011). Down regulation of miR-29a corresponded to an increase in 
both total MMP2 levels and ratio of active:inactive form of the enzyme, resulting in vessel dilation 
from pathological remodelling of the aortic extracellular matrix (Jones et al 2011). However, in 
dermal fibroblasts, upregulation of miR-29a reduced TIMP1 secretion by targeting TGFβ activated 
kinase 1 binding protein 1, an upstream regulator of TIMP1. This produced a functional increase in 
MMP1 levels, leading to collagen degradation (Ciechomska et al 2014).  
The therapeutic use of miR-29a has also been explored in experimentally induced injury models of 
murine patellar tendon and equine SDFT (Millar et al 2015, Watts et al 2017). Application of 
exogenous miR-29a at the site of injury significantly reduced type III collagen synthesis in early stage 
repair, without affecting collagen I synthesis. 
Due to limited sample availability, we were unable to use the same cohort of tendinopathic samples 
exclusively for RT-qPCR validation of RNA-seq data. In addition to the two remaining SSP samples, 
we also included three samples of tendinopathic PTT from an independent cohort. Ideally, full 
validation of data requires results are replicated, using an alternative analytical method, in both 
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dependent and independent samples. Notwithstanding the fact we utilised tendinopathic samples 
which conform to these descriptions, the low numbers involved need to be considered. Although 
miR-29a expression was dramatically different between diseased SSP and PTT tendons, this was 
exceptional, as the other miRNAs investigated demonstrated far greater concordance in this respect 
(Appendix 2, Figure A2.2 (B-K)). For the purpose of investigating the influence of miRNA 
dysregulation on basic processes relevant to tendinopathy in general, we therefore elected to group 
all diseased tendon together as a single cohort for further consideration.  
  
RT-qPCR detected significant reductions in miR-34a and miR-34c expression in human tendinopathic 
tissue (Figure 3.2 (B) and (D) respectively), confirming RNA-seq data (Table 3.6). Neither of these 
were observed to change however in diseased equine SDFT (Figure 3.3 (B) and (D) respectively). No 
change in miR-34b with disease was detected in either species, using either analytical technique, 
validating stable expression of this miRNA (Table 3.6). Both pro- and anti-fibrotic activity of miR-
34a is reported in a murine model of pulmonary fibrosis, with the effect appearing to be age 
dependent (Cui et al 2017). Young miR-34a-/- mice developed more severe fibrosis than young 
wild type, whereas miR-34a was up regulated in the fibrotic lungs of old mice.  
Depletion of miR-34b and miR-34c is reported in degenerate neurological tissue from human 
Parkinson’s Disease patients (Miñones-Moyano et al 2011). Differentiated neuronal cells treated 
with specific miR-34b and miR-34c inhibitors demonstrated abnormal mitochondrial morphology, 
with evidence of mitochondrial depolarisation, increased ROS generation and reduced cellular ATP 
content (Miñones-Moyano et al 2011). These changes were accompanied by a concurrent reduction 
in protein deglycase DJ-1 and the E3 ubiquitin ligase Parkin, both essential for the clearance of 
dysfunctional mitochondria.  
Additionally, miR-34 plays an important role in cell proliferation, differentiation and apoptosis. 
Ectopic expression of miR-34 induced cell cycle arrest in both primary and tumour-derived 
murine and human cell lines, cellular senescence in primary human fibroblasts, and apoptosis in 
mouse embryonic fibroblasts, reducing proliferative potential (He et al 2007). The transcriptional 
activator protein p53 accumulates in response to a variety of cellular stressors and DNA damage, 
resulting ultimately in the endpoints of apoptosis, senescence or cell cycle arrest (He et al 2007). 
Genes encoding all three miR-34 family isoforms are direct transcriptional targets of p53, 
providing a mechanism for indirect p53-mediated suppression of gene expression, indeed, 
overexpression of miR-34a in colorectal cancer cells resulted in a disproportionate 
downregulation of mRNA and proteins involved in cell cycle regulation (Kaller et al 2011).  In 
addition to being regulated by p53, miR-34a also acts to indirectly increase activity of the p53 
signalling pathway by directly targeting silent mating type information regulation 2 homolog 1 
(sirtuin 1; SIRT1) (Yamakuchi et al 2008). SIRT1 deacetylates p53, rendering it inactive and 
promoting its degradation. Therefore, miR-34a suppression of SIRT1 promotes accumulation of 
active p53, creating a positive feedback loop increasing activity of the p53 signalling pathway 
(Yamakuchi et al 2008). Our findings suggest a possible role for miR-34a and miR-34c in human 
tendinopathy, with reduced expression impacting on mitochondrial dynamics and promoting 




RNA-seq data identified miRs -181a, -181c and -181d as being down regulated in human SSP tendon 
with disease (Appendix 3, Table A3.2). RT-qPCR validation confirmed these findings (Figure 3.2 (E), 
(G) and (H) respectively), but interestingly, this was not replicated in equine tissue (Figure 3.3 (E), (G) 
and (H)). However, miR-181b, the only family member not altered in human tissue, was significantly 
reduced with equine SDFT disease (Figure 3.3 (F)). Equine variants of miRs -181c and -181d are 
currently not described (miRBase release 22.1, Kozomara et al 2019). However, seed sequences, 
critical for miRNA:target interactions, are highly conserved between miR-181 family members, and 
across species, indicating that in horses, miR-181b may perform an analogous regulatory function to 
that of -181a, -181c and -181d in humans. Downregulation of miR-181b in human SSP tendinopathy 
was detected by RNA-seq (Appendix 3, Table A3.2), but did not reach statistical significance, as was 
confirmed by RT-qPCR (Figure 3.2 (F)). In humans, miR-181a is mapped to two genomic loci, on 
chromosomes 1 and 9, in both cases clustered with miR-181b. In the equine genome, two locations 
are also listed for miR-181a, but on chromosomes 25 and 30, only clustering with miR-181b on 
chromosome 25 (miRBase release 22.1, Kozomara et al 2019). This difference in chromosomal 
location and cluster frequency may explain the disparity in observed expression of these family 
members between species. Further detail on miR-181 family members, including species 
comparison, sequences and genomic location is given in Chapter 4, Table 4.1 and Chapter 5, Tables 
5.1 and 5.3. The miR-181 family is implicated in a wide range of processes pertinent to tendinopathy: 
inflammation (Xie et al 2013), fibrosis (Chen et al 2018), autophagy (Liu et al 2017), and 
mitochondrial biogenesis and function (Indrieri et al 2019, Goljanek-Whysall et al 2020). Validated 
miR-181 targets include SIRT1, ubiquitin-binding protein p62, Parkin, protein deglycase DJ-1, 
cytochrome c oxidase I, interleukin 1 alpha, peroxiredoxin 3 and tumour necrosis factor. Both pro- 
and anti-apoptotic effects have been described for miR-181a (Pop-Bica et al 2018, Rezaei et al 2019), 
with miRs -181a, -181b and -181c shown to be induced by hypoxia (Kulshreshtha et al 2007, 
Nallamshetty et al 2013). Strongly up regulated during differentiation, miR-181 participates in 
both establishing and regenerating the skeletal muscle phenotype, in part by downregulating the 
homeobox protein HOXA11 - a repressor of the differentiation process (Naguibneva et al 2006). 
Our group has shown miR-181a reduction is a consistent finding in human and murine skeletal 
muscle with ageing and is implicated in age-related degenerative changes. These include defective 
insulin, MAPK and TGFβ signalling (Soriano-Arroquia et al 2016) and disrupted mitochondrial 
dynamics and autophagy (Goljanek-Whysall et al 2020). Thus, as tendon is a functionally integral and 
anatomically adjacent component of the musculotendinous unit, it was interesting to see that 
several miR-181 family members demonstrated reduced expression in tendon pathology. However, 
it is also important to note that donors of tendinopathic SSP and PTT tissue were significantly older 
than those from whom control tissue was obtained and an age effect cannot be ruled out. Incidence 
of tendinopathy in both human and equine species increases with age (Paavola et al 2002, Ely et al 
2009, Thorpe et al 2010), and intriguingly, we have previously shown miR-181b expression to be up 
regulated with ageing in clinically normal equine SDFT (Figure 3.3 (L), Bardell et al 2018). This 
disparity between normal age-related changes in miR-181b expression and that seen with disease, 
suggests this family of miRNAs may be important in determining differentiation between healthy 
and pathological phenotypes.   
We detected reductions in miR-199a and miR-199b in tendinopathic human SSP samples, and 
decreased expression of miR-199b in diseased equine SDFT (Table 3.6). Both miR-199a and -199b are 
pro-fibrotic, with miR-199a-5p up regulated in idiopathic pulmonary fibrosis and following bleomycin 
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induced lung injury in mice (Lino Cardenas et al 2013). Expression is up regulated following TGFβ 
exposure, and enhances its signalling pathways by reducing receptor internalisation, secondary to 
down regulation of caveolin 1. Upregulation of miR-199a-5p is also reported in renal and hepatic 
fibrosis, whilst miR-199b over expression is associated with myocardial fibrosis (da Costa Martins et 
al 2010). In porcine heart, miR-199a expression is abolished by a period of transient ischaemia, 
promoting increased levels of its targets SIRT1 and HIF1α (Rane et al 2009). Rapidly induced by 
hypoxia, HIF1α is a potent transcription factor, involved in promoting transcription of 
approximately 90% of genes that are up regulated during hypoxia and protective against hypoxia-
induced mitochondrial damage (Rane et al 2009).  As discussed above with miR-34a, enhanced 
accumulation of SIRT1 consequent to miR-199a downregulation, promotes deactivation and 
degradation of p53, reinforcing this effect. Accumulation of SIRT1 under hypoxic conditions 
stabilises HIF1α by downregulating prolyl hydroxylase 2 (PHD2). This enzyme additionally 
catalyses the formation of hydroxyproline and is therefore important in the stability of collagen. 
Knockdown of miR-199a results in almost complete reduction in PHD2 expression in cardiac 
myocytes, an effect reversed by inactivation of SIRT1 (Rane et al 2009). Downregulation of miR -
199a and miR-199b observed in diseased human and equine tendon, could therefore reflect a 
response to a hypoxic insult, with subsequent impaired production and stabilisation of ECM 
proteins. 
Here we have demonstrated that in humans, tendinopathy results in significant changes to the 
small non-coding RNA transcriptome, and validated these findings in a small, selected cohort of 
miRNAs known to be involved in relevant pathological processes. Additionally, we have 
presented evidence that some of these miRNAs show similar changes in equine SDFT 
tendinopathy. Whilst this is encouraging for the purposes of supporting equine tendon as a valid 
model for studying human tendinopathy, the extensive differences in miRNA profiles between 
healthy and diseased tissue warrants investigation of this dataset as a whole. This will be 
addressed in the following chapter, employing bioinformatics techniques to explore target 









In the previous chapter we identified significant alterations in miRNA expression profile with disease 
in the energy storing human SSP tendon compared with clinically normal control tissue. We further 
validated differential expression of a number of these miRNAs using RT-qPCR, and demonstrated 
comparable changes in the functionally similar equine SDFT. miRNAs function to repress translation 
of their target mRNA, thereby modulating gene expression. Critical to understanding the functional 
consequences of altered miRNA expression on cell phenotype, is, therefore identifying these target 
genes and how their interactions and downstream effects contribute to the disease state. With an 
average of 400 targets per miRNA proposed (Bartel 2009), it is estimated that 60% of human genes 
are regulated by miRNA targeting (Friedman et al 2009), conferring a profound influence on 
phenotype. 
Plant miRNAs demonstrate extensive complementarity to their mRNA target, facilitating target 
prediction through identification of complementary base sequences. However, the situation is more 
difficult in animals, with binding heavily influenced by the six to eight nucleotide seed sequence at 
the 5’ terminal of the miRNA. There are a number of different target prediction tools, but all 
incorporate this primary functional interaction within their algorithms, focussing on conservation of 
the miRNA seed sequence and subsequent Watson-Crick pairing to a complementary conserved 
nucleotide sequence in the 3’UTR of the mRNA target. Target prediction is however, further 
complicated by the number of contiguous Watson-Crick pairings necessary for effective target 
binding. This can vary between eight (8mer) and six (6mer), and, additionally by whether binding 
incorporates the terminal miRNA nucleotide or is offset, with the first one or two nucleotides being 
functionally redundant. Shorter 6mer sequences are generally reported to have reduced efficacy, are 
more likely to result in false positive predictions due to the increased probability of complementary 
sequences arising by chance, and therefore may be disregarded by more stringent prediction 
algorithms (Bartel 2009, Bartel 2018). Additionally, non-canonical binding can occur, with non-
contiguous Watson-Crick pairing, arising from seed sequence mismatches, compensated for by 
additional binding sites usually centred on nucleotides 13-16 towards the 3’ region of the miRNA 
(Bartel 2009). Other relevant factors which may be incorporated into target prediction algorithms 
include the accessibility of the mRNA binding region and the calculated thermodynamic stability of 
binding (Bentwich 2005, Kim et al 2016). As the field of miRNA research has developed, the number 
of experimentally validated miRNA targets has grown, confirming (or refuting) predictions from 
computational bioinformatic algorithms. This has led to the creation of manually curated databases 
such as miRecords (Xiao et al 2009), TarBase (Karagkouni et al 2018) and miRTarBase (Huang et al 
2020) which assimilate evidence of validated interactions, providing another resource for 
investigative research if discovery of novel miRNA:target binding is not the principal focus.    
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QIAGEN Ingenuity Pathway Analysis (IPA) (QIAGEN Inc., Redwood City, CA, USA, 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis, Krämer et al 2014) is 
an analytical tool drawn from an extensive database integrating both computational and manual 
curation methods for investigating miRNA:target interactions, the networks and pathways which 
these interactions influence and their ontological consequences. The microRNA Target Filter 
function within IPA incorporates computationally predicted miRNA-mRNA binding relationships 
derived from TargetScan (Agarwal et al 2015) and experimentally validated miRNA-mRNA 
interactions derived from TarBase (Karagkouni et al 2018), miRecords (Xiao et al 2009) and Ingenuity 
Knowledge Base (QIAGEN Inc., Redwood City, CA, USA). Accordingly, this provides one of the most 
comprehensive and robust resources for investigation of the functional consequences of altered 
miRNA expression over life course or associated with pathological conditions.  
Age-related changes in miRNA expression in uninjured human Achilles tendon have previously been 
reported (Peffers et al 2015), as have age- and disease-related changes in equine SDFT (Bardell et al 
2018). In this chapter, we utilised IPA to interrogate our dataset of miRNAs DE in human 
tendinopathy to identify targets and networks likely to be affected as a consequence. With such a 
large data set (223 miRNAs), the knowledge that each miRNA may target multiple gene transcripts, 
and transcripts are potentially targeted by more than one miRNA, we additionally employed a 
functional enrichment programme (ToppFun, Chen et al 2009, http://toppgene.cchmc.org) to 
investigate if certain biological processes were preferentially affected. Using this approach, we 
identified processes associated with maintaining cell viability, increasing cellularity, inflammation 
and fibrosis, and insulin, SMAD2/3, TGFβ, ERK1/2 and MAP2K1/2 signalling as being impacted by 
miRNA dysregulation.  
Having validated DE of a small panel of miRNAs in human tendinopathy, and identified three (miR-
29a, miR-181 and miR-199a) that were similarly DE with tendinopathy in equine SDFT, we then 
repeated this process with these miRNAs to identify mechanistic processes common to both species.  
Analysis underscored the processes identified above, reinforcing the importance of extracellular 
matrix (ECM) deposition and organisation (both collagenous and non-collagenous components), 
inflammation, and cell population dynamics. Thus we have identified processes active in clinical 
tendinopathy which are common to both human and equine species, and identified three miRNAs 







4.2.1 Target prediction and pathway analysis for miRNAs differentially expressed in 
human tendinopathy 
The QIAGEN IPA tool was used to assess the biological inference of the 223 miRNAs significantly DE 
(log2 fold change ≥1.5 with Bejaminin-Hochberg adjusted P-value <0.05) between tendinopathic SSP 
samples and healthy controls (listed in Appendix 3, Table A3.2). Data were uploaded using both 
miRBase (Kozomara et al 2019) and Ensembl (release 102, Yates et al 2019, 
https://www.ensembl.org) identifiers, with log2 fold change. This produced 186 analysis ready 
molecules (170 down regulated, 16 up regulated) following deduplication performed by the 
software, which clusters mature miRNAs sharing the same seed sequences. Core Analysis was run 
using default software settings.  
To identify potential miRNA targets, we then utilised the microRNA Target Filter function available in 
IPA. All 223 miRNAs were uploaded into the microRNA Target Filter programme, of which 182 
miRNAs had targeting information available, returning 17,547 putative mRNA targets. The data set 
was then filtered (Figure 4.1 (A)) for confidence of miRNA:target interactions (Experimentally 
Observed and High (predicted)), which reduced our dataset to 182 miRNAs targeting 11,295 mRNAs. 
Further filters were then applied for ‘Disease’ (‘Connective Tissue Disorders’ and ‘Skeletal and 
Muscular Disorders’ - reducing to 182 miRNAs targeting 4534 mRNAs) and ‘Tissue/Cell Line’ (‘Tissues 
and Primary Cells’ and ‘Fibroblasts’) giving 167 miRNAs targeting 464 mRNAs (Appendix 4, Table 
A4.1). These 464 molecules were assigned a log2 fold change value of zero, as DE data was not 
available. These were uploaded to IPA in combination with the identity and log2 fold change values 
of the DE miRNAs. The initial dataset of 687 molecules reduced to 650 analysis ready molecules 
following deduplication, and Core Analysis of these genes was run.  Canonical pathways, diseases 
and biological functions, and gene networks relevant to these were then further explored.  
Functional enrichment of the target genes identified was then investigated using the ToppFun 
function of the ToppGene Suite software (Chen et al 2009, http://toppgene.cchmc.org). The HGCN 
gene identifier symbols for all 464 target genes were uploaded and functional enrichment analysis 
run, analysing for the feature ‘GO: Biological Process’. Significance was determined by incorporating 
FDR correction with P-value cut off set to 0.05 into the calculation function. 
 
4.2.2. Target prediction and pathway analysis for differentially expressed miRNAs 
common to both human and equine tendinopathy 
In the previous chapter, we identified miR-29a-3p and miR-199a-5p and members of the miR-181 
family (hsa-miR-181a-3p, hsa-miR-181c-3p and -5p, hsa-miR-181d-5p, and eca-miR-181b) as showing 
significant downregulation in both human and equine tendinopathy (Chapter 3, Table 3.6). We 
therefore next focussed target prediction and network analysis on these miRNAs.  
In formatting data for uploading to IPA, the Ensembl and miRBase gene identifiers for the human 
orthologues of each miRNA were used, as only human, mouse and rat content are fully supported in 
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IPA. Based on sequence similarity, four miRNAs with corresponding log2 fold change values were 
uploaded: hsa-miR-29a-3p and hsa-miR-199a-5p, both of which have identical sequences between 
human and equine species (Table 4.1), and hsa-miR-181b-5p (for which an arbitrary log2 fold change 
value of -1.5 was assigned, thereby defining it as meeting the minimal requirements for significance) 
and hsa-miR-181d-5p. Equine variants of miR-181c and miR-181d are not described (miRBase release 
22.1, Kozomara et al 2019), however hsa-miR-181d only differs from eca-miR-181b by a single base, 
and hsa-miR-181b-5p and eca-miR-181b have identical sequences (Table 4.1).  Additionally, 3p/5p 
variants of miR-181 family members are not described in the equine species (miRBase release 22.1, 
Kozomara et al 2019). This resulted in three analysis ready molecules: miR-29b-3p (representing hsa-
miR-29a-3p/eca-miR-29a), miR-181a-5p (representing hsa-miR-181d-5p and hsa-miR-181b-5p/eca-
miR-181b) and miR-199a-5p (representing hsa-miR-199a-5p/eca-miR-199a-5p), following grouping 
of mature miRNAs into clusters based on common seed sequences by the IPA software. Core 
Analysis was run using default software settings. 
To identify potential targets for these miRNAs, we then utilised the microRNA Target Filter function 
as described above (Section 4.2.1), following the same filtering process (Figure 4.1 (B)). Initial 
analysis predicted 2630 mRNA targets for these three seed sequence configurations. This reduced to 
727 after filtering for confidence of miRNA:target interactions (Experimentally Observed and High 
(predicted)), 326 mRNAs after filtering for ‘Disease’ (Connective Tissue Disorders and Skeletal and 
Muscular Disorders), and further to 48 mRNA targets after  applying filters for ‘Tissue/Cell Line’ 
(Tissues and Primary Cells and Fibroblasts). These targets are listed in Appendix 4, Table A4.2. These 
48 molecules were assigned a log2 fold change value of zero, as DE data was not available and 
uploaded to IPA, in combination with the identity and log2 fold change values of the four DE 
miRNAs. The initial dataset of 53 molecules reduced to 51 analysis ready molecules following 
deduplication of miRNAs and targets, and Core Analysis was then run. Canonical pathways, diseases 
and biological functions, and gene networks relevant to these were then further explored. 
Functional enrichment of target genes was investigated using the ToppFun function of the ToppGene 
Suite software (Chen et al 2009, http://toppgene.cchmc.org). The HGCN gene identifier symbols for 
the 48 target genes were uploaded and functional enrichment analysis run, analysing for the feature 
‘GO: Biological Process’. Significance was determined by incorporating FDR correction with P-value 
cut off set to 0.05 into the calculation function. 
 
4.2.3. Statistical analysis 
QIAGEN IPA performs two primary statistical tests. The P-value of overlap is calculated using a right-
tailed Fisher’s Exact test for all analyses (canonical pathways, disease and functions, regulator effects 
and networks), with significance indicated if P ≤ 0.05.   
Inclusion of directional expression data permits calculation of z-scores for the functions canonical 
pathways, upstream regulators and diseases and functions. Z-scores predict downstream effects 
based on correlation between the expression pattern of molecules in the experimental dataset with 
that reported in published databases, from which Ingenuity Knowledge Base is populated. A z-score 
≥ 2 predicts activation, whilst a z-score ≤ -2 predicts inhibition.   
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Additionally, for networks identified as significant (P ≤ 0.05) using a right-tailed Fisher’s Exact test, a 
network score is reported. This numerical value ranks significant networks according to the degree 
of relevance of network eligible (‘analysis ready’) molecules in the experimental dataset to networks 
contained in the Ingenuity Knowledge Base. The network score is based on the P-value calculated 








miRNA Identity Sequence 
hsa-miR-29a-3p u a g c a c c a u c u g a a a u c g g u u a   
eca-miR-29a u a g c a c c a u c u g a a a u c g g u u a   
                                                
hsa-miR-199a-5p c c c a g u g u u c a g a c u a c c u g u u c 
eca-miR-199a-5p c c c a g u g u u c a g a c u a c c u g u u c 
                                                
hsa-miR-181a-5p a a c a u u c a a c g c u g u c g g u g a g u 
eca-miR-181a a a c a u u c a a c g c u g u c g g u g a g u 
                                                
hsa-miR-181b-5p a a c a u u c a u u g c u g u c g g u g g g u 
eca-miR-181b a a c a u u c a u u g c u g u c g g u g g g u 
                                                
hsa-miR-181c-5p a a c a u u c a a c c u g u c g g u g a g u   
                                                
hsa-miR-181d-5p a a c a u u c a u u g u u g u c g g u g g g u 
                                                
hsa-miR-181a-3p a c c a u c g a c c g u u g a u u g u a c c   
hsa-miR-181b-3p c u c a c u g a a c a a u g a a u g c a a     
hsa-miR-181c-3p a a c c a u c g a c c g u u g a g u g g a c   
hsa-miR-181d-3p c c a c c g g g g g a u g a a u g u c a c     
 
Table 4.1 Sequences are conserved between human (hsa) and equine (eca) orthologues of miR-
29a-3p, miR-199a-5p, miR-181a and miR-181b. Seed sequences of 5p variants of all four human 
miR-181 family membes are identical, but this feature is not conserved in the corresponding 3p 
variants. In the equine species, miR-181c and miR-181d are not recognised, nor are 5p/3p variants of 
miR-181a or miR-181b. Seed sequences are shown in red. Sequences obtained from miRBase 
(release 22.1, Kozomara et al 2019). 
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Figure 4.1 Flowchart illustrating filters applied during target prediction for: A) 223 human miRNAs 
differentially expressed in tendinopathy. B) Three miRNAs differentially expressed in both human 
and equine tendinopathy. Target prediction and filtering performed using Ingenuity Pathway 
Analysis (IPA; www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) microRNA 
Target Filter function which clusters miRNAs on the basis of common seed sequences (see text for 






4.3 Results  
 
4.3.1 Target prediction and pathway analysis for miRNAs differentially expressed in 
human tendinopathy 
Core Analysis of DE miRNAs 
Initial Core Analysis of all 223 miRNAs previously identified as significantly DE returned top biological 
functions of cellular development (P = 4.70E-02 – 5.29E-15), growth and proliferation (P = 4.70E-02 – 
5.29E-15) and movement (P = 4.70E-02 – 3.34E-11), cell death and survival (P = 4.32E-02 – 5.10E-07), 
and cell cycle (P = 4.61E-02 – 8.37E-06). Figure 4.2 illustrates a heat map, sized by number of genes 
and coloured according to activity (z-score), with all disease and function categories demonstrating 
significant activation (P<0.05, z-score ≥2, orange) or deactivation (P<0.05, z-score ≤-2, blue) listed in 
Table 4.2. Interestingly, activity of inflammatory response or inflammatory disease, or connective 
tissue disorders, were not predicted to be significantly affected. 
 
Annotated functions ‘Apoptosis’ and ‘Necrosis’ and ‘G1/S phase transition of fibroblast cell lines’ and 
‘Maturation of chondrocyte cell lines’ were further explored for associated miRNAs. Inhibited 
functions apoptosis and necrosis were associated with 36 miRNAs (Figure 4.3 (A)) and 39 miRNAs 
(Figure 4.3 (B)) respectively. Activated functions G1/S phase transition of fibroblast cell lines and 
























Figure 4.2 Core analysis of 223 human miRNAs differentially expressed with tendinopathy 
identifies top biological functions most significantly affected are associated with cellular 
development, proliferation, movement and viability. Heatmap squares sized according to number 
of associated miRNAs and coloured according to activation (z-score; ≥2 = activation (orange); ≤-2 = 
inhibition (blue)). Intensity of colour reflects magnitude of z-score <-2 or >2). Where the software 
cannot predict activation or inhibition of biological functions from the available database, squares 
are coloured grey. See Table 4.2 for additional details.  
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Figure 4.3 Biological functions A. Apoptosis and B. Necrosis are predicted to be inhibited by the 



























Figure 4.4 Biological functions A. G1/S phase transition of fibroblast cell lines and B. Maturation of 
chondrocyte cell lines are predicted to be activated by the action of multiple miRNAs differentially 




Top scoring network, both in terms of score (57) and number of focus molecules (28) was associated 
with the terms neurological disease, organismal injury and abnormalities, and psychological 
disorders. Removal of the molecules chorionic gonadotrophin (CG) and follicle stimulating hormone 
(FSH) from the network reduced this to 23 focus molecules. This network implicated insulin, SMAD 
2/3, TGFβ, ERK1/2 and MAP2K1/2 as important signalling pathways impacted by altered miRNA 






















Figure 4.5 Top scoring network identified by Ingenuity Pathway Analysis of 223 differentially 
expressed human miRNAs identifies potential dysregulation of insulin, SMAD2/3, TGFβ, ERK1/2 
and MAP2K1/2 signalling in tendinopathy. Network represented following removal of Follicle 
Stimulating Hormone (FSH) and Chorionic Gonadotrophin (CG). Green indicates miRNA expression 
reduced in tendinopathy, intensity of colour reflects magnitude of reduction. Grey indicates 
relationship effect not predicted.  
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Core analysis of DE miR target genes 
We then investigated target interactions for the 650 analysis ready molecules identified by the IPA 
microRNA Target Filter function subsequent to our applied filters (section 4.2.1, Figure 4.1 (A)) and 
deduplication by the software.   
Core analysis of the 464 mRNA targets derived following application of these filters identified top 
diseases and functions associated with the terms cancer, organismal injury and abnormalities, 
inflammation and connective tissue disorders (Table 4.3). Predicted activation (z-scores) indicated 
decreased activation of apoptosis and necrosis, with increased activity of functions related to 
cellular growth, migration and proliferation (Table 4.4). Top molecular and cellular functions 
identified were associated with cell activity, development and viability (Table 4.3), whilst top 
canonical pathways implicated were related to tumour microenvironment, fibrosis and inflammation 
(Table 4.3). The two top scoring networks were associated with the terms cell death and survival, 
gastrointestinal and hepatic system disease (score 49, 31 focus molecules, Figure 4.6 (A)) and cancer, 
organismal injury and abnormalities and reproductive system (score 44, 29 focus molecules, Figure 
4.6 (B)). Significant upstream regulators were identified as TNF (P = 1.44E-144), IL1β (P = 3.68E-127) 
and TGFβ1 (P = 2.81E-124). 
 
Functional enrichment of identified target genes was then investigated using the ToppFun function 
of the ToppGene Suite software (Chen et al 2009, http://toppgene.cchmc.org). The HGCN gene 
identifier symbols for all 464 target genes were uploaded and functional enrichment analysis run 
using the calculation function with FDR correction and P-value cut off set to 0.05, for the feature 
‘GO: Biological Process’. Top ten gene ontology (GO) terms ranked in terms of number of molecules 




Canonical Pathway P-value 
Tumour microenvironment  8.35E-53 
Hepatic fibrosis signalling 7.27E-47 
Hepatic fibrosis/hepatic stellate cell activation 6.28E-46 
Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis 2.62E-42 
Role of osteoblasts, osteoclasts and chondrocytes in rheumatoid arthritis 2.16E-40 
  
Diseases and Disorders P-value range Number of molecules 
Cancer 1.62E-40 – 4.56E-138 546 
Organismal injury and abnormalities 1.10E-39 – 4.56E-138 572 
Inflammatory response 5.83E-40 – 2.21E-128 409 
Connective tissue disorders 6.77E-40 – 1.94E-107 322 
Inflammatory disease 1.04E-40 – 1.94E-107 370 
   
Molecular and Cellular Functions   
Cellular movement 5.41E-40 – 1.50E-137 376 
Cellular development 4.28E-40 – 1.81E-129 451 
Cellular growth and proliferation 4.28E-40 – 1.81E-129 439 
Cell death and survival  7.19E-40 – 4.39E-124 407 
Cell-to-cell signalling and interaction 5.83E-40 – 4.77E-103 325 
  
 
Table 4.3 Ingenuity Pathway Analysis predictions of most significant canonical pathways, diseases 
and disorders and molecular and cellular functions likely to be implicated as a result of miRNA 
dysregulation in human tendinopathy.  Core analysis performed on 464 putative mRNA targets of 













































































































































































































































































































Figure 4.6 (preceding page) Top scoring networks reflecting dysregulated miRNA:target 
interactions in human tendinopathy are associated with the terms:  A. Cell death and survival, 
gastrointestinal and hepatic system disease (score 49, 31 focus molecules) and B. Cancer, organismal 
injury and abnormalities reproductive system disease (score 44, 29 focus molecules). Green indicates 
miRNA expression reduced in tendinopathy, red indicates miRNA expression increased in 
tendinopathy. Intensity of colour reflects magnitude of reduction. Grey indicates relationship effect 





Table 4.5 Biological processes (as described by gene ontology (GO) terms) associated principally 
with control of cellular proliferation, viability and localisation, signalling and metabolic activity are 
enriched in the mRNA population targeted by miRNAs DE in human tendinopathy. Target gene 
identification and functional enrichment analysis performed using IPA microRNA Target Filter 
(www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) and Toppgene Suite 
(toppgene.cchmc.org) respectively. Highlighted terms are common to rankings by both hit count and 
q-value. FDR BH = False Discovery Rate derived using Benjamini Hochberg correction. 
Gene Ontology P-value q-value 
FDR BH 
Hit Count 
in Query List ID Term 
Ranked by number of associated target molecules     
GO:0042127 Regulation of cell population proliferation 3.99E-109 3.36E-105 227 
GO:0010941 Regulation of cell death 1.31E-79 1.38E-76 198 
GO:0009719 Response to endogenous stimulus 2.22E-83 6.23E-80 196 
GO:1901700 Response to oxygen-containing compound 3.63E-83 7.63E-80 196 
GO:0009967 Positive regulation of signal transduction 6.08E-83 1.02E-79 195 
GO:0019220 Regulation of phosphate metabolic process 2.58E-74 1.32E-71 193 
GO:0051174 Regulation of phosphorus metabolic process 2.82E-74 1.32E-71 193 
GO:0048870 Cell motility 4.11E-74 1.65E-71 190 
GO:0051674 Localization of cell 4.11E-74 1.65E-71 190 
GO:0016477 Cell migration 1.93E-79 1.81E-76 188 
Ranked by q-value for FDR    
GO:0042127 Regulation of cell population proliferation 3.99E-109 3.36E-105 227 
GO:0008284 Positive regulation of cell population proliferation 3.66E-86 1.54E-82 160 
GO:0009719 Response to endogenous stimulus 2.22E-83 6.23E-80 196 
GO:1901700 Response to oxygen-containing compound 3.63E-83 7.63E-80 196 
GO:0009967 Positive regulation of signal transduction 6.08E-83 1.02E-79 195 
GO:0035295 Tube development 8.67E-83 1.22E-79 167 
GO:0051094 Positive regulation of developmental process 2.66E-81 3.20E-78 184 
GO:0010941 Regulation of cell death 1.31E-79 1.38E-76 198 
GO:0016477 Cell migration 1.93E-79 1.81E-76 188 
GO:0030334 Regulation of cell migration 1.05E-77 8.85E-75 149 
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4.3.2. Target prediction and pathway analysis for differentially expressed miRNAs 
common to both human and equine tendinopathy 
To investigate mechanistic processes common to human and equine tendinopathy, a separate 
analysis was then run focussing on miR-29a-3p, miR-199a-5p and members of the miR-181 family, 
which had shown significantly reduced expression in tendinopathic tissue from both human and 
equine species (see Chapter 3, Table 3.6).  
 
Core analysis of the four DE miRs common to horse and man 
Core Analysis of the human orthologues of these four dysregulated miRNAs (three clusters following 
grouping of mature miRNAs based on common seed sequences by the IPA software) returned top 
biological functions of cellular movement (P = 2.32E-02 – 1.89E-04), cell-to-cell signalling and 
interaction (P = 6.57E-04 – 3.94E-04), cell death and survival (P = 4.98E-02 – 5.26E-04) and cellular 
development, growth and proliferation (P = 4.84E-02 – 5.58E-04).  
The only identified network containing all three focus molecules was associated with the terms 
connective tissue disorders, organismal injury and abnormalities and skeletal and muscular disorders 
(Figure 4.7). Over represented in the 27 organic molecules identified in this network, were those 
associated with composition and organisation of the extracellular matrix.  Both collagenous 
(collagens COL1A1, COL4A1, COL4A5, COL5A1, COL5A2, COL5A3, COL14A1) and non-collagenous 
(biglycan (BGN), fibrillin 1 (FBN1)) matrix proteins were identified, together with those associated 
with matrix organisation, maturation and homeostasis; cartilage associated protein (CRTAP), lysyl 
oxidase like 2 (LOXL2), procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2), disintegrin and 
metalloproteinase with thrombospondin motifs family members 2 and 14 (ADAMTS2, ADAMTS14), 
integrin alpha-3 (ITGA3) and epithelial discoidin domain-containing receptor 1 (DDR1), which, 
additionally regulates cell-matrix interactions and cell migration, proliferation, differentiation and 
survival. Other network proteins also related to these latter processes were dual specificity protein 
phosphatase 2 (DUSP2), neurogenic locus notch homolog protein 4 (NOTCH4) and protein 
phosphatase 1D (PPM1D). Reinforcing the maturation of chondrocyte cell lines function identified in 
the main dataset (Figure 4.4 (B)), this network also included homeobox protein Hox-A11 (HOXA11) 
and Wnt Family Member 5B (WNT5B).  
Other network proteins implicated in cell-matrix interactions in addition to DDR1 were basement 
membrane proteins nidogen 1 and nidogen 2 (NID1, NID2), important in cell adhesion and critical in 
establishment of tissue architecture during organ development (Bader et al 2005). Inflammation 
associated proteins DUSP2 and pulmonary surfactant-associated protein A1 (SFTPA1) were also 
identified (Figure 4.7). 
Regulators and components of the transforming growth factor beta/mothers against 
decapentaplegic (TGFβ/SMAD) signalling were also represented, with promotors myocardin 
(MYOCD) and transforming growth factor beta-1-induced transcript 1 protein (TGFB1I1) being 
identified, as well as and transforming growth factor beta receptor type 3 (TGFBR3). 
The presence of hydrogen peroxide in this network also alluded to an association of these miRNAs 






















Figure 4.7 Top network associated with dysregulation of miR-29a-3p, miR-181a-5p and miR-199a-
5p common to both human and equine tendinopathy. This was the only network containing all 
three miRNAs and was associated with the terms connective tissue disorders, organismal injury and 
abnormalities and skeletal and muscular disorders. Green indicates miRNA expression reduced in 
tendinopathy, intensity of colour reflects magnitude of reduction. Grey indicates relationship effect 






Core analysis of the mRNA targets of four DE miRs 
Using the same filtering criteria previously applied within the IPA microRNA Target Filter function 
(section 4.2.1, Figure 4.1 (B)), we next identified 48 mRNA targets for these three focus molecules 
(Appendix 4, Table A4.2). Core analysis of these 48 mRNA targets identified top canonical pathways 
related to fibrosis signalling and activation, tumour microenvironment and signalling associated with 
epithelial-mesenchymal transition and pancreatic neoplasia (Table 4.6). Top diseases and functions 
were associated with the terms cancer, organismal injury and abnormalities, and skeletal and 
muscular disorders (Table 4.6). Activation (z-scores) indicated either no net activity pattern was 
predicted, or it was not possible to calculate from the data contained within the IPA database.  Top 
molecular and cellular functions identified were associated with cellular movement and signalling, 
and cell proliferation, development and viability (Table 4.6).  
 
 
Canonical Pathway P-value 
Hepatic fibrosis signalling  1.00E-19 
Hepatic fibrosis/hepatic stellate cell activation 3.46E-18 
Tumour microenvironment 8.06E-17 
Regulation of epithelial mesenchymal transition by growth factors 8.24E-15 
Pancreatic adenocarcinoma signalling  2.38E-12 
  
Diseases and Disorders P-value range Number of molecules 
Cancer 8.59E-08 – 3.52E-23 51 
Organismal injury and abnormalities 8.63E-08 – 3.52E-23 51 
Skeletal and muscular disorders 6.48E-08 – 3.07E-19 45 
Cardiovascular disease 8.26E-08 – 3.60E-18 36 
Reproductive system disease 6.48E-08 – 1.65E-17 46 
   
Molecular and Cellular Functions   
Cellular movement 6.64E-08 – 4.68E-21 39 
Cell-to-cell signalling and interaction 6.82E-08 – 1.86E-17 32 
Cellular development 7.40E-08 – 1.08E-16 43 
Cellular growth and proliferation 7.40E-08 – 1.08E-16 39 
Cell death and survival 7.87E-08 – 1.49E-16 38 
  
 
Table 4.6 Ingenuity Pathway Analysis predictions of most significant canonical pathways, diseases 
and disorders and molecular and cellular functions implicated as a result of dysregulation of miR-
29a-3p, miR-181a-5p and miR-199a-5p common to human and equine tendinopathy.  Core analysis 
performed on 48 putative mRNA targets of four miRNAs. IPA analysis utilised human orthologues of 
relevant miRNAs and clustered miRNAs sharing common seed sequences (see text for details). See 
text (section 4.2) for details of target filters applied. 
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Interrogating the database for the term cell viability, implicated miR-181a-5p as the key miRNA for 
this function (Figure 4.8). The top scoring network (score 34, 15 focus molecules) was associated 
with the functions tissue development, connective tissue disorders and organismal injury and 
abnormalities (Figure 4.9 (A)), whilst the second scoring network (score 20, 10 focus molecules) was 
associated with tissue development, organismal injury and abnormalities and cancer (Figure 4.9 (B)). 
Upstream regulators identified were SMAD3 (P = 8.30E-21) and HRas proto-oncogene, GTPase 





















Figure 4.8 miR-181a-5p expression regulates cell viability in both human SSP and equine SDFT 
tendinopathy. Green indicates miRNA expression reduced in tendinopathy, intensity of colour 
reflects magnitude of reduction. Orange dashed line indicates relationship is predicted activation, 







































Figure 4.9 (preceding page) Top scoring networks reflecting dysregulated miRNA:target 
interactions common to  human and equine tendinopathy are associated with the terms:  A. Tissue 
development, connective tissue disorders, organismal injuries and abnormalities (score 34, 15 focus 
molecules) and B. Tissue development, organismal injury and abnormalities, cancer (score 20, 10 
focus molecules). Green indicates miRNA expression reduced in tendinopathy, intensity of colour 





Chronic inflammation is regulated by miRNAs in both human and equine tendinopathy 
Inflammatory disease and response was identified as significant by core analysis of predicted target 
genes regulated by DE miRNAs in our human tendinopathy dataset (Table 4.3). This was not, 
however, replicated by core analysis of genes targeted by miRs -29a, -181 and -199a common to 
both human and equine tendinopathy. We therefore revisited the full dataset of human DE miRNAs 
and interrogated it using the term ‘chronic inflammatory disorder’. This resulted in identification of 
21 miRNAs associated with this process, which contained the three focus miRNAs common to human 
and equine tendinopathic samples (Figure 4.10 (A)). Further, we then interrogated our core analysis 
of predicted targets for these miRNAs using the same term, which confirmed all three miRNAs and 




























Figure 4.10 Ingenuity Pathway Analysis indicated miRNA dysregulation in both human and equine 
tendinopathy is associated with chronic inflammation. A. miRNAs identified from DE human miRNA 
dataset in SSP tendinopathy, showing significantly reduced expression associated with chronic 
inflammation; miRNAs contained within red box were also identified as significantly reduced in 
diseased equine SDFT. B. Predicted targets of miRNAs significantly reduced in both equine SDFT and 
human SSP tendinopathy associated with chronic inflammation. Green indicates miRNA expression 
reduced in tendinopathy, intensity of colour reflects magnitude of reduction. Grey indicates 





Functional enrichment of the target genes identified was then investigated using the ToppFun 
function of the ToppGene Suite software (Chen et al 2009, http://toppgene.cchmc.org). The HGCN 
gene identifier symbols for all 48 target genes were uploaded and functional enrichment analysis run 
using the calculation function with FDR correction and P-value cut off set to 0.05, for the feature 
‘GO: Biological Process’. Top ten gene ontology (GO) terms ranked in terms of number of molecules 





Table 4.7 Biological processes (as described by gene ontology (GO) terms) associated principally 
with control of cellular recruitment, tissue development and extracellular matrix organisation are 
enriched in the mRNA population targeted by miR-29a-3p, miR-181a-5p and miR-199a-5p, which 
show reduced expression in both human and equine tendinopathy. Target gene identification and 
functional enrichment analysis performed using IPA microRNA Target Filter 
(www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) and Toppgene Suite 
(toppgene.cchmc.org) respectively. Highlighted terms are common to rankings by both hit count and 
q-value. FDR BH = False Discovery Rate derived using Benjamini Hochberg correction. 
Gene Ontology P-value q-value 
FDR BH 
Hit Count 
in Query List ID Term 
Ranked by number of associated target molecules     
GO:0035295 Tube development 3.86E-19 3.01E-16 26 
GO:0051241 Negative regulation of multicellular organismal process 3.97E-15 1.55E-12 24 
GO:0009887 Animal organ morphogenesis 8.14E-16 5.08E-13 23 
GO:0072359 Circulatory system development 3.24E-15 1.45E-12 23 
GO:0016477 Cell migration 1.35E-12 2.64E-10 23 
GO:0051674 Localization of cell 9.71E-12 1.26E-09 23 
GO:0048870 Cell motility 9.71E-12 1.26E-09 23 
GO:0051094 Positive regulation of developmental process 2.95E-12 4.99E-10 22 
GO:0030198 Extracellular matrix organization 1.38E-23 4.31E-20 21 
GO:0043062 Extracellular structure organization 2.33E-21 3.63E-18 21 
Ranked by q-value for FDR    
GO:0030198 Extracellular matrix organization 1.38E-23 4.31E-20 21 
GO:0043062 Extracellular structure organization 2.33E-21 3.63E-18 21 
GO:0001501 Skeletal system development 3.57E-20 3.71E-17 21 
GO:0035295 Tube development 3.86E-19 3.01E-16 26 
GO:0009887 Animal organ morphogenesis 8.14E-16 5.08E-13 23 
GO:0009611 Response to wounding 2.71E-15 1.41E-12 19 
GO:0072359 Circulatory system development 3.24E-15 1.45E-12 23 
GO:0051241 Negative regulation of multicellular organismal process 3.97E-15 1.55E-12 24 
GO:0035239 Tube morphogenesis 4.95E-15 1.72E-12 21 





Alterations in extracellular matrix composition and organisation are known to be important 
precursors and consequences of clinical tendinopathy (Archambault et al 2007, Corps et al 2006, 
Jelinsky et al 2011, Magnusson et al 2002). In this chapter, we have identified enhancement of 
cellular proliferation and inhibition of cellular degeneration as fundamental processes influenced by 
altered miRNA expression in human SSP tendinopathy. Additionally, the three miRNAs we validated 
as showing reduced expression in both human SSP and equine SDFT tendinopathy (miR-29a-3p, miR-
181a-5p and miR-199a-5p), recapitulated regulation of cell differentiation, proliferation and fate, as 
well as inflammation, as important mechanisms common to both species.  
The appearance of terms associated with neoplastic disease (tumour microenvironment, cancer and 
pancreatic adenocarcinoma; Tables 4.3 and 4.6) in IPA output may seem surprising. However, this 
reflects overrepresentation of experimental data, generated from this research field, incorporated 
into the Ingenuity Knowledge Base resource. Nevertheless, neoplastic transformation is consistent 
with modified control of apoptosis and cell cycle regulation, and increased cellular proliferation. In 
accordance with this, core analyses run on both miRNA data sets returned top biological functions 
associated with cellular movement, development, growth and proliferation and viability (Figures 4.2 
and 4.3, Tables 4.2 and 4.4). Similarly, the term hepatic fibrosis (Tables 4.3 and 4.6) was interpreted 
as representative of general fibrotic disease processes. Despite filtering all DE miRNAs from the 
human tendinopathy dataset for the terms connective tissue disorders and fibroblasts, the absence 
of predicted activation or inhibition of connective tissue disorders reported in Figure 4.2 and Table 
4.2, likewise reflects the lack of published, validated evidence, or low confidence of computationally 
predicted interactions of these miRNAs in regulating connective tissue disorders. Thus interpretation 
of the IPA output must be undertaken with caution and an understanding of the limitations inherent 
in the database from which the output is derived.  
The dataset of DE human miRNAs derived from RNA-seq implicated processes associated with 
neurodegenerative disease, whilst analysis of those miRNAs also DE in equine SDFT tendinopathy, 
implied musculoskeletal and connective tissue associations. Both, however, identified TGFβ/SMAD 
and mitogen-activated protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) signalling as 
being relevant, within the top scoring networks, and as significant upstream regulators (Figures 4.5 
and 4.7). Both datasets additionally suggest a transition of fibroblasts to a more cartilaginous 
phenotype as part of the response to injury. Reduced expression of miRs -23a-3p, -30c-5p, -34a-5p 
and -205-5p is associated with increased activation of chondrocyte maturation (Figure 4.4 (B)). 
Additionally, HOXA11 and WNT5B, both identified in the top network containing miRs -29a, -181 and 
-199a (Figure 4.7), regulate chondrocyte proliferation and differentiation (Gross et al 2012, Yang et 
al 2003).  
TGFβ signalling is important in immunity, inflammation, fibrosis and neoplastic disease (Massagué 
2012), mediating cellular proliferation, differentiation, apoptosis and migration (Hu et al 2018). At 
the cellular level, TGFβ family members regulate cell growth, differentiation, adhesion, migration 
and death, in a strongly developmental, context-dependent and cell type-specific manner. These 
multifunctional cytyokines are able to inhibit cell proliferation whilst promoting cell growth and 
enhancing stem cell pluriporency, as well as also driving differentiation (Massagué 2012, Morikawa 
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et al 2016). Canonical TGFβ signalling occurs via the activation (phosphorylation) of SMAD 
transcription factors, which act to integrate regulatory inputs, and are pivotal in the context-
dependent modulation of TGFβ signalling (Massagué 2012). Activated SMAD2 and SMAD3 molecules 
form heterotrimeric oligomers with SMAD4, and are imported into the nucleus where they function 
to control transcriptional regulation. The ultimate cellular response is therefore influenced by the 
intensity of the TGFβ signal, the interaction of SMAD proteins with other, potentially lineage specific, 
transcription factors (thus forming complexes with diverse regulatory consequences on 
transcription), and epigenetic influences (such as DNA methylation, chromatin remodelling and 
expression of non-coding RNA species) (Massagué 2012). SMAD proteins also participate in non-
canonical pathways and are phosphorylated by mitogen-activated protein kinases (MAPKs) 
subsequent to growth factor expression, cellular stress and cyclin-dependent kinase 4 expression 
during G1 phase progression in the cell cycle (Massagué 2012). 
SMAD 2 and 3, identified in the top scoring miRNA network from our human dataset, are the two 
major regulators promoting TGFβ1 mediated fibrosis. SMAD7 acts as a negative feedback regulator 
of the pathway, blocking SMAD3 expression (Hu et al 2018), and facilitating polyubiquitylation and 
hence degradation of TGFβ receptors (Massagué 2012). Myocardin (MYOCD), identified in our 
network in Figure 4.7, promotes SMAD3-mediated TGFβ signalling in mouse fibroblast cells (Tong et 
al 2020). 
Activated SMAD proteins are also known to stimulate maturation of a specific set of miRNAs in 
human vascular smooth muscle cells, including hsa-miR-199a-5p (Davis et al 2010), which we 
identified as significant in both our human and equine datasets.  
As well as intracellular effects, TGFβ is secreted in an inactive, complexed form (Rifkin 2005). These 
latent TGFβ binding protein (LTBP) complexes interact with a number of matrix components 
including collagen, fibronectin and fibrillin-1. This targets TGFβ to regions of the ECM, but LTBP-ECM 
binding also controls activation. Therefore, disruption to ECM protein composition during 
tendinopathy may disrupted growth factor activation and signalling (Rifkin 2005). 
MAPK signalling pathways are highly evolutionarily conserved, key signalling pathways consisting of 
a cascade of three sequentially activated kinases. Three MAPK families have been characterised, 
extracellular-signal-regulated kinases (ERKs), Jun amino-terminal kinases (JNKs) and stress-activated 
protein kinases (p38/SAPKs) (Zhang and Liu 2002). Identified as components of the top scoring 
network from our human miRNA dataset, MAP2K1/2 and ERK1/2 (Figure 4.5) act as intermediate 
(MAP2K1/2) and terminal (ERK1/2) elements of the ERK cascade. This ‘module’ responds primarily to 
growth factors and mitogens, to induce cell growth, differentiation, adhesion and survival (Morrison 
2012). Additionally, the MAPK/ERK cascade promotes apoptosis and regulates lysosomal dynamics 
(Toy-Miou-Leong et al 2004).  
Applying filters for musculoskeletal and connective tissue disorders and fibroblast cell type will 
fundamentally skew the output for predicted target molecules and therefore the processes and 
networks identified as being impacted. Consequently, terms associated with fibrotic, connective 
tissue and musculoskeletal diseases, and networks and pathways incorporating proteins involved in 
ECM deposition, organisation and turnover are to be expected, and were indeed evident (Tables 4.3 
and 4.6, Figures 4.6 and 4.9). However, terms associated with cellular proliferation, recruitment, 
signalling and viability, as well as inflammation remained prominent (Tables 4.3 and 4.6). It therefore 
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seems that clinical tendinopathy engenders a state favouring an increase in cell population and 
protective against cellular degeneration. 
In refining our investigation to include only those miRNAs validated by RT-qPCR that showed DE in 
both human and equine tendinopathy, we focussed on miR-29a-3p, miR-199a-5p and miR-181. 
Mature sequences for hsa-miR-29a-3p and eca-miR-29a are identical, as are mature sequences for 
hsa-miR-199a-5p and eca-miR-199a-5p (Table 4.1), facilitating direct comparison. For miR-181, the 
situation is more complex. Family members miR-181c and miR-181d (both showing significantly 
reduced expression in human tendinopathy) are not recognised in the equine species.  However, 
miR-181b, whilst not DE in our human samples, was significantly reduced in our equine 
tendinopathic cohort.  Additionally, miR-181b sequences are identical between human and equine 
species and hsa-miR-181d-5p differs from hsa-miR-181b-5p (and, therefore, also eca-miR-181b) by 
only a single nucleotide (Table 4.1).  
IPA microRNA Target Filter clusters miRNAs according to the seed sequence of the mature miRNA. 
For instance, hsa-miR-29a-3p, hsa-miR-29b-3p and hsa-miR-29c-3p all share the seed sequence 
UAGCACCA and are all represented by hsa-miR-29b-3p in the IPA output (Figures 4.3, 4.5, 4.7 and 
4.10). hsa-miR-199a-5p and hsa-miR-199b-5p share the seed sequence CCCAGUGU, so although 
identified as hsa-miR-199a-5p in the output (Figures 4.7 and 4.10), this also represents hsa-miR-
199b-5p.  
As all four hsa-miR-181-5p variants, and both eca-miR-181 family members, share a common seed 
sequence (Table 4.1) indicating they share similar targets, and, as the IPA software clusters mature 
miRNAs sharing the same seed sequences for target prediction purposes, incorporating one miR-
181-5p variant into IPA analysis will capture targets predicted for 5p variants of all four human and 
both equine family members. Seed sequences differ between all four 3p variants of hsa-miR-181, 
however, precluding extension of this assumption to these variants (Table 4.1). Although miR-181a-
3p and miR-181c-3p were significantly DE in human tendinopathy, corresponding equine variants of 
these sequences are not recognised. Consequently, 3p variants were not included in IPA Core and 
Target Filter analyses.  
miR-29a is known to be reduced in human SSP tendinopathy (Millar et al 2015), to directly target 
COL1A1 and COL3A1 transcripts (Maurer et al 2010) and, by regulating the effect of IL33, play a key 
role in the transition from type I to type III collagen deposition in early tendinopathy (Millar et al 
2015). miR-199a expression is up regulated in fibrotic diseases (Lino Cardenas et al 2013), whilst 
downregulation, as we observed in both equine and human tendinopathic samples, is observed in 
hypoxia, secondary to ischaemia, and associated with impaired collagen production and crosslink 
formation (Rane et al 2009).   
Whilst there is little information on the direct relationship between miR-181 and tendon disease, 
this miRNA has a pervasive influence on biological processes. Reduced expression of miR-181, as 
we observed with tendinopathic samples, is reported in a wide range of neoplastic diseases, 
associated with increased cellular proliferation, migration and neoplastic transformation, and 
inhibited apoptosis (Pop-Bica et al 2018, Rezaei et al 2019). Treatment of mouse embryonic 
fibroblasts (3T3-L1 pre-adipocytes) with miR-181a-5p mimic promoted adipogenesis, and inhibited 
proliferation by inducing cell cycle arrest in G1 phase (Ouyang et al 2016). These authors 
demonstrated that miR-181a-5p directly targets SMAD7. Reduced levels of inhibitory SMAD7 
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increased phosphorylation of SMAD3, enhanced TGFβ signalling, resulting in cell cycle arrest. Wang 
and co-workers (2015) showed miR-181b directly targets TGFβR1 and caused cell cycle arrest in G1 
phase. Upregulation of miR-181b, however, reduced activation of SMAD3 in non small cell lung 
cancer cell lines (Wang et al 2015). Although TGFβR1 was identified as a target by the IPA microRNA 
Target Filter software in our analysis, it was predicted to be a target of miR-29a-3p, not miR-181 
(Appendix 4, Table A4.2).  
The role of inflammation in tendinopathy is controversial, but it has been shown to be important 
in early human rotator cuff tendinopathy (Millar et al 2010, Mosca et al 2018). Additionally, 
failure of resolution of an early inflammatory response is an important driver of chronic human 
Achilles and equine tendinopathy (Dakin et al 2014, Dakin et al 2018). Core Analysis of the human 
miRNA-target gene dataset identified the pro-inflammatory cytokines IL1β and TNF as significant 
upstream regulators. Network analysis of the genes targeted by the three miRNAs DE in both 
human and equine tendinopathy additionally identified inflammation-associated molecules. 
DUSP2, a mitogen and stress induced phosphatase located in the cell nucleus,  interacts with 
MAPK signalling pathways and regulates T-cell differentiation, activation, and expression of  IL6, 
IL17, TNF and IL1β (Lu et al 2015). SFTPA1 acts through the Toll-like receptor 4 (TLR4) signalling 
pathway. Inflammatory responses are regulated by miR-181 in osteoarthritis through the NFκB 
pathway (Zhu and Yang 2019) and in human fibroblasts via Toll-like receptor signalling pathway 
(Galicia et al 2014). 
Regulation of MAPK signalling by miR-181 also impacts on the competency of apoptotic and 
autophagic processes, with miR-181a implicated in deficiency of these processes, by this mechanism, 
in the neurodegenerative condition Parkinson’s Disease (Liu et al 2017). Of the three miRNAs 
demonstrating reduced expression in both human and equine tendinopathy, miR-181a-5p was the 
only one associated with cell viability (Figure 4.8). Age-associated downregulation of miR-181a in 
murine myocytes is associated with defective mitochondrial biogenesis and function (Goljanek-
Whysall et al 2020). The inclusion of hydrogen peroxide in our top network of miRNAs from both 
human and equine tendinopathy (Figure 4.7) alludes to the relevance of oxidative stress, a 
consequence of mitochondrial dysfunction, in tendinopathy. 
We have shown that tendinopathy engenders a physiological milieu promoting cellular proliferation 
and differentiation, whilst inhibiting necrotic and apoptotic pathways. These changes appear to be 
consistent in both human and equine species, and occur concurrently with chronic inflammation.  
With miR-181 reported to regulate so many of the biological processes considered to be relevant in 
the development of tendinopathy, and our data showing that miR-181 expression was reduced  in 
both human and equine tendinopathy, we were interested to further explore the ramifications of 
altered miR-181 levels in tenocytes. We hypothesised that the role of miR-181 in multiple biological 
processes such as inflammation, autophagy and mitochondrial dynamics indicate it may have an 
important influence in tendinopathy, by regulating these processes. In the next chapter, we utilise 
gain and loss of function of miR-181a-5p to determine how this impacts on expression of genes 









The reduction in miR-181 expression in both human and equine clinical tendinopathy identified in 
Chapter 3 suggests this family of miRNAs are important regulators of pertinent biochemical 
functions in tendon across species.  
The miR-181 family consists of four highly conserved members, miR-181a, b, c and d. In humans, 
miR-181a and b are clustered together at two distinct genomic loci, on chromosomes 1 and 9, with 
miR-181c and d clustered together on chromosome 19. In the horse, miR-181a and b cluster 
together on chromosome 25, with miR-181a also mapping to a second locus on chromosome 30 
(Table 5.1). Family members miR-181c and miR-181d are not described in this species (miRBase 
release 22.1, Kozomara et al 2019).  
 
Identity Accession number Chromosome Start End 
Human     
hsa-miR-181a-1 MI0000289 1 198859044 198859153 
hsa-miR-181a-2 MI0000269 9 124692442 124692551 
hsa-miR-181b-1 MI0000270 1 198858873 198858982 
hsa-miR-181b-2 MI0000683 9 124693710 124693798 
hsa-miR-181c MI0000271 19 13874699 13874808 
hsa-miR-181d MI0003139 19 13874875 13875011 
Equine     
eca-miR-181a MI0012920 25 28672622 28672731 
eca-miR-181a-2 MI0012936 30 26398918 26399027 
eca-miR-181b MI0012921 25 28673901 28673989 
 
Table 5.1 Identity and genomic location of human and equine miR-181 family members. Details 
from miRBase release 22.1 (Kozomara et al 2019). hsa = Homo sapiens, eca= Equus caballus. 
 
TargetScan (release 7.2, 2018, Agarwal et al 2015, www.targetscan.org) lists 1371 putative human 
transcripts as miR-181 targets, conferring the ability of this family to affect multiple pathways 
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concurrently. It is also one of the most abundant miRNAs carried in human plasma exosomes (Huang 
et al 2013). Unsurprisingly, considering these factors, miR-181 has been associated with a diverse 
and often contradictory range of effects. Whilst divergent effects may be expected in different 
tissues, they have also been reported within the same cell type. Both pro- and anti-oncogenic roles 
are reported (Yang et al 2017), as well as protective and detrimental effects on myocardial function 
(Das et al 2017). Yang and co-workers (2017) report a reduction in cell viability with increasing miR-
181a expression up to a concentration of 50 nM. Above this, the reverse effect is observed, with 
promotion of cell growth.  In myocardiocytes, differences in subcellular compartmentalisation of 
different miR-181 family members is attributed to the conflicting phenotypes observed (Das et al 
2017). Participation in both feedforward and feedback regulatory loops adds another level of 
complexity to their function (Tsang et al 2007, Ye et al 2018). 
miR-181 is known to be associated with mitochondrial biogenesis and function (Indrieri et al 2019, 
Goljanek-Whysall et al 2020), autophagy (Liu et al 2017), fibrosis (Chen et al 2018) and inflammation 
(Xie et al 2013), all processes implicated in the pathogenesis of tendinopathy. An association 
between miR-181 dysregulation and tendinopathy has not, however, previously been reported. 
We performed gain and loss of function studies to assess the impact of miR-181 dysregulation on 
tenocyte function in equine tenocyte monolayer culture, to assess its potential role in tendinopathy. 
Intracellular delivery of Cy5-labelled miR-181a mimic and FITC-labelled antagomiR reagents was 
confirmed visually by fluorescence microscopy and quantitatively by RT-qPCR.  Transcript levels  of 
miR-181 validated targets relevant to the pathways above (sirtuin 1 (SIRT1), ubiquitin-binding 
protein p62 (P62/SQSTM1), Parkin (PARK2), protein deglycase DJ-1 (PARK7/DJ-1), cytochrome c 
oxidase I (COXI), interleukin 1 alpha (IL1α), peroxiredoxin 3 (PRDX3) and tumour necrosis factor 
(TNF)), were determined by RT-qPCR.  
SIRT1 has protective effects against hypoxia, inflammation, cellular senescence and apoptosis 
(Rahman and Islam 2011). Tendon stem cells constitutively express SIRT1, and up- or down-
regulation is associated with altered differentiation into osteogenic or adipogenic lineages (Liu et al 
2016). Cellular stress upregulates mitophagy to remove dysfunctional mitochondria and preserve 
cellular energy metabolism. Disruption of this process results in accumulation of key autophagy 
related proteins Parkin (product of the PARK2 gene) and P62/SQSTM1, precipitating cellular 
degeneration (Goljanek-Whysall et al 2020). Cytochrome c oxidase (COX) is the terminal enzyme in 
the energy transducing respiratory chain. Complexes I, II and III of this 13 subunit structure are 
encoded by the mitochondrial genome and are the site of reactive oxygen species production. COXI 
is involved in formation of the transmembrane proton gradient and is one of the main sites of 
reactive oxygen species production (Lenaz et al 2006). DJ-1 protein is sensitive to oxidative stress 
and co-localises with COXI, itself becoming oxidised and stabilising mitochondrial membrane 
potential (Hayashi et al 2009). Expression of PRDX3 and peroxiredoxin 5 (PRDX5) is restricted to 
mitochondria. Human tenocytes constitutively express PRDX5 and expression is up regulated in 
tendinopathy, supporting the role of oxidative stress in this disease (Wang et al 2001). We 
investigated expression of PRDX3 which is crucial for mitochondrial homeostasis in skeletal muscle 
(Lee et al 2014). Evidence supports an inflammatory component to tendinopathy (Millar et al 2010) 
and IL1α and TNF are among the most frequently studied cytokines in this area (Morita et al 2017). 
Both IL1α and TNF are suggested to be up regulated in early disease, although clinical and 
experimental evidence is not consistent (Morita et al 2017). 
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Additionally, expression of genes interacting with the targets above, or active in the same pathways 
were investigated. Interestingly, a permissive relationship has been identified between 
peroxiredoxin 6 (PRDX6) and IL1 and TNF signalling. PRDX6 exhibits dual functions, with both 
antioxidant and phospholipase A2 activity (Kim et al 2011). This confers pro-inflammatory and pro-
apoptotic effects by upregulating the pro-inflammatory cytokine IL1β and caspase activation. PRDX6 
also enhances TNF induced leukotriene production. Therefore, we broadened our targeting of IL1 
signalling, including interleukin 1 beta (IL1β) and interleukin 1 receptor accessory protein (IL1RAP) 
expression. We also included nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), 
mothers against decapentaplegic homolog 7 (SMAD7) and interleukin 7 (IL7). NFκB signalling is 
linked to inflammation in chronic tendinopathy (Abraham et al 2019) and SMAD7 regulates TGFβ-
driven fibrosis and inflammation (Zhu et al 2011). Fibroblasts subjected to chronic and autoimmune-
driven inflammation express IL7 to stimulate proliferation and infiltration of inflammatory cells 
(Harada et al 1999).   
To further explore mitochondrial functionality and dynamics in the context of tendinopathy, 
cytochrome c oxidase subunit IV (COXIV) and translocase of outer mitochondrial membrane 20 
(TOMM20) expression were investigated. COXIV is encoded by genomic DNA and expression is up 
regulated in response to HIF1α released under oxidative stress, protecting mitochondrial function 
(Hao et al 2018). TOMM20 is an integral part of the import channel for mitochondrial targeted 
proteins and expression levels can provide an indication of mitochondrial architecture and mass. 
We were interested to explore mitochondrial morphology and dynamics in cultured tenocytes and 
the influence of miR-181 on mitochondrial autophagy. To investigate this, we induced mitochondrial 
depolarisation using the oxidative phosphorylation uncoupling agent carbonyl cyanide m-
chlorophenylhydrazone (CCCP) and determined localisation of TOMM20, microtubule-associated 
proteins 1A/1B light chain 3B (LC3B), DJ-1, autophagosome adaptor protein P62/SQSTM1 and the E3 
ubiquitin ligase Parkin, using immunocytochemistry. TOMM20 staining permits mitochondrial 
morphology to be visualised, indicating the degree of interconnectivity or fragmentation of these 
organelles (Tan et al 2019). Mitochondrial fragmentation releases cytochrome c into the cell 
cytoplasm, recruiting protein DJ-1 to mitigate oxidative damage. Depolarisation of the mitochondrial 
membrane stabilises phosphatase and tensin homologue-induced putative kinase 1 (PINK1) causing 
recruitment of Parkin, which mediates polyubiquitination of outer mitochondrial membrane 
proteins (Palikaras et al 2018). P62/SQSTM1 possesses both ubiquitin and LC3B binding regions, 
thereby interacting with both the ubiquitinated dysfunctional mitochondria and the autophagosome 
membrane-associated protein LC3B, initiating autophagosome formation and targeting damaged 
mitochondria for selective degradation (Sánchez-Martín and Komatsu 2018). P62/SQSTM1 can also 
interact with the soluble, non-membrane bound form of LC3B, permitting assessment of the 
autophagosomes compartment functionality in mitochondrial clearance (McCoy and Cookson 2011).  
Whilst we found no significant differences in transcript levels between treatment groups of the 16 
targets assessed by RT-qPCR, this may indicate that regulation of these genes occurred by altering 
translation rather than transcript stability. However, intracellular distribution patterns of TOMM20, 
LC3B, DJ-1, P62/SQSTM1 and Parkin suggested miR-181 has a regulatory effect on mitochondrial 






5.2.1 Treatment of tenocyte cultures 
Primary equine tenocytes from eight donors (Table 5.2) were propagated for 24 hours prior to 
treatment with cholesterol-conjugated Cy5-tagged mmu-miR-181a-5p mimic, fluorescein-tagged 23 
nucleotide (nt) single strand RNA antagomiR, or 21 nt single strand RNA scrambled control 
sequence. Final treatment concentrations were 100 nM (mimic and scrambled control) and 200 nM 
(antagomiR). Live cell imaging to confirm uptake of fluorescence was performed using a Nikon 
Eclipse Ti-E fluorescent microscope.  
 
Sample ID Sex Age (years) Passage number 
EqDB5 MN 5 4 
EqDB30 MN 3 2 
EqDB7 MN 5 2 
EqDB9 F 12 4 
EqDB10 F 18 3 
EqDB11 F 3 2 
EqDB12 F 8 3 
EqDB18 MN 9 4 
 
Table 5.2 Donor and tenocyte passage details for equine superficial digital flexor tendon-derived 
tenocytes cultured for mmu-miR-181a-5p mimic, antagomiR and scrambled control treatment 
studies. F = female, MN = male neutered. 
 
 
5.2.2 Reverse transcription quantitative real-time polymerase chain reaction  
Forty eight hours after transfection, cells were lysed for RNA extraction and gene expression 
analysis. Reverse transcription to cDNA used 500 ng RNA template for gene expression and 100 ng 
RNA template for miRNA expression analyses.  
Recapitulating our work in normal and diseased equine superficial digital flexor tendon, and based 
on previous reports (Sperveslage et al 2014, Bignotti et al 2016), three candidate reference genes, 
small nuclear RNA-U6, small nucleolar RNA-61 (SNORD61), and small nucleolar RNA-68 (SNORD68) 
were investigated for use as internal control.  Reinforcing our previous findings (Chapter 3, section 
3.2.3 and Appendix 2, Table A2.1), SNORD61 demonstrated the greatest stability of expression 
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between treatment groups, with threshold cycle (Ct) values varying by less than four cycles between 
biological replicates, and less than two across treatment groups (Appendix 5, Table A5.1). Levels of 
miR-181a, b, c and d were determined using commercially available primers (Qiagen, Manchester, 
UK) and normalised to SNORD61 expression. Relative expression values were then summed to give 
total miR-181 expression for each sample.  
Stability of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression across treatment groups 
was confirmed, with Ct values varying by less than two cycles between biological replicates, and less 
than 1.4 across treatment groups (Appendix 5, Table A5.2), justifying its use as internal control for 
normalisation of target gene expression (Panina et al 2018).  Primers were designed for eight 
validated miR-181 targets (SIRT1, P62/SQSTM1, PARK2/Parkin, PARK7/DJ-1, COXI, IL1α, PRDX3 and 
TNF) and a further eight genes associated with oxidative stress (PRDX6), apoptotic (COXIV, IL7, 
TOMM20) and inflammatory (IL1β, IL1RAP, NFκB, SMAD7) pathways. Target gene expression was 
calculated relative to that of GAPDH. 
Primer sequences and RT-qPCR details are given in Chapter 2, section 2.12.1, Tables 2.11, 2.12 and 
2.13, and section 2.12.3, Figure 2.3 respectively. For all RT-qPCR data, technical replicates were run 
in triplicate and expression relative to SNORD61 or GAPDH calculated using the delta Ct method 
(Livak and Schmittgen 2001).  For graphical representation, transcript expression was normalised to 
that of the scrambled control treatment group. 
 
5.2.3 Induction of mitophagy and immunocytochemistry  
For immunocytochemistry, tenocytes were exposed to the oxidative phosphorylation uncoupling 
agent carbonyl cyanide m-chlorophenylhydrazone (CCCP) at a concentration of 20 µM, dissolved in 
dimethyl sulfoxide (DMSO), or DMSO alone, for six hours, 24 hours after mimic, antagomiR or 
scrambled control treatment. Tenocytes were then fixed in ice cold methanol and immunostained 
for autophagy markers as described in Chapter 2, section 2.7. Mounted preparations were produced 
in triplicate and preparations examined for overall cellular distribution and quality and consistency 
of staining. Images were obtained using a Zeiss Axio Imager M2 fluorescent microscope with Zeiss 
ZEN Imaging software (blue edition 3.1). Images showing consistent patterns of fluourescence, 
representative of all sections from each treatment group were selected for detailed description of 
protein localisation in response to treatments. 
 
5.2.4 Statistical analysis 
Statistical analysis of gene expression was performed using GraphPad Prism version 5.01 for 
Windows (GraphPad Software, San Diego California USA, www.graphpad.com). Data were analysed 
non-parametrically using the Kruskal Wallis test with Dunn’s test for pairwise comparisons, to 
include mimic, antagomiR and scrambled control sequence treated groups. Comparisons between 
scrambled control sequence treated and untreated groups, where performed, utilised the Mann-
Whitney test and are presented in Appendix 5, Figure A5.1. Significance was assumed if P<0.05.  





5.3.1 Validation of miR-181a-5p overexpression and inhibition in tenocytes  
Sequence homology for microRNA-181 family members across murine, equine and human species 
was confirmed, justifying use of transfection reagents based on murine sequences and human 
sequence-directed primers (Table 5.3). Sequences for equine variants of miR-181c or miR-181d, 
however, are not reported (miRBase release 22.1, Kozomara et al 2019).   
We first established optimal final working concentrations for our intended treatments. Based on 
previous work in myoblasts by our group (Soriano-Arroquia et al 2016), tenocyte cultures were 
incubated for 48 hours with concentrations of 50 and 100 nM mmu-miR-181a-5p mimic, 10, 50, 100, 
200, 400 nM and 1 µM antagomiR and 100 nM scrambled control oligonucleotide. Total miR-181 
expression was then determined using RT-qPCR. Results indicated that concentrations of 100 nM for 
mimic and scrambled control oligonucleotide, and 200 nM for antagomiR were suitable (Figure 5.1). 
The apparent increase in total miR-181 expression detected with the 400 nM and 1 µM antagomiR 
treatments was interesting. This could reflect high levels of the antagomiR activating a feedback 
mechanism, stimulating miR-181 expression, or be artefactual, resulting from the specific 







miRNA Identity Sequence 
mmu-miR-181a-5p a a c a u u c a a c g c u g u c g g u g a g u 
eca-miR-181a a a c a u u c a a c g c u g u c g g u g a g u 
hsa-miR-181a-5p a a c a u u c a a c g c u g u c g g u g a g u 
                        
mmu-miR-181b-5p a a c a u u c a u u g c u g u c g g u g g g u 
eca-miR-181b  a a c a u u c a u u g c u g u c g g u g g g u 
hsa-miR-181b-5p a a c a u u c a u u g c u g u c g g u g g g u 
                        
mmu-miR-181c-5p a a c a u u c a a c c u g u c g g u g a g u  
hsa-miR-181c-5p a a c a u u c a a c c u g u c g g u g a g u  
                        
mmu-miR-181d-5p a a c a u u c a u u g u u g u c g g u g g g u 
hsa-miR-181d-5p a a c a u u c a u u g u u g u c g g u g g g u 
 
Table 5.3 miR-181a and b show complete homology between murine (mmu), equine (eca) and 
human (hsa) species. miR-181c and -d are conserved between murine and human species, equine 
variants of these are not reported. Sequences were obtained from miRBase (release 22.1). Seed 
































Figure 5.1 mmu-miR-181a-5p mimic and antagomiR successfully increase and suppress miR-181 
expression in equine tenocytes. Values represent relative expression, normalised to SNORD61, for 
all four miR-181 family members and total miR-181. In graphical representation, M = miR-181a-5p 
mimic, AM = antagomiR, SC = scrambled control, UT = untreated control. Number following 
treatment group identifier indicates concentration (nM) of respective treatment. Relative expression 





5.3.2 miR-181a predicted target gene analysis  
We next investigated the expression of miR-181 target genes in response to miR-181a gain or loss of 
function. Equine primary tenocytes from eight donors (Table 5.2) were treated with mmu-miR-181a-
5p mimic, antagomiR or scrambled control sequence oligonucleotides, RNA isolated and RT-qPCR 
performed.  
Based on RT-qPCR evaluation, the success of treatment was variable. All miR-181a mimic treated 
cultures showed upregulation of total miR-181. Typically, of the four miR-181 family members, miR-
181b showed greatest increase, being responsible for 42-69% of the total miR-181 expression in this 
treatment group. Response to antagomiR treatment was more subtle and varied. In antagomiR 
treated cultures from five donors, total miR-181 expression were lower than that exhibited by the 
scrambled control treated group (Figure 5.2).  
Target gene expression was only investigated in the five biological replicates in which total miR-181 
expression was lower in the antagomiR treated group than the scrambled control treated group. 
Results represent comparisons between mimic, antagomiR and scrambled control sequence treated 
groups. Comparisons between scrambled control sequence treated and untreated cultures, when 
performed, are presented in Appendix 5, Figure A5.1. None of the 16 targets examined showed 
significantly different expression between treatment groups.  Normalising transcript expression to 
that of the scrambled control group showed the greatest variation in response to gain or loss of miR-
181 function was demonstrated by P62/SQSTM1 and PARK2 (Figure 5.3). In addition to transcript 
expression, quantification of protein product by Western blot analysis would have strengthened our 



























miR-181a miR-181b miR-181c miR-181d
EqDB5-5(P4) EqDB30-3(P2) EqDB9-12(P4) EqDB10-18(P3) EqDB12-8(P3)















Figure 5.2 microRNA-181 expression in mmu-miR-181a-5p mimic, antagomiR and scrambled 
control treated equine primary tenocyte monolayer culture. Values represent relative expression, 
normalised to SNORD61, for all four miR-181 family members and total miR-181. Five biological 
replicates were used for gene expression analysis. In graphical representation, M = miR-181a-5p 
mimic, AM = antagomiR, SC = scrambled control, UT = untreated control. Relative expression values 

























































   
 






















































































































































































P=0.44 P=0.99 P=0.96 
P=0.78 P=0.76 
P=0.97 
























































































Figure 5.3 (includes preceding page) The effects of miR-181a overexpression and inhibition on 
expression of selected target genes in equine tenocytes from five biological replicates. Y–axis 
values represent expression relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
normalised to scrambled control treatment group. M = miR-181a-5p mimic, AM = antagomiR, SC = 
scrambled control. P-values calculated from delta Ct values, using Kruskal-Wallis test with Dunn’s 









5.3.3 The role of miR-181 in regulation of mitochondrial dynamics in equine tenocytes 
In order to investigate the role of miR-181 in regulation of autophagy and mitochondrial dynamics, 
mitochondrial depolarisation was induced in primary equine tenocytes using the oxidative 
phosphorylation uncoupling agent carbonyl cyanide m-chlorophenylhydrazone (CCCP). To confirm 
treatment effect, tenocytes were incubated with 20 µM CCCP for six hours (Kagan et al 2016, Webb 
et al 2017), followed by immunofluorescent staining for the outer mitochondrial membrane protein 
TOMM20. In DMSO treated tenocytes, mitochondria appeared to form extensive interconnected 
networks. In CCCP treated tenocytes, fragmentation of mitochondrial networks, with a punctate, 





Figure 5.4 Mitochondrial network fragmentation in response to incubation with carbonyl cyanide 
m-chlorophenylhydrazone (CCCP). Equine tenocytes incubated with A) dimethyl sulfoxide (DMSO) 
for six hours, B) 20 µM CCCP in DMSO for six hours. TOMM20 = translocase of outer mitochondrial 





Next, to investigate the effect of miR-181 on autophagy-associated proteins, mitophagy was induced 
in mmu-miR-181a-5p mimic, antagomiR and scrambled control treated tenocytes by incubation with 
20 µM CCCP or DMSO control for six hours. Uptake of mimic and antagomiR treatments was 
confirmed by fluorescence imaging of live cell cultures immediately prior to cells being fixed, 
permeabilised and processed for immunostaining (Figure 5.5). No-primary-antibody controls were 
performed and confirmed no detectable residual fluorescence from mimic or antagomiR treatments, 
absence of background signal and lack of non-specific binding of secondary fluorophore-conjugated 
antibody (Figure 5.6). Fluorescence associated with Cy5 and FITC labelling of miR-181 mimic and 





Figure 5.5 Successful transfection of mmu-miR-181a-5p mimic and antagomiR into primary equine 
tenocytes. Live cell images of transfection reagent uptake 48 hours after treatment and immediately 
prior to processing for immunocytochemistry. A) Fluorescein labelled single strand RNA-23 







Figure 5.6 Fluorophore-conjugated secondary anti-mouse and anti-rabbit antibodies do not 
generate a signal following incubation with equine tenocytes in absence of primary antibody.  
Tenocytes incubated for six hours with DMSO prior to fixing, permeabilisation and incubation for 
one hour with: A-C Alexa Fluor 488-conjugated goat anti-mouse antibody, D-F Alexa FluorTM 488-
conjugated goat anti-rabbit antibody, G-I Alexa FluorTM 594-conjugated goat anti-rabbit antibody, J-L 
Alexa Fluor 594-conjugated goat anti-mouse antibody. Images obtained at 593 nm (A, D, G, J), 510 
nm (B, E, H, K), 447 nm (C, F, I, L). Nuclear counterstaining with DAPI (4′,6-diamidino-2-phenylindole). 




The regulation of autophagy and mitochondrial turnover was next established by immunostaining 
for LC3B, DJ-1, P62/SQSTM1, Parkin and TOMM20. Increased mitochondrial biogenesis and 
clearance exert protective effects in the face of mitochondrial dysfunction (Indrieri et al 2019). 
Terminally differentiated tenocytes show a slow rate of turnover, with proliferation and apoptotic 
indices reported as 5-8% and less than 25% respectively in adult tendon (Chuen et al 2004, Russo et 
al 2015). In such cells, mitochondrial homeostasis plays a pivotal role in maintaining cellular viability 
and longevity (Okatsu et al 2010). 
LC3B positive aggregates (punctae) are considered to be specific markers for autophagosomes, and 
can be indicative of both autophagy induction and impairment (Runwal et al 2019). Co-staining for 
the outer mitochondrial membrane protein TOMM20 reveals how mitochondrial morphology is 
affected by treatment protocols, indicating the degree of connectivity or fragmentation, and permits 
examination of interactions between mitochondria and autophagosomes (Tan et al 2019).  In DMSO 
treated cells, TOMM20 staining revealed mitochondrial connectivity was preserved, with networks 
present in all treatment groups. Scattered LC3B punctae were evident in mimic and antagomiR, but 
rare in scrambled treated groups, indicating that miR-181 levels may be affecting autophagic activity 
(Figure 5.7). LC3B punctae were negative for TOMM20, indicating either effective degradation of 
autophagosome-encapsulated mitochondria, or phagophore nucleation had occurred around an 
alternative substrate.  CCCP treatment resulted in formation of LC3B punctae evenly dispersed 
throughout the cytoplasm of scrambled treated tenocytes, but no apparent increase in punctae 
formation in mimic or antagomiR treated groups. LC3B punctae again appeared to be negative for 
TOMM20 staining. Following CCCP exposure, presence of TOMM20 positive punctae, with 
predominantly perinuclear localisation, in all treatment groups indicated disaggregation of 
mitochondrial networks. In the miR-181 mimic treated group, these aggregations were particularly 
prominent and spatially distinct from regions of increased LC3B fluorescence, which were localised 
towards the periphery of the tenocytes (Figure 5.7). Depolarised, ubiquitinated mitochondria are 
known to accumulate in the perinuclear region prior to degradation, proposed as a protective 
cellular response to aid compartmentalisation of abnormal protein aggregates (Okatsu et al 2010). In 
antagomiR and scrambled treated groups, LC3B distribution was more uniform. Less pronounced 
perinuclear accumulation of TOMM20 positive punctae was evident in antagomiR treated tenocytes, 
potentially indicating effective mitophagic clearance, however, overall TOMM20 staining intensity 
appeared decreased, suggesting a reduction in mitochondrial population, which was maintained in 
the mimic treated group. Consistent with this, distribution of LC3B positive punctae tended to be 
more closely associated with regions of increased TOMM20 positive structures (Figure 5.7). These 
data can be interpreted as either an increase in autophagic flux in miR-181 mimic treated cells, or 
that increased miR-181 levels prevent recruitment of LC3B to damaged mitochondria. These data 
present inconclusive evidence for the role of miR-181 in an induced mitophagy model of autophagic 





Figure 5.7 Immunofluorescence images of miR-181a-5p mimic, antagomiR and scrambled control 
treated equine tenocytes subjected to six hours of CCCP/DMSO exposure. TOMM20 = Translocase 
of outer mitochondrial membrane 20, LC3B = Microtubule-associated proteins 1A/1B light chain 3B, 
DAPI = 4′,6-diamidino-2-phenylindole, CCCP = carbonyl cyanide m-chlorophenylhydrazone, DMSO = 
dimethyl sulfoxide. Images 63 x magnification, oil immersion lens, bar = 50 µm.  
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We next looked at the distribution of DJ-1, a protein recruited rapidly to depolarised mitochondria 
as a protective mechanism against oxidative damage (Taira et al 2004). Uniformly dispersed DJ-1 
punctae were present throughout the cytoplasm in all DMSO treated tenocytes, with no distinct 
pattern of distribution. In tenocytes incubated with DMSO, mitochondrial networks seemed to be 
preserved in antagomiR and scrambled treated cells, with miR-181 mimic treatment resulting in 
more mitochondrial remodelling as indicated by the presence of TOMM20-positive punctae rather 
than mitochondrial networks (Figure 5.8).  In CCCP treated tenocytes, mitochondrial punctae rather 
than networks were detected in miR-181 mimic-, antagomiR- and scrambled treated cells (Figure 
5.8) confirming that CCCP induced autophagy. Moreover, in antagomiR treated cells, mitochondrial 
loss seemed to occur, whereas this was not the case for mimic treated cells, as compared to controls 
(Figure 5.8). Distribution patterns of TOMM20 positive aggregates differed between treatment 
groups, being predominantly perinuclear in miR-181 mimic treated cells, peripheral in antagomiR 
treated cells and intermediate in scrambled control treated cells (Figure 5.8). 
CCCP treatment resulted in fewer DJ-1 positive punctae present in tenocytes treated with mimic, 
antagomiR or scrambled control. These punctae showed a less uniform distribution pattern than 
DMSO controls, with a tendency for dense perinuclear localisation in miR-181 mimic treated, and 
more peripheral location in antagomiR treated cells. Scrambled control treated tenocytes showed an 
intermediate distribution pattern (Figure 5.8). In CCCP treated tenocytes, DJ-1 colocalised with areas 
more densely populated with mitochondrial punctae in mimic-, antagomiR- and scrambled treated 
tenocytes. CCCP induces reactive oxygen species (ROS) mediated apoptosis (Park et al 2015) and DJ-
1 is known to localise to the mitochondria under conditions of oxidative stress, where it has a 
protective function (Taira et al 2004). 
Our data suggest a role of miR-181 in mitochondrial turnover as shown by TOMM20 positive 
punctae rather than networks in DMSO treated controls. Following induction of mitophagy, a more 
appropriate perinuclear condensation of TOMM20 positive staining occurred in miR-181 mimic and 
scrambled control treated tenocytes, but not in antagomiR treated ones. We were not able to 
determine definite treatment-dependent changes in co-localisation or levels of DJ-1 with 
mitochondrial marker TOMM20, suggesting that DJ-1 recruitment to damaged mitochondria occurs 





Figure 5.8 Immunofluorescence images of miR-181a-5p mimic, antagomiR and scrambled control 
treated equine tenocytes subjected to six hours of CCCP/DMSO exposure. TOMM20 = Translocase 
of outer mitochondrial membrane 20, DJ-1 = Protein deglycase DJ-1 (PARK7), DAPI = 4′,6-diamidino-
2-phenylindole, CCCP = carbonyl cyanide m-chlorophenylhydrazone, DMSO = dimethyl sulfoxide. 
Images 63 x magnification, oil immersion lens, bar = 50 µm.  
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We then investigated P62/SQSTM1, an autophagy receptor protein up regulated during mitophagy, 
which interacts with both ubiquitin and LC3B and plays a protective role in ROS-mediated cell death 
through induction of the NRF2 pathway (Sánchez-Martín and Komatsu 2018).  
In DMSO controls, antagomiR treated tenocytes demonstrated a generalised loss of mitochondria as 
evidenced by a reduction in TOMM20 positive structures overall. In miR-181 mimic treated cells, 
TOMM20 positive structures were punctiform indicating lack of mitochondrial networks.  Similarly, 
following CCCP exposure, TOMM20 staining revealed a more punctate than networked appearance 
of mitochondria in mimic treated cells, indicating greater remodelling. Weaker TOMM20 signal 
potentially indicating mitochondrial loss, was evident in the antagomiR and scrambled treated 
groups.  
In DMSO controls, cells from all treatment groups showed a well demarcated, distinct perinuclear 
localisation of P62/SQSTM1 similar to that reported by Viiri and co-workers (2010) (Figure 5.9). 
These authors showed, in proteasome-inhibited human retinal pigment epithelial cells, that 
P62/SQSTM1 promoted perinuclear accumulation of ubiquitinated proteins in lysosomal vesicles, 
where P62/SQSTM1 colocalised strongly with the chaperone protein HSP70 (heat shock protein 70)  
(Viiri et al 2010).  There appeared to be subtle differences between treatment groups, with a more 
‘concentrated’ perinuclear appearance in the miR-181 mimic group, slightly less so in the antagomiR 
treated group, and more diffuse, although still predominantly perinuclear in the scrambled treated 
group (Figure 5.9).  
In CCCP treated tenocytes, P62/SQSTM1 localisation appeared less organised in comparison. 
Distribution was still predominantly perinuclear, but showed a more disrupted and fragmented 
pattern. Punctae were more widely dispersed throughout the cytoplasm in mimic, compared to 
antagomiR or scrambled treated cells, consistent with an up regulation of P62/SQSTM1 labelling of 
substrates targeted for autophagy, although these did not map to TOMM20 positive punctae (Figure 
5.9). In scrambled treated cells, localisation was less concentrated around the nuclei, with diffuse 
cytoplasmic staining evident, whereas in mimic and antagomiR treated cells, localisation was more 
clearly defined.  
There appeared to be no consistent association between localisation of TOMM20 and P62/SQSTM1 
positive regions. Whilst P62/SQSTM1 is reported to be widely distributed at the subcellular level 
(Sánchez-Martín and Komatsu 2018), perinuclear localisation of P62/SQSTM1 has been reported 
following CCCP treatment of HeLa cells and mouse embryonic fibroblasts (MEFs), reflecting 
perinuclear clustering of depolarised mitochondria (Okatsu et al 2010). Moreover, these authors 
report that although P62/SQSTM1 is not essential for mitochondrial degradation, it is critical for the 
normal perinuclear clustering of defective mitochondria.  
Taken together, these data suggest that miR-181 is associated with increased turnover of 
mitochondria as evidenced by TOMM20 positive punctate morphology, with preservation of overall 
mitochondrial population, whilst weaker TOMM20 signal in DMSO- and CCCP-exposed antagomiR 
treated tenocytes appeared to reduce mitochondrial population. miR-181 appeared to exert some 
effect on P62/SQSTM1 localisation, but no conclusive interaction could be determined from our 
data. The preponderance for perinuclear accumulation of P62/SQSTM1 observed consistently, albeit 
to varying degrees, in all treatment groups may represent a cell type-specific distribution pattern, or 
reflect a role for this protein unrelated to autophagy.  Indeed, P62/SQSTM1 is known to function as a 
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central signalling molecule in multiple cellular pathways including adipogenesis, antioxidant 
responses, endosomal trafficking, apoptosis and inflammation (Sánchez-Martín and Komatsu 2018). 
Autophagic degradation of depolarised mitochondria has been shown to occur in MEFs in the 
absence of P62/SQSTM1 in a Parkin-dependent manner (Okatsu et al 2010), therefore we next 




Figure 5.9 Immunofluorescence images of miR-181a-5p mimic, antagomiR and scrambled control 
treated equine tenocytes subjected to six hours of CCCP/DMSO exposure. TOMM20 = Translocase 
of outer mitochondrial membrane 20, P62 = ubiquitin-binding protein p62, DAPI = 4′,6-diamidino-2-
phenylindole, CCCP = carbonyl cyanide m-chlorophenylhydrazone, DMSO = dimethyl sulfoxide. 
Images 63 x magnification, oil immersion lens, bar = 50 µm.  
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Parkin is rapidly and robustly recruited to depolarised mitochondria where it ubiquitinates outer 
mitochondrial membrane proteins, targeting these organelles for autophagic elimination. Parkin also 
becomes ubiquitinated and degraded during this process (Seirafi et al 2015). In miR-181 mimic, 
antagomiR and scrambled treated tenocytes exposed to DMSO, uniform cytoplasmic distribution of 
Parkin was evident, although staining was weak. Networked mitochondria, as indicated by TOMM20 
staining, were seen, indicating little mitophagic activity (Figure 5.10). Following incubation with 
CCCP, Parkin distribution remained uniform and weak, in miR-181 mimic and scrambled treated 
groups. In antagomiR treated tenocytes however, Parkin accumulation was evident in association 
with more dense regions of TOMM20 positive mitochondrial staining (Figure 5.10). Mitochondrial 
connectivity seemed to be preserved to some extent in antagomiR treated cells, although networks 
appeared contracted and centralised towards the perinuclear region. The presence of TOMM20 
positive punctae revealed complete disruption of mitochondrial networks in the mimic and 
scrambled treated groups (Figure 5.10). Following exposure to CCCP, recruitment of Parkin to 
depolarised mitochondria and subsequent ubiquitination occurs rapidly (within 1 hour) with 
subsequent concentration to the perinuclear region in under 4 hours prior to degradation (Okatsu et 
al 2010). Treatment of cells with CCCP produces rapid depolarisation of the entire mitochondrial 
network, resulting in levels of damaged mitochondria not seen under physiological conditions 
(Seirafi et al 2015). It is possible therefore that in miR-181 mimic treated tenocytes incubated with 
CCCP for six hours, mitophagy had already occurred and TOMM20 positive staining revealed residual 
mitochondria remaining as a consequence of mitophagic clearance being overwhelmed.  
Based on these data, it appears that miR-181 may regulate the levels of Parkin in mitophagy-
inducing conditions, such as CCCP treatment. Specifically, inhibition of miR-181 in CCCP treated 
tenocytes resulted in accumulation of Parkin in these cells. Some co-localisation between Parkin and 
TOMM20 was observed in the CCCP/antagomiR treated cells, and mitochondrial networks seemed 
‘shrunk’ rather than disaggregated into punctae as in scrambled/CCCP treated cells (Figure 5.10). 
This suggest that the recruitment of Parkin to mitochondria is not affected by inhibition of miR-181 
activity, but autophagy is stalled as indicated by the lack of TOMM20 positive punctae. These data 
also suggest that miR-181 may promote mitophagy through regulating progression of autophagy 




Figure 5.10 Immunofluorescence images of miR-181a-5p mimic, antagomiR and scrambled control 
treated equine tenocytes subjected to six hours of CCCP/DMSO exposure. TOMM20 = Translocase 
of outer mitochondrial membrane 20, PARK2 = Parkin, DAPI = 4′,6-diamidino-2-phenylindole, CCCP = 
carbonyl cyanide m-chlorophenylhydrazone, DMSO = dimethyl sulfoxide. Images 63 x magnification, 





In this chapter, we investigated the effect of miR-181 overexpression and inhibition on selected 
target gene expression in primary equine tenocytes, following treatment with miR-181a mimic, 
antagomiR or scrambled control. Additionally we utilised a model of induced mitophagy to 
determine the effect of miR-181 on mitochondrial dynamics and remodelling. Our results suggest 
miR-181 regulates mitochondrial turnover.  
Due to their involvement in cell differentiation, proliferation and apoptosis, the miR-181 family has 
been extensively studied in cancer development and progression, with family members miR-181a 
and -b most frequently reported. Both pro- and anti-apoptotic effects have been described for miR-
181a in breast cancer, by targeting both B-cell lymphoma 2 (BCL2) and BCL-2 interacting mediator of 
cell death (BIM) respectively. Downregulation in a wide range of cancer types resulted in increased 
cellular proliferation, migration and neoplastic transformation, with inhibition of apoptosis (Pop-Bica 
et al 2018, Rezaei et al 2019). However, upregulation of miR-181a in breast, gastric, and colorectal 
cancer and lymphoblastic leukaemia is also associated with increased cellular proliferation and 
migration. Inhibition of apoptosis and autophagy has also been described, by promoting BCL2 
activity and targeting autophagy related gene 5 (Rezaei et al 2019). Over expression of miR-181b, 
also reported in numerous types of cancer, disrupts the cell cycle, increasing the proportion of 
quiescent cells and triggering apoptosis. In lung cancer, tumour suppressive actions have been 
ascribed to targeting transcription factor SOX6, disrupting cell differentiation and proliferation (Zhou 
et al 2019). Suppressed proliferation and induced apoptosis have also been described in astrocytoma 
(Zhi et al 2014). Conversely, miR-181b upregulation is associated with cellular proliferation and 
invasion in ovarian cancer. Many of the oncogenic effects of miR-181a and -b have been associated 
with promotion of TNF, IL1, MAPK, TGFβ, and TIMP3 activity (Rezaei et al 2019). miR-181c and miR-
181d are less frequently reported, but have  been described as tumour suppressive in glioblastomas 
and ovarian cancer, with downregulation promoting TGFβ and MAPK activity, favouring cell 
proliferation, malignant transformation and a pro-inflammatory environment (Rezaei et al 2019). 
Evidence from studies of neoplastic diseases suggests expression patterns and functional 
consequences of miR-181 are highly variable and cell-type specific. Contradictory effects both 
between and within tissue types have been attributed to selective intracellular 
compartmentalisation and concentration dependent effects (Yang et al 2017). A ‘context-dependent’ 
role has also been reported for other miRNAs, where expression may occur predominantly at a 
particular stage of development, within a particular cell type, or be localised to a specific subcellular 
compartment. These contextual determinants illustrate that the presence of a functional target site 
is not, in isolation, sufficient for regulation to occur, as the immediate intracellular environment may 
under certain circumstances, prevent silencing complex functionality (Carroll et al 2013, Erhard et al 
2014).  
The greatest increase in miR-181 expression we observed in response to mimic treatment was in 
miR-181b. The mimic transfection reagent was based on the murine miR-181a-5p sequence and 
primers used to confirm transfection success were designed to target mature 5p variants of all four 
human miR-181 family members. Sequence identity is conserved across murine, equine and human 
species and differences between family members are minor (Table 5.3). Only a single nucleotide 
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deletion (guanine at position 11) accounts for the difference between miR-181a and miR-181c, 
whilst miR-181b and miR-181d differ from miR-181a only by three and four nucleotide substitutions 
respectively. Whilst miR-181b was the most highly expressed of the miR-181 family in equine tendon 
identified in Chapter 3, (Figure 3.3 (F and L)), changes in expression of miR-181 family members -c 
and -d, which are not recognised in miRBase, could represent mis-priming events during PCR 
amplification. Discrimination between targets with very similar sequences can be problematic using 
PCR technology due to mis-priming events, with primer design, cycle parameters and reagent factors 
all impacting on quantitative accuracy. Boyle and co-workers (2009) investigated maximising PCR 
discrimination between targets containing single nucleotide polymorphisms (SNP). Conditions that 
favour primer-template annealing, including lower cycling temperature relative to primer melting 
temperature and longer annealing and elongation times maximised accuracy.  These authors also 
found SNP location at the 3' end of the primer influenced quantification more strongly than the 
same SNP located at the 5' end. Additionally, results varied with different master mixes, using the 
same primers and cycle settings (Boyle et al 2009). We used commercially available primers, 
specified as directed against individual miR-181 family members (Qiagen Ltd, Manchester, UK). Short 
sequence length targets offer limited ability to alter primer sequences, however primer sensitivity 
and specificity is reportedly enhanced by using locked nucleic acid (LNA) oligonucleotides when 
detecting and differentiating small or highly similar DNA or RNA targets. These nucleotides contain a 
methylene bridge connecting the ribose 2′-oxygen and 4′-carbon, increasing conformational stability 
(Qiagen Ltd., Manchester, UK, technical support, personal communication). It would be interesting 
to incorporate this in future work. These factors underpin the importance of protocol optimisation 
and consistency. 
Using RT-qPCR, we did not detect statistically significant differences in the expression of the eight 
validated target genes (SIRT1, P62/SQSTM1, PARK2, PARK7/DJ-1, COXI, IL1α, PRDX3 and TNF) 
following gain and loss of miR-181 function (Figure 5.3). Similarly, transcript expression of PRDX6, 
IL1β, IL1RAP, NFκB, SMAD7, IL7, COXIV and TOMM20, genes which interact with them, or are 
involved in pathways relevant to inflammation, apoptosis, or mitochondrial dynamics were not 
different (Figure 5.3). This was disappointing, but may be due to miR-181 inhibiting translation, 
rather than promoting degradation of these transcripts as shown previously (Soriano-Arroquia et al 
2016, Bartel 2018). 
Oligonucleotides are charged, non-biologically stable molecules, which require modification or 
formulation to enable cellular delivery. Efficacy is defined by both the ability to be delivered to, and 
biological availability within the cell (Ly et al 2017). We used cholesterol-conjugated and 
phosphorothionate and 2’-O-methylation modified oligonucleotides to improve cellular penetrance 
and stability. Uptake of mimic and antagomiR treatments was confirmed visually and using RT-qPCR, 
indicating treatments were effectively delivered. Quantification of miR-181 expression by RT-qPCR 
did show variable efficacy of treatments however (Figure 5.2). This may consequently have increased 
variation in target gene expression, accounting for lack of significant differential gene expression 
between treatment groups (Figure 5.3). AntagomiR treatment was only considered successful in five 
out of eight biological replicates, based on antagomiR treated levels of total miR-181 being below 
those of the scrambled control treated group (Figure 5.2). We chose to perform gene expression 
analysis only on these five biological replicates, to increase confidence in results. Cholesterol 
conjugated 2’-O-Me antagomiRs (such as we used) are reported to promote miRNA degradation 
(Stenvang et al 2012). If miR-181 is not degraded by interaction with the antagomiR, however, then 
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it will still be detected by RT-qPCR, even though in the intracellular environment it would still be 
susceptible to inhibition. This may have resulted in unnecessary exclusion of valid data sets. 
Conversely, it has been reported that the majority of internalised compounds are trapped 
unproductively in lysosomes and other ‘oligonucleotide sinks’, and that the addition of serum to 
culture media strongly inhibits functional efficacy of cholesterol modified siRNAs (Ly et al 2017). 
Further work could assess efficacy of alternative transfection protocols such as use of cationic 
liposome transfection reagents or electroporation, or reduction or absence of serum enrichment to 
culture media. Additionally, a greater number of technical replicates may allow selection of samples 
with more consistent transfection results between biological replicates.  
In a heterogenous population, variation in baseline gene expression and response to cell treatments 
between biological replicates is to be expected, and consistent with the context-dependent effect of 
miRNAs referred to above. Tenocytes used were derived from horses on the basis of availability, and 
therefore subject to a range of environmental, genetic and epigenetic factors. A more homogenous 
sample population would have been preferable. Additionally, increasing the number of biological 
replicates would be useful to counteract inherent variability and that of treatment efficiency. Gene 
expression was only assessed at the transcript level which may account for the lack of observed 
effect. miRNAs act principally as post transcriptional regulators of gene expression, so it may be 
assumed that transcript levels will not be affected, only  translation into the functional protein. 
However, the effect on translational repression, although rapid, is reported to be weak and of 
limited importance in the post-embryonic state (Eichhorn et al 2014). Destabilisation of mRNA is 
believed to be the major mechanism by which miRNAs mediate gene expression control, with mRNA 
levels reputedly providing an almost quantitative reflection of miRNA mediated repression (Bartel 
2018). Moreover, the function of the  protein products depends of their post-translational 
modification and their turnover is fast, therefore levels of these proteins may not be indicative of 
their function (Goljanek-Whysall et al 2020).This would support our assessment of gain and loss of 
function effects by quantifying only transcript expression. However, gain and loss of miR-181a 
function significantly affects SIRT1 protein expression in myotubes, without corresponding 
alterations in mRNA levels (Soriano-Arroquia et al 2016). Robust assessment of gene expression 
should, therefore include quantification of both transcript and protein product.  Protein 
quantification would have provided an additional, complementary analysis of effect and the absence 
of this is a major limitation to interpretation of our results.  
We therefore investigated autophagy-related protein function by analysing localisation of TOMM20, 
LC3B, DJ-1, P62/SQSTM1 and Parkin, in control conditions (DMSO) and following mitophagy induction 
using the decoupling agent CCCP (Figures 5.7, 5.8, 5.9, 5.10). Using immunocytochemistry, we 
identified treatment-related changes in localisation of, principally, Parkin and to a lesser extent 
P62/SQSTM1 and LC3B following mitochondrial membrane destabilisation. However we were not able 
to quantify the co-localisation of mitophagic and autophagic proteins with TOMM20 to determine the 
exact process by which miR-181 regulated mitochondrial turnover. Distribution and co-localisation of 
proteins labelled with spectrally distinct fluorescent markers can be assessed by several methods. 
Simple descriptive techniques, such as reported here, assess colour overlay of green and red 
fluorescence. Overlapping signals produce predominantly yellow pixels, indicating co-localisation 
within subcellular compartments (Comeau et al 2006). This, however, requires comparable 
fluorescence intensities of the two markers and does not permit quantification of degree co-
localisation (Moser et al 2017). This is overcome by statistical analysis of pixel-intensity correlation, 
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commonly using Pearson’s correlation coefficient to measure covariance between signals, but 
becomes inaccurate in samples with unequal numbers of densities detected by each channel. Accuracy 
is improved by calculation of co-localised coefficients (termed M1 and M2), with defined threshold 
values for each channel, which correlate pixel intensity detected by the two fluorescence channels 
relative to the total fluorescence in each channel. These methods are incorporated into plug-ins for 
commecially available or free software, and could have been utilised to quantify co-localisation using 
the ImageJ software (Rasband, W.S. U. S. National Institutes of Health, Bethesda, Maryland, USA, 
https://imagej.nih.gov/ij/, 1997-2018), employed in Chapters 6 and 7 for band densitometry analysis 
of Western blot images. The dynamic range and accuracy of these methods is, however, still debated 
(Comeau et al 2006). Combination of these techniques with object recognition to calculate an object-
corrected Pearson coefficient has been propsed as a more robust measure of co-localisation (Moser 
et al 2017). Co-localisation does not, however, imply functional interaction between the molecules of 
interest. 
Mitochondria are dynamic organelles, with the capacity to undergo both movement and 
morphological changes. Brownian motion, short and long range stochastic, directed motion (at 
speeds reaching 1 µm s-1 at 37oC), extension and retraction, fission and fusion all contribute to 
frequent dynamic reorganisation (McCarron et al 2013). Mitochondrial morphology and distribution 
vary considerably with cell type, between cultured and native cells, and between embryonic and 
mature tissue. Mitochondrial appearance can also vary regionally within cells (McCarron et al 2013). 
In fibroblasts, mitochondria are usually filamentous structures 1-10 µm in length and approximately 
700 nm in diameter, with the ability to form reticular networks. In mammalian cells, however, 
network formation appears to be far more prevalent in cultured than native cells (McCarron et al 
2013). Formation of continuous networks permits rapid diffusion of solutes within the organelle and 
mitigation of focal dysfunctionality from mutated mitochondrial DNA or dysfunctional membrane 
and matrix proteins, thereby maintaining oxidative capacity within the cell (Karbowski and Youle 
2003). Fusion and fission occurring as an obligatory physiological function, are more frequently 
reported in cultured rather than native cells. These events usually occur at equal frequency, to 
maintain overall mitochondrial number and morphology. Fusion is dependent on the proteins 
mitofusin 1 and 2 (MFN1, MFN2) and optic atrophy 1 protein (OPA1), whilst fission requires 
dynamin-related protein 1 (DRP1) and its outer mitochondrial membrane adaptor fission protein 1 
(hFIS1). Mutations in these proteins are fatal in mice, whilst in humans, mutations in the fusion 
proteins cause serious neurological deficits.  Morphological and distribution changes may be 
associated with altered cellular energy requirements (increased connectivity increasing respiratory 
activity), calcium signalling, or ROS signalling (McCarron et al 2013). 
Fission and fusion have also been associated with apoptosis and as a means of controlling 
mitochondrial quality through autophagy. In early apoptosis, mitochondrial networks disintegrate, 
producing punctiform fragmented structures. Release of proteins such as cytochrome c from the 
intermembrane space during this process can activate procaspase-9 and subsequently apoptotic 
effector proteases caspase-3 and -7 (Karbowski and Youle 2003). Inhibiting fission has been shown 
to be protective, reducing cardiomyocyte death, myocardial infarct size and renal tubular cell 
apoptosis in models of ischaemia-reperfusion injury. However, enhanced fission, driven by 
overexpression of DRP1, maintained viability of HeLa cells by preventing calcium dependent 
apoptosis (Szabadkai et al 2004), suggesting fission may also be a protective mechanism to separate 
dysfunctional or damaged mitochondria for targeted degradation.  
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Of the proteins assessed by immunocytochemistry, pattern of TOMM20 staining indicates whether 
mitochondrial networks are intact or dispersed, reflecting degree of mitochondrial remodelling. 
Mitochondrial network disruption occurred in response to induced mitochondrial depolarisation, 
confirming effect of CCCP treatment. In miR-181 mimic treated tenocytes, mitochondrial content 
appeared to be preserved, suggesting mitochondrial turnover was enhanced with miR-181 
upregulation. In the majority of samples, Alexa FluorTM 594 (red) conjugated secondary antibody was 
used to image TOMM20 localisation. The exception was in those cells co-stained for Parkin, in which 
Alexa FluorTM 488 (green) was used. This inconsistency was a function of convenience, reflecting 
availability of relevant compatible primary and secondary antibodies.  Image resolution and 
definition was superior for proteins labelled with the green rather than red fluorophore-conjugated 
secondary antibody. This may have facilitated observation of more subtle changes in mitochondrial 
morphology in association with Parkin co-staining, whilst precluding identification of these in the 
other samples. Indeed, we identified CCCP induced mitochondrial network disintegration in all 
samples with the exception of miR-181 antagomiR treated cells co-stained for Parkin, where a 
mitochondrial pattern intermediate between punctiform and networked was evident (Figure 5.10). 
This could suggest inhibition of miR-181 produced some measure of protection against 
mitochondrial degradation, or progression of the degradative process had been interrupted. 
Accumulation of the other proteins investigated can indicate upregulation of autophagy, or 
disruption to autophagic flux, with impaired clearance from the cell.  
Although not statistically significant at the transcript level, localisation of proteins P62/SQSTM1 and 
Parkin demonstrated the most obvious alterations with miR-181 overexpression or inhibition 
following mitochondrial depolarisation (Figures 5.9, 5.10). P62/SQSTM1 is an autophagosome 
adaptor protein, targeting other proteins for selective autophagy by virtue of possessing both LC3B-
interacting and ubiquitin binding regions. Parkin is recruited to the outer membrane of damaged 
mitochondria following phosphatase and tensin homologue-induced putative kinase 1 (PINK1) 
stabilisation, where it mediates polyubiquitination of outer mitochondrial membrane proteins, 
targeting them for proteasomal degradation (Palikaras et al 2018). 
Autophagy is part of a suite of highly conserved cellular processes, including apoptosis and 
necroptosis which initiate and regulate programmed cell death (Su et al 2015). These processes 
operate with a basal level of activity that alters in response to a range of cellular stressors (Sánchez-
Martín and Komatsu 2018). Each mechanism consists of well-defined sophisticated pathways which 
interact through several key intermediates, one of which is P62/SQSTM1 (Su et al 2015). 
Dysregulation of miR-181 and subsequent expression of P62/SQSTM1 and co-targets PARK2 and DJ-1 
is associated with disrupted autophagic pathways and degenerative changes in skeletal muscle 
(Goljanek-Whysall et al 2020). On this basis, we investigated how miR-181 influenced the 
distribution of LC3B, P62/SQSTM1, DJ-1, and Parkin following mitochondrial uncoupling. LC3B is an 
autophagosome membrane-associated protein that targets receptors expressed on the surface of 
damaged mitochondria and is a marker of enhanced autophagic sequestration or reduced clearance 
(McCoy and Cookson 2011). In addition to functioning in catabolic pathways, P62/SQSTM1 plays a 
protective role in ROS-mediated cell death by binding kelch like ECH associated protein 1 (KEAP1), 
preventing it targeting nuclear factor erythroid 2 (NRF2) for proteosomal degradation. Stabilisation 
of NRF2 results in its accumulation and nuclear translocation, activating transcription of antioxidant 
enzymes (Park et al 2015). DJ-1 is recruited to depolarised mitochondria as a protective mechanism 
against oxidative damage, becoming directly oxidised, and stimulating mitochondrial fusion (Taira et 
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al 2004, McCoy and Cookson 2011). The outer mitochondrial membrane kinase PINK1 recruits Parkin 
following mitochondrial depolarisation, initiating ubiquitin-dependent mitophagy and enhancing cell 
survival by suppressing both mitochondria-dependent and independent apoptosis (Palikaras et al 
2018).  
Goljanek-Whysall and co-workers (2020) reported that the downregulation of miR-181a with ageing 
is associated with defective mitochondrial dynamics and a dysfunctional autophagic response in 
myoblasts, characterised by accumulation of autophagy-associated proteins and abnormal 
mitochondria. Overexpression of miR-181a/b is also reported to stimulate mitochondrial metabolism 
and osteogenic induction in human chondrocytes (Zheng et al 2019). Conversely, Ouyang and 
colleagues (2012) reported inhibition of miR-181a in murine astrocytes is associated with a reduction 
in oxidative stress and cell death, with preserved mitochondrial function. Although these authors did 
not measure mitophagic flux, they reported miR-181a inhibition increased levels of the anti-
apoptotic proteins myeloid leukaemia cell differentiation protein (MCL1) and BCL2, to which they 
attributed their findings (Ouyang et al 2012). Investigating mitochondrially-mediated central 
neurodegeneration both in vitro and in vivo, Indrieri and co-workers (2019) reported inhibition of 
miR-181a and -b was protective against cell death following protonophore treatment of neurones in 
a model of induced autophagy similar to the one we employed. Deletion of miR-181a and -b in mice 
resulted in increased expression of NRF2 and PPARGC1A (peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha) transcripts and mitochondrial DNA, indicating increased mitochondrial 
biogenesis. Concurrently, PARK2 was up regulated and Parkin and P62/SQSTM1 were enriched in the 
mitochondrial compared to the cytosolic cell fraction, although overall levels of Parkin and 
P62/SQSTM1 were reduced (Indrieri et al 2019). These authors concluded that miR-181 inhibition 
stimulated mitochondrial turnover and increased autophagic flux in CNS tissues, maintaining 
neuronal viability.    
Our results show elements that are consistent with miR-181 upregulation enhancing mitochondrial 
turnover, thereby maintaining a functional population in the cell, or mir-181 inhibition exerting a 
protective effect by mitigating mitochondrial damage and preventing degradation.   Precipitation of 
mitochondrial dysfunction resulted in LC3B accumulation in mimic treated cells that did not coincide 
with regions of punctate TOMM20 staining. This distribution pattern could suggest either failure of 
LC3B to localise to damaged mitochondria, leading to accumulation within the cell, or that 
recruitment to damaged mitochondria and degradation of lysosome-associated LC3B had already 
occurred. Peripheral LC3B positive regions may represent an increase in production of LC3B in the 
soluble form prior to becoming bound to lysosomal membrane. Whilst DJ-1 and TOMM20 
localisation patterns showed a degree of similarity in mimic treated cells, corresponding with the 
expected response, this appeared more precise in antagomiR treated cells, although overall 
mitochondrial content seemed reduced (Figure 5.8). The more dense perinuclear clustering of DJ-1 
and TOMM20 positive punctae in the CCCP/miR-181 mimic treated cells could reflect an increase in 
ROS production associated with mitochondrial biogenesis (Yoboue and Devin 2012). The role of 
P62/SQSTM1 is complex. P62/SQSTM1 condensate dispersal throughout the cytoplasm, seen 
particularly in mimic treated cells, would be consistent with its role in inducing nucleation of 
autophagosomal membranes through its interaction with LC3B (Sánchez-Martín and Komatsu 2018). 
Two forms of LC3B are present in the cell, unconjugated LC3BI and lipid membrane conjugated 
LC3BII. Classically, LC3B positive aggregates (punctae) are considered to be specific markers for 
autophagosomes, but LC3BI can form accumulations with P62/SQSTM1 in autophagy-impaired cells 
216 
 
(Runwal et al 2019). Co-staining of P62/SQSTM1 and LC3B in future work could confirm whether this 
occurs with altered miR-181 expression. 
P62/SQSTM1 accumulation may be beneficial in oxidative stress by stabilising NRF2, which then 
induces expression of multiple antioxidant related genes, autophagy related proteins and further 
expression of P62/SQSTM1 itself (Sánchez-Martín and Komatsu 2018). However, as P62/SQSTM1 is 
removed mainly by autophagy, once bound it should be removed rapidly, and accumulation of 
P62/SQSTM1 inclusions are commonly interpreted as a marker of autophagy impairment (Lippai and 
Löw 2014). The more widespread distribution of punctate P62/SQSTM1 inclusions in the mimic 
treated group would be consistent with labelling of substrates for targeted autophagic degradation, 
although the difference between mimic and antagomiR treatments is less marked than with other 
proteins investigated. Parkin accumulation was evident in antagomiR treated tenocytes, but 
mitochondrial clusters were still visible, indicating stalled autophagy in CCCP treated cells. 
Distribution, however, was more concordant with that of mitochondrial staining, suggesting 
recruitment to dysfunctional mitochondria. Extensive mitochondrial network disruption into 
punctae, suggesting active mitophagy following CCCP exposure, was evident in the mimic and 
scrambled treated groups, but Parkin staining was inconclusive.  
In conclusion, we believe our data supports the hypothesis that miR-181 regulates mitochondrial 
dynamics, with miR-181 upregulation increasing mitochondrial turnover, whilst inhibition of miR-181 
function impedes autophagic flux.  Although the mechanism remains unclear, the accumulation of 
Parkin in association with abnormal, ‘condensed’ mitochondrial networks suggests that recruitment 
or activation of this enzyme may be an important step. The observed downregulation of miR-181 
with clinical tendinopathy in both human and equine species may, therefore, represent a reduced 
capacity to remove dysfunctional mitochondria and stimulate regeneration. Further investigation of 
the effects of miR-181 on tenocyte function is warranted, and is investigated further in Chapter 6, in 
a more physiologically representative model, using three-dimensional tendon constructs to further 




Chapter 6 - Functional analysis of miR-181 in equine tenocytes - 3D 
tendon constructs  
 
6.1 Introduction 
The investigation of pathophysiological changes occurring in tendinopathy using clinical samples 
from human patients often yields inconsistent results (see Chapter 1, section 1.2.1). This may be due 
to sample acquisition from a highly heterogenous population with different genetic, epigenetic and 
lifestyle factors. Compounding this, adherence to ethical and informed consent requirements further 
impacts on access to samples, limiting sample numbers and uniformity of age, sex and stage and 
severity of disease. Typically, by the time tissues are acquired, non-surgical interventions have been 
attempted and disease is usually advanced. Additionally, healthy tissue without comorbidities is 
difficult to obtain, making tendon one of the more challenging tissues to investigate in man.   
Animal models of tendinopathy present an alternative option, offering the capability for limiting 
environmental, population and disease variables. In addition to ethical considerations, however, 
there are considerable limitations in translatable integrity to human clinical disease. There is also no 
single, reliable mechanism for induction of clinically relevant disease in an animal model (Lui et al 
2011). 
Cell culture techniques allow for ultimate control over environmental conditions, and detailed 
interrogation of biochemical pathways, but at the expense of cells being in a very artificial milieu. 
Tenocytes naturally form nanotubular processes 100-500 nm in diameter, extending for several 
hundred micrometers and forming complex three-dimensional networks within an abundant, 
complex and well-organised extracellular matrix structure. Gap junctions occur between adjacent 
tenocytes, demonstrating a capacity for intercellular communication (Egerbacher et al 2020).  
The mechanoresponsive nature of tenocytes suggests that behaviour in monolayer culture, with cells 
adherent to rigid tissue culture plastic, may not fully reflect the in vivo situation. Tissue engineering 
techniques involve cultivation of cells within an artificial three-dimensional extracellular matrix, 
providing a more physiologically appropriate environment in which to investigate function. The use 
of both collagen and fibrin gel scaffolds have been described for producing tendon-like tissue 
(Kapacee et al 2008, Kapacee et al 2010, Kharaz et al 2016). Static tension generated by maturation-
contraction of a fibrin gel matrix stimulates embedded tenocytes to produce fibripositors and 
linearly aligned collagen fibril bundles absent in transected, tension-free constructs or monolayer 
culture conditions (Kapacee et al 2008). Histological analysis of tissue-engineered tendon and 
ligament constructs has however demonstrated significant differences to native tissue. Kharaz and 
co-workers (2016) reported greater cellularity in artificially synthesised tissues, with canine-derived 
tenocytes exhibiting a more fibroblastic appearance than in native tendon, and a much looser matrix 
architecture. Additionally, natural and engineered tissues demonstrate distinctly different 
proteomes. Although several matrix proteins were common to both tissue types (including collagens 
type 1, 3, 5 and 6, decorin, biglycan, lumican and tenascin c), they represented a much smaller 
proportion of the overall proteins in engineered versus natural tissue (Kharaz et al 2016).  
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Our data from monolayer tenocyte culture suggested miR-181 levels may regulate mitochondrial 
turnover. Therefore, we undertook gain and loss of miR-181 function studies in fibrin gel constructs 
generated using equine tendon derived tenocytes. Additionally, network analysis results reported in 
Chapter 4 (section 4.3.2), implicated miR-181a interaction with insulin and MAPK signalling pathways 
(Figure 4.5). Consequently, we extended investigation of target gene expression performed in 
monolayer culture in Chapter 5, to included insulin-like growth factor I (IGF1), insulin-like growth 
factor I receptor (IGF1R), insulin receptor (IR) and mitogen activated protein kinase 14 (MAPK). 
Interestingly, miR-181a is one of only seven miRNAs shown to be consistently down regulated in 
murine and human skeletal muscle during ageing (Soriano-Arroquia et al 2016). This may imply 
disruption to insulin and MAPK signalling is important in age-related deterioration of skeletal muscle 
as well as pathological changes in tendon. 
The polypeptide hormones insulin and IGF1 regulate similar cellular functions, including promoting 
cellular growth and differentiation, vesicle trafficking, activation of protein kinases and 
transcriptional activation and repression (Saltiel and Pessin 2002). The insulin and IGF1 receptors 
share significant sequence homology, with both consisting of disulphide-linked dimers capable of 
binding and activation by insulin and IGF1 (Ward and Lawrence 2009).  Both phosphatidylinositol 3-
kinase (PI3K) and MAPK pathways are activated downstream of insulin and IGF1, and are responsible 
for the majority of the mitogenic and anabolic effects of receptor activation (Rains and Jain 2011, 
Disser et al 2019). IGF1 is critical in tenocyte proliferation and tendon development and growth in 
mice, inducing expression of the transcription factors early growth response 1 and 2 and scleraxis 
(Disser et al 2019). IGF1 injection into the patellar tendon of men increases protein production, 
irrespective of recipient age (Nielsen et al 2014). In an equine model of tendinopathy, injection of 
IGF1 into collagenase-induced lesions increased cellularity and hydroxyproline levels (Dahlgren et al 
2002). The latter study also reported reduced lesion size and perilesional swelling with IGF1 
treatment, although no increase in collagen, glycosaminoglycan production, nor any histological or 
mechanical benefit were identified.  
MAPK activation represents a point of convergence of IR/IGF1 and TGFβ signalling pathways. TGFβ is 
a potent inducer of scleraxis, an important regulator of extracellular matrix deposition, and critical in 
commitment and maintenance of progenitor cells to tenogenic differentiation (Pryce et al 2009, Tan 
et al 2020).  
To further investigate the disruption to mitochondrial dynamics and autophagy-associated proteins 
suggested in Chapter 5, levels of the proteins translocase of outer mitochondrial membrane 20 
(TOMM20), cytochrome c oxidase subunit 4 (COXIV), microtubule-associated proteins 1A/1B light 
chain 3B (LC3B), ubiquitin-binding protein p62 (P62/SQSTM1) and Parkin (PARK2), were analysed by 
Western blotting. Additionally, we included BCL-2 interacting protein 3 (BNIP3), lysosomal-
associated membrane protein 1 (LAMP1), mitofusin 1 (MFN1), mitofusin 2 (MFN2) and nuclear 
factor erythroid 2 (NRF2) in our analysis.  
BNIP3 can induce different forms of cell death including apoptosis, necrosis, and autophagy. The 
predominant mechanism is dependent on cell type and context, being associated with and without 
cytochrome c oxidase release, and with both caspase dependent and independent pathways. 
Expression is induced by hypoxia, through interaction of HIF1α with binding sites in the promotor 
region and BNIP3 then localises to the mitochondrial membrane, inducing opening of the 
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mitochondrial permeability transition pore, resulting in mitochondrial depolarisation (Zhang and Ney 
2009).  
LAMP1 is an abundant membrane spanning glycoprotein component of the lysosomal membrane. In 
concert with the structurally similar LAMP2, it is estimated these produce a nearly continuous 
carbohydrate layer on the inner surface of the lysosomal membrane (Andrejewski et al 1999). The 
presence of LAMP molecules is one of the defining features of the lysosomal compartment, and their 
abundance and specificity are important in maintaining structural integrity of lysosomal membranes, 
functional competence in transmembrane trafficking and interaction with other cellular components 
(Eskelinen 2006). Indeed, LAMPs are critical for lysosome-autophagosome fusion in the final stages 
of autophagy, with autophagic activity regulating LAMP expression (Morell et al 2016).  
Mitochondria are dynamic organelles, with networks undergoing frequent fusion and fission. MFN1 
and MFN2 function independently and cooperatively to promote mitochondrial fusion. This process 
is both facilitatory for mitochondrial function and protective, providing a mechanism to restore and 
maintain mitochondrial membrane potential (Chen et al 2003). Three distinct molecular complexes 
are generated, MFN1 and MFN2 homotypic oligomers and MFN1-MFN2 heterotypic oligomers. 
Although both mitofusin homotypes are capable of driving mitochondrial fusion independently, their 
relative importance is cell type specific, and disruption to either MFN1 or MFN2 expression can lead 
to severe mitochondrial fragmentation (Chen et al 2003).  
NRF2 is a critical transcription factor involved in the regulation of cellular antioxidant defence 
mechanisms. Basal levels of NRF2 are low due to KEAP1 facilitated ubiquitination. Exposure to 
reactive oxygen species, however, renders KEAP1 unable to bind NRF2, promoting its accumulation 
and subsequent transcription of cytoprotective genes (Komatsu et al 2010). NRF2 is also up 
regulated in response to P62/SQSTM1 accumulation occurring as a consequence of increased 
activation or interruption of autophagy (Komatsu et al 2010, Lau et al 2010). Increased cellular NRF2 
levels also upregulate both mitochondrial biogenesis and mitophagy (Piantadosi et al 2008, Fang et 
al 2017). 
As tendon structure is highly specialised to support its mechanical function, we additionally 
investigated the architectural consequences of manipulation of miR-181 levels.  Histological and 
ultrastructural examination of constructs using transmission electron microscopy (TEM) allowed us 
to gain additional information on mitochondrial morphology, and a more complete picture of the 
impact of how miR-181 upregulation and inhibition in tenocytes influences extracellular matrix 
production and organisation. Our data suggests that miR-181a treated tenocytes demonstrate an 





6.2 Methods  
 
6.2.1 Generation of tendon constructs 
Tenocytes were isolated from equine SDFT samples acquired from seven donors (Table  6.1).  
 
 
Sample ID Sex Age (years) Passage number 
EqDB1 F 9 3 
EqDB3 MN 9 3 
EqDB7 MN 5 3 
EqDB9 F 12 3 
EqDB10 F 18 3 
EqDB12 F 8 4 
EqDB24 F 9 3 
 
Table 6.1 Donor and tenocyte passage details for equine superficial digital flexor tendon-derived 
tenocytes used to generate three-dimensional constructs. F = female, MN = male neutered. 
 
Eighteen constructs were generated from each biological replicate, to allow duplicate treatments 
with miR-181a mimic, antagomiR and scrambled sequence control to be processed for histology, 
RNA and protein extraction. Additionally, untreated controls were produced for three of the 
biological replicates. Superficial digital flexor tendon-derived tenocytes (600,000 per construct) were 
seeded into pre-prepared six well plates (Chapter 2, section 2.4.2) in a fibrinogen/thrombin matrix, 
as described in Chapter 2, section 2.4.3 and incubated at 37oC in a 5% CO2, 5% O2 atmosphere. 
Twenty four hours later (day 1), complete tenogenic culture medium (see Chapter 2, section 2.4.1) 
was treated with cholesterol-conjugated Cy5-tagged mmu-miR-181a-5p mimic, FITC-tagged 23 
nucleotide (nt) single strand RNA antagomiR, or 21 nt single strand RNA scrambled control sequence 
oligonucleotides. Final treatment concentrations of 100 nM (miR-181a mimic and scrambled control) 
and 200 nM (antagomiR) were based on those optimised for use in monolayer culture (Chapter 5, 
section 5.3.1). Media was changed and treatments repeated every 2-3 days until constructs were 
harvested on day 28, when they were randomly allocated for downstream processing for either RNA 





6.2.2 Reverse transcription quantitative real-time polymerase chain reaction 
Total RNA extraction was performed on constructs from all donors. Reverse transcription to cDNA 
used 100 ng RNA template for gene expression and 50 ng RNA template for miRNA expression 
analyses. Expression of miR-181a/b/c/d was determined using commercially available primers 
(Qiagen, Manchester, UK, see Chapter 2, Table 2.10) and normalised to SNORD61 as internal control 
(previously validated for this purpose as a stable small non-coding RNA (Chapter 5, section 5.2.2; 
Appendix 5, Table A5.1)). Relative expression values were then summed to give total miR-181 
expression for each sample.  
Primers were designed for insulin-like growth factor I (IGF1), insulin-like growth factor I receptor 
(IGF1R), insulin receptor (IR) and mitogen activated protein kinase 14 (MAPK), in addition to the 
targets previously investigated in monolayer culture (Chapter 5, section 5.2.2; peroxiredoxin 3 
(PRDX3), peroxiredoxin 6 (PRDX6), sirtuin 1 (SIRT1), Parkin (PARK2), protein deglycase DJ-1 (PARK7), 
mothers against decapentaplegic homolog 7 (SMAD7), ubiquitin-binding protein p62 (P62/SQSTM1), 
tumour necrosis factor (TNF), interleukin 1 alpha (IL1α), interleukin 1 beta (IL1β), interleukin 1 
receptor accessory protein (IL1RAP), interleukin 7 (IL7), nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB), translocase of outer mitochondrial membrane 20 (TOMM20), cytochrome c 
oxidase subunit I (COXI), cytochrome c oxidase subunit 4 (COXIV)).  
Target expression was normalised to that of the housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH; previously demonstrated to exhibit acceptable stability for this purpose 
(Chapter 5, section 5.2.2; Appendix 5, Table A5.2)). Primer sequences and RT-qPCR details are listed 
in Chapter 2, section 2.12, Tables 2.11, 2.12 and 2.13 and Figures 2.2 and 2.3 respectively). For all 
RT-qPCR data, technical replicates were run in triplicate and expression relative to SNORD61 or 
GAPDH calculated using the delta Ct method (Livak and Schmittgen 2001). For graphical 
representation, transcript expression was normalised to that of the scrambled control treatment 
group.  
 
6.2.3 Protein expression 
Protein extraction was performed on constructs from all donors. Following protein extraction and 
quantification (Chapter 2, sections 2.13.2 and 2.13.3), sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed using five micrograms of protein in 15 µL loading 
volume. Semi-dry transfer to polyvinylidene fluoride (PVDF) membrane was confirmed using 
Ponceau staining prior to immunofluorescent evaluation of target proteins TOMM20, BNIP3, LAMP1, 
COXIV, LC3B, P62/SQSTM1, Parkin, MFN1, MFN2 and NRF2. Vinculin was used as loading control for 
normalisation. Images were acquired using the LI-COR Odyssey CLx Imaging System at emission 
wavelengths of 700 nm and 800 nm. Details of protocols and antibodies are given in Chapter 2, 
sections 2.14 and 2.15.  
Semi-quantitative analysis of protein expression was performed by band densitometry using ImageJ 
1.52 software (Rasband, W.S. U. S. National Institutes of Health, Bethesda, Maryland, USA, 
https://imagej.nih.gov/ij/, 1997-2018). Target protein band densities were measured and 
normalised to band intensity of corresponding vinculin loading control. Graphical representation of 
relative expression between groups is given in Figure 6.7. 
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6.2.4 Histology and transmission electron microscopy 
Histological assessment was performed on constructs from all donors. For light microscopy, 
mounted sections were stained with haematoxylin and eosin, Masson’s trichrome and elastin von 
Gieson’s stains and imaged using a Nikon Eclipse 80i microscope (Chapter 2, section 2.16.1). 
Histological appearance was assessed using a novel grading scheme based on Bonar (Cook et al 
2004) and Movin (Movin et al 1997) scales. Variables assessed were extracellular matrix 
organisation, cell shape, cell distribution cellular alignment, cellularity and collagen arrangement 
(Figure 6.1).  
Constructs from four donors were processed for TEM. Ultrathin (60-90 nm) resin embedded sections 
were stained with uranyl acetate and lead citrate and viewed and imaged on a Phillips EM208S 
Transmission Electron Microscope at 80 kV (Chapter 2, section 2.16.2). 
 
6.2.5 Statistical analysis 
Transcript expression, protein levels and construct scoring data were analysed using GraphPad Prism 
version 5.01 for Windows (GraphPad Software, San Diego California USA, www.graphpad.com). 
Transcript expression and construct scoring data were analysed non-parametrically using the Kruskal 
Wallis test with Dunn’s test for pairwise comparisons. Analysis was performed between miR-181a 
mimic, antagomiR and scrambled control sequence treated groups. Comparisons between 
scrambled control sequence treated and untreated groups, where performed, utilised the Mann-
Whitney test when conditions for its application were satisfied, or the Student t test where less than 
three data points were present in one comparator group. These results are presented in Appendix 6, 
Figures A6.1 and A6.3. Significance was assumed if P<0.05.  One way ANOVA was also run on 
histology scores for interest, but did not affect outcomes. 
Protein levels derived from Western blot images were analysed using one way ANOVA with Tukey’s 
multiple comparison test for pair-wise comparisons. Analysis was performed between miR-181a 
mimic, antagomiR and scrambled control sequence treated groups. Significance was assumed if 
P<0.05.   

































Figure 6.1 Modified grading scheme used for construct scoring. Scoring system based on the Bonar 
(Cook et al 2004) and Movin (Movin et al 1997) scores for classification of histopathological findings 
of tendinopathy. 
Characteristic Score 
Extracellular Matrix organisation  
- Compact  
- In part compact, in part loose 






- Spindle-shaped (normal) 
- Mixture of spindle and round cells 






- Homogenous Distribution of cells 





- Uniaxial  





- Low Cellularity  
- Intermediate Cellularity  






- Parallel arrangement, tight cohesive bundles, 
homogenous polarisation pattern, normal 
crimping 
- Separation of individual fibre bundles, 
maintenance of overall bundle architecture     
- Bundle changes; loss of demarcation of bundles, 
loss of normal polarisation pattern 
- Marked separation of bundles, complete loss of 
architecture  











6.3 Results  
 
All constructs were produced from third passage tenocytes except those from donor EqDB12. This 
was due to an error in thrombin/fibrinogen ratio used during preparation, resulting in batch failure 
three days after seeding. A subsequent set of constructs was produced successfully, but from 
passage four cells (Figure 6.2).  
 
 
Figure 6.2 Equine tenocyte-fibrin gel constructs from biological replicate EqDB12. A. Constructs 
created from third passage tenocytes failed at 3 days due to incorrect thrombin:fibrin ratio used 
during preparation. B. Replacement constructs created using fourth passage tenocytes and correct 
thrombin:fibrin ratio. 
 
Mature constructs were non-adherent to the SylgardTM base in all cases, attached only to the anchor 
points at each end. Wet weights (mean ± SD) for constructs used for RNA extraction were 6.97 ± 
2.55 mg and did not differ between treatment groups (P = 0.50). Constructs for protein extraction 
were 9.02 ± 2.45 mg; weights did not differ between treatment groups (P = 0.58).  Despite random 
allocation to processing pipeline, constructs used for protein extraction were significantly (P 
<0.0001) heavier than those used for RNA extraction.  
 
6.3.1 Validation of miR-181a-5p overexpression and inhibition in tendon constructs 
Constructs were created from seven donors. We first confirmed treatment effect by RT-qPCR 
evaluation of relative total miR-181 expression, normalised to SNORD61. Response to treatment was 
variable, but in all constructs analysed, miR-181a mimic treatment resulted in substantial 
upregulation of total miR-181. Of the four miR-181 family members, miR-181b showed greatest 
increase in expression in response to miR-181a mimic treatment, being responsible for 98-99% of 
the total miR-181 expression in this treatment group. Response to antagomiR treatment was more 
subtle and varied. In antagomiR treated constructs from five donors, total miR-181 expression was 















miR-181a miR-181b miR-181c miR-181d
EqDB1-9(P3) EqDB3-9(P3) EqDB9-12(P3) EqDB10-18(P3) EqDB12-8(P4)















Figure 6.3 microRNA-181 expression in mmu-miR-181a-5p mimic, antagomiR and scrambled 
control treated equine tendon constructs. Values represent relative expression, normalised to 
SNORD61, for all four miR-181 family members and total miR-181. Five biological replicates used for 
gene expression analysis. In graphical representation, M = miR-181a-5p mimic, AM = antagomiR, SC 
= scrambled control, UT = untreated control. Relative expression values are given in the table below 
graph. 
Mimic AntagomiR Scrambled Untreated Mimic AntagomiR Scrambled Untreated Mimic AntagomiR Scrambled Mimic AntagomiR Scrambled Mimic AntagomiR Scrambled
181a 1.738 0.022 0.028 0.024 0.428 0.519 0.029 0.012 0.499 0.174 0.146 0.623 0.336 0.070 2.200 0.522 0.240
181b 202.330 0.691 1.307 0.885 102.912 0.537 0.845 0.639 67.125 0.544 0.653 135.953 0.638 1.157 225.348 1.308 4.389
181c 1.449 0.005 0.030 0.006 0.253 0.025 0.012 0.010 0.171 0.008 0.008 0.320 0.020 0.034 0.574 0.022 0.087
181d 0.715 0.218 0.266 0.347 0.370 0.108 0.463 0.272 0.128 0.214 0.301 0.278 0.374 0.361 0.735 0.549 1.484
Total 181 206.232 0.937 1.631 1.262 103.964 1.190 1.349 0.934 67.922 0.940 1.108 137.174 1.368 1.622 228.856 2.401 6.200
EqDB1 EqDB3 EqDB9 EqDB10 EqDB12
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6.3.2 miR-181a predicted target gene analysis 
Once treatment effect was determined, target gene expression was analysed in constructs from the 
five donors demonstrating total mIR-181 expression in the antagomiR treated group below that of 
the scrambled control group. Data showed considerable variability, with data points indicating 
exaggerated increases in relative expression displayed for PRDX3: antagomiR (AM) and scrambled 
control (SC), PARK7: mimic (M), IL7: AM, P62/SQSTM1: AM, TNF: AM, NFκB: AM, PARK2: AM, 
TOMM20: AM and SC and COXI: SC.  
On re-examination of RT-qPCR data, the EqDB10 antagomiR treated sample was removed from 
analysis as the GAPDH Ct value was five cycles (more than three times the standard deviation) higher 
than the mean values for all samples. This is consistent with producing artificially elevated target 
gene expression values. EqDB9 was responsible for AM and SC group outliers for PRDX3 and group 
M for PARK7. EqDB3 was responsible for SC group outliers for TOMM20 and COXI. No reason to 
justify exclusion of these data points could be determined, therefore they were retained in the 
analysis.  
None of the 20 targets examined showed significantly different expression between treatment 





































































































































































































































































     
 
P=0.44 P=0.77 P=0.79 
P=0.77 P=0.53 
P=0.26 P=0.91 P=0.27 















































































































































































Figure 6.4 (includes preceding page) The effects of miR-181a overexpression and inhibition on the 
expression of selected target genes in three-dimensional equine tenocyte-fibrin gel constructs 
from five biological replicates. Y–axis values represent expression relative to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), normalised to scrambled control treatment group. M = miR-
181a-5p mimic, AM = antagomiR, SC = scrambled control. P-values calculated from delta Ct values, 
using Kruskal-Wallis test with Dunn’s test for pairwise comparisons. Graphs show median and 
interquartile range.                     
P=0.71 P=0.87 





6.3.3 Protein expression 
As miRNAs can regulate the expression of their targets via mRNA degradation or inhibition of 
translation, based on the mitochondrial turnover phenotype identified in Chapter 5, we next 
investigated the effect of miR-181a mimic and antagomiR treatments on expression of the 
autophagy- and mitochondria-related proteins TOMM20, COXIV, LC3B, P62/SQSTM1, Parkin, BNIP3, 
LAMP1, MFN1, MFN2 and NRF2. Size of constructs precluded division for processing for both protein 
and RNA extraction to confirm miR-181a treatment effect. Results from constructs for all seven 
donors are therefore presented.  
Loading 5 µg protein per lane for SDS-PAGE generated detectable fluorescent signal for TOMM20, 
BNIP3, LAMP1, COXIV, LC3B and P62/SQSTM1, but not MFN1, MFN2, NRF2 or Parkin. Samples were 
re-run for these targets using 10 µg protein per lane, and produced useable data for NRF2 and 
Parkin, but still failed to produce detectable signal for MFN1 and MFN2.  
All mmu-miR-181a-5p mimic treated constructs demonstrated a strong, broad signal at 
approximately six kilo Daltons (kDa), with two to three fainter parallel bands proximally, between 
the 8 and 15 kDa markers. This phenomenon was evident prior to membrane incubation with 
Ponceau stain, primary, or secondary antibodies (Figure 6.5), and following incubation with primary 
and secondary antibodies directed against all targets (see Appendix 6, Figure A6.2). Whilst this may 
be due to protein degradation, it is most likely artefact related to the fluorescent Cy5 label carried by 
the miR-181a mimic treatment. Interestingly, we did not see this signal in the immunofluorescence 
images from monolayer culture work reported in Chapter 5 (Figure 5.5). Emission maximum for Cy5 
is 694 nm, consistent with observed signal detection at 700 nm, but absent at 800 nm on the 
imaging platform used. The signal was also detected directly after electrophoretic transfer of protein 
to PVDF membranes, prior to incubation with any stains or antibodies. The mass of the double 
stranded RNA mimic is approximately 13 kDa and that of the denatured fluorescent strand 
approximately 6.5 kDa, consistent with the position of the bands observed (Horizon Discovery Ltd, 




Figure 6.5 Fluorescence associated with Cy5 labelling of mmu-miR-181a-5p mimic treatment is 
preserved during protein extraction from fibrin gel equine tendon constructs, SDS-PAGE and 
electrophoretic transfer to polyvinylidene fluoride (PVDF) membrane, and visible on subsequent 
fluorescent imaging. Images are of PVDF membranes from seven biological replicates prior to 
application of Ponceau stain or incubation with primary or secondary antibodies. SDS-PAGE = 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, M = mimic treated, AM = antagomiR 
treated, SC = scrambled control treated, UT = untreated. Images acquired using LI-COR Odyssey CLx 
Imaging System at 700 nm wavelength. 
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We assumed miR-181a treatment success in constructs analysed for protein levels, was analogous to 
that determined by RT-qPCR in constructs processed for gene expression (Figure 6.3). Additionally, 
none of the primary antibodies used have documented reactivity with equine proteins. Specific 
immunogenic sequences against which antibodies were raised were available for anti-BNIP3, -COXIV, 
-LAMP1, -LC3B, -MFN1, -MFN2 and -NRF2 antibodies. For those directed against P62/SQSTM1, 
Parkin, TOMM20 and Vinculin, immunisation was specified as being against the full length protein 
(abcam plc, Cambridge, UK, technical support, personal communication). Sequence alignment was 
performed to determine homology with the corresponding equine proteins using the Basic Local 
Alignment Search Tool (BLAST; National Center for Biotechnology Information, Bethesda, USA), with 
results given in Table 6.2. Greater than 85% homology of immunogen sequences is recommended to 
support likely cross-reactivity with a novel protein (abcam plc, Cambridge, UK, technical support, 
personal communication).  
 
 
Protein Epitope Homology (%) 
BNIP3 Amino acids 95-200 95 
COXIV Amino acids 128-169 76 
LAMP1 Amino acids 76-311 73 
LC3B Amino acids 1-100 100 
MFN1 Amino acids 1-741 59 
MFN2 Amino acids 661-757 98 
NRF2 Amino acids 108-413 86 
P62/SQSTM1 Whole protein 93 
Parkin Amino acids 399-465 94 
TOMM20 Whole protein 99 
Vinculin Whole protein 89 
 
Table 6.2 Sequence homology between immunogen epitopes and corresponding equine protein 
sequences. BNIP3 = BCL-2 interacting protein 3, COXIV = cytochrome c oxidase subunit 4, LAMP1 = 
lysosomal-associated membrane protein 1, LC3B = microtubule-associated proteins 1A/1B light chain 
3B, MFN1 = mitofusin 1, MFN2 = mitofusin 2, NRF2 = nuclear factor erythroid 2, P62/SQSTM1 = 
ubiquitin-binding protein p62, PARK2 = Parkin, TOMM20 = translocase of outer mitochondrial 
membrane 20. Sequence homology determined using Protein BLAST (National Center for 




Images of sufficient quality for semi-quantitative analysis of protein expression were obtained with 
all samples for TOMM20, five samples for LC3B and NRF2, four samples for BNIP3 and three samples 
for Parkin, P62/SQSTM1, LAMP1 and COXIV. MFN1 and MFN2 were not quantifiable. 
The autophagy receptor protein P62/SQSTM1 was significantly up regulated with antagomiR 
treatment, indicating either an increase in autophagy, or a chronic elevation consistent with 
autophagy stalling (Figure 6.6 (E) and Figure 6.7). Accumulation of P62/SQSTM1 is protective in ROS-
mediated cell death, by exerting a permissive effect on NRF2 mediated upregulation of antioxidant 
gene transcription (Park et al 2015). However, P62/SQSTM1 is removed mainly by autophagy and, 
once bound to a ubiquitinated substrate, is rapidly degraded. Accumulation is therefore commonly 
interpreted as a marker of autophagy impairment (Lippai and Löw 2014). However, poor quality 
Western blots, with undetectable signal in four of the biological replicates, limited the number of 
samples available for analysis.   
The transcription factor NRF2 was quantifiable in five of the biological replicates, with undetectable 
signal in the remaining two. Significant upregulation of NRF2 was seen in miR-181a mimic treated 
constructs (Figure 6.6 (C) and and Figure 6.7). This was interesting, given the elevation of 
P62/SQSTM1 identified in the antagomiR treated group, and the reported effect of P62/SQSTM1 
accumulation on stabilising NRF2 levels (Park et al 2015). However, this is still consistent with a 
cellular response to oxidative stress and upregulation of both mitochondrial biogenesis and 
mitophagy in the miR-181a mimic treated group, and suggests that permissive effect of P62/SQSTM1 
on NRF2 levels may be weak and obscured by a more robust direct response associated with 
mitochondrial turnover (Piantadosi et al 2008, Fang et al 2017).  
Despite low sequence homology, COXIV signal was detectable in all biological replicates as two 
bands of approximately 15 and 20 kDa, but was only quantifiable in three of these (Figure 6.6 (H), 
Appendix 6, Figure A6.2). COXIV is an important regulatory subunit of the cytochrome c oxidase 
complex and, whilst located on the inner mitochondrial membrane, is encoded by nuclear DNA (Hao 
et al 2018). Two isoforms of COXIV, COXIV-1 and COXIV-2 have been identified (Hüttemann et al 
2001), but only differ in molecular weight by approximately 1 kDa. Previous work in our group with 
other cell types identified the lower molecular weight band as the region of interest and we used 
this for quantification. Based on this, COXIV demonstrated a significant upregulation in the miR-181a 
mimic treated group (Figure 6.7), consistent with increased mitochondrial biogenesis and optimising 
efficiency of the mitochondrial respiratory chain (Hao et al 2018), supporting the finding of increased 
NRF2 in this group. COXIV undergoes a range of post-translational modifications (acetylation, 
methylation, succinylation, phosphorylation and ubiquitination are all described (Hornbeck et al 
2015)) which may result in detection of unexpected molecular weight products. Alternatively, this 
may be an off-target interaction. 
TOMM20 is a major component of the mitochondrial translocation complex, with a crucial role in 
mitochondrial biogenesis, capable of direct recognition of cytosolic mitochondrial protein precursors 
(Hernández et al 1999). TOMM20 was detected and quantifiable in all samples, but its expression did 
not differ between treatment groups. Encoded by the nuclear genome, the stability of this marker of 
mitochondrial abundance implies a balance in mitochondrial biogenesis irrespective of applied 
treatment (Figure 6.6 (A) and Appendix 6, Figure A6.2).   
232 
 
BNIP3 specifically localises to mitochondria. Under conditions of oxidative stress, BNIP3 expression is 
up regulated by HIF1 and activated by oxidation of an N-terminal cysteine residue (Gustafsson 2011). 
Activation results in depolarisation of the mitochondrial membrane, mediated by the proapoptotic 
BCL2 family members BAX and BAK, and/or opening of the mitochondrial permeability transition 
pore. These mechanisms precipitate apoptosis via cytochrome c and reactive oxygen species (ROS) 
release, with or without caspase activation (Zhang and Ney 2009, Gustafsson 2011). BNIP3 also 
possesses an LC3B-interacting domain, conferring ability to facilitate mitochondrial turnover by 
targeting mitochondria for removal by autophagosomes (Gustafsson 2011). BNIP3 quantification 
was possible in four of the biological replicates, with undetectable signal in the remaining three. 
Similar to NRF2 and COXIV, BNIP3 was significantly up regulated in miR-181a mimic treated 
constructs, indicating an increase in mitophagy and mitochondrial-mediated catabolic pathways in 
this group (Figure 6.6 (D) and Figure 6.7). 
LC3B signal was detected in all samples as two bands at approximately 14 and 16 kDa. This is 
consistent with cleavage of the LC3B precursor molecule by autophagy related 4B cysteine peptidase 
(ATG4B) to form LC3BI (detected at 16 kDa). LC3BI is activated by autophagy-related protein 7 
(ATG7), transferred to autophagy-related protein 3 (ATG3) and conjugated to phospholipid to form 
LC3BII. LC3BII is the form associated with isolation membranes and autophagosomes, and detected 
at 14 kDa (Mizushima and Yoshimori 2007). Failure of transfer of the loading control precluded 
quantification in two of the replicates. Neither LC3BI or II were differentially expressed between 
treatment groups, but the relative proportions of the two forms, as expressed by the LC3BII/I ratio, 
appeared to alter. A higher ratio was found in the miR-181a mimic treated group, but this difference 





Figure 6.6 Representative Western blot images from mmu-miR-181a-5p mimic (M), antagomiR 
(AM) and scrambled control (SC) treated equine tendon constructs. A. TOMM20 predicted 
molecular weight 16 kDa. B. LC3B predicted molecular weights; LC3BI 16 kDa, LC3BII 14 kDa. C. NRF2 
predicted molecular weight 61 kDa. D. BNIP3 predicted molecular weight 22 kDa. E. P62/SQSTM1 
predicted molecular weight 61 kDa. F. Parkin predicted molecular weight 52 kDa. G. LAMP1 
predicted molecular weight 45 kDa. H. COXIV predicted molecular weight 17 kDa. Vinculin used as 
loading control, predicted molecular weight 124 kDa. UT = untreated.  Images acquired using LI-COR 
Odyssey CLx Imaging System at emission wavelengths 700 nm (vinculin) and 800 nm (all other 
targets). P-values calculated using one way ANOVA with Tukey’s multiple comparison test for 









































































































































































































P=0.28 P=0.60 P=0.15 





Figure 6.7 (preceding page) Target protein levels in mmu-miR-181a-5p mimic (M), antagomiR (AM) 
and scrambled control (SC) treated equine tendon constructs from five biological replicates. 
Fluorescent images acquired using LI-COR Odyssey CLx Imaging System at emission wavelengths 700 
nm (vinculin) and 800 nm (all other targets). Expression calculated using densitometric analysis in 
ImageJ 1.52 software (https://imagej.nih.gov/ij/, 1997-2018), normalised to vinculin as loading 
control. P-values calculated using one way ANOVA with Tukey’s multiple comparison test for 
pairwise comparisons. * = P <0.05, ** = P<0.01. 
 
6.3.4 Role of miR-181 in regulation of mitochondrial dynamics  
Next, to evaluate mitochondrial morphology and evidence of autophagy, we evaluated construct 
cellular morphology at the ultrastructural level using TEM. Representative electron micrographs are 
shown in Figure 6.8. Scattered necrotic and apoptotic cells were evident in all samples, but in 
general cells appeared alive with a good nuclear morphology. In scrambled control treated samples, 
some mitochondria were swollen, but most were of normal appearance (Figure 6.9). Swelling of 
mitochondria, with loss of cristae was seen in some antagomiR treated samples, showing a general 
degenerative process, which could potentially lead to cell death (Figure 6.9). In miR-181a mimic 
treated samples there were normal and swollen mitochondria, although number of abnormal 
mitochondria appeared to be greatest in this group. There was also an increased number of 
structures consistent with lysosomes. Some structures identified in the miR-181a mimic treated 
constructs could represent late stage autophagolysosomes containing mitochondria (Figures 6.9 and 
6.10). These data suggest that mir-181a up regulated mitophagy, consistent with data in Chapter 5 
showing changes in mitochondrial turnover in response to miR-181a mimic treatment or inhibition.   
Three types of mitophagy have been described. Types 1 and 2 result in production of 
mitophagosomes, membrane bound vesicles containing degenerate mitochondria, which 
subsequently fuse with lysosomes. Type 3 mitophagy, also termed micromitophagy, results in 
formation of distinctive multivesicular bodies from sequestration of small mitochondrial-derived 
vesicles (Lemasters 2014). Some rare doughnut shaped or ring mitochondria were evident, which 
may be consistent with Type 1 or 2 mitophagy (Figure 6.10). There was no evidence of 
micromitophagy in any of the samples. None of the structures identified were definitive for 
mitophagy, or micromitophagy, but equally, these cannot be ruled out.  These processes can only be 
definitively proven by visualising the early phase where a mitochondrion is surrounded by a 
membrane or a multivesicular body is formed (Lemasters 2014). Myelin figures were also present in 
both miR-181a mimic and antagomiR treated samples, which could be representative for 


























Figure 6.8 Representative transmission electron micrographs of equine tendon construct 
ultrastructure. Black arrowheads indicate fibripositors (untreated control and miR-181a mimic 











Figure 6.9 Representative transmission electron micrographs of mitochondrial morphology of 
equine tendon constructs. N = nucleus, black arrowheads = normal mitochondria, white arrowheads 
= pathological mitochondria demonstrating swollen appearance with loss of cristae. Bar: * = 1 µm, 













Figure 6.10 Transmission electron micrograph of mmu-miR-181a-5p mimic treated sample. Image 
showing higher magnification of mitochondria. Black arrowheads indicate normal mitochondria, 
white arrowheads indicate possible late stage pathological mitochondria, characterised by ring or 
doughnut shape, consistent with the appearance of late stage autophagolysosomes containing 
mitochondria.  
 
6.3.5 Role of miR-181 in regulation of tendon construct structure  
Finally, to assess whether manipulation of miR-181 levels resulted in observable structural 
differences in our constructs, we evaluated TEM images in conjunction with routine histological 
preparations of constructs from all seven biological replicates.  
In TEM images, collagen fibrils were evident in sections from all treatment groups, showing typically 
parallel arrangement and alignment with the long axis of the constructs. Structures consistent with 
the appearance of fibripositors were occasionally identified in sections from untreated control and 
miR-181a mimic treated groups, indicating active collagen fibril deposition in the extracellular matrix 
(Figure 6.8). Despite the lack of observed fibripositors in antagomiR and scrambled treated 
constructs, alignment and arrangement of collagen fibrils indicated that fibril deposition had 
occurred by a similar mechanism to those in the miR-181a mimic and untreated control groups.   
Transverse sections demonstrated constructs were roughly cylindrical in shape, with distinct septae 
dividing regions of more densely staining tissue, reminiscent of tendon fascicular structure. 
Subjectively, miR-181a mimic treated constructs presented a more irregular, disorganised structure 







Figure 6.11 Longitudinal and transverse sections of mmu-miR-181a-5p mimic, antagomiR and 
scrambled control treated equine tendon constructs. Representative images from one donor 
illustrate: top row - mimic treated constructs, middle row – antagomiR treated constructs; bottom 
row scrambled control treated constructs. 10 x magnification, longitudinal sections stained with 





To objectively assess the effects of miR-181a mimic and antagomiR treatment on the histological 
appearance, we employed a novel grading scheme. This scheme evaluated six attributes of the 
constructs, generating a total score between zero and 11. We first confirmed the ability of our 
devised scheme to differentiate between constructs subjectively evaluated as representative of 




Figure 6.12 Differentiation of construct architecture using a novel grading scheme.  A. Total score = 
0 - ‘normal’ tendon structure (H&E 10 x magnification). B. Total score = 10, - ‘abnormal’ tendon 
structure (Masson’s Trichrome 10 x magnification). 
 
 
Elastin von Gieson’s staining was poor, resulting in 16/144 (11%) missing values. Consequently, these 
sections were excluded from further analysis and only haematoxylin and eosin (H&E) and Masson’s 
Trichrome stained sections evaluated. Constructs were graded independently by two operators 
blinded to treatment group. Results of independent gradings and the average of their combined 
scores are given in Figures 6.13, 6.14 and 6.15 respectively. There was no significant difference 
between treatment group scores generated using either total score or assessing each variable 
independently. This applied to analyses from each independent grader’s scoring, or if both grader’s 
scores were averaged. This did not change if results were analysed either by one way ANOVA or 
Kruskal Wallis tests. Comparison of histology of scrambled control treated and untreated constructs 
is given in Appendix 6, Figure A6.3. 
We investigated inter- and intra-rater repeatability of the scoring system using Cohen’s kappa 
coefficient (κ). Intra-rater repeatability showed substantial agreement for total scores, whilst 
individual components of the grading scheme varied widely from agreement equivalent to chance to 
near perfect agreement (Table 6.3). There was a difference between individual components 
depending on staining method used, with cell distribution performing worst in H&E stained sections 






















































































































P = 0.45 P = 0.10 P = 0.99 
P = 0.31 P = 0.37 P = 0.45 
P = 0.67 













































     
 
 
Figure 6.13 (includes preceding page) Tendon construct histological scoring for H&E and Masson’s 
Trichrome stained sections of mmu-miR-181a-5p mimic (M), antagomiR (AM) and scrambled 
control (SC) treated tendon constructs from seven biological replicates. Results show the average 
of two consecutive blinded gradings by the same operator (First grader). P-values obtained using 









P = 0.49 P = 0.55 P = 0.67 






















































































































P = 0.79 P = 0.73 P = 0.51 
P = 0.37 P = 0.56 P = 0.94 
P = 0.73 

















































Figure 6.14 (includes preceding page) Tendon construct histological scoring for H&E and Masson’s 
Trichrome stained sections of mmu-miR-181a-5p mimic (M), antagomiR (AM) and scrambled 
control (SC) treated tendon constructs from seven biological replicates. Results show blinded 
grading by the Second grader. P-values obtained using Kruskal-Wallis test with Dunn’s test for 







P = 0.75 
P = 0.98 

















































































































P = 0.37 P = 0.90 P = 0.78 
P = 0.59 P = 0.59 P = 0.72 
P = 0.43 
















































Figure 6.15 (includes preceding page) Tendon construct histological scoring for H&E and Masson’s 
Trichrome stained sections of mmu-miR-181a-5p mimic (M), antagomiR (AM) and scrambled 
control (SC) treated tendon constructs from seven biological replicates. Results show the average 
of two independent, blinded gradings by two operators (First and Second graders). P-values 
obtained using Kruskal-Wallis test with Dunn’s test for pairwise comparisons. Graphs show median 
and interquartile range.  
  
P = 0.56 
P = 0.86 











ECM Organisation 0.77 0.78 0 = agreement equivalent to chance 
Cell Shape 0.29 -0.04 0.1 - 0.20 = slight agreement 
Cell Distribution -0.07 0.70 0.21 - 0.40 = fair agreement 
Cell Alignment 0.47 0.78 0.41 - 0.60 = moderate agreement 
Cellularity 0.71 0.82 0.61 - 0.80 = substantial agreement 
Collagen Arrangement 0.67 0.73 0.81 - 0.99 = near perfect agreement 
Total Score  0.68 0.64 1 = perfect agreement 
 
Table 6.3 Intra-rater repeatability for tendon construct scoring scheme. Weighted Cohen’s kappa 
coefficients (κ) for both haematoxylin and eosin (H&E) and Masson’s Trichrome stained sections. 
ECM = extra cellular matrix. Interpretation values taken from 
www.statisticshowto.datasciencecentral.com/cohens-kappa-statistic/ 
 
Inter-rater repeatability was poor, particularly with H&E stained sections (Table 6.4). Three variables, 
including total score gave agreement equivalent to that obtained by chance alone. Total score with 
Trichrome stained sections showed only fair agreement, with no individual component returning 









ECM Organisation 0.20 0.51 
Cell Shape 0.20 0.06 
Cell Distribution 0.09 0.03 
Cell Alignment 0.07 0.56 
Cellularity 0.29 0.53 
Collagen Arrangement 0.29 0.51 
Total Score  0.04 0.38 
 
Table 6.4 Inter-rater repeatability for tendon construct scoring scheme. Weighted Cohen’s kappa 
coefficients (κ) for both haematoxylin and eosin (H&E) and Masson’s Trichrome stained sections. 







In this chapter, we have shown  that miR-181 influences autophagy and mitochondrial turnover, as 
supported by the increase in BNIP3, NRF2 and COXIV levels in miR-181a treated constructs, and 
elevated P62/SQSTM1 in antagomiR treated ones. Additionally, investigation of ultrastructural 
changes in our constructs identified evidence of increased mitochondrial degradation with miR-181a 
mimic treatment, although this was not quantified.  
Consistent with results obtained in monolayer culture, comparative expression of miR-181 family 
members indicated miR-181b was most abundant in miR-181a mimic treated constructs. Family 
members a, and c were also consistently increased, but at levels several orders of magnitude lower 
than miR-181b. Variable expression was evident for miR-181d. In four of the biological replicates, 
miR-181d expression in miR-181a mimic treated constructs was below that seen in the scrambled 
control constructs, and in two of these, miR-181d expression was also lower than that of the 
antagomiR treated samples (Figure 6.2). Sequence similarity of miR-181 family members, 
conservation between species and limitations of quantification by RT-qPCR have been previously 
discussed in Chapter 5.  
miR-181a mimic  treatment appears to possess very good stability, evidenced by very high levels of 
miR-181 detected. This presumably results from accumulation of repeated treatments during 
construct maturation, in comparison with levels detected following a single treatment in monolayer 
culture (Chapter 5, Figure 5.3). Additionally, Cy5 fluorescence detection during imaging of Western 
blots was not observed following a single treatment of human tenocytes in monolayer culture 
(Chapter 7, Figure 7.3; Appendix 7, Figure A7.2).  
Similar to the situation in monolayer culture reported in Chapter 5, miR-181a mimic treatment 
consistently resulted in increased (although variably so) total miR-181 expression, whilst antagomiR 
treatment produced less consistent results. Accumulation of active molecules resulting in higher 
than intended cellular concentrations may have resulted in aberrant cellular responses and impacted 
on our results. Treatment concentrations used were those optimised for a single treatment regime 
in monolayer tenocyte culture, based on previous evidence of efficacy in myoblast cultures (Soriano-
Arroquia et al 2016, Goljanek-Whysall et al 2020). In primary mouse astrocytes, a 50 pM 
concentration of miR-181a and b mimic have been shown to result in degenerative mitochondrial 
changes, with 10 pM mimic producing a 16-fold increase in detected miR-181a (Ouyang et al 2012).  
Experimental evidence of alterations in miRNA expression suggest far smaller fold changes are 
associated with significant pathological processes.  
Effective treatment concentrations will depend on the cell type studied. Neural cells typically show 
long population doubling times, with between 144 hours and up to 350 hours reported for rat and 
human astrocytes respectively (Geisert et al 1996, Lundin et al 2018). A relatively static cell 
population will favour stability of intracellular concentration of treatment reagents. Whilst 
population doubling times of approximately 350 hours have been reported in murine tenocytes (Lee 
et al 2018), equine tenocytes proliferate at a much higher rate, with a doubling time of 
approximately 40 hours (Bavin et al 2017), necessitating higher or more frequent treatment dosing 
to compensate for this. Considering the context-dependent effect of miRNAs and the variable and 
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conflicting reports of the consequences of altered miR-181a expression, comparison between cell 
types must be undertaken with caution.  
Further work could assess the efficacy of alternative transfection protocols or the inclusion of a 
greater number of technical replicates, as discussed in Chapter 5, to allow selection of samples with 
more consistent treatment results between biological replicates. Indeed, opposing effects on cell 
viability have been reported in human retinoblastoma, MCF-7 breast cancer and umbilical vein 
endothelial cells following an increase in concentration of miR-181a to which cells were exposed, 
from 50 nM to 80 nM (Yang et al 2017).  Additionally, it would be interesting to determine if there is 
a temporal effect of chronic exposure to altered miR-181 expression by harvesting constructs at 
different time points during maturation, or by exposing mature constructs to a single treatment.   
As previous target network analysis identified miR-181 involvement in insulin and MAPK signalling 
pathways (Chapter 4, section 4.3.2), we included IR, IGF1, IGF1R, and MAPK in our gene expression 
analysis, in addition to those targets investigated in monolayer culture. None of the targets 
investigated demonstrated evidence of differential expression at the transcript level in our three-
dimensional model. Transcript expression level however may not truly reflect functional 
consequences of miRNA up or down regulation if the miRNA does not act as an upstream regulator 
of transcript expression, or influence mRNA degradation. Additional factors that may have impacted 
on the results are the disparity in age and sex of biological donors. Both age and sex influence gene 
expression in native and tissue engineered tendon (Pease et al 2017). We included constructs 
derived from two male (neutered) and five female horses between five and 18 years of age. These 
inconsistencies may have been sufficient to obscure miR-181 induced effects.  
The primary antibodies used in protein detection were not validated for use with equine proteins. 
However, all but COXIV, LAMP1, MFN1 might be expected to work based on sequence conservation. 
COXIV and LAMP1, however, generated useable data, whilst MFN2 failed to generate a detectable 
signal despite theoretical compatibility. The quality of Western blots was variable, limiting the 
number of samples that could be analysed with confidence, and the volume of material available 
precluded further attempts at improving results for protein expression. Results were however, 
generated for eight of the targets investigated. 
A lack of detectable signal may have been expected with MFN1, LAMP1, COXIV and potentially NRF2, 
on the basis of differences of sequence identity between intended target and the equine 
homologues (Table 6.2). However, we achieved some success with LAMP1, COXIV and NRF2, whilst 
MFN2 failed, despite good sequence conservation between species. The lack of detectable signal 
may therefore represent shortcomings in the experimental methods. 
LAMP1, P62/SQSTM1, COXIV and Parkin signal was either poorly expressed or inconsistent (Figure 
6.4 (G), (E), (H) and (F) respectively and Appendix 6, Figure A6.2). For LAMP1 and COXIV, this may 
reflect weak affinity of the primary antibody for the equine protein due to poor sequence homology 
(Table 6.2). For P62/SQSTM1 and Parkin, sequence homology was above 90%, indicating the 
likelihood of cross-reactivity, therefore this may reflect inadequate protein loading or failure of 
electrophoretic transfer. Neither LAMP1 or Parkin demonstrated altered expression between 
treatment groups (Figure 6.6 (G) and (F) respectively and Figure 6.7), although Western blots were of 
poor quality (Appendix 6, Figure A6.2). The lack of significance in PARK2 expression and Parkin level 
is interesting, as, of the proteins assessed in Chapter 5, Parkin demonstrated perhaps the most 
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striking change in accumulation and localisation in response to altered miR-181 activity (Chapter 5, 
section 5.3.3). Significant upregulation of BNIP3 with miR-181a mimic treatment indicated an 
upregulation in programmed cell death pathways. BNIP3 localises to mitochondria when 
overexpressed, where it interacts with the mitochondrial permeability transition pore, causing 
depolarisation and autophagosome formation. BNIP3 induced autophagy has been shown to have a 
protective effect against cell death in ischaemia-reperfusion injury models as well as precipitating 
autophagic cell death either by excessive autophagy, or alternative pathways (Zhang and Ney 2009).    
LC3B is the most widely used marker of autophagy (Mizushima and Yoshimori 2007) and we were 
able to assess expression in five of our biological replicates. Although LC3BII has a higher molecular 
weight than LC3BI, due to its conjugation with phosphatidylethanolamine it migrates faster during 
electrophoresis than LC3BI to generate a signal at approximately 14 kDa. Quantity of LC3BII 
reportedly correlates with number of autophagosomes, but is also degraded by autophagy. LC3BII 
additionally demonstrates a greater degree of immune reactivity than LC3BI. This frequently results 
in a stronger LC3BII signal, without necessarily indicating increased amount of LC3BII. This appears to 
be particularly evident when the antibody is raised against the N-terminus of the peptide. Within-
sample analysis of total LC3B or ratio of LC3BI to LC3BII is therefore controversial as an indicator of 
autophagy. However, between-sample comparison of LC3B signal intensity should be an appropriate 
method of comparing autophagic activity (Mizushima and Yoshimori 2007). Expression of LC3BI and 
II was not significantly different between treatment groups, but LC3BI/LC3BII ratios did appear to 
differ, in a manner consistent with increased autophagy in the miR-181a mimic treated group. 
P62/SQSTM1 is an important component of the autophagic process and expression can be used to 
support LC3B expression data (Mizushima and Yoshimori 2007). P62/SQSTM1is primarily degraded 
through selective autophagy and reduced expression is frequently used as a marker of autophagic 
flux (Sánchez-Martín and Komatsu 2018). However, a protective effect has also been described by 
P62/SQSTM1 mediated inactivation of KEAP1, promoting NRF2 accumulation. This activates the 
cellular stress response, counteracting apoptotic cell death (Komatsu et al 2010, Park et al 2015). 
Interestingly, elevated P62/SQSTM1 associated with increased mitophagy and autophagic flux and 
has been reported with down regulation of miR-181a and b in murine tissue (Indrieri et al 2019). 
Accumulation of P62/SQSTM1 with inhibition of miR-181a has also been reported in C2C12 
myoblasts, and in vivo in murine muscle, associated with impaired autophagy (Goljanek-Whysall et al 
2020). In monolayer equine tenocyte culture, P62/SQSTM1 was indicated as being reduced following 
miR-181 over expression (Chapter 5, Figure 5.3), and a similar, but non-significant change was 
evident in the constructs. Results should be interpreted with caution due to the low number of 
Western blots of sufficient quality for analysis, which may account for the failure to achieve 
significance. 
We identified a significant increase in NRF2 expression with miR-181a mimic treatment, which is 
consistent with a protective cellular response and an increase in mitochondrial turnover, 
maintaining functional mitochondrial mass (Piantadosi et al 2008, Fang et al 2017). Supporting this, 
COXIV expression was also increased in this treatment group. COXIV is the terminal enzyme in the 
respiratory chain located on the inner mitochondrial membrane and encoded by nuclear DNA. In a 
microwave-induced model of oxidative stress in neurones, upregulation of COXIV protected 
mitochondrial function and was associated with mitochondrial regeneration (Hao et al 2018).The 
presence of two COXIV isoforms has been described in yeast, fish, human, rat and mouse, 
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(Hüttemann et al 2001) and their relative expression alters with cellular metabolic activity. We 
detected two distinct bands close to the predicted molecular weight of COXIV, although we cannot 
say that this represents expression of two isoforms in equine cells. The upregulation of COXIV in the 
miR-181a mimic treated group is consistent with an increase in mitochondrial biogenesis, although 
expression of TOMM20 was unchanged, which may have been expected to increase in parallel. 
However, stability of TOMM20 levels demonstrated that mitochondrial mass was maintained in the 
face of increased autophagy. This suggests an overall increase in mitochondrial turnover, consistent 
with maintaining an appropriate balance between mitochondrial regeneration and autophagic 
degradation. The upregulation of COXIV may additionally represent altered relative levels of COXIV 
isoforms with upregulation of miR-181, to optimise COX activity, O2 consumption, and ROS 
generation, with the target of reduced oxidative damage (Hao et al 2018). It would be interesting to 
investigate expression ratios of these isoforms in future work. 
In addition to the variability in quality of Western blots precluding some samples from analysis, we 
did not perform RT-qPCR to assess miR-181 expression in constructs processed for protein 
extraction, to confirm success of treatment uptake.  We assumed an equivalent effect to that 
determined in the constructs processed for gene expression analysis. However, this may have been 
an incorrect assumption and may have resulted in inclusion of constructs in which antagomiR 
treatment had failed using the criteria we applied for gene expression analysis, where only five of 
the seven biological replicates were included.  
We did not further explore the role of miR-181 in regulating mitophagy by using CCCP or 
bafilomycin, to induce mitophagy or inhibit autophagic flux, respectively, in our model. This 
represents a limitation to interpretation of our findings, but could be incorporated in future work. 
Additionally, transfection of tenocytes with a dual fluorophore, pH sensitive, mitochondrial-targeted 
reporter construct could be included to more accurately assess lysosomal turnover of mitochondria 
(Allen et al 2013).  
Analysis of TEM images indicated occasional necrotic and apoptotic cells in all treatment groups, but 
overall there was good cell viability in all constructs from all treatment groups. Narrow diameter 
fibrils arranged in parallel orientated bundles were evident in all constructs examined, consistent 
with the appearance of collagen fibrils (Kapacee et al 2008). Structures resembling fibripositors were 
occasionally seen, but only in untreated control and miR-181a mimic treated sections (Figure 6.10).   
These axially aligned protrusions of plasma membrane represent the sites of collagen fibril 
alignment and deposition and are responsible for orchestrating the parallel alignment and 
organisation of collagen in the extracellular matrix in embryonic tendon (Canty et al 2004). Indeed, 
fibripositors are crucial to initiate collagen fibril deposition in this manner (Kapacee et al 2008). In 
post-embryonic tendon, fibripositors are absent, with continued increase in collagen fibril diameter 
occurring by accretion of extracellular collagen (Canty et al 2004). We only identified occasional 
fibripositors, and then only in miR-181a mimic and untreated constructs (Figure 6.8). This may be a 
stochastic function of the sections examined, as parallelism of collagen fibrils in all sections 
examined would suggest fibripositors had been present in all treatment groups (Kapacee et al 2008). 
Absence of identifiable fibripositors in antagomiR and scrambled treated constructs could represent 
accelerated maturation in these treatment groups, although Kapacee and co-workers (2008) 
reported that they persist for at least 12 weeks post-contraction in fibrin gel tendon constructs. 
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Alternatively, as tension is required for production and function of fibripositors (Kapacee et al 2008), 
static tension may have dissipated to a degree incompatible with their maintenance. 
TEM also permitted further investigation of altered miR-181 levels on mitochondrial dynamics. Some 
swollen mitochondria, with a loss of cristae were seen in scrambled control and antagomiR treated 
samples, indicating degenerative changes (Figure 6.9). Normal and swollen mitochondria were 
evident in miR-181a mimic treated samples, but also increased numbers of structures consistent 
with autophagolysosomes. Autophagy is a highly conserved catabolic process designed to promote 
cell survival under conditions of stress (Dikic and Elazar 2018). Damaged mitochondria release pro-
apoptotic proteins and reactive oxygen species, and three types of selective mitochondrial 
autophagy are described. Type 1 is classically described in response to nutrient deprivation, and is 
suppressed following insulin release. Type 2 is typically initiated in response to mitochondrial 
depolarisation. Type 3 mitophagy is a very selective process for removal of damaged mitochondrial 
components, rather than the whole organelle. All three types can be triggered in response to 
oxidative stress (Lemasters 2014).Types 1 and 2 both involve LC3B and isolation of damaged 
mitochondria into autophagosomes, but by distinct mechanisms. Type 1 progresses by small LC3B-
phospholipid conjugates adjacent to the targeted mitochondria coalescing, to progressively 
surround and envelope it. This process often occurs simultaneously with mitochondrial fission. Once 
isolation is complete, these mitophagosomes fuse with lysosomes, resulting in mitochondrial 
digestion. Type 2 differs in that LC3B is recruited directly to the surface of the damaged 
mitochondria until complete enclosure is achieved, and occurs without evidence of mitochondrial 
fission. Once mitophagosomes have been formed, Types 1 and 2 are morphologically 
indistinguishable. Structures consistent with Type 1 or 2 mitophagy were observed in miR-181a 
mimic treated samples (Figure 6.10). Elevation of BNIP3 levels in miR-181a mimic treated constructs 
would support this finding, as this mitochondrial membrane protein is known to interact with LC3B, 
targeting mitochondria for autophagosomal degradation (Gustafsson 2011).  In Type 3 mitophagy, 
vesicles highly enriched for oxidised proteins bud off from the parent mitochondria. These 
subsequently accumulate into highly characteristic multivesicular bodies prior to lysosomal fusion. 
We did not identify any of these multivesicular bodies in any sections examined. Type 2 mitophagy is 
dependent on phosphatase and tensin homologue-induced putative kinase 1 (PINK1) mediated 
Parkin recruitment. This is also suggested to be essential for Type 3 mitophagy, whereas Type1 
occurs prior to mitochondrial depolarisation in a PINK1-Parkin independent manner (Lemasters 
2014). We did not demonstrate any changes in PARK2 transcript or Parkin protein abundance with 
miR-181 expression.  
Numerous histopathological scoring systems have been used by researchers to evaluate human 
tendinopathy and animal models of induced disease (Lui et al 2011). Scoring systems have been 
devised to quantitatively evaluate histological features of tendon rupture, tendinopathies, 
enthesiopathies and tendon and enthesis repair (Loppini et al 2015). These systems contain 
elements, such as degree of vascularisation, that are not applicable to artificially produced 
constructs in vitro. Indeed, there are no universally recognised grading systems specifically for tissue 
engineered tendon constructs in vitro. It is recommended that scoring systems investigating in vitro 
tissue engineered tendon should evaluate cellularity, collagen type, collagen architecture, 
fibroblasts, inflammatory infiltrate and angiogenesis (Loppini et al 2015). Inflammatory infiltrate and 
angiogenesis however are only applicable to assessing healing response following grafting of in vitro 
engineered tissue into the in vivo environment.  
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For our scoring system we devised a scale, utilising factors described in two well recognised and 
widely applied tendinopathy scoring systems, the Movin and Bonar grading schemes. These scoring 
systems show a high level of correlation, producing comparable assessment of similar characteristics 
in tendon tissue (Maffulli et al 2008). The Bonar score has four categories, and the Movin score is 
more detailed, with eight. One category in each score is dedicated to cellular morphology, one to 
vascularity and the remainder to extra cellular matrix (ECM) characteristics. Both utilise a four-point 
scale within each category with zero representing normal and four markedly abnormal. Our scheme 
had six categories, two assessing ECM qualities and four tenocyte morphology and distribution. The 
final grading scheme was biased to cellular characteristics based on the findings of Cook and co-
workers (2004) and Doroski and colleagues (2007). The former authors report that morphological 
changes in tenocytes are more prevalent than ECM changes in asymptomatic tendinopathy.  Doroski 
et al (2007) recommend that success of tendon tissue-engineering techniques should consider 
viability and proliferation of cells in the construct, in addition to amount and type of ECM production 
and spatial organisation. We utilised staining protocols commonly employed for assessment of 
tendon integrity; haematoxylin and eosin (H&E) for cellularity and collagen degeneration, Masson’s 
trichrome and von Gieson’s stains for collagen and other matrix proteins (Loppini et al 2015). 
Initial application of the scoring scheme indicated it could differentiate between constructs 
subjectively described as well-organised tendon-like tissue and those with abnormal, irregular 
architecture (Figure 6.7). Subjectively, miR-181a mimic treated constructs appeared to exhibit a 
more disorganised structure, but this was not confirmed by our grading scheme where wider 
application failed to detect a significant difference between constructs from different treatment 
groups. This may reflect a true finding, that miR-181 treatments did not influence outcome, or reveal 
a lack of sensitivity at identifying more subtle differences. There was considerable variability 
between constructs within each treatment group, which may account for lack of significant 
difference between them. Additionally, whole constructs were processed for histology, therefore, as 
with the analysis of protein expression, we did not evaluate miR-181 levels in these samples. We 
assumed miR-181a mimic treatment would be universally successful, as shown with RT-qPCR 
analysis for those constructs used in gene expression analysis. However, we have previously 
identified inconsistent results with either success of the antagomiR treatment, or the ability to 
identify its success, both in monolayer culture (Chapter 5, section 5.3.2) and three-dimensional 
constructs (section 6.3.1). This represents a limitation to interpretation of data from the antagomiR 
treated group.   
A grading system should be easily applicable, sensitive and repeatable, generating consistent data 
whether used repeatedly by one individual, or by several individuals (Maffulli et al 2008, McHugh 
2012). Staining technique influenced scoring, and assessment of inter-rater repeatability indicates 
the scheme requires refinement. The schemes on which ours was based were devised for use in 
native tendon, the Movin score for Achilles tendon, the Bonar for patellar tendon (Maffulli et al 
2008). Both schemes use semi quantitative assessment descriptors, which we adapted in our 
descriptors. This introduces a subjective element to assessment. Inclusion of more precisely defined 
quantitative elements, such as used in the modified Watkins score for tendon repair (Ide et al 2009), 
may improve discriminative power. We were unable to demonstrate a difference in tendon 
construct architecture between treatment groups using our scheme and this requires further 
development. There remains a need for a scoring system to accurately describe tendon construct 
structure in vitro. 
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Our data suggest that lysosomal activity and mitochondrial turnover is greater in miR-181a mimic 
treated tendon constructs. We observed differences in cellularity and organisation and structure of 
the extracellular matrix of constructs, but the grading scheme we employed did not demonstrate 
these were significantly different between treatments. The modified scheme we employed requires 
refinement to increase its sensitivity and reproducibility. Identification of similarities and differences 




Chapter 7 - Validation of miR-181 function in human tenocytes 
 
7.1 Introduction 
The reduction in miR-181 expression in both human and equine clinical tendinopathy identified in 
Chapter 3 suggests this family of microRNAs are important regulators of tenocyte biochemical 
function in both species. Mitochondrial dynamics and function (Indrieri et al 2019, Goljanek-Whysall 
et al 2020) and autophagy (Liu et al 2017), key factors in maintaining cell viability and function, are 
known to be regulated by miR-181. Gain and loss of function studies are thus critical to the 
assessment of miR-181 dysregulation on tenocyte function and we have demonstrated success in 
employing these techniques in equine tenocytes in both monolayer culture (Chapter 5) and three-
dimensional tissue engineered tendon constructs (Chapter 6).  
Human tendon is a difficult tissue to study as healthy tissue is challenging to obtain, whilst 
pathological tissue is usually only available once disease is well advanced, and often following 
unsuccessful conservative or medical interventions.  Equine tendon has been described as a good 
model for investigation of biomechanical function and pathological processes in human tendon 
(Dudhia et al 2007, Innes and Clegg 2010, Lui et al 2011, Thorpe et al 2014). To support this, authors 
quote the similarities in mechanical function between equine and human energy storing tendons, 
longevity and athletic function of both species, and their predisposition to naturally occurring age 
and overuse related disease. For equine tendon to be truly considered a robust model, it is 
important to elucidate if there are similarities in the biochemical pathways disrupted during disease, 
as only then can research utilising this more readily available tissue be considered truly translational 
to the human field. Alteration in intracellular distribution of LC3B, DJ-1, P62/SQSTM1 and Parkin 
with gain and loss of miR-181 function in equine monolayer culture implicated miR-181 activity as 
influencing autophagy and mitochondrial dynamics (Chapter 5, section 5.3.3). This effect was 
reinforced by changes in levels of autophagy and mitochondrial related proteins P62/SQSTM1, NRF2, 
COXIV and BNIP3 in response to altered miR-181 activity. Additionally, we have shown 
ultrastructural evidence of up regulated mitophagy with increased miR-181 activity in three-
dimensional tissue engineered constructs (Chapter 6, Figures 6.7 and 6.9). We were interested, 
therefore, in determining whether these changes were reproduceable in human tenocytes cultured 
under similar conditions. 
Mitochondria are dynamic organelles both in terms of absolute intracellular mass and morphology. 
Mitochondrial content reflects the bioenergetic requirements of the cell, whilst morphology is 
controlled by fission and fusion, processes fundamental to maintaining mitochondrial integrity 
(Karbowski and Youle 2003, Palikaras et al 2018). In addition to ATP generation, mitochondria are 
also critical participants in cell cycle control, inflammation, calcium signalling and calcium induced 
apoptosis and redox signalling (Archer 2013).  
Selective autophagic clearance of mitochondria (mitophagy) occurs at a basal rate dictated by 
specific tissue requirements to maintain mitochondrial quality, and is up regulated under conditions 
of cellular stress, independent of bulk (non-selective) autophagy (Palikaras et al 2018). Additionally, 
mitochondrial clearance has been described in several cell types as a natural component of tissue 
development, reflecting a change from oxidative phosphorylation to glycolysis (Palikaras et al 2018). 
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Tenocytes switch from predominantly oxidative phosphorylation to anaerobic glycolysis during 
maturation of tendon, with reversal of this process during injury and repair (Birch et al 1997, 
Thankam et al 2018). Thus, appropriate control of tenocyte mitochondrial content and function may 
form a critical aspect of tendon homeostasis, adaptation and response to injury.  
Impairment of mitophagy results in progressive accumulation of defective mitochondria, decline in 
cellular function and tissue damage (Palikaras et al 2018) and is associated with age related 
deterioration in skeletal muscle mass and function (Goljanek-Whysall et al 2020), neurodegenerative 
diseases (Chen et al 2019), proliferative, apoptosis resistant diseases (Archer 2013) and 
cardiomyopathies (Palikaras et al 2018). Increased mass of mitochondria coupled with a reduction in 
their functional competence is also a feature of the senescent phenotype in fibroblasts (Passos et al 
2010). Dysfunctional mitochondria generate higher levels of reactive oxygen species (ROS) which can 
trigger development of the senescence-associated secretory phenotype (Chapman et al 2019). In 
chondrocytes, elevated ROS production is associated with increased production of matrix 
metalloproteinases 1 and 3, indicating a role in enhanced matrix degradation (Reed et al 2014). 
Superoxide anion (O2-) radicals, the most prominent ROS produced by electron leak from the 
electron transport chain, are capable of non-enzymatic degradation of Type I collagen (Monboisse et 
al 1983). 
The emerging role of miR-181 in influencing mitochondrial dynamics was introduced in Chapter 5. 
Downregulation of miR-181a in skeletal muscle reduced mitophagy and resulted in accumulation of 
abnormal mitochondria (Goljanek-Whysall et al 2020). Overexpression of miR-181a and b stimulated 
mitochondrial metabolism in human chondrocytes (Zheng et al 2019).  In astrocytes, miR-181a 
downregulation was protective of mitochondrial membrane potential and reduced production of 
ROS (Ouyang et al 2012), whilst deletion of miR-181a and b in neuronal cells increased expression of 
PPARGC1A and mitochondrial DNA, indicating a role in mitochondrial biogenesis (Indrieri et al 2019). 
In murine cardiac myocytes, deletion of miR-181c and d increased COXIV levels (Das et al 2017).   
In this chapter, we have extended our investigation of altered miR-181 activity on levels and 
distribution of mitochondrial and autophagy related proteins seen in equine primary tenocytes, to 
human primary tenocytes. We have demonstrated successful delivery of miR-181a mimic and 
antagomiR treatments to human tenocytes, confirmed by visualisation of intracellular fluorescence 
from tagged mimic and antagomiR reagents and reinforced by RT-qPCR. Focussing on mitochondrial 
and autophagy related genes P62/SQSTM1, PARK2, COXI, COXIV, LC3B, TOMM20 and IR, we have 
additionally demonstrated that, as with equine tenocytes, transcript levels are not affected by miR-
181a activity, but miR-181 appears to act through regulation of translation and localisation of 
autophagy related proteins. Consequently, we believe this work supports the hypothesis that equine 
tenocytes can serve as an acceptable model for investigation of the effects of pathological processes 







7.2.1 Treatment of tenocyte cultures 
Primary human tenocytes from three donors (Table 7.1) were propagated for 24 hours prior to 
treatment with cholesterol-conjugated Cy5-tagged mmu-miR-181a-5p mimic, FITC-tagged 23 
nucleotide (nt) single strand RNA antagomiR, or 21 nt single strand RNA scrambled control 
sequence. Final treatment concentrations were 100 nM (mimic and scrambled control) and 200 nM 
(antagomiR). Live cell imaging to confirm uptake of fluorescence was performed using a Nikon 
Eclipse Ti-E fluorescent microscope. Forty-eight hours after treatment, cells were lysed for either 
RNA or protein extraction. 
 
Sample ID Sex Age (years) Ethnicity Passage number 
LMB-JL-280 Male 18 Chinese 2 
LMB-SF-282 Female 26 White British 3 
LMB-RL-286 Male 24 White British 3 
 
Table 7.1 Donor and tenocyte passage details for human semitendinosus and gracilis tendon-
derived tenocytes cultured for mmu-miR-181a-5p mimic, antagomiR and scrambled control 
treatment studies. 
 
7.2.2 Reverse transcription quantitative real-time polymerase chain reaction  
Total RNA extraction was followed by reverse transcription to cDNA, for which 50 ng RNA template 
was used for both gene and miRNA expression analyses.  
Expression of miR-181a/b/c/d was determined using commercially available primers (Qiagen, 
Manchester, UK; Chapter 2, section 2.12.1, Table 2.10) and normalised to SNORD61 as internal 
control (previously validated for this purpose as a stable small non-coding RNA in equine tenocytes 
(Chapter 3, section 3.2.3; Appendix 2, Table A2.1 and Chapter 5, section 5.2.2; Appendix 5, Table 
A5.1) and confirmed in human tenocytes (Appendix 7, Table A7.1)). Relative expression values were 
then summed to give total miR-181 expression for each sample.  
Primers were designed for three validated miR-181 targets (P62/SQSTM1, PARK2/Parkin and COXI) 
and a further four genes (LC3B, TOMM20, IR and COXIV). Target gene expression was normalised to 
that of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH; previously 
demonstrated to exhibit acceptable stability for this purpose in equine tenocytes (Chapter 5, section 
5.2.2; Appendix 5, Table A5.2) and confirmed in human tenocytes (Appendix 7, Table A7.2)).  
Primer sequences and RT-qPCR details are listed in Chapter 2, sections 2.12.1 (Table 2.14), 2.12.2 
(Figure 2.2) and 2.12.3 (Figure 2.3) respectively. For all RT-qPCR data, technical replicates were run in 
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triplicate and expression relative to SNORD61 or GAPDH calculated using the delta Ct method (Livak 
and Schmittgen 2001). For graphical representation, transcript expression was normalised to that of 
the scrambled control treatment group.  
 
7.2.3 Protein levels 
Protein extraction was performed on cultures from all three biological replicates. Following protein 
extraction and quantification (Chapter 2, sections 2.13.2 and 2.13.3), sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) was performed, initially using 5 µg protein in 15 µL 
loading volume. If this generated blots of inadequate quality for analytical purposes, protein loading 
was increased up to a maximum of 20 µg protein in 60 µL loading volume. Semi-dry transfer to 
polyvinylidene fluoride (PVDF) membrane was confirmed using Ponceau staining prior to 
immunofluorescent evaluation of target proteins TOMM20, LC3B, P62/SQSTM1, COXIV and Parkin. 
Vinculin was used as loading control for normalisation. Images were acquired using the LI-COR 
Odyssey CLx Imaging System at emission wavelengths of 700 nm and 800 nm. Details of protocols 
and antibodies are given in Chapter 2, sections 2.14 and 2.15.  
Semi-quantitative analysis of protein expression was performed by band densitometry using ImageJ 
1.52 software (Rasband, W.S. U. S. National Institutes of Health, Bethesda, Maryland, USA, 
https://imagej.nih.gov/ij/, 1997-2018). Target protein band densities were measured and 
normalised to band intensity of corresponding vinculin loading control. Graphical representation of 
relative expression between groups is given in Figure 7.3. 
 
7.2.4 Induction of mitophagy and immunocytochemistry  
For immunocytochemistry, tenocytes were exposed to the oxidative phosphorylation uncoupling 
agent carbonyl cyanide m-chlorophenylhydrazone (CCCP) for six hours, at a concentration of 20 µM, 
dissolved in dimethyl sulfoxide (DMSO), or DMSO alone, 24 hours after miR-181a mimic, antagomiR 
or scrambled control treatment. Tenocytes were then fixed in ice cold methanol and immunostained 
for mitochondrial and autophagy markers as described in Chapter 2, section 2.7. Images were 
obtained using a Zeiss Axio Imager M2 fluorescent microscope with Zeiss ZEN Imaging software (blue 
edition 3.1).  
 
7.2.5 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.01 for Windows (GraphPad 
Software, San Diego, California, USA, www.graphpad.com). Gene expression data were analysed 
non-parametrically using the Kruskal Wallis test with Dunn’s test for pairwise comparisons, to 
include miR-181a mimic, antagomiR and scrambled control sequence treated groups. Comparisons 
between scrambled control sequence treated and untreated groups utilised the Mann-Whitney test 
and are presented in Appendix 7, Figure A7.1. Significance was assumed if P<0.05. 
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Protein levels derived from Western blot images were analysed using one way ANOVA with Tukey’s 
multiple comparison test for pair-wise comparisons. Analysis was performed between miR-181a 
mimic, antagomiR and scrambled control sequence treated groups. Comparisons between 
scrambled control sequence treated and untreated groups utilised the Student-t test and are 
presented in Appendix 7, Figure A7.3. Significance was assumed if P<0.05. 




7.3.1 Validation of miR-181a-5p overexpression and inhibition in tenocytes 
Human tenocytes from three donors (Table 7.1) were treated with mmu-miR-181a-5p mimic, 
antagomiR and scrambled control sequence oligonucleotides. Sequence homology between murine 
and human orthologues/paralogues of miR-181 family members was previously confirmed, and 
reported in Chapter 5 (Table 5.3), validating our use of treatments based on murine sequence data 
and human sequence-directed primers. Data were analysed based on relative total miR-181 
expression as determined by RT-qPCR, normalised to SNORD61.  
Based on RT-qPCR evaluation, all miR-181a mimic treated cultures demonstrated substantially 
increased total miR-181 levels, with levels in one of the replicates approximately fourteen times that 
of the other two (Figure 7.1). Similar to the situation in equine tenocytes, miR-181b was identified as 
responsible for the greatest proportion (87-92%) of the increase in total miR-181 levels (Figure 7.1). 
Total miR-181 levels were much lower in all other treatment groups by comparison, and more 
equivalent between all three biological replicates (Figure 7.1).  The same pattern of expression, with 
total miR-181 levels in antagomiR treated cultures higher than those detected in the scrambled 
control treated group, but lower than that in the untreated control groups was also common to all 
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Figure 7.1 microRNA-181 expression in mmu-miR-181a-5p mimic (M), antagomiR (AM) and 
scrambled control (SC) treated human primary tenocyte monolayer culture in three biological 
replicates. Values represent relative expression, normalised to SNORD61, for all four miR-181 family 
members and total miR-181. UT = untreated control. Relative expression values are given in the 
table below graph. 
Mimic AntagomiR Scrambled Untreated Mimic AntagomiR Scrambled Untreated Mimic AntagomiR Scrambled Untreated
miR-181a 0.403 0.006 0.002 0.002 0.247 0.004 0.003 0.017 6.840 0.018 0.005 0.029
miR-181b 8.920 0.057 0.027 0.060 9.586 0.065 0.039 0.180 130.397 0.081 0.072 0.108
miR-181c 0.587 0.008 0.001 0.003 0.364 0.003 0.004 0.011 7.809 0.008 0.004 0.011
miR-181d 0.342 0.222 0.159 0.277 0.184 0.373 0.221 0.704 0.720 0.406 0.391 0.693




7.3.2 miR-181a target gene analysis  
Following determination of treatment effect, expression of seven selected genes (COXI, COXIV, 
TOMM20, PARK2, P62/SQSTM1, LC3B and IR) was investigated in all three biological replicates. Data 
were analysed using the non-parametric Kruskal-Wallis test with Dunn’s test for pairwise 
comparisons, significance was assumed if P<0.05. Comparisons between mimic, antagomiR and 
scrambled control sequence treated groups are presented in Figure 7.2. Comparisons between 
scrambled control sequence treated and untreated cultures are presented in Appendix 7, Figure 
A7.1. Similar to our results following miR-181 gain and loss of function equine tenocyte, we detected 
no difference in transcript expression between treatment groups for any of the targets investigated 


















































































































































   
 
























Figure 7.2 The effects of miR-181a overexpression and inhibition on expression of selected target 
genes in human tenocytes from three biological replicates. Y–axis values represent expression 
relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), normalised to scrambled control 
treatment group. M = miR-181a-5p mimic, AM = antagomiR, SC = scrambled control. P-values 
calculated from delta Ct values, using Kruskal-Wallis test with Dunn’s test for pairwise comparisons. 
Graphs show median and interquartile range. 
P = 0.72 P = 0.48 P = 0.72 
P = 0.06 P = 0.83 P = 0.83 
P = 0.66 
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7.3.3 Protein expression (Western blotting) 
As miR-181 levels did not appear to influence target gene transcript stability, we next investigated 
the effect of miR-181 function on protein translation.  Levels of the protein product of five of the 
previously selected genes (TOMM20, P62/SQSTM1, LC3B, COXIV and PARK2) were investigated by 
SDS-PAGE and Western blotting. Protein extracts from mmu-miR-181a-5p mimic, antagomiR and 
scrambled control treated tenocytes were probed using primary antibodies directed against the 
proteins TOMM20, P62/SQSTM1, LC3B, COXIV and Parkin, with vinculin used as loading control for 
normalisation. 
Images of sufficient quality for semi-quantitative analysis of protein levels were obtained for all 
samples using 5 µg protein per well for COXIV, 15 µg protein per well for P62/SQSTM1 and 20 µg 
protein per well for TOMM20 and LC3B. No signal was detected in any of the samples for Parkin 
using 5, 10 or 20 µg of protein per well. Parkin was therefore unquantifiable. Representative images 
are shown in Figure 7.3; all images are shown in Appendix 7, Figure A7.2. 
LC3B signal was detected in all samples as two bands at approximately 14 and 16 kDa. Signal at the 
16 kDa level, consistent with identification of the soluble, unconjugated form LC3BI (Mizushima and 
Yoshimori 2007), was prominent and did not differ between treatment groups (Figure 7.3 (A)). The 
signal generated at 14 kDa, consistent with the phospholipid conjugated form LC3BII (Mizushima and 
Yoshimori 2007), was distinct but much weaker (Figure 7.3 (A)). Significantly (P<0.001) lower levels 
of LC3BII were detected in miR-181a mimic treated tenocytes than in other treatment groups (Figure 
7.3 (A)). No difference in LC3BII levels was evident between antagomiR and scrambled control 
treatments. Consequently, the LC3BII/LC3BI ratio was significantly (P=0.002) lower in miR-181a 
mimic treated, versus comparator groups (Figure 7.3 (A)). LC3BII is considered to be a standard 
marker for autophagosomes, but is itself degraded by the process of autophagy (Runwal et al 2019). 
Reduced levels are therefore consistent with enhanced autophagic activity or reduced 
autophagosome formation. The similarity of LC3BI levels between treatment groups would tend to 
support the latter scenario, as classically, during increased autophagic activity LC3BI levels decrease, 
with a concomitant increase in LC3BII, with prolonged periods of enhanced autophagy resulting in 
reduced levels of both forms (Mizushima and Yoshimori 2007). 
The outer mitochondrial membrane transport complex component TOMM20 showed significantly 
(P=0.002) lower levels in the miR-181a mimic treated group than the scrambled control, but not 
antagomiR treated tenocytes (Figure 7.3 (B)). AntagomiR treatment resulted in TOMM20 levels 
intermediate between those following miR-181a mimic and scrambled control treatments, but was 
not statistically significantly different from either (Figure 7.3 (B)). This nuclear genome-encoded 
protein is frequently used as, and considered a reliable marker of, mitochondrial mass (Song et al 
2018, Buso et al 2019). Reduced levels in the miR-181a mimic treated group indicated an imbalance 
between mitophagy and mitochondrial biogenesis. This suggest that, consistent with the reduction 
in LC3BII levels, TOMM20 is degraded by increased miR-181 activity due to enhanced autophagic 
clearance of mitochondria.  
No significant differences between groups were detected for levels of autophagy receptor protein 
P62/SQSTM1, or cytochrome c oxidase regulatory subunit COXIV, (Figure 7.3 (C) and 7.3 (D) 
respectively). Whilst P62/SQSTM1 has been described as essential for Parkin-mediated mitophagy 
(Youle and Narendra 2010), it also promotes aggregation of ubiquitinated mitochondria targeted for 
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degradation independent of mitophagy (Narendra et al 2010). This may explain the lack of difference 
in P62/SQSTM1 levels between treatment groups in the face of evidence compatible with increased 
mitophagy outlined above.  
Similar to the situation in equine tenocytes, two distinct bands were consistently detected for COXIV 
at approximately 15 and 20 kDa (Appendix 7, Figure A7.2D). As stated in Chapter 6 (section 6.3.3), 
two isoforms of COXIV are described (Hüttemann et al 2001), but these differ in molecular weight 
only by approximately 1 kDa. We postulated this could be due to an off target interaction in equine 
tenocytes, but the presence of a similar phenomenon in human cells where these antibodies have 
validated activity, suggests this most likely represents post-translational modification of this nuclear 
encoded protein (Hornbeck et al 2015). We determined quantification using the lower (15 kDa) 
band, consistent with our applied methodology in equine tenocytes (Chapter 6, section 6.3.3). 
Similar levels detected in all treatment groups suggests occurrence of equivalent mitochondrial 

















































































































































Figure 7.3 (includes preceding page) Representative Western blot images and target protein levels 
in mmu-miR-181a-5p mimic (M), antagomiR (AM) and scrambled control (SC) treated human 
tenocytes from three biological replicates. A. LC3B predicted molecular weights; LC3BI 16 kDa, 
LC3BII 14 kDa. B. TOMM20 predicted molecular weight 16 kDa. C. P62/SQSTM1 predicted molecular 
weight 61 kDa. D. COXIV predicted molecular weight 17 kDa. Vinculin used as loading control, 
predicted molecular weight 124 kDa. UT = untreated.  Images acquired using LI-COR Odyssey CLx 
Imaging System at emission wavelengths 700 nm (vinculin) and 800 nm (all other targets). See 
Appendix 7, Figure A7.2 for all images. Protein levels calculated using densitometric analysis in 
ImageJ 1.52 software (https://imagej.nih.gov/ij/, 1997-2018), normalised to vinculin as loading 
control. P-values calculated using one way ANOVA with Tukey’s multiple comparison test for 






7.3.4 Role of miR-181 in regulation of mitochondrial dynamics 
To further investigate the effects of miR-181 on mitochondrial dynamics and autophagy-associated 
proteins, mitophagy was induced in mmu-miR-181a-5p mimic, antagomiR and scrambled control 
treated tenocytes. As conducted in equine tenocyte culture (Chapter 5, section 5.3.3), treated 
human tenocytes were incubated for six hours with a 20 µM solution of the oxidative 
phosphorylation uncoupling agent carbonyl cyanide m-chlorophenylhydrazone (CCCP) dissolved in 
DMSO, or DMSO alone, as control (Kagan et al 2016, Webb et al 2017). We confirmed uptake of 
mimic and antagomiR treatments by fluorescence imaging of live cell cultures immediately prior to 
cells being fixed, permeabilised and processed for immunostaining (Figure 7.4). No-primary-antibody 
controls were performed and confirmed no residual, detectable fluorescence from miR-181a mimic 
or antagomiR treatments (Figure 7.5). Additionally, neither background signal, nor non-specific 
binding of secondary fluorophore-conjugated antibody were evident (Figure 7.5). Consistent with 
the situation in equine tenocytes, fluorescence associated with Cy5 and FITC labelling of miR-181 




Figure 7.4 Successful transfection of mmu-miR-181a-5p mimic and antagomiR into primary human 
tenocytes. Live cell images of transfection reagent uptake 48 hours after treatment and immediately 
prior to processing for immunocytochemistry. A. Fluorescein labelled single strand RNA-23 





Figure 7.5 Fluorophore-conjugated secondary anti-mouse and anti-rabbit antibodies do not 
generate a signal following incubation with human tenocytes in absence of primary antibody.  
Tenocytes incubated for six hours with DMSO prior to fixing, permeabilisation and incubation for 
one hour with: A-C Alexa FluorTM 488-conjugated goat anti-rabbit antibody, D-F Alexa Fluor 594-
conjugated goat anti-mouse antibody. Images obtained at 593 nm (A and D), 510 nm (B and E), 447 





The regulation of autophagy and mitochondrial turnover was then established by immunostaining 
for the proteins TOMM20, DJ-1, LC3B, P62/SQSTM1 and Parkin, as previously investigated in equine 
tenocytes (Chapter 5, section 5.3.3). 
LC3B positive punctae are frequently regarded as specific markers of autophagosomes, representing 
the phosphatidylethanolamine conjugated form (LC3BII) specific to autophagosomal membranes 
(Runwal et al 2019).  Occurrence of LC3B positive punctae has also been described when 
autophagosome formation is inhibited, representing LC3BI localisation to P62/SQSTM1 aggregates 
which accumulate secondarily to autophagy impairment (Runwal et al 2019).  
In DMSO treated controls, mitochondrial networks were present in all treatment groups. LC3B 
positive punctae were evident in all treatment groups, distributed throughout the cells, however, 
miR-181a mimic treated cells showed considerably fewer punctate structures than either antagomiR 
or scrambled control treated cells. AntagomiR and scrambled treated groups showed a similar 
abundance of LC3B positive punctae, but overall these appeared to be larger and more prominent in 
the antagomiR treated group (Figure 7.6).  
Exposure to CCCP induced mitochondrial network fragmentation in tenocytes from all treatment 
groups, as demonstrated by punctate TOMM20 staining pattern, indicating CCCP treatment had 
been successful (Figure 7.6). Markedly, increased numbers of LC3B positive punctae were apparent 
in both miR-181a mimic and scrambled control treated groups, whilst number appeared reduced or 
unchanged in the antagomiR treated group, in comparison with DMSO controls (Figure 7.6). Increase 
in LC3B positive punctae with CCCP treatment in mimic and scrambled groups is consistent with an 
increase in LC3BII positive autophagosome formation, or impaired degradation, or representative of 
LC3BI aggregations associated with ubiquitin and P62/SQSTM1 under autophagy deficient conditions 
(Runwal et al 2019). The relative lack of alteration in LC3B positive punctae number and distribution 
between CCCP treated tenocytes and DMSO controls in the antagomiR treated group suggests that 
inhibition of miR-181 activity prevents recruitment of autophagosomal membranes to dysfunctional 
mitochondria. Whereas immunoblotting can differentiate between LC3BI and LC3BII on the basis of 
different molecular weights and migration speeds in SDS-PAGE separation, fluorescent signal 
acquired during immunocytological imaging does not make this distinction. When considered in 
conjunction with the protein quantification results based on Western blot analysis above (Figure 
7.3), these results suggest that miR-181 mimic treated cells are recruiting and degrading LC3BII 
appropriately, indicating progression of mitophagy, whilst in antagomiR treated tenocytes, the 










Figure 7.6 Immunofluorescence images of miR-181a-5p mimic, antagomiR and scrambled control 
treated human tenocytes subjected to six hours of CCCP/DMSO exposure. TOMM20 = Translocase 
of outer mitochondrial membrane 20, LC3B = Microtubule-associated proteins 1A/1B light chain 3B, 
DAPI = 4′,6-diamidino-2-phenylindole, CCCP = carbonyl cyanide m-chlorophenylhydrazone, DMSO = 
dimethyl sulfoxide. Images 63 x magnification, oil immersion lens, bar =  50 µm.   
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We next investigated localisation of protein DJ-1, reported to localise to mitochondrial complex I 
under basal conditions, an effect which is rapidly enhanced under conditions of oxidative stress. 
Under these conditions it exerts a protective effect, becoming oxidised to maintain mitochondrial 
function (Hayashi et al 2009).  
In DMSO controls, TOMM20 staining indicated mitochondrial networks were present, with staining 
more prominent in the antagomiR treated group. CCCP treatment resulted in mitochondrial 
disruption, as evidenced by more punctate appearance of TOMM20 staining in all treatment groups 
(Figure 7.7).   
DMSO controls showed weak and diffuse DJ-1 staining in both miR-181a mimic and scrambled 
control treated cells. AntagomiR treatment resulted in greater accumulation of DJ-1 with some DJ-1 
positive punctae present, suggesting DJ-1 recruitment to mitochondria (Figure 7.7). This is 
compatible with the observed stronger TOMM20 signal in this treatment group, suggesting 
preservation of mitochondrial function in these cells (McCoy and Cookson 2010). 
In tenocytes incubated with CCCP, the effect of antagomiR treatment appeared to be lost, as we 
observed no difference in DJ-1 expression or distribution between treatment groups; miR-181a 
mimic, antagomiR and scrambled control treated groups all demonstrated diffuse staining without 
localisation to mitochondria (Figure 7.7).  
These data suggest miR-181 activity may regulate DJ-1 recruitment (seen in DMSO controls), but the 
effect is weak in the face of widespread mitochondrial dysfunction, as this was not evident following 






Figure 7.7 Immunofluorescence images of miR-181a-5p mimic, antagomiR and scrambled control 
treated human tenocytes subjected to six hours of CCCP/DMSO exposure. TOMM20 = Translocase 
of outer mitochondrial membrane 20, DJ-1 = Protein deglycase DJ-1 (PARK7), DAPI = 4′,6-diamidino-
2-phenylindole, CCCP = carbonyl cyanide m-chlorophenylhydrazone, DMSO = dimethyl sulfoxide. 
Images 63 x magnification, oil immersion lens, bar = 50 µm.  
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The autophagy receptor protein P62/SQSTM1 regulates formation of protein aggregates targeted for 
selective degradation through interactions with both ubiquitin and LC3B (Komatsu et al 2007). 
Similarly to LC3B, P62/SQSTM1 is also degraded during autophagy and levels can accumulate if 
autophagy is disrupted. However, P62/SQSTM1 accumulation can also exert a protective effect 
against oxidative damage by induction of the NRF2 pathway (Sánchez-Martín and Komatsu 2018), 
and P62/SQSTM1 has been reported to prevent CCCP-induced apoptosis (Park et al 2015).  
In DMSO controls, TOMM20 staining indicated that mitochondrial networks were preserved (Figure 
7.8). P62/SQSTM1 positive structures were more aggregated around the nuclei in the antagomiR 
treated group than others, in regions of more intense perinuclear TOMM20 staining, potentially 
indicative of appropriate recruitment to dysfunctional, perinuclear mitochondria, or an 
inappropriate accumulation due to impaired functional progression of mitophagy. Scrambled 
treatment showed less distinct perinuclear aggregation with a more even distribution of 
P62/SQSTM1 punctae. An intermediate pattern was demonstrated in miR-181a mimic treated 
tenocytes, with less distinct perinuclear localisation than antagomiR treated cells and punctae 
dispersed throughout the cell cytoplasm (Figure 7.8). 
In CCCP/miR-181a mimic treated tenocytes, TOMM20 staining was punctated, with punctae 
distributed throughout the cytoplasm. Overall, TOMM20 staining was reduced in the miR-181a 
mimic treated group compared with the antagomiR and scrambled control groups (Figure 7.8). 
AntagomiR treated tenocytes showed a similarly punctate pattern of TOMM20 positive structures, 
but with a more distinct perinuclear distribution, whilst scrambled treatment showed more diffuse 
TOMM20 staining, with some suggestion of maintained mitochondrial networks.  
P62/SQSTM1 positive aggregates were condensed in a perinuclear distribution pattern in the 
antagomiR and scrambled treated groups, both of which showed some degree of co-localisation with 
regions of more intense TOMM20 positive staining, this being more convincing in the scrambled 
treated group (Figure 7.8). There was a far looser perinuclear association of P62/SQSTM1 punctae 
demonstrated in miR-181a mimic treated cells, with punctae more widely dispersed throughout the 






Figure 7.8 Immunofluorescence images of miR-181a-5p mimic, antagomiR and scrambled control 
treated human tenocytes subjected to six hours of CCCP/DMSO exposure. TOMM20 = Translocase 
of outer mitochondrial membrane 20, P62 = ubiquitin-binding protein p62, DAPI = 4′,6-diamidino-2-
phenylindole, CCCP = carbonyl cyanide m-chlorophenylhydrazone, DMSO = dimethyl sulfoxide. 
Images 63 x magnification, oil immersion lens, bar = 50 µm.   
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The E3 ubiquitin ligase Parkin, in concert with PINK1 is recognised as a critical component involved in 
the autophagic removal of depolarised mitochondria (Springer and Kahle 2011). Rapidly recruited to 
depolarised mitochondria, Parkin ubiquitinates outer mitochondrial membrane proteins, targeting 
these organelles for autophagic elimination. A parallel, but mitophagy-independent function has also 
been described, where Parkin recruits P62/SQQSTM1 to form clusters of dysfunctional mitochondria 
(Narendra et al 2010). Proposed as a protective mechanism whereby surface area available for 
interaction with other cytosolic components is reduced, sequestration of large intracellular 
aggregates formed in this way may be detrimental to cell function and survival, as these are resistant 
to intracellular degradation (Narendra et al 2010).  
In DMSO controls, TOMM20 staining revealed well defined mitochondrial networks in tenocytes in 
miR-181a mimic, antagomiR and scrambled control treated groups (Figure 7.9). Parkin staining was 
finely punctate in all treatment groups. In scrambled treated cells, Parkin signal was weak and 
diffusely distributed. In both miR-181a mimic and antagomiR treated cells, Parkin signal was 
stronger, with some areas of accumulation.  No TOMM20-Parkin co-localisation was evident in any 
of the treatment groups (Figure 7.9).  
In CCCP treated cells, mitochondrial networks were fragmented and showed a punctate staining 
pattern in all treatment groups (Figure 7.9). Parkin staining in mimic and antagomiR treated groups 
was diffuse, without evidence of co-localisation with TOMM20 positive structures. In scrambled 
treated cells, there were regions of Parkin accumulation, similar in appearance to those seen in the 
miR-181a mimic and antagomiR treated groups exposed only to DMSO. Also in the CCCP/scrambled 
treated group, there was a suggestion of Parkin co-localisation with regions of more densely 







Figure 7.9 Immunofluorescence images of miR-181a-5p mimic, antagomiR and scrambled control 
treated human tenocytes subjected to six hours of CCCP/DMSO exposure. TOMM20 = Translocase 
of outer mitochondrial membrane 20, PARK2 = Parkin, DAPI = 4′,6-diamidino-2-phenylindole, CCCP = 
carbonyl cyanide m-chlorophenylhydrazone, DMSO = dimethyl sulfoxide. Images 63 x magnification, 





In Chapters 5 and 6, we identified an effect of altered miR-181 activity on intracellular distribution 
and levels of key autophagy and mitochondrial related proteins. We additionally presented 
ultrastructural evidence of up regulated mitophagy subsequent to increased miR-181 levels in 
equine tenocytes and tendon constructs. Equine tendon has been proposed as a valid model for the 
study of pathophysiological processes relevant to human tendinopathy. Determination of similar 
mechanistic processes under equivalent conditions would substantiate this hypothesis, reinforcing 
the validity of this model. To this end, we have extended our investigation of overexpression and 
inhibition of miR-181a to human primary tenocytes in this chapter. The effect of miR-181a mimic, 
antagomiR and scrambled control treatments on both transcript and protein levels of selected target 
genes was determined in monolayer culture. We additionally utilised the CCCP-induced mitophagy 
model previously employed in equine tenocytes (Chapter 5, section 5.3.3) to determine the effect of 
miR-181 overexpression and inhibition on mitochondrial homeostasis. Our results suggest that miR-
181 levels impact on autophagic processes, including mitochondrial degradation, by affecting both 
levels and distribution of key autophagy-associated proteins.  
Treatment of tenocyte cultures with mmu-miR-181a mimic resulted in a substantial increase in total 
miR-181 in all cultures compared with other treatment groups. In two of the biological replicates, 
total miR-181 levels in miR-181a mimic treated cells were equivalent, whilst more than 10 times this 
level was detected in the third (Figure 7.1), recapitulating the variability in miR-181a mimic 
treatment effect previously observed (Chapter 5, Figure 5.2, Chapter 6, Figure 6.3). Again, miR-181b 
was the family member identified as being most abundant (Figure 7.1), as with miR-181a mimic 
treated equine tenocytes. In human tenocytes, miR-181b was responsible for 87-92% of the increase 
in total miR-181 levels, proportionally more than that identified in equine tenocyte monolayer 
culture (Chapter 5, section 5.3.2, Figure 5.2), but similar to that found in equine tendon constructs 
(Chapter 6, section 6.3.1, Figure 6.3). All four miR-181 family members are described in both human 
and murine species and each shows 100% homology between species (miRBase release 22.1, 
Kozomara et al 2019; Chapter 5, Table 5.3). This phenomena is therefore unlikely related to our use 
of human sequence directed primers in a species for which they have not been validated, but 
indicates that the primers used lack the sensitivity to differentiate between highly homologous short 
target sequences, as discussed in Chapter 5. Future work should investigate the use of locked nucleic 
acid oligonucleotide primers to improve sensitivity and specificity of RT-qPCR, and ideally include a 
greater number of biological and technical replicates, to allow selection of samples showing a more 
consistent treatment effect.   
Total miR-181 was greater in antagomiR treated cells than in the scrambled control treated cultures 
in all three biological replicates. Although this was evident in some equine tenocyte cultures, in most 
cases antagomiR treatment of equine cells resulted in lower miR-181 levels than that expressed 
following scrambled control treatment (Chapter 5, section 5.3.2, Chapter 6, section 6.3.1). With 
equine cultures and constructs we only performed gene expression analysis in cultures where total 
miR-181 levels in antagomiR treated cultures was below that of the scrambled control treated 
group, to improve confidence in our results. This was not possible in human cultures due to the low 
number of biological replicates and consistent miR-181 expression pattern between all replicates. As 
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discussed in Chapter 5, we used a cholesterol conjugated 2’-O-Me antagomiR, modifications 
reported to promote miRNA degradation (Stenvang et al 2012). Accordingly, successful antagomiR 
treatment should have resulted in miR-181 levels being lowest in this treatment group. However, if 
miR-181-antagomiR interaction does not result in degradation, miR-181 will still be detected by RT-
qPCR, even though in the intracellular environment it would still be susceptible to inhibition. The 
disparity in miR-181 levels observed between equine and human tenocytes following antagomiR 
treatment may reflect a difference in cellular response between the species, or a stochastic 
consequence of the low number of biological replicates available from human donors. Further 
investigation of these differences could include the use of alternative transfection protocols and 
culture conditions as discussed in Chapter 5. Additionally, inclusion of a greater number of biological 
replicates and/or increasing the number of technical replicates would be useful to determine if this 
is a consistent effect.  Further to this, of the three biological replicates available, whilst ages were 
similar (within a range of eight years), two were from white British patients, one from a Chinese 
patient, and the cohort contained one female and two males. Ethnicity influences miRNA, and 
subsequently gene expression, under basal conditions in lymphoblastoid cell lines (Huang et al 
2011), and in early stage breast cancer tissue (Nassar et al 2017). In human Achilles tendon, 
alterations in miRNA expression with ageing differs between male and female subjects (Pease et al 
2017). Our results should, therefore, be interpreted with the caveat that differences in sex and 
ethnicity in our study cohort may have influenced our results, masking subtle changes due 
specifically to manipulation of miR-181 levels. 
Similar to our findings with equine tenocytes in both monolayer culture (Chapter 5, Figure 5.3) and 
three-dimensional tissue engineered constructs (Chapter 6, Figure 6.4), we observed no difference in 
transcript expression of any of the target genes investigated using RT-qPCR (Figure 7.2). We did 
however identify significant decreases in levels of protein products of two of the genes of interest, 
LC3BII and TOMM20, in the miR-181a mimic treated group (Figure 7.3). The lack of significant 
changes in transcript expression, coupled with the identification of significant differences in the 
levels of these two proteins indicates that miR-181 acts through orchestrating alterations in protein 
translation rather than transcript stability (Soriano-Arroquia et al 2016, Bartel 2018), as discussed in 
Chapter 5. This is corroborated by our findings in equine tendon constructs in Chapter 6, where 
transcript expression of P62/SQSTM1 and COXIV was unchanged, but significant differences in levels 
of both of these proteins were detected (Chapter 6, Figures 6.4 and 6.7).    
LC3BII is the phosphatidylethanolamine-conjugated form of the ubiquitin-like LC3 protein, present 
on the surface of phagophores and autophagosomes (Runwal et al 2019). Nascent LC3B is rapidly 
converted to the soluble cytoplasmic form LC3BI by the action of the protease autophagy related 4B 
cysteine peptidase (ATG4B). LC3BI is then further modified by the activity of autophagy-related 
protein 7 (E1-like activating enzyme, ATG7), autophagy-related protein 3 (E2-like conjugating 
enzyme, ATG3) and conjugated to phospholipid by the ATG16L complex (E3-like ligase enzyme) to 
form LC3BII (Mizushima and Yoshimori 2007, Kimura et al 2009). Induction of autophagy enhances 
the lipidation reaction, reflecting increased autopagosome formation (Kimura et al 2009). Lysosome 
fusion, to create the mature autophagolysosome results in lysosomal proteases degrading LC3BII 
located on the inner aspect of the membrane, whilst that on the outer surface is delipidated by 
ATG4 to regenerate the soluble LC3BI form (Kimura et al 2009). The reduction in LC3BII observed in 
the miR-181a mimic treated group, with consequent reduction in LC3BII/LC3BI ratio, is therefore 
consistent with enhanced autophagic activity with accelerated completion of autophagolysosome 
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degradation, or interruption of the enzymatic lipidation of LC3BI indicating inhibition of autophagic 
activity (Kimura et al 2009). However, the increase in LC3B positive punctae observed in miR-181a 
mimic treated tenocytes following incubation with CCCP (Figure 7.6), would tend to support the 
former interpretation. This is substantiated by a similar response in the scrambled control treated 
group, as this treatment should be inert, having no impact on intrinsic intracellular processes. 
Equally consistent with this is lack of observed effect in the antagomiR treated group following 
induced mitophagy, indicating that downregulation of miR-181 activity inhibited this process (Figure 
7.6).   
Despite retaining an independent genome, mitochondria only derive approximately 1% of their 
proteins from their intrinsic genetic code (Schmidt et al 2010). This necessitates a sophisticated 
import system to translocate cytosolic precursor proteins across the double membrane of the 
organelle to the mitochondrial matrix. This is achieved by the synchronous function of the 
translocase of the outer membrane (TOM) and the translocase of the inner membrane (TIM) 
multiprotein complexes.  TOMM20 is one of three preprotein receptors forming part of the TOM 
complex of mitochondria and is necessary for the recognition and transfer of targeted proteins 
through the TOM40 channel into the intermembrane space for further processing by the TIM 
complex (Schmidt et al 2010). TOMM20 levels are considered a reliable marker of mitochondrial 
mass (Song et al 2018, Buso et al 2019), with increased expression shown to correlate with increased 
mitochondrial mass in several types of malignant tumours (Park et al 2019). Reduction in TOMM20 
levels in the miR-181a mimic treated group, concurrent with reduced LC3BII levels, suggests that 
miR-181 upregulation may increase mitophagic activity. In skeletal muscle, miR-181a up regulated 
levels of TOMM20 (encoded by the nuclear genome) and COXI and MT-ND1 (NADH-ubiquitone 
oxidoreductase chain 1) both encoded by the mitochondrial genome, with concurrent reduction in 
autophagy-associated proteins P62/SQSTM1, DJ-1 and Parkin. This indicated upregulation of both 
mitochondrial biogenesis and mitophagy, maintaining a functional population of morphologically 
normal mitochondria (Goljanek-Whysall et al 2020). Interestingly, neither TOMM20 nor LC3BII levels 
in tendon constructs showed alterations in response to treatment (Chapter 6, Figure 6.7). 
Unfortunately, determination of protein levels in equine tenocyte monolayer culture in response to 
upregulation and inhibition of miR-181 activity (Chapter 5) was not performed, precluding direct 
comparison of effect between species. However, in tissue-engineered constructs developed using 
equine tenocytes, we did detect significant differences in levels of proteins NRF2, COXIV and BNIP3, 
which all showed higher relative levels in the miR-181a mimic treated group, and P62/SQSTM1, 
which showed higher levels with antagomiR treatment (Chapter 6, Figure 6.7). These differences in 
protein dynamics in response to miR-181 treatments may reflect differences in culture environments 
and temporal exposure to treatments, or species specific differences. Additionally, autophagy 
related proteins are tightly controlled and have a fast turnover, therefore detecting differences in 
levels may be problematic. Alternatively, miR-181 may regulate mitophagy further upstream than 
these proteins, accounting for changes in their localisation rather than levels. Further work should 
replicate the monolayer culture work in equine tenocytes to enable direct comparison of protein 
levels under equivalent conditions. 
Western blots derived from human samples were of far greater quality and consistency compared to 
those performed on extracts from equine tenocytes, potentially reflecting the fact that primary 
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antibodies were validated against human proteins, but also that, with the exception of COXIV, 
greater mass of protein was loaded per sample for electrophoresis than with equine tenocytes.  
The complete lack of detectable signal for Parkin, even with increased mass of protein loaded onto 
the gels, was disappointing. Although Parkin was one of the proteins visualised least successful by 
Western blot immunoreactivity in equine tendon constructs, sufficient signal was obtained to enable 
analysis in three out of seven biological replicates, using half the amount of protein. Similar 
protocols were followed with human and equine tenocyte protein extracts and Ponceau staining 
indicated successful protein transfer to PVDF membranes with all three human biological replicates. 
A primary mouse monoclonal antibody directed against amino acids 399-465 at the C-terminus of 
the protein was used (ab77924, abcam, Cambridge, UK), identical to that used successfully for 
immunocytological assessment of Parkin localisation (Figure 7.9 (and Chapter 5, Figure 5.10)), 
although at a lower dilution (1:200 versus 1:100). Parkin has been described as a difficult protein to 
work with, as the structural stability and enzymatic activity are sensitive to thermal, denaturing and 
reducing conditions (Seirafi et al 2015). However, neither of the experimental methodologies 
employed here required preservation of the tertiary structure or catalytic activity, indeed Western 
blot analysis requires reduction and denaturation of proteins. The reason for the lack of detectable 
immunoreactivity following SDS-PAGE remains unclear. Further work investigating miR-181 influence 
on Parkin expression will require additional optimisation of this technique. 
We utilised the CCCP-induced model of mitophagy previously reported with human C2C12 myoblasts 
and cervical adenocarcinoma HeLa cells (Kagan et al 2016, Webb et al 2017), and employed in our 
equine monolayer tenocyte culture work (Chapter 5). Staining for the outer mitochondrial 
membrane protein TOMM20 revealed a punctate staining pattern in all CCCP treated cells consistent 
with mitochondrial network fragmentation, indicating treatment success (Miyazono et al 2018). 
Consistent with reduced LC3BII protein levels in miR-181 mimic treated tenocytes (Figure 7.3), miR-
181a mimic treated DMSO control cultures showed reduced LC3B positive punctae in comparison 
with antagomiR and scrambled control treated groups (Figure 7.6). Induction of mitophagy resulted 
in substantial increases in LC3B positive punctae in both miR-181a mimic and scrambled control 
treated groups, with little appreciable change in the antagomiR treated group (Figure 7.6). This likely 
represents an increase in autophagosome formation, indicating increased autophagic activity, not 
observed in the antagomiR treated group. Alternatively, this could represent accumulation of 
autophagic vesicles in miR-181a mimic and scrambled control treated cells as a result of failure of 
autophagosomes to progress to autolytic degradation, and/or accumulation of LC3BI aggregates in 
association with P62/SQSTM1, described in autophagy deficient cells (Runwal et al 2019). In equine 
monolayer culture, the scrambled control treated group exhibited a similar change to that apparent 
with human tenocytes following exposure to CCCP (Chapter 5, Figure 5.7). In miR-181a mimic 
treated equine tenocytes exposed to CCCP, whilst an increase in LC3B positive punctae was not 
observed, accumulation of LC3B immunofluorescence was evident. Again, the least change was seen 
in the antagomiR treated cells (Chapter 5, Figure 5.7). Thus, it appears that in both human and 
equine tenocytes, LC3B activity is regulated in a broadly similar fashion by miR-181. 
Protein DJ-1 showed little change, either with treatment, or following CCCP exposure in human 
tenocytes (Figure 7.7). Equine tenocytes under similar conditions demonstrated greater numbers of 
DJ-1 positive punctae in all treatment groups, and changes in punctae distribution following CCCP 
exposure, although little effect of miR-181 treatments was found (Chapter 5, Figure 5.8). DJ-1 is 
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recruited to damaged mitochondria under conditions of oxidative stress, where it exerts a protective 
effect on mitochondrial function (McCoy and Cookson 2011). The differences in DJ-1 punctae 
formation and distribution observed between species may reflect differences in tenocyte 
susceptibility to oxidative stress under basal conditions. CCCP treatment results in rapid and 
complete depolarisation of the mitochondrial network, resulting in supra-physiological levels of 
damage (Seirafi et al 2015). Our data would suggest that the effect of miR-181 on DJ-1 is weak in 
both human and equine species, with any impact rendered undetectable under conditions of 
enhanced cellular stress.  
The strikingly well demarcated, condensed perinuclear distribution of P62/SQSTM1 observed in 
equine tenocyte cultures in all treatment groups, incubated with DMSO (Chapter 5, Figure 5.9) was 
not replicated in human tenocytes under equivalent conditions (Figure 7.8). Perinuclear aggregates 
were observed, but these were far more fragmented and ill-defined. However, following incubation 
with CCCP, more distinct perinuclear accumulation was evident in antagomiR and scrambled control 
treated tenocytes, with a wider dispersal pattern observed in the miR-181 mimic treated group 
(Figure 7.8). These changes are all reminiscent of the situation observed in equine tenocytes 
exposed to the same conditions (Chapter 5, Figure 5.9). Therefore, under basal conditions (DMSO 
exposure) miR-181 activity appears to influence P62/SQSTM1 localisation to some degree, but this 
effect is enhanced under conditions requiring increased autophagic activity (CCCP treatment). 
Depolarised, ubiquitinated mitochondria cluster in perinuclear aggregates prior to degradation, a 
process shown to require P62/SQSTM1 recruitment in HeLa cells and mouse embryonic fibroblasts 
(Narendra et al 2010, Okatsu et al 2010). This is consistent with the enhanced perinuclear 
accumulation of P62/SQSTM1 positive aggregates observed following incubation with CCCP in 
antagomiR and scrambled control treated tenocytes (Figure 7.8). However, mitochondrial 
degradation can occur in the absence of P62/SQSTM1 (Narendra et al 2010, Okatsu et al 2010), and 
P62/SQSTM1 is known to function as a central signalling molecule in multiple cellular pathways in 
addition to being an autophagy receptor protein (Sánchez-Martín and Komatsu 2018). The more 
dispersed appearance of P62/SQSTM1 punctae observed in the CCCP/miR-181a mimic treated 
tenocytes may therefore represent involvement in autophagy of other cellular components, or 
processes unrelated to autophagy.   
In equine tenocytes, immunocytological studies identified Parkin as one of the proteins showing 
greatest alteration in accumulation and co-localisation with TOMM20 punctae in antagomiR treated 
cells following CCCP-induced mitophagy (Chapter 5, Figure 5.10). In human tenocytes we did not 
observe this. Parkin staining was weak in both miR-181a mimic and antagomiR treated cells exposed 
to DMSO, with a suggestion of accumulation in the scrambled control group, whilst the reverse 
situation appeared to be evident after incubation with CCCP (Figure 7.9). Parkin levels and activity 
are tightly controlled within the cell, but once activated, Parkin demonstrates low substrate 
specificity and is itself ubiquitinated, facilitating its own degradation (Seirafi et al 2015). Mitophagy 
can proceed through different mechanisms, dictated by the effects of multiple signalling cascades, in 
turn determined by specific cellular contexts (Lemasters 2014, Palikaras et al 2018). Consequently, 
mitophagy can proceed through Parkin dependent and independent mechanisms. These utilise other 
ubiquitin E3 ligases such as SMAD specific E3 ubiquitin protein ligase 1 (SMURF1), mitochondrial E3 
ubiquitin protein ligase 1 (MUL1), siah E3 ubiquitin protein ligase 1 (SIAH1), E3 ubiquitin protein 
ligase Autocrine Motility Factor Receptor (Gp78) and Ariadne RBR E3 ubiquitin protein ligase 1 
(ARIH1) to generate ubiquitin chains, which then recruit autophagy adaptor proteins to the labelled 
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mitochondria (Palikaras et al 2018). Unfortunately, due to the complete lack of detectable Parkin 
signal generated following Western blot imaging, we were unable to use Parkin quantification to 
inform our interpretation of Parkin localisation determined immunocytologically. It is possible that 
mitophagy in equine tenocytes is more dependent on Parkin-mediated mechanisms, with Parkin-
independent mechanisms being more important in human tenocytes, although this cannot be 
conclusively determined from our results. Equally, the CCCP-induced mitophagy model utilised 
concentration and time exposure factors optimised in equine tenocytes, which we assumed would 
be appropriate for use in human tenocytes. However, our results suggest this protocol may 
engender a different response and future work should determine if the experimental methodology 
could be refined specifically for human tenocytes.  
We have identified changes in the level of key autophagy-associated protein LC3BII in response to 
upregulation of miR-181 activity in association with a reduction in mitochondrial mass as determined 
by levels of the outer mitochondrial membrane protein TOMM20. Unlike in equine tenocytes, LC3BII 
was significantly lower in miR-181a mimic treated than other groups, with LC3BII/LC3BI ratio lower 
(a non-significant increase in LC3BII/LC3BI ratio was seen in equine tenocyte culture). Overall, our 
data suggest that miR-181 activity regulates mitochondrial dynamics and autophagy related proteins 
in both equine and human tenocytes, mechanisms fundamental to maintaining cellular functionality 
and adaptability and therefore critical maintaining tissue integrity and repair. Although the 
mechanisms may not be entirely analogous between species, and require further investigation, we 
believe that our data are broadly supportive of the use of equine tenocytes as a model of 
pathophysiological mechanisms in human cells.  Further work should seek to specifically interrogate 
the effect of miR-181 on mitochondrial architecture and turnover. This could include using targeted 
delivery of a pH-sensitive fluorescent reporter protein to the mitochondrial matrix (mt-Keima; 
Katayama et al 2011), or a tandem GFP-mCherry pH-sensitive probe targeted to the outer 
mitochondrial membrane proteins (mito-QC; Allen et al 2013, McWilliams et al 2016), which more 
accurately identify lysosomal delivery of labelled mitochondria. Disruption to mitochondrial 
dynamics may contribute to tendon disease through ROS-induced enzymatic and non-enzymatic 
degradation of extracellular matrix proteins, or progression of tenocytes to a chronic pro-
inflammatory senescence associated secretory phenotype, in which cell cycle arrest and further 






Chapter 8 – General discussion, conclusion and progression of work 
 
Tendon injuries represent over half of all musculoskeletal injuries sustained in UK jump racing 
(Williams et al 2001), the majority affecting the superficial digital flexor tendon (SDFT) of the 
forelimb (Ely et al 2009, Perkins et al 2005). In the general human population, incidence of 
tendinopathies varies between 0.3-5.5% (Littlewood et al 2013, Albers et al 2014), increasing to 11% 
in athletic individuals, and with a prevalence of 18.5-44.6% in some sporting disciplines (Lian et al 
2005, Lopes et al 2012). Aetiology is multi-factorial and incompletely understood (Wertz et al 2013), 
but chronic, asymptomatic deterioration at the cellular and molecular level precedes clinically 
apparent disease (Sharma and Maffulli 2005, Millar et al 2010, Millar et al 2015). Altered gene 
expression is reported in ageing healthy (Peffers et al 2015) and chronically diseased (Ireland et al 
2001) tendon, with increased expression of genes associated with apoptosis and autophagy and 
altered relative expression of MMPs and TIMPs reported in Achilles tendinopathy (Ireland et al 2001, 
Alfredson et al 2003, Jones et al 2006,  Corps et al 2006). This suggests enhanced catabolism of both 
collagenous and non-collagenous matrix increasing the likelihood of mechanical loading resulting in 
tissue disruption (Peffers et al 2014). Once this occurs, mechanical integrity is never fully restored 
(Sharma and Maffulli 2005). There is a need to understand the mechanisms that precipitate and 
drive the changes that result in clinical disease.  As powerful regulators of gene expression, miRNAs 
are likely implicated in these processes and provide an opportunity to approach tendinopathy 
therapeutics from a novel angle. This study has highlighted substantial changes occurring in the 
small non-coding RNA transcriptome associated with tendinopathy in both human and equine 
species, and identified some similarity between the two species. 
 
8.1 Tissue sample collection 
Human tissue samples utilised in this study consisted of tendinopathic supraspinatus and posterior 
tibial tendon (PTT), with semitendinosus and gracilis tendon as controls. In humans a number of 
elastic energy storing tendons are associated with clinically important disease – rotator cuff, Achilles, 
PTT. Human tendon tissue samples typically only become available in the chronic stages of disease, 
when patients undergo surgery, therefore early stage disease samples are rarely encountered. 
Additionally, results presented in this study suggest that response to injury may differ between 
elastic energy storing tendons from different anatomical locations. Acquisition of control tissue is 
also problematic as there are only limited, specific tendons from which samples can be obtained, 
dictated by recognised reconstructive or salvage procedures being performed. Therefore, tendons 
from different anatomical locations with dissimilar structures and subjected to varied intensities, 
durations and loading regimes are often compared, introducing bias. Likewise, heterogeneity in age, 
sex, ethnicity, genetic and lifestyle factors of sample donors all contribute to sample variability of 
both diseased and control tissue.  
It is extremely rare for horses to undergo surgery for tendon injury, with the exception of acute 
traumatic lacerations, which are not representative of the degenerative changes seen in 
tendinopathies. Clinically apparent tendon disease rarely results in euthanasia as conservative 
management is often attempted. Therefore, acquisition of tendon samples is to a large degree 
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opportunistic, with tendinopathic tissue often identified incidentally post-mortem. Additionally, 
samples are often collected from abattoir material, therefore clinical history is unavailable. Where 
diseased tissue is identified, however, control tissue from the same tendon, or from the analogous 
tendon in the contralateral limb (if disease is not bilateral) is easily obtained, enhancing the value of 
comparative analyses. As with human tissue though, these samples only represent the changes seen 
with chronic disease, although the duration of disease and prior treatment history will likely be 
unknown. Counteracting these problems, is the fact that the SDFT is overrepresented in equine 
tendon disease, making collection of a single tendon more clinically and experimentally relevant. 
The method of tenocyte isolation differed between equine and human tissue in this study. 
Collagenase digestion of equine SDFT yielded abundant viable tenocytes which demonstrated 
excelleny proliferative capacity. This method failed to yield any cells from human tissue samples, 
necessitating an alternative approach. Human tenocytes were derived through the explant method 
and demonstrated a more rounded appearance and slower growth characteristics than equine cells 
harvested by digestion. Whilst these gross differences may reflect heterogeneity in tenocyte 
morphology and behaviour between species, it is possible that the different methods of isolation 
contributed to this. Nichols and co-workers (2021) reported that explanted murine tenocytes 
isolated from flexor digitorum longus (FDL) tendon exhibited different morphology and reduced 
proliferative capacity than those obtained by digestion. Additionally, expression of SCX, MKX and 
COL1A1 was reduced, whilst that of COL3A1, periostin, CD248 and α-smooth muscle actin was 
increased, compared to digestion isolated cells. Expression of tenogenic and fibroblast activation 
markers were also different between cells subjected to digestion and those in intact FDL tendon 
(Nichols et al 2021). The authors concluded that isolation by any method alters cell bahaviour 
compared to that exhibited in intact tendon, but removal of matrix cues via digestion resulted in a 
different activation profile to that expressed by cells migrating out of explanted tissue. Further, 
application of these isolation protocols to murine tail, flexor carpi ulnaris and Achilles tendon 
identified that, in addition to isolation method, tendon of origin also significantly affects tendon cell 
population and behaviour in in vitro culture (Nichols et al 2021). Comparing digestion and explant 
methods in MSC isolation from equine SDFT, Gittel and colleagues (2013) reported similar growth 
characteristics and lineage differentiation capacities between methods, but higher yields and SCX 
expression following digestion isolation, suggesting this is the method of choice in equine tissue 
(Gittel et al 2013). The lack of tendon cell lines mandates isolation and culture of primary tendon 
cells, but there is no standard protocol reported for this purpose. Differences in tendon of origin and 
isolation techniques employed in this study may have contributed to the differences observed 
between species. 
Whilst samples obtained from surgical or cadaveric sources may reflect the clinical population, 
elucidating the basic, mechanistic processes independent of the inherent confounders becomes 
problematic. These factors present limitations in interpretation of results derived using samples 
obtained in these ways, thus there remains a need to develop a suitable model in which cellular 





8.2 Comparison of sncRNA transcriptome changes in human and equine 
tendinopathy 
RNA-seq of human tendon tissue generated a large, unbiased data set. The sensitivity and specificity 
of this technology permits differentiation of single nucleotide differences in highly similar 
transcripts, allows identification of small changes in expression and suffers from less technical 
variation than RT-qPCR. We used a targeted approach to determine miRNA expression in equine 
SDFT, but in future work it would be interesting to perform small RNA-seq on samples of 
tendinopathic and healthy equine SDFT. This would permit a more comprehensive exploration of 
similarities in expression profiles between species. There is obviously a cost implication in this but a 
larger, unbiased and more robust data set would result.  
Filtering target prediction algorithms using the terms musculoskeletal and connective tissue 
disorders and fibroblast cell type biased the bioinformatics output, but interestingly, terms 
associated with cellular proliferation and survival and inflammation were prominent. Cell 
proliferation, differentiation or viability assays were not performed in either monolayer cell cultures 
or three-dimensional constructs during this study, although light and electron microscopy images 
indicated cell viability was maintained. Given the bioinformatics analysis prediction of increased 
cellular proliferation and reduced apoptotic potential, it would be interesting to further pursue this 
by performing cell viability and proliferation assays on tenocytes recovered from tendinopathic and 
control tissue, and in miR-181 mimic and antagomiR treated cultured cells in future studies. This is 
particularly relevant in light of the context- and family member-specific effects of miR-181 on these 
functions, widely reported in relation to carcinogenesis (Liu et al 2014, Pop-Bica et al 2018, Rezaei et 
al 2019, Yang et al 2017).  
Incorporation of terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining to 
identify DNA fragmentation as a robust marker of apoptotic cell death (Molloy et al 2006) could be 
easily incorporated into future work. Likewise, cell proliferation assays which measure DNA synthesis 
by assimilation of bromodeoxyuridine, a thymine analogue into DNA, or overall metabolic activity 
within cells using fluorescent or colourimetric dyes such as luciferase or tetrazolium reduction assays 
(Riss et al 2013 (updated 2016)) could be employed. 
Network analysis reported in this study identified expression of genes implicated in fibroblast 
transition to a more chondrogenic phenotype (WNT5B and HOXA11), and miR-181 is reported to 
regulate chondrogenic differentiation in mesenchymal stem cells (Zhao et al 2018). Ageing increases 
chondrogenic potential of human stem cells (Peffers et al 2016) and transition to a more 
chondrogenic phenotype in equine SDFT (Webbon 1978, Ali et al 2021). A more cartilaginous 
phenotype is also reported in collagenase induced tendinopathy (Lui et al 2009) and naturally 
occurring Achilles (Maffulli et al 2006) and rotator cuff (Sharma and Maffulli 2005, Yokota et al 2005) 
tendinopathies. Upregulation of additional chondrogenic markers such as SOX9, ACAN and COMP 
could be further explored in future work. Differential expression of collagen subtypes, principally 
types I, II and III would also be enlightening.  
Bioinformatics analysis also identified chronic inflammation as an important process influenced by 
dysregulated miRNAs in both human and equine tendinopathy. This supports the theory that failure 
to resolve early inflammation constitutes an important driver of degenerative changes (Dakin et al 
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2014, Dakin et al 2018). Further research into how inflammatory pathways can be controlled is 
needed.   
 
8.3 Development of a tendon construct model 
The lack of homogeneity between clinical samples and the reliance on those expressing chronic 
changes makes the prospect of experimentally induced tendinopathies attractive. This would permit 
investigation of early disease processes in a population of similar animals. However, there are 
significant anatomical differences in tendon structure in rats and mice to those of humans, and there 
is no universally recognised overuse model for initiating disease. Many permutations of treadmill 
speed, incline, frequency and duration of running have been used by different investigators, and 
willingness of animals to participate is also variable. Standardisation of stimulus across all 
experimental subjects therefore may not occur.  Models have been developed to induce injury in a 
specific tendon, such as that developed by Soslowsky and co-workers (2000) to injure rat 
supraspinatus tendon, based on histological and biomechanical assessment (Soslowsky et al 2000). 
Broadly in alignment with the transcriptomic and bioinformatics analyses reported in this thesis, rats 
subjected to a treadmill-running regime designed to induce overuse supraspinatus tendon injury 
demonstrated significant DE of several apoptosis, growth, differentiation and developmental-related 
genes (Molloy et al 2006).  
Extrapolation of one model to the study of other tendons must be viewed with caution, as changes 
have been shown not to occur in the Achilles tendon using Soslowsky’s model (Huang et al 2004). 
One model can even produce conflicting results on the same tendon, with the same exercise 
protocol used to successfully induce overuse injury in rat Achilles tendon (Glazebrook et al 2008) 
also reported to improve Achilles mechanical properties (Heinemeier et al 2012). Additionally, gene 
expression profile was different to that found in either tendinopathy (Ireland et al 2001) or following 
short-term loading (Heinemeier et al 2007).  
Chemically induced lesions such as those produced by injection of collagenase, or surgical sectioning, 
do not mimic the natural disease process. Although these models have been described in horses 
(Watts et al 2012) and laboratory animals (Oryan et al 2008, Sugg et al 2014), they are far removed 
from the naturally occurring changes which precipitate tendon disease in the native population. The 
use of tendon explants from cadaveric material has many advantages in studying the molecular 
adaptations and biomechanical properties of equine tendon, however the effect of post-mortem 
changes (fascicular swelling) and processing techniques (non-physiological storage, freeze/thaw 
cycles) have not been fully quantified. Equally, it is often not possible to determine the clinical 
history or background to the animals from which these tendons were harvested.  
In vitro monolayer cell culture techniques, whilst allowing investigation of large amounts of cellular 
material and cell products, represent a non-physiological situation, as cellular arrangement, 
alignment and organisation within a three-dimensional matrix are not replicated (Arnoczky et al 
2007). If equine tenocytes can be demonstrated to respond biochemically in a similar manner to 
human tenocytes, tissue engineering can provide an alternative to live animal and cadaveric models 
and lends itself to testing under controlled, reproducible conditions. This study presents evidence 
that equine and human tenocytes do share some commonality in response to changes occurring 
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with tendon disease. Additionally we have successfully generated three-dimensional tissue 
engineered constructs using primary equine tenocytes and maintained them for 28 days in culture. 
The constructs used in this study were exposed to static tension, which does not replicate the 
normal in vivo situation, and utilised primary tenocytes embedded in a fibrin matrix, which bears 
little similarity to normal extracellular matrix. However, fibrin gels have been reported to 
demonstrate improved tenogenic gene expression patterns and better collagen fibril alignment 
compared to collagen gel-based matrices (Breidenbach et al 2015). These authors showed that 
murine tendon and ligament progenitor cells embedded in fibrin gel exhibited continual 
improvement of tenogenic marker expression over 14 days of culture. Significant upregulation of 
SCX, TNC and FMOD expression, relative to collagen gel-based constructs was demonstrated, with a 
temporal increase in SCX over 14 days followed by enhanced expression of COL1A1, COL3A1, MKX, 
FMOD and TNMD in the latter stages of culture, with a concurrent degradation of fibrin. 
Subjecting three-dimensional constructs to cyclical mechanical loading programmes can mimic the 
mechanical stimuli to which native tendon responds, but, whilst this has been done, there is again 
no loading program universally recognised as physiologically appropriate or representative of 
overuse. Devising such a programme would be useful. A strain magnitude up to 5% and frequency of 
1 Hz has been described with tendon explants (Screen et al 2005, Maeda et al 2009), and protocols 
have been described using tissue engineered tendon constructs subjected to cyclical 2.4% strain for 
up to 14 days (Nirmalanandhaan et al 2007, Breidenbach et al 2015). However, higher strains, up to 
10% are reported to be required in fibrin-based constructs compared to collagen gel-based ones to 
increase collagen production and mechanical properties (Breidenbach et al 2015). Future work 
should look at developing mechanical loading programmes which mimic physiologically appropriate 
and overuse regimes that can be applied to tissue engineered tendon constructs.  
Quantitative evaluation of tissue-engineered tendon construct phenotype requires refinement. The 
modified grading scheme employed in this study was not able to objectively confirm the subjective 
impression of differences in construct phenotype subsequent to gain or loss of miR-181 activity. 
Histological scoring systems for tissue-engineered tendon constructs have been described, but 
typically, to quantify their behaviour once implanted in vivo (Loppini et al 2015). These, 
consequently, contain elements irrelevant to the in vitro situation. To the author’s knowledge, the 
only scoring matrix described relevant to purely in vitro tissue-engineered three-dimensional 
constructs is that reported by Nakanishi and co-workers (Nakanishi et al 2019). This, however, was 
applied to scaffold-free constructs, created using a bio-3D printer, from spontaneously formed 
multicellular human dermal fibroblast spheroids, a methodology very different from that utilised in 
this study. These authors reported statistically significant, identifiable differences between 
constructs matured under tension-free or tension-loaded conditions, based on cellular density, 
orientation and phenotype, as well as alignment and size of fibres. Nakanishi and co-workers’ 
grading matrix was a novel, modified scoring system based on that described by Watkins (1985) to 
describe healing of surgically created lesions in equine SDFT (Watkins et al 1985). The grading 
system employed in this thesis, similarly, used elements applicable to ECM organisation and 
tenocyte morphology and distribution, but derived from the Movin (Movin et al 1997) and Bonar 
(Cook et al 2004) human tendinopathy grading systems. This did not detect differences in construct 
morphology resulting from over expression or inhibition of miR-181 during maturation under static 
tension. There remains the need to design a sensitive, objective method of quantifying histological 
appearance of tissue-engineered three-dimensional tendon constructs. Such schemes will likely 
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need precisely, quantitatively defined elements and be devised for specific construction 
methodologies, depending on whether or not a scaffold medium is employed, and if so, may even 
require to be specific for substrate type (collagen or fibrin gel).  
 
8.4 Primer specificity 
Results from this study suggest primer specificity was poor for the four hsa-miR-181 family 
members. Despite treatment with miR-181a-5p mimic, the highest detected levels, consistently in 
both equine and human studies, were for miR-181b. Discrimination between targets with very 
similar sequences can be problematic using PCR technology as mis-priming events, primer design, 
cycle parameters and reagent factors all impact on quantitative accuracy. Locked nucleic acid (LNA) 
technology may improve this. Since performing this study, the commercially available miR-181 
primers utilised have been discontinued by the manufacturer, who now only supply LNA primers. 
These are purported to offer greater sensitivity in discriminating between targets with highly similar 
sequences, and it would be interesting to investigate this.  
 
8.5 Optimisation of miR-181 transfection protocol 
Treatment of cell cultures with miR-181a-5p mimic and the antagomiR oligonucleotide yielded 
inconsistent results. Whilst all mimic treated cultures demonstrated an increase in total miR-181 
levels, expression levels relative to the housekeeping gene varied by between six and ten times for 
equine and human monolayer cultures and by up to four times in the three-dimensional equine 
tenocyte constructs. AntagomiR treatments resulted in more consistent relative expression of total 
miR-181 within experimental groups, but results were inconsistent in relation to that determined in 
scrambled control treated groups. The antagomiR treatment was designed to bind miR-181 
transcripts, inhibiting their ability to bind endogenous targets. Additionally, cholesterol conjugated 
2’-O-Me modifications, included in the design to increase oligonucleotide stability, are reported to 
promote miRNA degradation following binding (Stenvang et al 2012). The scrambled control 
oligonucleotide should have exerted no biological effect. This did not appear to be reflected in the 
results obtained. Although cellular uptake was confirmed by visualising intracellular fluorescence, 
and the activity of miR-181 transcripts should still have been inhibited by the antagomiR, alternative 
methods of transfection may yield more consistent results and could be explored. By reducing data 
variability, this would generate more homogenous samples to allow for a more robust comparison.  
 
8.6 Antibody optimisation 
In both human and equine samples, semi-quantitative evaluation of protein abundance and 
visualisation of their cellular distribution relied on immunological techniques. More consistent and 
better quality data was obtained from human than equine tenocytes. There are limited antibodies 
available commercially which are raised against and/or validated for use with equine-specific 
proteins. The use of mass spectrometry based label-free quantitative proteomics offers a highly 
accurate, reproducible and automated technique for direct comparison of complex protein mixtures 
between samples. This technique has been successfully applied to equine synovial (Anderson et al 
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2019) and peritoneal (Bardell et al 2019) fluid samples, with proven ability to differentiate between 
healthy and diseased states. Whilst liquid chromatography tandem mass spectrometry (LC-MS/MS) 
would be an ideal methodology to allow quantitation and differentiation of protein abundances 
between experimental groups and is applicable to novel species, it will not provide information on 
protein distributions and validation would still require use of an alternative, robust technique. 
Western blot results were of much better and consistent quality in human samples than those from 
equine tissues, indicating a limitation of available antibodies to quantitate the equine variants of the 
proteins of interest. Therefore, development of antibodies, such as the method described by 
Caterson and co-workers (1985), complementary to epitopes of equine proteins would offer a 
substantial advantage, both in identifying distribution changes and providing a mechanism for 
validation of LC-MS/MS results. 
 
8.7 The role of miR-181 in autophagy and mitochondrial dynamics 
Downregulation of miR-181 was observed in equine and human tendinopathy. Our group has 
previously identified a role of miR-181a in regulating mitochondrial dynamics in ageing skeletal 
muscle (Goljanek-Whysall et al 2020).  In this tissue type, downregulation of miR-181a with ageing 
resulted in accumulation of autophagy related proteins P62/SQSTM1, DJ-1 and Parkin, abnormal 
mitochondria, and reduction in functional mitochondrial mass (Goljanek-Whysall et al 2020). Using 
miR-181 gain and loss of function studies in both equine and human primary tenocyte cultures, 
including in conjunction with a model of induced mitophagy, this study has identified an effect of 
miR-181 on autophagy related proteins BNIP3, P62/SQSTM1, LC3B, DJ-1 and Parkin. Additionally, an 
effect on markers of mitochondrial dynamics and oxidative stress NRF2, TOMM20 and COXIV, in 
concert with ultrastructural changes in mitochondrial morphology was observed. Data presented in 
this thesis indicate that miR-181 regulates mitochondrial dynamics and autophagy in tenocytes. 
Perturbations in these processes, resulting in accumulation of defective proteins and an abnormal, 
dysfunctional mitochondrial population, may be important contributing factors in tendinopathy. 
Indeed, other authors, using different experimental methodologies, have suggested that an 
accumulation of partially degraded matrix proteins with ageing may contribute to mechanical 
weakening and subsequent failure of equine SDFT (Thorpe et al 2010). Disruption to mitochondrial 
dynamics may contribute to tendon disease through ROS-induced enzymatic and non-enzymatic 
degradation of extracellular matrix proteins, or progression of tenocytes to a chronic pro-
inflammatory senescence associated secretory phenotype, in which cell cycle arrest and further 
mitochondrial degradation promote continued tissue deterioration. In order to fully elucidate the 
molecular mechanisms, further investigation of autophagy progression and mitochondrial dynamics 
is warranted. Refinement of the treatment protocol in tendon constructs and temporal effect of 
chronic exposure to altered miR-181 activity, by harvesting constructs at different time points during 
maturation, and by exposing mature constructs to a single treatment would also be useful. Further 
work should also seek to more closely examine the spatial relationship between autophagy related 
proteins and mitochondria. Use of dual fluorophore pH sensitive mitochondrial-targeted reporter 
constructs such as mt-Keima (Katayama et al 2011) or mito-QC (Allen et al 2013, McWilliams et al 
2016) could accurately assess lysosomal turnover of mitochondria.  
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Using starvation- and rapamycin-induced models of autophagy in human breast cancer (MCF-7), 
hepatocarcinoma (Huh-7) and chronic myelocytic  leukaemia (K562) cell lines, Tekirdag and co-
workers (2013) demonstrated miR-181a directly targets autophagy-related 5 (ATG5), regulating both 
transcript and protein levels . ATG5 is a key protein required in the progression and formation of the 
mature autophagic vesicle. Over expression of miR-181a reduced phagophore formation, as 
indicated by presence of GFP-labelled LC3BII aggregates in all three cell types, concurrent with 
reduced P62/SQSTM1 degradation, whilst autophagy was stimulated following transfection with 
miR-181a antagomiR. By this mechanism, downregulation of miR-181 levels seen in both human and 
equine tendinopathic samples would favour phagophore elongation and progression to mature 
autophagic vesicles. Inhibition of autophagy by increased miR-181a activity is also reported by Liu 
and co-workers (2017). These authors demonstrated downregulation of miR-181a in a human 
neuroblastoma cell line model of Parkinson’s Disease (PD). Subsequent over expression of miR-181a 
altered the LC3BII/LC3BI ratio, reduced BECLIN1 expression and decreased numbers of apoptotic 
neurones. These authors proposed inhibition of p38 MAPK/JNK signalling as the mechanism 
responsible. Downregulation of miR-181a is reported in clinical PD, and inhibition of miR-181a 
activity in vitro enhanced apoptosis in this cell type (Liu et al 2017). No apparent difference in LC3B 
punctae formation with miR-181 mimic or antagomiR treatment was evident in equine tenocyte 
monolayer culture, either under basal conditions (DMSO treatment) or following CCCP-induced 
mitophagy. In human tenocytes however, punctae were less abundant under basal conditions in 
miR-181a mimic treated tenocytes, but following CCCP treatment, LC3B positive punctae increased 
markedly in mimic- and scrambled-treated tenocytes, whilst no change was observed in the 
antagomiR treated group. This suggested autophagy was stimulated in the presence of miR-181, but 
inhibited in the presence of the antagomiR. Additionally, reduced LC3BII/LC3BI ratio with miR-181a 
mimic treatment, detected by Western blot, indicated that miR-181a may promote autophagy and 
LC3BII degradation, supporting  Goljanek-Whysall and co-workers (2020), but contrary to  the work 
of Tekirdag and colleages (2013). Results however could be interpreted as mir-181 upregulating 
autophagy, or inhibiting autophagic flux. This requires further analysis, by inclusion of a treatment 
group exposed to an autophagic flux inhibitor such as bafilomycin, and using the mito-QC or mt-
Keima reporter constructs which were not utilised in this study. 
The most studied mechanism of mitochondrial degradation by autophagy is the PINK1:Parkin 
pathway (Montava-Garriga and Ganley 2020). Here, stabilisation and activation of PINK1 on the 
outer membrane of depolarised mitochondria recruits and activates Parkin. This accelerates 
ubiquitination of mitochondrial surface proteins, targeting them for degradation. However, the 
PINK1:Parkin pathway responds differently in the face of changes in magnitude and duration of 
mitochondrial depolarisation (Bowling et al 2019). This may have accounted for some of the 
inconsistencies observed between equine and human tenocytes exposed to CCCP-induced 
mitochondrial depolarisation, as both rapid and delayed autophagy have been reported (Bowling et 
al 2019). Additionally, other E3-ubiquitin ligases may act in concert with, or independently of, Parkin 
downstream of PINK1. Therefore, stabilisation of PINK1 alone, independent of Parkin activation, is 
sufficient to recruit autophagy receptors to dysfunctional mitochondria (Montava-Garriga and 
Ganley 2020). Basal level mitophagy also occurs in PINK1:Parkin deficient mice, suggesting an 
alternative ubiquitin-independent pathway of physiological importance (McWilliams et al 2018).  
In equine tenocyte culture, Parkin demonstrated the greatest change in intracellular distribution 
with inhibition of miR-181 function following CCCP induced mitophagy. Distribution corresponded to 
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that of dysfunctional mitochondria, as indicated by TOMM20 staining, however it was not clear 
whether this represented an appropriate response, or interruption to autophagy progression. This 
effect was not, however, reproduced in human tenocytes, suggesting a different response. 
Unfortunately, quantification of Parkin abundance was precluded by absence of observable signal in 
Western blots and the reason for this requires further investigation. The BCL2 family of outer 
mitochondrial membrane (OMM) proteins possess the ability to recruit autophagosomal membranes 
by direct interaction in the absence of ubiquitin (Villa et al 2018, Montava-Garriga and Ganley 2020). 
Several members of this family of proteins, which have both pro- and anti-apoptotic effects, are 
targeted by miR-181a (Ouyang et al 2012). It may be that there are species differences in the 
importance of ubiquitin-dependent -independent autophagy pathways. Over expression of miR-181a 
in primary murine astrocytes decreased levels of the anti-apoptotic BCL2 family proteins MCL1 and 
BCL2, with the reverse effect seen following miR-181a antagomiR treatment (Ouyang et al 2012). No 
effect on BCL2 levels with over expression or inhibition of miR-181a in human cancer cell lines was 
seen however (Tekirdag et al 2013). Expression of the pro-apoptotic family member BNIP3 is 
increased during hypoxia (Zhang et al 2008). BNIP3 reduces mitochondrial membrane potential, 
resulting in mitochondrial swelling, increased ROS production and stimulation of hypoxia-induced 
mitophagy/autophagy (Liu and Frazier 2015). Significantly higher levels of BNIP3 were observed in 
tendon constructs treated with miR-181a mimic, where swollen mitochondria with loss of cristae 
were also more apparent. It would be interesting to further explore the relative activities of 
ubiquitin-dependent and –independent pathways in tenocytes. Levels of BNIP3 were not assessed in 
human tenocytes and should be performed in future work. Interestingly, elevated levels of COXIV 
were also detected in miR-181a mimic treated tendon constructs, consistent with increased 
mitochondrial biogenesis. These data combined, suggest miR-181 regulates mitochondrial turnover, 
not just mitophagy.  
There is a limited, but growing, body of work investigating the effect of miR-181 on autophagy and 
mitochondrial dynamics. Results can be conflicting, or difficult to corroborate, due to different 
experimental methodologies, cell types, or the novel aspect of the research. Results presented in 
this thesis support a role of miR-181 in regulating autophagy/mitophagy in tenocytes, but precludes 
conclusive determination as to whether this regulation is positive or negative. Effects of miR-181a 
and b on mitochondrial metabolism and function are reported in primary human chondrocytes 
(Zheng et al 2019) and in neuro- and myo-degenerative disease models (Ouyang et al 2012, Das et al 
2017, Liu et al 2017, Indrieri et al 2019, Goljanek-Whysall et al 2020). Extrapolation of these findings 
to the situation in tenocytes must be undertaken cautiously, given the context dependent nature of 
miRNA effects within and between cell types and disease processes (Das et al 2017, Yang et al 2017). 
 
8.8 Concluding remarks 
This project has demonstrated substantial changes in the small non-coding RNA (sncRNA) 
transcriptome occur with human tendinopathy, and identified similar changes in expression of three 
miRNAs (miR-29a, miR-181 and miR-199a) in equine tendinopathy. This suggests commonality in 
processes between the two species that supports the translational value of using equine tissue in the 
investigation of human disease. Additionally, results from gain and loss of miR-181 function in 
human and equine tenocyte monolayer culture, and equine tenocytes embedded in tissue-
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engineered three-dimensional constructs, indicate that miR-181 levels influence efficiency of 
autophagic processes, including mitochondrial degradation, by affecting both abundance and 
distribution of key autophagy-associated proteins. This work contributes to the understanding of the 
basic mechanistic processes which contribute to the disease state, therefore helping to inform how 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table A2.1 Small nucleolar RNA-61 (SNORD61) demonstrates greater stability of expression than 
small nucleolar RNA-68 (SNORD68) and small nuclear RNA-U6 (U6) in healthy and diseased equine 
superficial digital flexor tendon. 
 
Figure A2.1 Boxplots of regularised log counts obtained by RNA-seq for miRNA families subsequently 
evaluated by RT-qPCR. 
 
Figure A2.2 Differential expression of microRNAs used for RT-qPCR validation of human tendon RNA-






Table A2.1 Small nucleolar RNA-61 (SNORD61) demonstrates greater stability of expression than 
small nucleolar RNA-68 (SNORD68) and small nuclear RNA-U6 (U6) in healthy and diseased equine 
superficial digital flexor tendon. Threshold cycle (Ct) values are presented for 11 biological 
replicates, each run in triplicate. For two biological replicates both healthy and diseased tissue was 
available. Av = average (mean), D = diseased, H = healthy, SD = standard deviation, Max = maximum, 




Identity (Years) Difference Difference Difference
Ct Av Ct Ct Av Ct (D-H) Ct Av Ct Ct Av Ct (D-H) Ct Av Ct Ct Av Ct (D-H)
H1 3 23.66 23.54 32.46 32.47 22.42 22.33
H1 23.42 32.62 22.07
H1 24.23 32.34 22.5
H2 25 22.51 22.74 31.6 32.11 20.59 20.63
H2 22.66 32.07 20.58
H2 23.04 32.67 20.72
H3 4 20.16 20.07 29.5 29.69 20.05 20.09
H3 20.81 29.5 20.11
H3 19.97 30.08 20.1
H16 3 22.02 21.99 31.13 31.3 21.94 21.84
H16 23.28 31.54 21.69
H16 21.96 31.22 21.89
H18 19 21.46 21.77 30.48 30.56 19.69 19.86
H18 21.77 30.27 19.73
H18 22.09 30.93 20.16
H23 6 23.58 23.61 30.01 28.91 5.3 29.57 29.77 28.75 31.7 1.93 21.21 21.29 20.89 20.83 -0.46
H23 23.64 27.9 29.7 31.66 21.1 20.75
H23 23.61 28.83 30.05 31.74 21.56 20.85
H24 9 18.52 18.61 27.57 27.92 9.31 28.17 28.59 32.87 32.4 3.81 21.21 21.22 21.92 21.97 0.75
H24 19.25 29.91 28.85 32.22 20.95 22.05
H24 18.69 28.26 28.76 32.1 21.49 21.94
H27 18 32.13 31.72 33.33 33.64 22.79 22.86
H27 31.72 33.96 22.86
H27 31.32 33.62 22.93
H47 7 25.81 26.09 31.75 31.89 20.65 20.49
H47 26.36 32.02 20.43
H47 26.1 31.03 20.4
H52 6 22.67 22.6 31.16 31.16 21.97 21.85
H52 22.57 31.2 21.67
H52 22.57 31.12 21.92
H62 7 23.19 23.15 30.19 30.22 21.49 21.3
H62 22.94 30.36 21.26
H62 23.32 30.11 21.14
23.15 23.01 25.87 25.73 2.73 31.02 31.02 31.22 31.47 0.45 21.26 21.26 21.29 21.29 0.02
3.69 3.91 2.8 2.8 1.62 1.68 1.04 0.83 1.02 1.05 0.6 0.64
32.13 31.72 30.01 28.91 33.96 33.64 32.87 32.4 22.93 22.86 22.05 21.97
18.52 18.61 22.57 22.6 28.17 28.59 28.75 30.22 19.69 19.86 20.4 20.49































































































































































Figure A2.1 (includes preceding 4 pages) Boxplots of regularised log counts obtained by RNA-seq 
for miRNA families subsequently evaluated by RT-qPCR. A. miR-29a-3p.  B. miR-34a-5p.  C. miR-
34b-3p.  D. miR-34c-3p. E. miR-34c-5p.  F. miR-181a-3p.  G. miR-181a-5p.  H. miR-181b-3p.  I. miR-
181b-5p.  J. miR-181c-3p. K. miR-181c-5p.  L. miR-181d-5p.  M. miR-199a-3p.  N. miR-199a-5p.         




























































































































































































































































































































































































































































































Figure A2.2 (includes preceding 3 pages) Differential expression of microRNAs used for RT-qPCR 
validation of human tendon RNA-seq data, according to tendon type. Relative expression of A. 
miR-29a, B. miR-34a, C. miR-34b, D. miR-34c, E. miR-181a, F. miR-181b, G. miR-181c, H. miR-181d, I. 
miR-199a, J. miR-199b, K. miR-let-7f between Control (healthy hamstring) and tendinopathic 
supraspinatus (SSP) and posterior tibial (PTT) tendons. Data were normalised to SNORD61 
expression. Comparisons between Control and PTT utilised Mann Whitney U test; comparisons 
between Control and SSP utilised Student’s t-test. Graphs show median and inter-quartile range. * = 
P <0.05; ** = P <0.01. 






Table A3.1 Differential expression profiles of non-miRNA small RNA transcripts identified by RNA-seq 
from six healthy and six diseased human tendon samples. 
 
Table A3.2 Differential expression profiles of miRNA transcripts identified by RNA-seq from six 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0004481 chr22;chr9 -2.57 9.06E-07 hsa-let-7a-3p
MIMAT0026472 chr21 -3.40 1.75E-07 hsa-let-7c-3p
MIMAT0000067 chr9;chrX -2.11 0.00715716 hsa-let-7f-5p
MIMAT0031892 chr20 -2.84 0.014948579 hsa-miR-1-5p
MIMAT0004553 chr9 -3.75 0.001763863 hsa-miR-7-1-3p
MIMAT0000252 chr15;chr19;chr9 -3.60 3.05E-10 hsa-miR-7-5p
MIMAT0000441 chr1;chr15;chr5 -3.41 0.000340162 hsa-miR-9-5p
MIMAT0000253 chr17 -1.74 0.007508314 hsa-miR-10a-5p
MIMAT0004556 chr2 -3.05 9.97E-05 hsa-miR-10b-3p
MIMAT0000254 chr2 -3.12 3.62E-07 hsa-miR-10b-5p
MIMAT0000068 chr13 -4.62 1.86E-05 hsa-miR-15a-5p
MIMAT0000417 chr3 -2.13 0.002220854 hsa-miR-15b-5p
MIMAT0000069 chr13;chr3 -5.05 1.33E-17 hsa-miR-16-5p
MIMAT0004518 chr3 -3.30 1.08E-05 hsa-miR-16-2-3p
MIMAT0000070 chr13 -4.52 3.17E-16 hsa-miR-17-5p
MIMAT0000072 chr13 -3.48 0.023365177 hsa-miR-18a-5p
MIMAT0000073 chr13 -5.01 1.10E-06 hsa-miR-19a-3p
MIMAT0000074 chr13;chrX -6.57 7.27E-08 hsa-miR-19b-3p
MIMAT0000075 chr13 -4.27 5.06E-11 hsa-miR-20a-5p
MIMAT0001413 chrX -4.39 0.00021927 hsa-miR-20b-5p
MIMAT0000076 chr17 -4.85 1.77E-24 hsa-miR-21-5p
MIMAT0000077 chr17 -3.66 3.86E-10 hsa-miR-22-3p
MIMAT0000078 chr19 -3.64 8.84E-11 hsa-miR-23a-3p
MIMAT0000079 chr9 -2.62 2.93E-05 hsa-miR-24-1-5p
MIMAT0000080 chr19;chr9 -2.70 1.49E-09 hsa-miR-24-3p
MIMAT0004497 chr19 -3.71 1.22E-15 hsa-miR-24-2-5p
MIMAT0000082 chr12;chr3 -2.47 6.34E-08 hsa-miR-26a-5p
MIMAT0004681 chr12 -2.23 0.003354372 hsa-miR-26a-2-3p
MIMAT0000083 chr2 -3.77 5.48E-13 hsa-miR-26b-5p
MIMAT0000084 chr19 -2.46 0.000692675 hsa-miR-27a-3p
MIMAT0004501 chr19 -2.79 5.51E-09 hsa-miR-27a-5p
MIMAT0000419 chr9 -2.16 1.54E-07 hsa-miR-27b-3p
MIMAT0004502 chr3 -1.65 0.000319068 hsa-miR-28-3p
MIMAT0000085 chr3 -3.12 2.30E-07 hsa-miR-28-5p
MIMAT0000086 chr7 -1.91 7.22E-05 hsa-miR-29a-3p
MIMAT0000100 chr1;chr7 -3.77 1.07E-15 hsa-miR-29b-3p
MIMAT0004515 chr1 -1.52 0.032213347 hsa-miR-29b-2-5p
MIMAT0000681 chr1 -1.99 0.000171117 hsa-miR-29c-3p
MIMAT0000087 chr6 -2.95 8.44E-07 hsa-miR-30a-5p
MIMAT0000420 chr8 -3.45 2.72E-07 hsa-miR-30b-5p
MIMAT0004551 chr8 -5.27 4.42E-07 hsa-miR-30d-3p
MIMAT0000245 chr8 -1.59 3.66E-05 hsa-miR-30d-5p
MIMAT0000693 chr1 -1.60 0.031058981 hsa-miR-30e-3p
MIMAT0000692 chr1 -4.22 2.28E-13 hsa-miR-30e-5p
MIMAT0000090 chr9 -5.97 2.50E-12 hsa-miR-32-5p
MIMAT0000255 chr1 -2.03 0.002151014 hsa-miR-34a-5p
MIMAT0000686 chr11 -1.66 0.014910912 hsa-miR-34c-5p
MIMAT0000093 chr7 -2.56 3.40E-06 hsa-miR-93-5p
MIMAT0000095 chr7 -3.18 0.012041173 hsa-miR-96-5p
MIMAT0000096 chrX -2.53 5.35E-05 hsa-miR-98-5p




Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0000098 chr11 -2.97 1.41E-12 hsa-miR-100-5p
MIMAT0000099 chr1;chr9 -6.35 3.38E-29 hsa-miR-101-3p
MIMAT0004513 chr1 -4.23 0.000353944 hsa-miR-101-5p
MIMAT0037312 chr9 -3.76 0.022552453 hsa-miR-101-2-5p
MIMAT0000101 chr20;chr5 -2.55 1.87E-07 hsa-miR-103a-3p
MIMAT0000103 chrX -4.64 0.000622224 hsa-miR-106a-5p
MIMAT0000680 chr7 -3.21 2.12E-06 hsa-miR-106b-5p
MIMAT0000104 chr10 -2.70 4.35E-05 hsa-miR-107
MIMAT0004592 chr11 -2.29 1.69E-07 hsa-miR-125b-1-3p
MIMAT0004603 chr21 -2.31 1.00E-10 hsa-miR-125b-2-3p
MIMAT0000423 chr11;chr21 -2.98 4.71E-20 hsa-miR-125b-5p
MIMAT0000445 chr9 -3.17 1.51E-06 hsa-miR-126-3p
MIMAT0000444 chr9 -1.92 0.002065876 hsa-miR-126-5p
MIMAT0004604 chr14 -4.50 1.22E-09 hsa-miR-127-5p
MIMAT0000425 chr11 -5.79 8.79E-09 hsa-miR-130a-3p
MIMAT0000426 chr17 -1.96 0.000500724 hsa-miR-132-3p
MIMAT0000447 chr14 -1.60 0.000478835 hsa-miR-134-5p
MIMAT0004606 chr14 -4.84 6.14E-11 hsa-miR-136-3p
MIMAT0000448 chr14 -4.75 1.02E-10 hsa-miR-136-5p
MIMAT0004597 chr16 -2.76 2.12E-06 hsa-miR-140-3p
MIMAT0000431 chr16 -5.37 1.10E-30 hsa-miR-140-5p
MIMAT0000434 chr17 -5.42 5.47E-11 hsa-miR-142-3p
MIMAT0000433 chr17 -4.46 0.000283781 hsa-miR-142-5p
MIMAT0000435 chr5 -4.76 1.41E-13 hsa-miR-143-3p
MIMAT0004599 chr5 -2.40 0.000223936 hsa-miR-143-5p
MIMAT0004600 chr17 -6.32 3.82E-08 hsa-miR-144-5p
MIMAT0004601 chr5 -2.88 6.72E-06 hsa-miR-145-3p
MIMAT0000437 chr5 -1.54 0.009340063 hsa-miR-145-5p
MIMAT0000449 chr5 -2.81 1.26E-06 hsa-miR-146a-5p
MIMAT0002809 chr10 -3.25 2.66E-10 hsa-miR-146b-5p
MIMAT0000243 chr7 -4.33 2.29E-18 hsa-miR-148a-3p
MIMAT0000759 chr12 -1.78 0.00348891 hsa-miR-148b-3p
MIMAT0004699 chr12 -2.65 8.30E-06 hsa-miR-148b-5p
MIMAT0000757 chr8 -1.71 0.001032975 hsa-miR-151a-3p
MIMAT0004697 chr8 -2.59 1.68E-05 hsa-miR-151a-5p
MIMAT0000438 chr17 -3.02 1.81E-06 hsa-miR-152-3p
MIMAT0000452 chr14 -2.31 0.005239835 hsa-miR-154-5p
MIMAT0000270 chr1 -4.28 9.25E-07 hsa-miR-181a-3p
MIMAT0004559 chr19 -4.12 0.000196064 hsa-miR-181c-3p
MIMAT0000258 chr19 -2.59 0.000196613 hsa-miR-181c-5p
MIMAT0002821 chr19 -2.82 6.14E-11 hsa-miR-181d-5p
MIMAT0000259 chr7 -3.17 0.000810915 hsa-miR-182-5p
MIMAT0000455 chr22 -3.52 3.93E-07 hsa-miR-185-5p
MIMAT0000456 chr1 -2.72 4.95E-08 hsa-miR-186-5p
MIMAT0000458 chr15 -3.67 0.009003075 hsa-miR-190a-5p
MIMAT0000222 chr11 -2.59 0.002013938 hsa-miR-192-5p
MIMAT0004767 chr16 2.18 0.007485041 hsa-miR-193b-5p
MIMAT0000460 chr1;chr11 -4.16 1.60E-06 hsa-miR-194-5p
MIMAT0000461 chr17 -4.97 3.34E-11 hsa-miR-195-5p
MIMAT0000226 chr12;chr17 -4.31 2.92E-15 hsa-miR-196a-5p




Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0000232 chr1;chr19 -4.69 3.36E-18 hsa-miR-199a-3p
MIMAT0000231 chr1;chr19 -2.98 1.68E-11 hsa-miR-199a-5p
MIMAT0004563 chr9 -4.31 3.09E-15 hsa-miR-199b-3p
MIMAT0000263 chr9 -4.86 4.30E-21 hsa-miR-199b-5p
MIMAT0000682 chr1 -3.07 0.027415471 hsa-miR-200a-3p
MIMAT0000318 chr1 -3.95 2.91E-07 hsa-miR-200b-3p
MIMAT0000264 chr14 -4.71 0.000107844 hsa-miR-203a-3p
MIMAT0000266 chr1 -4.25 0.006652449 hsa-miR-205-5p
MIMAT0004960 chr14 -3.73 0.005264697 hsa-miR-208b-3p
MIMAT0000271 chr1 -1.95 2.62E-06 hsa-miR-214-3p
MIMAT0004564 chr1 -1.96 1.81E-05 hsa-miR-214-5p
MIMAT0000272 chr1 -3.82 0.000138578 hsa-miR-215-5p
MIMAT0000275 chr4;chr5 -3.50 8.85E-21 hsa-miR-218-5p
MIMAT0000278 chrX -1.64 0.002641838 hsa-miR-221-3p
MIMAT0004568 chrX -2.44 8.34E-05 hsa-miR-221-5p
MIMAT0000280 chrX -2.08 0.000276512 hsa-miR-223-3p
MIMAT0004570 chrX -3.50 3.96E-08 hsa-miR-223-5p
MIMAT0022696 chr17 -2.91 0.00542813 hsa-miR-301a-5p
MIMAT0000761 chr17 -1.62 0.04689793 hsa-miR-324-5p
MIMAT0001629 chr14;chr14 -2.91 0.00057691 hsa-miR-329-3p
MIMAT0000765 chr7 -5.88 3.17E-16 hsa-miR-335-5p
MIMAT0000754 chr14 -1.88 0.0103495 hsa-miR-337-3p
MIMAT0004702 chr7 -1.63 0.006299575 hsa-miR-339-3p
MIMAT0000750 chr5 -1.85 0.001345583 hsa-miR-340-3p
MIMAT0004692 chr5 -5.66 3.21E-28 hsa-miR-340-5p
MIMAT0004682 chrX -1.66 1.57E-05 hsa-miR-361-3p
MIMAT0000703 chrX -2.87 7.13E-10 hsa-miR-361-5p
MIMAT0000707 chrX -2.07 0.000318207 hsa-miR-363-3p
MIMAT0000710 chr16 -2.04 1.54E-05 hsa-miR-365a-3p
MIMAT0001621 chr14 -3.29 0.01184179 hsa-miR-369-5p
MIMAT0000724 chr19 -4.43 0.001677136 hsa-miR-372-3p
MIMAT0004688 chrX -6.76 2.92E-17 hsa-miR-374a-3p
MIMAT0000727 chrX -5.34 1.09E-20 hsa-miR-374a-5p
MIMAT0004956 chrX -5.20 5.04E-07 hsa-miR-374b-3p
MIMAT0004955 chrX -4.25 8.80E-05 hsa-miR-374b-5p
MIMAT0000730 chr14 -4.22 0.000704663 hsa-miR-377-3p
MIMAT0000733 chr14 -2.36 0.011406068 hsa-miR-379-5p
MIMAT0000736 chr14 -3.09 5.93E-07 hsa-miR-381-3p
MIMAT0022697 chr14 -5.13 5.39E-09 hsa-miR-382-3p
MIMAT0000737 chr14 -1.52 0.000415788 hsa-miR-382-5p
MIMAT0000738 chr8 -5.65 3.81E-05 hsa-miR-383-5p
MIMAT0001638 chr14 -3.33 8.74E-09 hsa-miR-409-5p
MIMAT0003329 chr14 -3.94 2.36E-08 hsa-miR-411-5p
MIMAT0003339 chrX -2.79 4.57E-05 hsa-miR-421
MIMAT0001343 chr3 -1.65 0.01635651 hsa-miR-425-3p
MIMAT0003393 chr3 -2.25 1.81E-06 hsa-miR-425-5p
MIMAT0001545_1 chrX -3.34 0.012196095 hsa-miR-450a-5p
MIMAT0004909 chrX -4.72 5.35E-05 hsa-miR-450b-5p
MIMAT0001631 chr17 -7.15 1.63E-14 hsa-miR-451a
MIMAT0001636 chrX -4.36 1.77E-05 hsa-miR-452-3p




Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0003885 chr17 -5.12 5.52E-08 hsa-miR-454-3p
MIMAT0003150 chr9 -4.44 7.53E-14 hsa-miR-455-5p
MIMAT0002173 chr11 -2.90 0.000399289 hsa-miR-483-3p
MIMAT0003180 chr14 -2.06 7.71E-05 hsa-miR-487b-3p
MIMAT0002805 chr7 -2.82 0.043943152 hsa-miR-489-3p
MIMAT0003161 chr14 -2.50 2.56E-06 hsa-miR-493-3p
MIMAT0002813 chr14 -2.49 0.001186299 hsa-miR-493-5p
MIMAT0002816 chr14 -4.69 3.45E-13 hsa-miR-494-3p
MIMAT0002817 chr14 -2.98 0.000463808 hsa-miR-495-3p
MIMAT0002820 chr17 -3.58 4.01E-11 hsa-miR-497-5p
MIMAT0002871 chrX -3.63 3.19E-18 hsa-miR-500a-3p
MIMAT0004774 chrX -1.67 6.68E-05 hsa-miR-501-3p
MIMAT0004775 chrX -2.89 9.47E-08 hsa-miR-502-3p
MIMAT0004975 chrX -3.92 0.002437028 hsa-miR-509-3-5p
MIMAT0026606 chr10 -3.01 0.028735277 hsa-miR-511-3p
MIMAT0002859 chr19;chr19 -2.48 0.014594778 hsa-miR-516b-5p
MIMAT0002888 chrX -2.16 1.66E-07 hsa-miR-532-5p
MIMAT0022705 chr14 -4.85 1.25E-05 hsa-miR-539-3p
MIMAT0003389 chrX -3.77 0.003068131 hsa-miR-542-3p
MIMAT0005874 chr10 -3.01 0.023254097 hsa-miR-548e-3p
MIMAT0003241 chr4 -3.78 3.39E-07 hsa-miR-576-5p
MIMAT0004797 chr5 -3.36 0.001032975 hsa-miR-582-3p
MIMAT0003250 chr5 -2.28 0.003205365 hsa-miR-585-3p
MIMAT0004801 chr7 -3.58 0.007500461 hsa-miR-590-3p
MIMAT0003266 chr8 -5.53 1.74E-06 hsa-miR-598-3p
MIMAT0003280 chr11 2.86 0.028222836 hsa-miR-612
MIMAT0004808 chr14 -2.07 0.00542813 hsa-miR-625-3p
MIMAT0004809 chr15 -1.98 0.003144318 hsa-miR-628-5p
MIMAT0003302 chr17 2.50 6.48E-07 hsa-miR-632
MIMAT0003321 chrX -3.32 0.006652116 hsa-miR-651-5p
MIMAT0003322 chrX -2.18 0.006697667 hsa-miR-652-3p
MIMAT0003328 chr7 -5.22 3.62E-07 hsa-miR-653-5p
MIMAT0004814 chr14 -1.81 0.000283076 hsa-miR-654-3p
MIMAT0003331 chr14 -4.17 4.57E-05 hsa-miR-655-3p
MIMAT0003338 chrX -5.85 1.04E-21 hsa-miR-660-5p
MIMAT0005949 chr1 -1.89 3.09E-05 hsa-miR-664a-3p
MIMAT0003880 chr7 -4.71 8.86E-08 hsa-miR-671-5p
MIMAT0004927 chr11 -3.93 0.002151014 hsa-miR-708-3p
MIMAT0004926 chr11 -4.16 2.29E-18 hsa-miR-708-5p
MIMAT0003879 chr14 -2.13 0.009831129 hsa-miR-758-3p
MIMAT0003886 chr19 -2.48 7.86E-06 hsa-miR-769-5p
MIMAT0004951 chr5 -2.08 0.04689793 hsa-miR-887-3p
MIMAT0004921 chr14 -4.18 0.0001279 hsa-miR-889-3p
MIMAT0004987 chr3 -2.67 0.01635651 hsa-miR-944
MIMAT0022838 chr14 -3.26 0.016722514 hsa-miR-1185-1-3p
MIMAT0005901 chr22 -2.39 0.017926381 hsa-miR-1249-3p
MIMAT0005906 chr4 -2.70 0.019068302 hsa-miR-1255a
MIMAT0005936 chr1 -3.73 0.003688757 hsa-miR-1278
MIMAT0005878 chr10 -2.06 0.001242288 hsa-miR-1287-5p
MIMAT0005881 chr12 1.90 4.08E-07 hsa-miR-1291




Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0015066 chr17 -3.72 0.003764746 hsa-miR-3065-5p
MIMAT0017991 chr13 -4.32 0.000138811 hsa-miR-3613-3p
MIMAT0017990 chr13 -5.92 7.49E-19 hsa-miR-3613-5p
MIMAT0018072 chr12 2.93 0.003390836 hsa-miR-3652
MIMAT0018074 chr7 2.38 0.020231885 hsa-miR-3654
MIMAT0018075 chr5 1.78 0.007443976 hsa-miR-3655
MIMAT0018191 chr1 2.64 0.000821911 hsa-miR-3917
MIMAT0019019 chr11 3.73 0.005572547 hsa-miR-4485-3p
MIMAT0019731 chr8 -4.75 2.85E-05 hsa-miR-4662a-5p
MIMAT0019744 chr9 3.90 0.019236461 hsa-miR-4667-3p
MIMAT0019761 chr1 -3.26 0.013506776 hsa-miR-4677-3p
MIMAT0019970 chr3 -3.16 0.041643603 hsa-miR-4796-5p
MIMAT0022472 chr6 -4.99 0.000201776 hsa-miR-5683
MIMAT0024598 chr12 1.67 0.008723689 hsa-miR-6125
MIMAT0025470 chr10 -4.27 0.000308331 hsa-miR-6507-5p
MIMAT0025856 chr21;chr21;chr21;chr21 4.00 1.16E-06 hsa-miR-6724-5p
MIMAT0041615 chr11 2.12 0.000215017 hsa-miR-10392-5p
MIMAT0041620 chr19 1.77 0.044227164 hsa-miR-10394-3p
MIMAT0049032 chr1 2.14 0.01825495 hsa-miR-12136
MIMAT0000062 chr9;chr11;chr22 -0.48 0.413965287 hsa-let-7a-5p
MIMAT0004482 chr22 -0.32 0.597128339 hsa-let-7b-3p
MIMAT0000063 chr22 0.24 0.682287116 hsa-let-7b-5p
MIMAT0000064 chr21 -0.33 0.492557966 hsa-let-7c-5p
MIMAT0004484 chr9 1.01 0.022552453 hsa-let-7d-3p
MIMAT0000065 chr9 -0.22 0.757174192 hsa-let-7d-5p
MIMAT0004485 chr19 -0.41 0.682287116 hsa-let-7e-3p
MIMAT0000066 chr19 0.59 0.279087895 hsa-let-7e-5p
MIMAT0004486 chr9 -0.86 0.130731986 hsa-let-7f-1-3p
MIMAT0004487 chrX 0.94 0.405841352 hsa-let-7f-2-3p
MIMAT0000414 chr3 0.00 0.998265009 hsa-let-7i-3p
MIMAT0004585 chr12 -0.97 0.09972312 hsa-let-7g-5p
MIMAT0000415 chr12 -0.86 0.016625071 hsa-let-7i-5p
MIMAT0000416 chr18;chr20 -3.01 0.0686688 hsa-miR-1-3p
MIMAT0000442_1 chr15 -2.51 0.321055779 hsa-miR-9-3p
MIMAT0004555 chr17 -1.04 0.652478678 hsa-miR-10a-3p
MIMAT0004488 chr13 -2.31 0.357464214 hsa-miR-15a-3p
MIMAT0004586 chr3 -2.79 0.059258826 hsa-miR-15b-3p
MIMAT0002891 chr13 0.58 0.633106555 hsa-miR-18a-3p
MIMAT0004494 chr17 -1.18 0.283713611 hsa-miR-21-3p
MIMAT0004495 chr17 -1.79 0.075724601 hsa-miR-22-5p
MIMAT0004496 chr19 1.04 0.383280593 hsa-miR-23a-5p
MIMAT0000418 chr9 -1.12 0.005404021 hsa-miR-23b-3p
MIMAT0004587 chr9 0.69 0.332851698 hsa-miR-23b-5p
MIMAT0000081 chr7 -1.31 0.002013938 hsa-miR-25-3p
MIMAT0004498 chr7 0.57 0.291605087 hsa-miR-25-5p
MIMAT0004500 chr2 0.13 0.896016639 hsa-miR-26b-3p
MIMAT0004588 chr9 -1.29 0.080771694 hsa-miR-27b-5p
MIMAT0004514 chr7 0.76 0.472257209 hsa-miR-29b-1-5p
MIMAT0004673 chr1 -1.14 0.022552453 hsa-miR-29c-5p
MIMAT0000088 chr6 -0.42 0.658966639 hsa-miR-30a-3p




Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0004550 chr6 -1.28 0.044845342 hsa-miR-30c-2-3p
MIMAT0004674 chr1 -1.65 0.101003672 hsa-miR-30c-1-3p
MIMAT0000244 chr1;chr6 -0.56 0.334727096 hsa-miR-30c-5p
MIMAT0004506 chr22 1.88 0.199699614 hsa-miR-33a-3p
MIMAT0004676 chr11 -0.14 0.948855971 hsa-miR-34b-3p
MIMAT0004677 chr11 -1.17 0.500440987 hsa-miR-34c-3p
MIMAT0000092 chr13;chrX -0.53 0.09758533 hsa-miR-92a-3p
MIMAT0004507 chr13 0.96 0.256119449 hsa-miR-92a-1-5p
MIMAT0003218 chr1 -0.17 0.800739207 hsa-miR-92b-3p
MIMAT0004792 chr1 0.48 0.593914457 hsa-miR-92b-5p
MIMAT0004509 chr7 -1.15 0.150282064 hsa-miR-93-3p
MIMAT0000094 chr4 -1.10 0.273151351 hsa-miR-95-3p
MIMAT0022842 chrX 1.78 0.202677653 hsa-miR-98-3p
MIMAT0004511 chr21 -0.97 0.161292322 hsa-miR-99a-3p
MIMAT0004678 chr19 0.35 0.472456379 hsa-miR-99b-3p
MIMAT0000689 chr19 0.07 0.860879455 hsa-miR-99b-5p
MIMAT0004512 chr11 0.17 0.93535566 hsa-miR-100-3p
MIMAT0009196 chr20 -3.14 0.094573 hsa-miR-103a-2-5p
MIMAT0004672 chr7 -1.13 0.000633555 hsa-miR-106b-3p
MIMAT0000421 chr18 -1.33 0.263628621 hsa-miR-122-5p
MIMAT0019876 chr18 -0.19 0.90215418 hsa-miR-122b-5p
MIMAT0004602 chr19 -3.13 0.071518821 hsa-miR-125a-3p
MIMAT0000443 chr19 -0.70 0.074494388 hsa-miR-125a-5p
MIMAT0000446 chr14 -1.42 5.78E-07 hsa-miR-127-3p
MIMAT0026477 chr2 0.94 0.593096342 hsa-miR-128-1-5p
MIMAT0000424 chr2;chr3 -0.17 0.898412989 hsa-miR-128-3p
MIMAT0004593 chr11 -1.87 0.15848136 hsa-miR-130a-5p
MIMAT0004680 chr22 0.15 0.823241614 hsa-miR-130b-5p
MIMAT0004594 chr17 -0.81 0.217976655 hsa-miR-132-5p
MIMAT0000427 chr18;chr20 -1.21 0.357252812 hsa-miR-133a-3p
MIMAT0026478 chr18;chr20 -1.08 0.426562915 hsa-miR-133a-5p
MIMAT0000770 chr6 -1.67 0.174919198 hsa-miR-133b
MIMAT0004552 chr11 0.60 0.230917505 hsa-miR-139-3p
MIMAT0000250 chr11 0.38 0.537384939 hsa-miR-139-5p
MIMAT0004608 chr5 -0.71 0.633106555 hsa-miR-146a-3p
MIMAT0004766 chr10 -0.76 0.477843246 hsa-miR-146b-3p
MIMAT0004549 chr7 -1.46 0.012069842 hsa-miR-148a-5p
MIMAT0000450 chr2 0.72 0.158435987 hsa-miR-149-5p
MIMAT0004610 chr19 0.36 0.808486171 hsa-miR-150-3p
MIMAT0000451 chr19 -0.14 0.772574778 hsa-miR-150-5p
MIMAT0026479 chr17 -1.14 0.032498843 hsa-miR-152-5p
MIMAT0000646 chr21 0.00 0.995646572 hsa-miR-155-5p
MIMAT0004558 chr9 0.52 0.504854156 hsa-miR-181a-2-3p
MIMAT0000256 chr1;chr9 -1.31 1.07E-05 hsa-miR-181a-5p
MIMAT0022692 chr1 -1.55 0.268502198 hsa-miR-181b-3p
MIMAT0000257 chr1;chr9 -1.02 0.000198381 hsa-miR-181b-5p
MIMAT0000261 chr7 -1.33 0.069836531 hsa-miR-183-5p
MIMAT0000454 chr15 1.22 0.452200962 hsa-miR-184
MIMAT0004929 chr1 1.63 0.107292608 hsa-miR-190b-5p
MIMAT0000440 chr3 -1.23 0.001334452 hsa-miR-191-5p




Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0004614 chr17 0.75 0.068543836 hsa-miR-193a-5p
MIMAT0002819 chr16 0.38 0.576818875 hsa-miR-193b-3p
MIMAT0004615 chr17 -0.20 0.664016217 hsa-miR-195-3p
MIMAT0009201 chr7 0.44 0.793351372 hsa-miR-196b-3p
MIMAT0000227 chr1 -0.03 0.958502163 hsa-miR-197-3p
MIMAT0022691 chr1 1.55 0.346933234 hsa-miR-197-5p
MIMAT0000228 chr3 1.68 0.10336532 hsa-miR-198
MIMAT0000617 chr12 -0.99 0.09395942 hsa-miR-200c-3p
MIMAT0022693 chr9 0.27 0.869087749 hsa-miR-204-3p
MIMAT0000265 chr9 -1.30 0.021160598 hsa-miR-204-5p
MIMAT0000462 chr6 -0.80 0.585452345 hsa-miR-206
MIMAT0000267 chr11 -1.49 0.002437028 hsa-miR-210-3p
MIMAT0026475 chr11 -0.30 0.88347376 hsa-miR-210-5p
MIMAT0000269 chr17 -1.39 0.256389703 hsa-miR-212-3p
MIMAT0022695 chr17 -0.20 0.764013058 hsa-miR-212-5p
MIMAT0004565 chr4 -2.70 0.175850826 hsa-miR-218-1-3p
MIMAT0000279 chrX -0.20 0.711266313 hsa-miR-222-3p
MIMAT0009198 chrX -2.16 0.14113579 hsa-miR-224-3p
MIMAT0000281 chrX -0.19 NA hsa-miR-224-5p
MIMAT0004679 chr20 -1.33 0.418927415 hsa-miR-296-3p
MIMAT0000687 chr14 -3.21 0.059792404 hsa-miR-299-3p
MIMAT0002890 chr14 -1.77 0.094161579 hsa-miR-299-5p
MIMAT0000683 chr4 -0.43 0.825161988 hsa-miR-302a-5p
MIMAT0000510 chr8 0.42 0.444745895 hsa-miR-320a-3p
MIMAT0037311 chr8 1.25 0.222733975 hsa-miR-320a-5p
MIMAT0005792 chr1;chr1 1.04 0.206260688 hsa-miR-320b
MIMAT0000755 chr14 -0.82 0.134660597 hsa-miR-323a-3p
MIMAT0000752 chr16 1.01 0.0103495 hsa-miR-328-3p
MIMAT0000751 chr19 -0.18 0.754020903 hsa-miR-330-3p
MIMAT0004693 chr19 -1.69 0.315220213 hsa-miR-330-5p
MIMAT0000760 chr12 0.04 0.978208228 hsa-miR-331-3p
MIMAT0004700 chr12 -1.70 0.052924829 hsa-miR-331-5p
MIMAT0004703 chr7 -1.33 NA hsa-miR-335-3p
MIMAT0000764 chr7 -1.32 0.061164623 hsa-miR-339-5p
MIMAT0000753 chr14 -0.80 0.052379399 hsa-miR-342-3p
MIMAT0004694 chr14 1.48 0.004268322 hsa-miR-342-5p
MIMAT0000772 chr14 -0.29 0.603761139 hsa-miR-345-5p
MIMAT0000773 chr10 -0.96 0.593096342 hsa-miR-346
MIMAT0000705 chrX -1.06 0.164733517 hsa-miR-362-5p
MIMAT0009199 chr16 1.24 0.011406068 hsa-miR-365a-5p
MIMAT0022834 chr17 -1.24 0.001583584 hsa-miR-365b-3p
MIMAT0022833 chr17 -0.59 0.491508778 hsa-miR-365b-5p
MIMAT0000721 chr14 -3.05 0.059275773 hsa-miR-369-3p
MIMAT0000722 chr14 -0.57 0.161848728 hsa-miR-370-3p
MIMAT0026483 chr14 -1.88 0.200661286 hsa-miR-370-5p
MIMAT0000729 chr14;chr14 -2.64 0.13134623 hsa-miR-376a-3p
MIMAT0002172 chr14 0.45 0.724586755 hsa-miR-376b-3p
MIMAT0000720 chr14 -2.56 0.191297903 hsa-miR-376c-3p
MIMAT0022861 chr14 -1.10 0.556815274 hsa-miR-376c-5p
MIMAT0004689 chr14 -2.00 0.142518008 hsa-miR-377-5p




Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0000731 chr5 -0.85 0.472257209 hsa-miR-378a-5p
MIMAT0019074 chr22 -0.90 0.652478678 hsa-miR-378i
MIMAT0001639 chr14 -0.21 0.579231772 hsa-miR-409-3p
MIMAT0026557 chr14 -0.98 0.593914457 hsa-miR-412-5p
MIMAT0001340 chr17 0.76 0.001025486 hsa-miR-423-3p
MIMAT0004748 chr17 0.84 0.036836424 hsa-miR-423-5p
MIMAT0004749 chrX 0.77 0.482222709 hsa-miR-424-3p
MIMAT0004757 chr14 -0.87 0.359107228 hsa-miR-431-3p
MIMAT0002814 chr14 0.56 0.30755675 hsa-miR-432-5p
MIMAT0001627 chr14 -0.84 0.023485045 hsa-miR-433-3p
MIMAT0010251 chr5 -0.13 0.938403518 hsa-miR-449c-5p
MIMAT0003884 chr17 -0.95 0.418743893 hsa-miR-454-5p
MIMAT0004784 chr9 0.07 0.920598316 hsa-miR-455-3p
MIMAT0004761 chr11 0.02 0.982647465 hsa-miR-483-5p
MIMAT0002174 chr16 -0.76 0.162829738 hsa-miR-484
MIMAT0002176 chr14 0.59 0.49317228 hsa-miR-485-3p
MIMAT0002175 chr14 -0.66 0.1401763 hsa-miR-485-5p
MIMAT0004762 chr8;chr8 0.66 0.652478678 hsa-miR-486-3p
MIMAT0002177 chr8;chr8 0.81 0.335355499 hsa-miR-486-5p
MIMAT0026559 chr14 -0.50 0.472567494 hsa-miR-487a-5p
MIMAT0002807 chr9 -0.56 0.580124105 hsa-miR-491-5p
MIMAT0004772 chr20 2.75 0.277879228 hsa-miR-499a-3p
MIMAT0002870 chr20 -1.24 0.504108054 hsa-miR-499a-5p
MIMAT0004773 chrX -0.55 0.667775057 hsa-miR-500a-5p
MIMAT0027032 chrX -1.77 0.368851687 hsa-miR-500b-3p
MIMAT0016925 chrX -1.50 0.223487963 hsa-miR-500b-5p
MIMAT0002872 chrX -0.47 0.525656503 hsa-miR-501-5p
MIMAT0002875 chrX -0.60 0.328713718 hsa-miR-504-5p
MIMAT0002876 chrX -0.35 0.49317228 hsa-miR-505-3p
MIMAT0004776 chrX 0.86 0.266119624 hsa-miR-505-5p
MIMAT0002878 chrX 0.48 0.764822298 hsa-miR-506-3p
MIMAT0002880 chrX -2.59 0.21199785 hsa-miR-508-3p
MIMAT0002808 chr10 0.10 0.915915476 hsa-miR-511-5p
MIMAT0002858 chr19 -2.38 0.253695548 hsa-miR-520g-3p
MIMAT0002835 chr19 -1.61 0.354169597 hsa-miR-526b-5p
MIMAT0004780 chrX -0.31 0.662587171 hsa-miR-532-3p
MIMAT0003163 chr14 -1.79 0.064947861 hsa-miR-539-5p
MIMAT0004920 chr14 -1.35 0.438926639 hsa-miR-541-3p
MIMAT0004954 chr14 -0.43 0.363806858 hsa-miR-543
MIMAT0022471 chr9 -3.01 0.142532723 hsa-miR-548aw
MIMAT0005875 chr22 -0.44 0.802633622 hsa-miR-548j-5p
MIMAT0005882 chr11 -2.45 0.079915648 hsa-miR-548k
MIMAT0005919 chr7;chr20 -0.77 0.521247118 hsa-miR-548o-3p
MIMAT0004800 chr7 -0.57 0.765686567 hsa-miR-550a-5p
MIMAT0003239 chr4 0.17 0.830674136 hsa-miR-574-3p
MIMAT0004795 chr4 -0.25 0.779295524 hsa-miR-574-5p
MIMAT0004796 chr4 -2.18 0.168033042 hsa-miR-576-3p
MIMAT0003246 chr5 -1.62 0.355924986 hsa-miR-581
MIMAT0003247 chr5 -1.71 0.472257209 hsa-miR-582-5p
MIMAT0003249 chr5 -0.53 0.690518857 hsa-miR-584-5p




Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0026619 chr8 -1.71 0.336535771 hsa-miR-597-3p
MIMAT0026621 chr10 -0.52 0.817038348 hsa-miR-605-3p
MIMAT0003283 chr12 -0.23 0.762993824 hsa-miR-615-3p
MIMAT0004804 chr12 -0.66 0.691512693 hsa-miR-615-5p
MIMAT0004805 chr12 -1.56 0.296452573 hsa-miR-616-3p
MIMAT0003287 chr12 0.37 0.669508161 hsa-miR-618
MIMAT0003297 chr15 -1.30 0.061164623 hsa-miR-628-3p
MIMAT0004810 chr15 -1.64 0.051478918 hsa-miR-629-5p
MIMAT0003309 chr19 0.42 0.745641731 hsa-miR-639
MIMAT0003311 chr19 -1.36 0.115712485 hsa-miR-641
MIMAT0003330 chr14 -0.97 0.021406543 hsa-miR-654-5p
MIMAT0022710 chr22 -2.01 0.072518398 hsa-miR-659-5p
MIMAT0005867 chr2 -1.14 0.559056293 hsa-miR-663b
MIMAT0005948 chr1 -0.48 0.509049413 hsa-miR-664a-5p
MIMAT0022272 chrX 1.20 0.133736071 hsa-miR-664b-3p
MIMAT0022271 chrX 1.41 0.000128008 hsa-miR-664b-5p
MIMAT0003881 chr14 2.23 0.18770723 hsa-miR-668-3p
MIMAT0004819 chr7 1.23 0.017266595 hsa-miR-671-3p
MIMAT0006790 chr11 -0.42 0.652478678 hsa-miR-675-3p
MIMAT0004284 chr11 -0.96 0.354738471 hsa-miR-675-5p
MIMAT0018204 chrX -0.85 0.572378395 hsa-miR-676-3p
MIMAT0004946 chr17 0.83 0.497029229 hsa-miR-744-3p
MIMAT0004945 chr17 -0.46 0.277285584 hsa-miR-744-5p
MIMAT0004957 chr1 2.18 0.096755139 hsa-miR-760
MIMAT0003888 chrX -0.17 0.883918735 hsa-miR-766-3p
MIMAT0022714 chrX 0.02 0.991930467 hsa-miR-766-5p
MIMAT0003887 chr19 -0.43 0.762533052 hsa-miR-769-3p
MIMAT0004911 chr5 -0.58 0.188777325 hsa-miR-874-3p
MIMAT0004949 chr6 1.70 0.138236968 hsa-miR-877-5p
MIMAT0004947 chr3 -0.48 0.694673039 hsa-miR-885-5p
MIMAT0026720 chr5 -1.17 0.245072758 hsa-miR-887-5p
MIMAT0004916 chrX -2.35 0.19644372 hsa-miR-888-5p
MIMAT0004902 chrX -0.26 0.882733863 hsa-miR-891a-5p
MIMAT0004978 chr19 -0.14 0.923553741 hsa-miR-935
MIMAT0004984 chr20;chr20;chr20;chr20;chr20 -0.83 0.03509809 hsa-miR-941
MIMAT0004985 chr1 0.03 0.982005235 hsa-miR-942-5p
MIMAT0005825 chr17 0.35 0.459273255 hsa-miR-1180-3p
MIMAT0005826 chr19 0.48 0.805339397 hsa-miR-1181
MIMAT0005573 chr16 0.33 0.742039684 hsa-miR-1225-3p
MIMAT0005572 chr16 0.96 0.478605097 hsa-miR-1225-5p
MIMAT0005583 chr12 -0.29 0.866372984 hsa-miR-1228-3p
MIMAT0005582 chr12 -2.37 0.206260688 hsa-miR-1228-5p
MIMAT0005896_2 chr2;chr5 1.15 0.403818715 hsa-miR-1244
MIMAT0005899 chr14 0.81 0.448238261 hsa-miR-1247-5p
MIMAT0005900 chr3 0.34 0.477076409 hsa-miR-1248
MIMAT0005914 chr1 -0.79 0.524367053 hsa-miR-1262
MIMAT0005924 chr19 -2.38 0.185804054 hsa-miR-1270
MIMAT0005796 chr5 -0.81 0.316849757 hsa-miR-1271-5p
MIMAT0005943 chr20 0.02 0.98509882 hsa-miR-1292-5p
MIMAT0005884 chr5 -2.55 0.070497333 hsa-miR-1294




Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0005797 chr2 0.25 0.741874573 hsa-miR-1301-3p
MIMAT0005891 chr5 0.09 0.951447935 hsa-miR-1303
MIMAT0005892 chr11 -0.40 0.806724019 hsa-miR-1304-5p
MIMAT0005950 chr22 1.21 0.442650954 hsa-miR-1306-3p
MIMAT0022726 chr22 -0.15 0.916236624 hsa-miR-1306-5p
MIMAT0005951 chr10 0.74 0.022552453 hsa-miR-1307-3p
MIMAT0022727 chr10 -0.43 0.689403951 hsa-miR-1307-5p
MIMAT0005795 chr19 -2.68 0.096485235 hsa-miR-1323
MIMAT0019776 chr11 -0.40 0.866372984 hsa-miR-1343-3p
MIMAT0006789 chrX 0.38 0.631529448 hsa-miR-1468-5p
MIMAT0039764 chr1 0.28 0.636443882 hsa-miR-1843
MIMAT0009451 chr1 0.60 0.762533052 hsa-miR-1976
MIMAT0017352 chr5 -1.22 0.35863189 hsa-miR-2277-5p
MIMAT0017950 chr2 -0.88 0.578415275 hsa-miR-2355-3p
MIMAT0019865 chr17 -0.70 0.709744638 hsa-miR-3064-3p
MIMAT0019864 chr17 0.67 0.383280593 hsa-miR-3064-5p
MIMAT0048635 chr10 1.96 0.439426813 hsa-miR-3085-5p
MIMAT0014986 chr1 -1.34 0.460343358 hsa-miR-3124-5p
MIMAT0014988 chr2 -1.01 0.690626022 hsa-miR-3125
MIMAT0014990 chr2 1.09 0.593096342 hsa-miR-3127-5p
MIMAT0014992 chr2 -2.74 0.08569919 hsa-miR-3129-5p
MIMAT0015038 chr11 0.30 0.869087749 hsa-miR-3164
MIMAT0019214 chr14 -0.71 0.611762436 hsa-miR-3173-5p
MIMAT0015070 chr19 -0.08 0.974698976 hsa-miR-3188
MIMAT0015084 chr22;chr22 -1.66 0.120559211 hsa-miR-3199
MIMAT0015085 chr22 -1.57 0.322011301 hsa-miR-3200-3p
MIMAT0018004 chr8 0.73 0.70506981 hsa-miR-3622a-3p
MIMAT0018003 chr8 -0.68 0.490504252 hsa-miR-3622a-5p
MIMAT0018006 chr8 -1.82 0.26055572 hsa-miR-3622b-3p
MIMAT0017982 chr1 1.38 0.151083919 hsa-miR-3605-3p
MIMAT0017981 chr1 -0.41 0.66142723 hsa-miR-3605-5p
MIMAT0022965 chr2 0.07 0.979007216 hsa-miR-3606-3p
MIMAT0017986 chr7 1.45 1.66E-07 hsa-miR-3609
MIMAT0017987 chr8 1.31 0.247138216 hsa-miR-3610
MIMAT0017989 chr12 -2.25 0.242772802 hsa-miR-3612
MIMAT0017992 chr17 -0.09 0.962870291 hsa-miR-3614-5p
MIMAT0017994 chr17 -1.29 0.088646747 hsa-miR-3615
MIMAT0018071 chr9 1.12 0.096766384 hsa-miR-3651
MIMAT0018183 chr22 -0.70 0.300156646 hsa-miR-3909
MIMAT0018187 chr12;chr12 -2.77 0.151083919 hsa-miR-3913-5p
MIMAT0018205 chr22 -1.37 0.333947059 hsa-miR-3928-3p
MIMAT0018349 chr6 0.89 0.483574147 hsa-miR-3934-5p
MIMAT0016888 chr20 -0.61 0.608822481 hsa-miR-4326
MIMAT0018941 chr1 1.26 0.296452573 hsa-miR-4426
MIMAT0018962 chr2;chr3 1.08 0.247595571 hsa-miR-4444
MIMAT0018968 chr4 1.89 0.28398691 hsa-miR-4449
MIMAT0019000 chr9 0.87 0.53316431 hsa-miR-4473
MIMAT0032116 chr11 3.24 0.065695892 hsa-miR-4485-5p
MIMAT0019058 chr17 0.59 0.246764647 hsa-miR-4521
MIMAT0019706 chr6 -1.85 0.293940343 hsa-miR-4645-3p




Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0019729 chr8 0.96 0.553584851 hsa-miR-4661-5p
MIMAT0019750 chr9 -2.05 0.24978591 hsa-miR-4670-5p
MIMAT0019764 chr10 0.89 0.682287116 hsa-miR-4680-5p
MIMAT0019768 chr10 0.79 0.289222123 hsa-miR-4683
MIMAT0019805 chr13 -2.97 0.14887605 hsa-miR-4705
MIMAT0019812 chr14 -1.02 0.38236541 hsa-miR-4709-3p
MIMAT0019811 chr14 0.78 0.405841352 hsa-miR-4709-5p
MIMAT0019855 chr17 -0.68 0.709744638 hsa-miR-4732-5p
MIMAT0019931 chr2 -0.05 0.984012474 hsa-miR-4775
MIMAT0019957 chr3 1.87 0.135822284 hsa-miR-4787-3p
MIMAT0021017 chr19 0.96 0.764822298 hsa-miR-4999-5p
MIMAT0021021 chr2 2.44 0.115416148 hsa-miR-5001-5p
MIMAT0021041 chr15 -1.61 0.394098292 hsa-miR-5009-5p
MIMAT0021044 chr17 -0.62 0.531107557 hsa-miR-5010-3p
MIMAT0021083 chr4 0.65 0.606667135 hsa-miR-5091
MIMAT0022491 chr1 1.66 0.428905534 hsa-miR-5698
MIMAT0022496 chr2 2.38 0.205388823 hsa-miR-5703
MIMAT0025458 chr21 -2.74 0.167665663 hsa-miR-6501-5p
MIMAT0025467 chr12 1.55 0.228121556 hsa-miR-6505-3p
MIMAT0025466 chr12 -1.43 0.260492679 hsa-miR-6505-5p
MIMAT0025468 chr16 0.70 0.682287116 hsa-miR-6506-5p
MIMAT0025479 chr16;chr16;chr16;chr16 2.34 0.138421742 hsa-miR-6511a-3p
MIMAT0025848 chr16;chr16 -0.51 0.631412567 hsa-miR-6511b-3p
MIMAT0025484 chr11 -0.13 0.945527201 hsa-miR-6514-5p
MIMAT0025487 chr19 -2.09 0.126767602 hsa-miR-6515-3p
MIMAT0030418 chr17 -1.05 0.052379399 hsa-miR-6516-3p
MIMAT0030417 chr17 -0.93 0.085602161 hsa-miR-6516-5p
MIMAT0025845 chr11 1.33 0.157126867 hsa-miR-6716-3p
MIMAT0025852 chr6 1.51 0.311852909 hsa-miR-6721-5p
MIMAT0027370 chr1 -0.36 0.874590657 hsa-miR-6734-3p
MIMAT0027369 chr1 0.73 0.70506981 hsa-miR-6734-5p
MIMAT0027513 chr19 1.06 0.489704077 hsa-miR-6806-3p
MIMAT0027537 chr22 0.26 0.898412989 hsa-miR-6818-3p
MIMAT0027554 chr3 -2.03 0.150112475 hsa-miR-6827-5p
MIMAT0027587 chr8 0.38 0.78186664 hsa-miR-6842-3p
MIMAT0027588 chr8 -0.86 0.504854156 hsa-miR-6843-3p
MIMAT0027605 chr9 -0.33 0.837080115 hsa-miR-6852-3p
MIMAT0027633 chr17 1.65 0.324176569 hsa-miR-6866-3p
MIMAT0027632 chr17 -1.48 0.067811003 hsa-miR-6866-5p
MIMAT0028120 chr6 2.80 0.088744721 hsa-miR-7111-3p
MIMAT0030020 chr8 -0.79 0.691512693 hsa-miR-7705
MIMAT0030021 chr15 0.60 0.27180229 hsa-miR-7706
MIMAT0030419 chr12 2.75 0.154755793 hsa-miR-7844-5p
MIMAT0030421 chr1 -0.72 0.690843217 hsa-miR-7846-3p
MIMAT0030999 chr12 0.31 0.823241614 hsa-miR-8072
MIMAT0041618 chr15 0.21 0.690518857 hsa-miR-10393-3p
MIMAT0041617 chr15 0.39 0.410559728 hsa-miR-10393-5p
MIMAT0041619 chr19 1.35 0.377885155 hsa-miR-10394-5p
MIMAT0041622 chr19 1.24 1.60E-06 hsa-miR-10395-3p
MIMAT0041621 chr19 1.24 1.50E-06 hsa-miR-10395-5p





Table A3.2 (includes preceding 11 pages) Differential expression profiles of miRNA transcripts 
identified by RNA-seq from six healthy and six diseased human tendon samples. miRNAs achieving 
statistically significant differential expression (Log2 Fold Change ≥1.5 with Bejaminin-Hochberg 
adjusted P-value (P adj) <0.05) between healthy and diseased cohortsare given in bold type at the 
top of the table. Chr = chromosome. 
  
Ensembl ID Chr Log2 Fold Change P (adj) Gene
MIMAT0041625 chr5 1.02 0.444966557 hsa-miR-10397-5p
MIMAT0041630 chr7 0.43 0.632133916 hsa-miR-10399-3p
MIMAT0041633_3 chr21 2.85 0.085602161 hsa-miR-10401-5p
MIMAT0041997 chr12 -0.27 0.741798201 hsa-miR-10527-5p
Red ground colour  = Negative fold change 
Blue ground colour = Positive fold change 





Table A4.1 Predicted mRNA targets of miRNAs significantly differentially expressed in human 
tendinopathy. 
 
Table A4.2 Predicted mRNA targets of miRNAs identified as significantly differentially expressed in 
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Table A5.1 Small nucleolar RNA-61 (SNORD61) expression in equine primary tenocytes is unaffected 
by treatment with miR-181a-5p mimic, antagomiR or scrambled control sequence oligonucleotides. 
 
Table A5.2 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in equine primary 
tenocytes is unaffected by treatment with miR-181a-5p mimic, antagomiR or scrambled control 
oligonucleotides. 
 
Figure A5.1 Expression of selected target genes does not differ between scrambled control sequence 






Table A5.1 Small nucleolar RNA-61 (SNORD61) expression in equine primary tenocytes is 
unaffected by treatment with miR-181a-5p mimic, antagomiR or scrambled control sequence 
oligonucleotides. Threshold cycle (Ct) values are presented for eight biological replicates, each run 
in triplicate. Untreated controls were not performed for two biological replicates. Columns 
demonstrate variation between biological replicates, rows demonstrate variation with treatment. 
Max = maximum, Min = minimum, SD = standard deviation. 
  
Donor Identity
(Passage number) Replicates Average Replicates Average Replicates Average Replicates Average Max Min Max - Min
EqDB5-5(P4) 28.61 28.86 28.31 28.79 29.73 29.97 30.22 30.49 30.49 28.79 1.70
EqDB5-5(P4) 28.97 28.87 30.22 30.37
EqDB5-5(P4) 29.01 29.18 29.97 30.87
EqDB30-3(P2) 30.18 30.13 29.11 30.03 29.43 29.91 29.35 29.81 30.13 29.81 0.32
EqDB30-3(P2) 30.27 30.64 30.35 30.07
EqDB30-3(P2) 29.94 30.34 29.94 30
EqDB7-5(P2) 27.36 27.31 27.06 27.89 28.82 29.04 29.13 29.18 29.18 27.31 1.88
EqDB7-5(P2) 27.45 28.49 28.92 29.18
EqDB7-5(P2) 27.11 28.11 29.39 29.24
EqDB9-12(P4) 27.88 27.85 29.34 29.20 28.62 29.28 27.4 27.31 29.28 27.31 1.97
EqDB9-12(P4) 27.64 28.86 29.86 27.31
EqDB9-12(P4) 28.03 29.41 29.37 27.22
EqDB10-18(P3) 28.26 28.21 28.82 29.06 30.12 29.67 29.67 28.21 1.46
EqDB10-18(P3) 27.98 29.09 29.31
EqDB10-18(P3) 28.4 29.28 29.59
EqDB11-3(P2) 29.58 29.47 30.1 29.69 28.06 28.11 28.57 28.69 29.69 28.11 1.58
EqDB11-3(P2) 29.47 29.4 28.2 29.16
EqDB11-3(P2) 29.37 29.58 28.08 28.35
EqDB12-8(P3) 28.45 28.27 28.28 28.31 29.23 28.76 28.76 28.27 0.49
EqDB12-8(P3) 28.23 28.48 28.16
EqDB12-8(P3) 28.13 28.18 28.88
EqDB18-9(P4) 28.32 28.03 30.64 29.44 29.69 29.42 28.11 28.34 29.44 28.03 1.41
EqDB18-9(P4) 28.03 29.23 30.1 28.4
EqDB18-9(P4) 27.74 28.46 28.47 28.5
Mean 28.52 28.52 29.05 29.05 29.27 29.27 28.97 28.97 29.27 28.52 0.75
SD 0.90 0.92 0.84 0.71 0.73 0.63 1.08 1.12 1.12 0.63 0.50
Max 30.27 30.13 30.64 30.03 30.35 29.97 30.87 30.49 30.49 29.97 0.51
Min 27.11 27.31 27.06 27.89 28.06 28.11 27.22 27.31 28.11 27.31 0.81
Max - Min 3.16 2.82 3.58 2.14 2.29 1.86 3.65 3.18 3.18 1.86 1.32
Ct Values





Table A5.2 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in equine primary 
tenocytes is unaffected by treatment with miR-181a-5p mimic, antagomiR or scrambled control 
oligonucleotides. Threshold cycle (Ct) values are presented for eight biological replicates, each run 
in triplicate. Untreated controls were not performed for two biological replicates. Columns 
demonstrate variation between biological replicates, rows demonstrate variation with treatment. 
Max = maximum, Min = minimum, SD = standard deviation. 
  
Donor Identity
(Passage number) Replicates Average Replicates Average Replicates Average Replicates Average Max Min Max - Min
EqDB5-5(P4) 16.54 16.46 16.83 16.80 16.73 16.69 16.77 16.75 16.80 16.46 0.34
EqDB5-5(P4) 16.44 16.53 16.73 16.69
EqDB5-5(P4) 16.41 17.04 16.62 16.80
EqDB30-3(P2) 17.37 17.36 17.15 17.12 17.19 17.09 16.54 16.64 17.36 16.64 0.72
EqDB30-3(P2) 17.42 17.10 17.01 16.59
EqDB30-3(P2) 17.29 17.10 17.08 16.78
EqDB7-5(P2) 16.64 16.80 16.40 16.49 17.09 17.11 16.74 16.91 17.11 16.49 0.62
EqDB7-5(P2) 16.79 16.38 17.24 17.12
EqDB7-5(P2) 16.96 16.69 17.01 16.87
EqDB9-12(P4) 16.09 16.03 16.45 16.46 16.36 16.30 16.46 16.45 16.46 16.03 0.43
EqDB9-12(P4) 15.86 16.50 16.32 16.46
EqDB9-12(P4) 16.14 16.44 16.22 16.43
EqDB10-18(P3) 16.05 16.22 16.11 16.10 16.07 15.93 16.22 15.93 0.28
EqDB10-18(P3) 16.29 16.09 15.69
EqDB10-18(P3) 16.31 16.11 16.04
EqDB11-3(P2) 16.97 17.04 16.52 16.63 16.20 16.40 16.64 16.66 17.04 16.40 0.64
EqDB11-3(P2) 17.11 16.61 16.52 16.66
EqDB11-3(P2) 17.03 16.77 16.47 16.68
EqDB12-8(P3) 16.02 15.86 16.06 16.04 15.86 16.02 16.04 15.86 0.18
EqDB12-8(P3) 15.99 16.07 15.95
EqDB12-8(P3) 15.57 15.98 16.26
EqDB18-9(P4) 15.60 15.80 17.22 17.17 16.60 16.69 16.44 16.36 17.17 15.80 1.37
EqDB18-9(P4) 15.95 17.15 16.58 16.34
EqDB18-9(P4) 15.86 17.14 16.89 16.30
Mean 16.45 16.45 16.60 16.60 16.53 16.53 16.63 16.63 16.63 16.45 0.18
SD 0.56 0.57 0.41 0.42 0.44 0.45 0.21 0.20 0.57 0.20 0.37
Max 17.42 17.36 17.22 17.17 17.24 17.11 17.12 16.91 17.36 16.91 0.45
Min 15.57 15.80 15.98 16.04 15.69 15.93 16.30 16.36 16.36 15.80 0.56
Max - Min 1.85 1.56 1.24 1.13 1.55 1.18 0.82 0.55 1.56 0.55 1.01












































































































































































































































































































































Figure A5.1 (includes preceding page) Expression of selected target genes does not differ between 
scrambled control sequence (SC) treated and untreated (UT) equine tenocytes. Y–axis values 
represent expression relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). P-values 
calculated from delta Ct values, using the Mann-Whitney test. Graphs show median and 
interquartile range. 
  
P=1.00 P=0.76 P=0.64 






Figure A6.1 Comparison between scrambled control (SC) treated and untreated (UT) equine tendon 
constructs on the expression of selected target genes. 
 
Figure A6.2 Western blot images from mmu-miR-181a-5p mimic (M), antagomiR (AM) and 
scrambled control (SC) treated equine tendon constructs. 
 
Figure A6.3 Comparison between scrambled control (SC) treated and untreated (UT) equine tendon 


















































































































































































































































P=0.08 P=0.06 P=0.03 
P=0.07 P=0.68 P=0.78 




































































































































































Figure A6.1 (includes preceding page) Comparison between scrambled control (SC) treated and 
untreated (UT) equine tendon constructs on the expression of selected target genes. Y–axis values 
represent expression relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). P-values 
calculated from delta Ct values, using Student-t test. Graphs show median and interquartile range. 
  







A. TOMM20 and Vinculin 
 
TOMM20 = translocase of outer mitochondrial membrane 20, predicted molecular weight 16 kDa. 
 
 
B. BNIP3 and Vinculin 
 
BNIP3 = Bcl-2 interacting protein 3, predicted molecular weight 22 kDa. 
 
 
C. LAMP1 and Vinculin
 





D. COXIV and Vinculin 
 
COXIV = cytochrome c oxidase subunit 4, predicted molecular weight 17 kDa. 
 
 
E. LC3B and Vinculin 
 
LC3B = microtubule-associated proteins 1A/1B light chain 3B, predicted molecular weight 15 kDa. 
 
 
F. P62/SQSTM1 and Vinculin 
 






G. NRF2 and Vinculin 
 
NRF2 = nuclear factor erythroid 2, predicted molecular weight 61 kDa. 
 
 
H. Parkin and Vinculin 
 
Parkin predicted molecular weight 52 kDa. 
 
 
Figure A6.2 (includes preceding 2 pages) Western blot images from mmu-miR-181a-5p mimic (M), 
antagomiR (AM) and scrambled control (SC) treated equine tendon constructs.  Vinculin used as 
loading control, predicted molecular weight 124 kDa. UT = untreated.  Images acquired using LI-COR 














































































































































































Figure A6.3 (includes preceding page) Comparison between scrambled control (SC) treated and 
untreated (UT) equine tendon constructs on histological scoring of haematoxylin and eosin (H&E) 
and Masson’s Trichrome stained sections. Results show average of two consecutive blinded 
gradings by the same operator (First grader). P-values obtained using Mann Whitney test. P-values 
















Table A7.1 Small nucleolar RNA-61 (SNORD61) expression in human primary tenocytes is unaffected 
by treatment with miR-181a-5p mimic, antagomiR or scrambled control sequence oligonucleotides. 
 
Table A7.2 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in human primary 
tenocytes is unaffected by treatment with miR-181a-5p mimic, antagomiR or scrambled control 
oligonucleotides. 
 
Figure A7.1 Comparison between scrambled control (SC) treated and untreated (UT) human 
tenocytes on the expression of selected target genes. 
 
Figure A7.2 Western blot images from mmu-miR-181a-5p mimic (M), antagomiR (AM) and 
scrambled control (SC) treated human tenocytes for three biological replicates. 
 
Figure A7.3 Comparison between scrambled control (SC) treated and untreated (UT) human 






Table A7.1 Small nucleolar RNA-61 (SNORD61) expression in human primary tenocytes is 
unaffected by treatment with miR-181a-5p mimic, antagomiR or scrambled control sequence 
oligonucleotides. Threshold cycle (Ct) values are presented for three biological replicates, each run 
in triplicate. Columns demonstrate variation between biological replicates, rows demonstrate 




Table A7.2 Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in human primary 
tenocytes is unaffected by treatment with miR-181a-5p mimic, antagomiR or scrambled control 
oligonucleotides. Threshold cycle (Ct) values are presented for three biological replicates, each run 
in triplicate. Columns demonstrate variation between biological replicates, rows demonstrate 
variation with treatment. Max = maximum, Min = minimum, SD = standard deviation. 
Donor Identity
Replicates Average Replicates Average Replicates Average Replicates Average Max Min Max - Min
LMB-JL-280 29.9 29.47 28.57 28.55 28.54 28.31 28.38 28.50 29.47 28.31 1.17
LMB-JL-280 29.39 28.4 28.19 28.67
LMB-JL-280 29.13 28.67 28.19 28.44
LMB-SF-282 28.98 28.70 27.94 28.75 27.92 28.27 29.12 29.79 29.79 28.27 1.52
LMB-SF-282 28.51 29.04 28.15 30.01
LMB-SF-282 28.61 29.28 28.73 30.23
LMB-RL-286 28.56 28.64 28.27 28.35 28.2 28.32 28.73 28.76 28.76 28.32 0.44
LMB-RL-286 28.7 28.45 28.27 28.73
LMB-RL-286 28.66 28.34 28.49 28.83
Mean 28.94 28.94 28.55 28.55 28.30 28.30 29.02 29.02 29.02 28.30 0.72
SD 0.47 0.46 0.41 0.20 0.25 0.03 0.66 0.68 0.68 0.03 0.65
Max 29.90 29.47 29.28 28.75 28.73 28.32 30.23 29.79 29.79 28.32 1.47
Min 28.51 28.64 27.94 28.35 27.92 28.27 28.38 28.50 28.64 28.27 0.37
Max - Min 1.39 0.83 1.34 0.40 0.81 0.05 1.85 1.29 1.29 0.05 1.24
Ct Values
Mimic treated AntagomiR treated Scrambled control treated Untreated control
Donor Identity
Replicates Average Replicates Average Replicates Average Replicates Average Max Min Max - Min
LMB-JL-280 20.65 20.64 20.15 20.18 20.43 20.41 20.28 20.27 20.64 20.18 0.46
LMB-JL-280 20.68 20.2 20.42 20.27
LMB-JL-280 20.6 20.19 20.38 20.27
LMB-SF-282 20.4 20.43 20.55 20.60 21.02 21.01 21.18 21.23 21.23 20.43 0.79
LMB-SF-282 20.46 20.65 21.01 21.3
LMB-SF-282 20.44 20.61 21 21.2
LMB-RL-286 20.19 20.09 20.37 20.48 20.31 20.31 20.41 20.43 20.48 20.09 0.39
LMB-RL-286 20.08 20.69 20.3 20.46
LMB-RL-286 19.99 20.37 20.32 20.42
Mean 20.39 20.39 20.42 20.42 20.58 20.58 20.64 20.64 20.64 20.39 0.26
SD 0.25 0.28 0.21 0.22 0.33 0.38 0.44 0.51 0.51 0.22 0.29
Max 20.68 20.64 20.69 20.60 21.02 21.01 21.30 21.23 21.23 20.60 0.62
Min 19.99 20.09 20.15 20.18 20.30 20.31 20.27 20.27 20.31 20.09 0.22
Max - Min 0.69 0.56 0.54 0.42 0.72 0.70 1.03 0.95 0.95 0.42 0.53
Ct Values













































































































































Figure A7.1 Comparison between scrambled control (SC) treated and untreated (UT) human 
tenocytes on the expression of selected target genes. Y–axis values represent expression relative to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). P-values calculated from delta Ct values, using 
Mann-Whitney test. Graphs show median and interquartile range. 
  
P=0.70 
P=0.70 P=0.10 P=0.70 
P=0.20 P=0.70 P=0.40 
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A. TOMM20 and Vinculin 
 
TOMM20 = translocase of outer mitochondrial membrane 20, predicted molecular weight 16 kDa. 
 
B. LC3B and Vinculin 
 
LC3B = microtubule-associated proteins 1A/1B light chain 3B, predicted molecular weight 15 kDa. 
 
C. P62/SQSTM1 and Vinculin 
 
P62/SQSTM1 = ubiquitin-binding protein p62, predicted molecular weight 61 kDa. 
 
D. COXIV and Vinculin 
 
COXIV = cytochrome c oxidase subunit 4, predicted molecular weight 17 kDa. 
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Figure A7.2 (preceding page) Western blot images from mmu-miR-181a-5p mimic (M), antagomiR 
(AM) and scrambled control (SC) treated human tenocytes for three biological replicates.  Vinculin 
used as loading control, predicted molecular weight 124 kDa. UT = untreated.  Images acquired using 





























































































































Figure A7.3 Comparison between scrambled control (SC) treated and untreated (UT) human 
tenocytes on the levels of selected target proteins. Protein levels calculated using densitometric 
analysis in ImageJ 1.52 software (https://imagej.nih.gov/ij/, 1997-2018), normalised to vinculin as 
loading control. P-values calculated using Student-t test. * = P <0.05, *** = P <0.001. Graphs show 
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